Senarai FUKKM

Records - of

Senarai ini telah dikemas kini sehingga 29 December 2014.

This list was updated since 29 December 2014.

Nama Generik

MDC

Kategori

Indikasi

Bentuk Dos

Abacavir Sulphate 600 mg and Lamivudine 300 mg TabletJ05AR02964T1001XXA*Antiretroviral combination therapy of HIV infection in adults and adolescents from 12 years of age with the following criteria: i)Patients unsuitable or failed other HAART treatment ii)Patients who are at high risk of renal impairment iii)Patients with osteoporosis or at high risk of bone lossADULTS & ADOLESCENT (> 12 years of age): Recommended dose is one tablet once daily. Not to be used in adults or adolescents weigh less than 40kg. CHILDREN : Not recommended
Acarbose 50 mg TabletA10BF01000T1001XXA/KKOnly for treatment of: i) Non insulin dependent diabetes mellitus (NIDDM) when diet therapy is insufficient ii) Non insulin dependent diabetes mellitus (NIDDM) in combination with existing conventional oral therapy where glycaemic control is inadequateInitially 50 mg daily, increase to 3 times daily up to 100 mg 3 times daily. Max 200 mg 3 times daily
Acetazolamide 250 mg TabletS01EC01000T1001XXBReduction of intraocular pressure in open-angle glaucoma, secondary glaucoma and peri-operatively in angle-closure glaucoma250mg 1-4 times a day, the dosage being titrated according to patient response
Acetazolamide 500 mg InjectionS01EC01000P4001XXBReduction of intra-ocular pressure in open-angle glaucoma, secondary glaucoma and peri-operatively in angle-closure glaucomaAdult : 250-1000mg per 24hours, usually in divided doses for amounts over 250mg daily
Acetylcysteine 200 mg/ml InjectionV03AB23520P3001XXA*Antidote for paracetamol poisoningDiluted with dextrose 5% and infused IV. Initial, 150 mg/kg IV in 200 ml over 60 minutes, then 50 mg/kg IV in 500 ml over 4 hours, followed by 100 mg/kg IV in 1000 ml over 16 hours. Total dose: 300mg/kg in 20 hour
Acetylsalicylic Acid 100 mg, Glycine 45 mg TabletB01AC06259T1001XXBPrevention of myocardial infarct, stroke, vascular occlusion and deep vein thrombosis. Transient ischaemic attacks1 tablet daily
Acetylsalicylic Acid 300 mg Soluble TabletN02BA01000T4001XXCMild to moderate pain300 - 900 mg every 4 - 6 hours as required. Max 4 g daily. Use in children not recommended
Acitretin 10 mg CapsuleD05BB02000C1001XXA*i) Severe form of psoriasis including erythrodermic psoriasis and local or generalized pustular psoriasis. ii) Severe disorders of keratinization, such as -congenital ichthyosis -pityriasis rubra pilaris -Darier's disease -other disorders of keratinization which may be resistant to other therapiesADULT: initially 25-30 mg daily for 2-4 weeks, then adjusted according to response, usually within range 25-50 mg daily for further 6-8 weeks (max: 75 mg daily). In disorders of keratinization, maintenance therapy of less than 20mg/day and should not exceed 50mg/day CHILD: 0.5mg/kg daily occasionally up to 1 mg/kg daily to a max. 35 mg daily for limited periods
Acitretin 25 mg CapsuleD05BB02000C1002XXA*i) Severe form of psoriasis including erythrodermic psoriasis and local or generalized pustular psoriasis. ii) Severe disorders of keratinization, such as -congenital ichthyosis -pityriasis rubra pilaris -Darier's disease -other disorders of keratinization which may be resistant to other therapiesADULT: initially 25-30 mg daily for 2-4 weeks, then adjusted according to response, usually within range 25-50 mg daily for further 6-8 weeks (max: 75 mg daily). In disorders of keratinization, maintenance therapy of less than 20mg/day and should not exceed 50mg/day CHILD: 0.5mg/kg daily occasionally up to 1 mg/kg daily to a max. 35 mg daily for limited periods
Acriflavine 0.1% LotionD08AA03000L6001XXC+Infected skin, lesions, cuts, abrasions, wounds and burns.Apply undiluted three times daily to the affected part .
Actinomycin D (Dactinomycin) 500 mcg/ml InjectionL01DA01110P4001XXAi) For solid tumours ii) Gestational trophoblastic diseasei) ADULT: 500 mcg IV daily for max of 5 days. CHILD: 1.5 mg/m2 once every 3 weeks (if weight less than 10 kg, 50 mcg/kg) ii) 500 mcg IV on Days 2, 4, 6, 8, 10, repeat every 7 - 10 days or 500 mcg IV bolus on Days 1 and 2, repeat every 15 days
Acyclovir 200 mg TabletJ05AB01000T1001XXA/KKi) Mucocutaneous Herpes Simplex infection in immunocompromised and AIDS patients ii) Primary and recurrent Varicella Zoster infection in immunocompromised and AIDS patients iii) Severe Kaposi Varicella Eruption (Eczema herpeticum) iv) Severe primary HSV infections (eg. Neonatal herpes, encephalitis, eczema herpeticum, genital herpes, gingival stomatitis, vaginal delivery with maternal vulva herpes) v) Severe and complicated varicella infection (eg. Encephalitis, purpura fulminans) vi) Severe zoster infection in paediatrics (eg. Encephalitis, purpura fulminans, immunocompromised patients and facial, sacral and motor zoster)i) ADULT: initially 400 mg 5 times daily for 7 - 14 days. CHILD less than 2 years: 200 mg 4 times daily, CHILD more than 2 years: 400 mg 4 times daily ii), iii) and iv) ADULT: 200 - 400 mg 4 times daily. CHILD: less than 2 years, half adult dose; more than 2 years, adult dose v) ADULT: 800 mg 5 times daily for 7 days vi) ADULT: 20 mg/kg (maximum: 800 mg) four times daily for 5 days, CHILD 6 years: 800 mg four times daily. CHILD less than 2 years; 400mg 4 times daily, more than 2 years; 800mg 4 times daily
Acyclovir 200 mg/5 ml SuspensionJ05AB01000L8001XXA*i) Mucocutaneous Herpes Simplex infection in immunocompromised and AIDS patients ii) Primary and recurrent Varicella Zoster infection in immunocompromised and AIDS patients iii) Severe Kaposi Varicella Eruption (Eczema herpeticum) iv) Severe primary HSV infections (eg. Neonatal herpes, encephalitis, eczema herpeticum, genital herpes, gingival stomatitis, vaginal delivery with maternal vulva herpes) v) Severe and complicated varicella infection (eg. Encephalitis, purpura fulminans) vi) Severe zoster infection in paediatrics (eg.Encephalitis, purpura fulminans, immunocompromised patients and facial, sacral and motor zoster)i) ADULT: initially 400 mg 5 times daily for 7 - 14 days. CHILD less than 2 years: 200 mg 4 times daily, CHILD more than 2 years: 400 mg 4 times daily ii), iii) and iv) ADULT: 200 - 400 mg 4 times daily. CHILD : less than 2 years, half adult dose; more than 2 years, adult dose. v) ADULT: 800 mg 5 times daily for 7 days vi) ADULT: 20 mg/kg (maximum: 800 mg) four times daily for 5 days, CHILD 6 years: 800 mg four times daily. CHILD: less than 2 years; 400mg 4 times daily, more than 2 years; 800 mg 4 times daily
Acyclovir 250 mg InjectionJ05AB01000P4001XXA*Treatment and prophylaxis of herpes simplex in immunocompromised, severe initial genital herpes and Varicella -ZosterADULT: 5 mg/kg by IV infusion 8 hourly for 5 days, doubled to 10mg/kg every 8 hourly in varicella-zoster in the immunocompromised and in simplex encephalitis (usually given for at least 10 days in encephalitis; possibly for 14 - 21 days). NEONATE & INFANT up to 3 months with disseminated herpes simplex: 20mg/kg every 8 hourly for 14 days (21 days in CNS involvement), varicella-zoster 10-20mg/kg every 8 hourly usually for 7 days. CHILD, 3 months - 12 years: Herpes simplex or Varicella Zoster: 250 mg/m2 8 hourly for 5 days, doubled to 500 mg/m2 8 hourly for varicella-zoster in the immunocompromised and in simplex encephalitis (usually given for 10 days in encephalitis)
Acyclovir 3% Eye OintmentS01AD03000G5101XXA*Only for the treatment of herpes simplex keratitisApply 1 cm 5 times daily. Continue for at least 3 days after healing
Acyclovir 5% CreamD06BB03000G1001XXA*Herpes simplex infections of the skin, including initial and recurrent labial and genital herpes simplex infectionsApply every 4 hours for 5 - 10 days
Acyclovir 800 mg TabletJ05AB01000T1002XXA/KKi) Mucocutaneous Herpes Simplex infection in immunocompromised and AIDS patients ii) Primary and recurrent Varicella Zoster infection in immunocompromised and AIDS patients iii) Severe Kaposi Varicella Eruption (Eczema herpeticum) iv) Severe primary HSV infections (eg. Neonatal herpes, encephalitis, eczema herpeticum, genital herpes, gingival stomatitis, vaginal delivery with maternal vulva herpes) v) Severe and complicated varicella infection (eg. Encephalitis, purpura fulminans) vi) Severe zoster infection in paediatrics (eg. Encephalitis, purpura fulminans, immunocompromised patients and facial, sacral and motor zoster)i) ADULT: initially 400 mg 5 times daily for 7 - 14 days. CHILD less than 2 years: 200 mg 4 times daily, CHILD more than 2 years: 400 mg 4 times daily ii), iii) and iv) ADULT: 200 - 400 mg 4 times daily. CHILD: less than 2 years, half adult dose; more than 2 years, adult dose v) ADULT: 800 mg 5 times daily for 7 days vi) ADULT: 20 mg/kg (maximum: 800 mg) four times daily for 5 days, CHILD 6 years: 800 mg four times daily. CHILD less than 2 years; 400mg 4 times daily, more than 2 years; 800mg 4 times daily
Adalimumab 40 mg InjectionL04AB04000P5001XXA*i) Third line treatment of: - Severe rheumatoid arthritis - Psoriatic arthritis - Ankylosing spondylitis after failure of conventional DMARDs or other biologics ii)Treatment of adults with moderate to severe chronic plaque psoriasis who have not responded to, have contraindication or are unable to tolerate phototherapy and/or systemic therapies including acitretin, methotreaxate and cyclosporinei)Severe rheumatoid arthritis, Psoriatic arthritis, Ankylosing spondylitis : Subcutaneous 40 mg every other week ii)Chronic plaque psoriasis : Initial, 80 mg SC, followed by 40 mg SC every other week starting one week after the initial dose
Adapalene 0.1% CreamD10AD03000G1001XXA*Acne vulgaris where comedones, papules and pustules predominate in those sensitive to benzoyl peroxide or topical tretinoin [third line treatment]Apply once daily to the affected areas after washing at bedtime
Adapalene 0.1% GelD10AD03000G3001XXA*Acne vulgaris where comedones, papules and pustules predominate in those sensitive to benzoyl peroxide or topical tretinoin [third line treatment]Apply once daily to the affected areas after washing at bedtime
Adefovir Dipivoxil 10 mg TabletJ05AF08000T1001XXA*i) Treatment of chronic HBeAg positive and HBeAg negative hepatitis B infection in adults with compensated liver function (lamivudine should be tried first) ii) Lamivudine-resistant chronic hepatitis B virus infection with either compensated or decompensated hepatitis function (only by hepatologist and gastroenterologist for approved indications)Adult (18-65 years): 10mg Once Daily Renal Dose Adjustment : 10mg every 48hours (30-49ml/min); 10mg every 72hours (10-29ml/min); 10mg every 7 days (Hemodialysis)
Adenosine 3 mg/ml InjectionC01EB10000P3001XXBRapid conversion of paroxysmal supraventricular tachycardia to sinus rhythmADULT: Initially: 3 mg given as a rapid IV bolus (over 2 seconds). Second dose: If the first dose does not result in elimination of the supraventricular tachycardia with in 1 or 2 minutes, 6 mg should be given also as a rapid IV bolus. Third dose: If the second dose does not result in elimination of the supraventicular tachycardia with in 1-2 minutes, 12 mg should be given also as a rapid IV bolus
Adrenaline Acid (Epinephrine) Tartrate 1 mg/ml InjectionC01CA24123P3001XXBCardiopulmonary resuscitation1 mg by intravenous injection repeated every 3-5 minutes according to response
Agomelatine 25 mg TabletN06AX22000T1001XXA*Major depressionThe recommended dose is 25mg once daily at bedtime, maybe increased to 50mg once daily at bedtime.
Albendazole 200 mg TabletP02CA03000T1001XXC+i) Single or mixed infestations of intestinal parasites ii) Strongyloides infectioni)Child 12-24months: 200mg as a single dose ii) Adult & Child above 2 years: 400mg as a single dose for 3 consecutive days; Child 12 - 24months: 200mg as a single dose for 3 consecutive days
Albendazole 200 mg/5 ml SuspensionP02CA03000L8001XXC+i) Single or mixed infestations of intestinal parasites ii) Strongyloides infectioni)Child 12-24months: 200mg as a single dose ii) Adult & Child above 2 years: 400mg as a single dose for 3 consecutive days; Child 12 - 24months: 200mg as a single dose for 3 consecutive days
Alcohol 70% SolutionD08AX08000L9901XXC+Use as antiseptic and disinfectantApply to the skin undiluted or when needed
Alendronate Sodium 70 mg and Cholecalciferol 5600 IU TabletM05BB03972T1002XXA*Osteoporosis in post menopausal women with a history of vertebral fracture and whom oestrogen replacement therapy is contraindicated. Review treatment after 2 years and if there is positive response, treatment may be continued up to 5 years and then re-evaluate. Treatment should be stopped if there is no positive response after 5 years. Otherwise, patient needs to be given drug holiday for 1 to 2 years and then continue treatment shall the benefit outweigh the risk.1 tablet once weekly [70mg/5600 IU]. Patient should receive supplemental calcium or vitamin D, if dietary vitamin D inadequate. The tablet should be taken at least half and hour before the first food, beverage, or medication of the day with plain water only. To facilitate delivery to stomach and thus reduce the potential for esophageal irritation, it should only be swallowed upon arising for the day with a full glass of water and patient should not lie down for at least 30 minutes and until after their first food of the day.
Alendronate Sodium 70 mg TabletM05BA04520T1001XXA*Osteoporosis in post menopausal women with a history of vertebral fracture and whom oestrogen replacement therapy is contraindicated. Review treatment after 2 years and if there is positive response, treatment may be continued up to 5 years and then re-evaluate. Treatment should be stopped if there is no positive response after 5 years. Otherwise, patient needs to be given drug holiday for 1 to 2 years and then continue treatment shall the benefit outweigh the risk.70 mg once weekly. Swallow the tablet whole with a full glass of plain water only on an empty stomach at least 30 minutes before breakfast (and any other oral medication); stand or sit upright for at least 30 minutes and do not lie down until after eating breakfast
Alfacalcidol 0.25 mcg CapsuleA11CC03000C1001XXA/KKi) Renal osteodystrophy in patients on haemodialysis ii) Hypoparathyroidism and pseudohypoparathyroidism iii) Adjunct to the management of tertiary hyperparathyroidism iv) Rickets and osteomalacia v) OsteoporosisInitial dose ADULT and CHILD above 20kg body weight : 1 mcg daily; CHILD under 20kg body weight : 0.05 mcg/kg/day. Maintenance dose : 0.25 mcg to 2 mcg daily
Alfacalcidol 1 mcg CapsuleA11CC03000C1002XXA/KKi) Renal osteodystrophy in patients on haemodialysis ii) Hypoparathyroidism and pseudohypoparathyroidism iii) Adjunct to the management of tertiary hyperparathyroidism iv) Rickets and osteomalacia v) OsteoporosisInitial dose ADULT and CHILD above 20kg body weight : 1 mcg daily; CHILD under 20kg body weight : 0.05 mcg/kg/day. Maintenance dose : 0.25 mcg to 2 mcg daily
Alfacalcidol 2 mcg/ml DropsA11CC03000D5001XXA*i) Renal osteodystrophy in patients on haemodialysis ii) Hypoparathyroidism and pseudohypoparathyroidism iii) Adjunct to the management of tertiary hyperparathyroidism iv) Rickets and osteomalacia v) OsteoporosisNEONATES : 0.1 mcg/kg/day
Alfacalcidol 2 mcg/ml InjectionA11CC03000P3001XXA*Treatment of: i) Renal osteodystrophy in patients on haemodialysis ii) Hypoparathyroidism and pseudohypoparathyroidism iii) Adjunct to the management of tertiary hyperparathyroidism iv) Rickets and osteomalacia v) OsteoporosisAdult: Initially, 1 mcg daily. Maintenance: 0.25-1 mcg daily. Child: Premature infants and neonates: 0.05-0.1 mcg/kg daily; <20 kg: 0.05 mcg/kg daily. Elderly: 0.5 mcg daily.
Alfentanil HCl 0.5 mg/ml InjectionN01AH02110P3001XXA*For use as short acting narcotic analgesic in short procedures and day-care surgical proceduresInitial dose: 20 - 40 mcg/kg. Supplemental dose: 15 mcg/kg or infusion 0.5 - 1.0 mcg/kg/min
Alfuzosin HCl 10 mg TabletG04CA01110T1001XXA*Treatment of functional symptoms related with benign prostatic hypertrophy (BPH)10 mg once a day pre bed
Alglucosidase alfa 5 mg/ml InjectionA16AB07000P4001XXA*Infantile-onset Pompe disease20 mg/kg of body weight administered once every 2 weeks as an intravenous infusion. Monitoring It is suggested that patients be monitored periodically for IgG antibody formation. Patients who experience Infusion-associated reactions suggestive of hypersensitivity may be tested for IgE antibodies to alglucosidase alfa. Treated patients who experience a decrease in benefit despite continued treatment with Alglucosidase Alfa, in whom antibodies are suspected to play a role, may be tested for neutralization of enzyme uptake or activity.
Alkaline Nasal DoucheR01A000999L5001XXBTo remove nasal plugTo be diluted with an equal volume of warm water before use
Allopurinol 100 mg TabletM04AA01000T1002XXA/KKi) Frequent and disabling attacks of gouty arthritis (3 or more attacks/year). ii) Clinical or radiographic signs of erosive gouty arthritis. iii) The presence of tophaceous deposits. iii) Urate nephropathy. iv) Urate nephrolithiasis. v) Impending cytotoxic chemotherapy or radiotherapy for lymphoma or leukaemiaInitial dose : 100-300 mg daily. Maintenance : 300-600 mg daily. Maximum: 900 mg daily
Allopurinol 300 mg TabletM04AA01000T1001XXA/KKi) Frequent and disabling attacks of gouty arthritis (3 or more attacks/year). ii) Clinical or radiographic signs of erosive gouty arthritis. iii) The presence of tophaceous deposits. iii) Urate nephropathy. iv) Urate nephrolithiasis. v) Impending cytotoxic chemotherapy or radiotherapy for lymphoma or leukaemiaInitial dose : 100-300 mg daily. Maintenance : 300-600 mg daily. Maximum: 900 mg daily
All-Trans Retinoic Acid 10 mg CapsuleL01XX14000C1001XXA*Acute promyelocytic leukaemiaInduction: 45 mg/m2 daily for 30 - 90 days. Maintenance: 45 mg/m2 daily for 2 weeks every 3 months. Renal/or hepatic insufficiency: 25mg/m2 daily for 30-90 days. Refer to protocols
Alprazolam 0.25 mg TabletN05BA12000T1001XXA/KKAnxiety disorders0.25 - 0.5 mg 3 times daily (elderly or delibitated 0.25 mg 2-3 times daily), increased if necessary to a total dose of 3 mg/day. Not recommended for children
Alprazolam 0.5 mg TabletN05BA12000T1002XXAAnxiety disorders0.25 - 0.5 mg 3 times daily (elderly or delibitated 0.25 mg 2-3 times daily), increased if necessary to a total dose of 3 mg/day. Not recommended for children
Alprazolam 1 mg TabletN05BA12000T1003XXAAnxiety disorders0.25 - 0.5 mg 3 times daily (elderly or delibitated 0.25 mg 2-3 times daily), increased if necessary to a total dose of 3 mg/day. Not recommended for children
Alprostadil 500 mcg/ml InjectionC01EA01000P3001XXA*For treatment of congenital heart diseases which are ductus arteriosus dependent0.05 - 0.1 mcg/kg/min by continuous IV infusion, then decreased to lowest effective dose
Alteplase 50 mg per vial InjectionB01AD02000P4001XXA*Thrombolytic treatment of acute ischaemic stroke.0.9 mg/kg (maximum of 90 mg) infused over 60 minutes with 10% of the total dose administered as an initial intravenous bolus. Treatment must be started as early as possible within 4.5 hours after onset of stroke symptoms and after exclusion of intracranial haemorrhage by appropriate imaging technique.
Aluminium Hydroxide 600 mg TabletA02AB01250T1001XXADyspepsia, hyperphosphataemia600 mg- 1.2 g 4 times daily and at bedtime or as required
Amantadine HCl 100 mg CapsuleN04BB01110C1001XXBParkinson's diseaseInitial dose: 100 mg daily and is increased to 100 mg twice daily (not later than 4 p.m.) after a week. Elderly over 65 years: less than 100 mg or 100 mg at intervals of more than 1 day
Amikacin 125 mg/ml InjectionJ01GB06183P3003XXAInfections due to susceptible organismsADULT: (IM or IV): 15 mg/kg/day 8 - 12 hourly for 7 - 10 days. Maximum: 1.5 g/day. CHILD: 15 mg/kg/day 8 - 12 hourly. Maximum: 1.5 g/day. Neonates: Initial loading dose of 10 mg/kg followed by 7.5 mg/kg/day 12 hourly. Maximum 15mg/kg/day
Amikacin 250mg/ml InjectionJ01GB06183P3002XXAInfections due to susceptible organismsADULT: (IM or IV): 15 mg/kg/day 8 - 12 hourly for 7 - 10 days. Maximum: 1.5 g/day. CHILD: 15 mg/kg/day 8 - 12 hourly. Maximum: 1.5 g/day. Neonates: Initial loading dose of 10 mg/kg followed by 7.5 mg/kg/day 12 hourly. Maximum 15mg/kg/day
Amiloride HCl 5 mg & Hydrochlorothiazide 50 mg TabletC03EA01900T1001XXBi) Diuretic as an adjunct to the management of oedematous states ii) Hypertensioni) Initially 1 - 2 tab daily adjusted according to response. Max : 4 tabs daily. ii) 1 -2 tabs daily as a single or divided dose
Amino Acids InjectionB05BA01910P3001XXASource of amino acids in patients needing IV nutritionDose to be individualised. ADULT usually 500-2000 ml by IV. ADULT usual requirement for amino acid: 1-2 g/kg/day
Amino Acids with Electrolytes InjectionB05BA10910P3002XXASource of amino acids and electrolytes in patients needing IV nutritionDose to be individualised. ADULT usual requirement for amino acid 1-2 g/kg/day
Amino Acids with Glucose with Electrolytes InjectionB05BA10910P3003XXASource of amino acids, carbohydrate and electrolytes in patients needing IV nutritionDose to be individualised. ADULT usual requirement for amino acid 1-2 g/kg/day, carbohydrate 4-6 g/kg/day
Amino Acids, Glucose and Lipid with Electrolytes InjectionB05BA10910P3001XXASource of amino acids, carbohydrate, lipid and electrolytes in patients needing IV nutritionDose to be individualised. ADULT: 500 - 2000 ml daily given by IV. ADULT usual requirement for amino acid 1-2 g/kg/ day, carbohydrate 4-6 g/kg/day, lipid 2-3 g/kg/day
Aminophylline 25 mg/ml InjectionR03DA05000P3001XXBReversible airways obstruction, acute severe brochospasmAdult: Loading dose: 5 mg/kg (ideal body weight) or 250-500 mg (25 mg/ml) by slow inj or infusion over 20-30 min. Maintenance infusion dose: 0.5 mg/kg/hr. Max rate: 25 mg/min. Child: Loading dose: same as adult dose. Maintenance dose: 6 mth-9 yr: 1 mg/kg/hr and 10-16 yr: 0.8 mg/kg/hr.
Amiodarone 200 mg TabletC01BD01110T1001XXA*Arrhythmias200 mg 3 times daily for 1 week, then reduced to 200 mg twice daily for another week. Maintenance dose, usually 200 mg daily or the minimum required to control the arrhythmia
Amiodarone 50 mg/ml InjectionC01BD01110P3001XXA*Arrhythmias when other drugs are contraindicated or ineffectiveInitial infusion of 5mg/kg via large venous access over 20-120 minutes with ECG monitoring; subsequent infusion given if necessary according to response up to a maximum of 1.2 g in 24 hours
Amisulpride 100 mg TabletN05AL05000T1001XXA*Treatment of psychoses, particularly acute or chronic schizophrenia disorders characterized by positive symptoms(e.g. delusion, hallucinations, thought disorders) and/or negative symptoms(e.g. blunted emotions, emotional and social withdrawal) including when the negative symptoms predominatePredominantly negative episodes: 50-300 mg once daily adjusted according to the patient?s response. Mixed episodes with positive and negative symptoms: 400-800 mg/day in 2 divided doses adjusted according to the patient?s response. Should be taken on an empty stomach (Preferably taken before meals)
Amisulpride 400 mg TabletN05AL05000T1002XXA*Treatment of psychoses, particularly acute or chronic schizophrenia disorders characterized by positive symptoms(e.g. delusion, hallucinations, thought disorders) and/or negative symptoms(e.g. blunted emotions, emotional and social withdrawal) including when the negative symptoms predominatePredominantly negative episodes: 50-300 mg once daily adjusted according to the patient?s response. Mixed episodes with positive and negative symptoms: 400-800 mg/day in 2 divided doses adjusted according to the patient?s response. Should be taken on an empty stomach (Preferably taken before meals)
Amitriptyline HCl 25 mg TabletN06AA09110T1001XXBDepressionInitially 25mg 3 times a day. Maintenance: 25-100mg daily in divided doses. Hospitalized patient: 100mg/day &gradually increase to 200-300mg/day. ADOLESCENT and ELDERLY: initially 20-30mg/day in divided doses w/ gradual increments. CHILD under 16 years are not recommended
Amlodipine 10 mg and Valsartan 160 mg TabletC09DB01935T1003XXA/KKEssential hypertension in patients whose blood pressure is not adequately controlled by monotherapyDoses range from amlodipine besylate 5 mg/valsartan 160 mg to amlodipine besylate 10 mg/valsartan 320 mg ORALLY once daily, with dose titration occurring every 1 to 2 weeks if necessary. MAX amlodipine besylate 10 mg/valsartan 320 mg
Amlodipine 10 mg TabletC08CA01000T1002XXBHypertension5 mg once daily. Max: 10 mg once daily
Amlodipine 5 mg and Valsartan 160 mg TabletC09DB01935T1002XXA/KKEssential hypertension in patients whose blood pressure is not adequately controlled by monotherapyDoses range from amlodipine besylate 5 mg/valsartan 160 mg to amlodipine besylate 10 mg/valsartan 320 mg ORALLY once daily, with dose titration occurring every 1 to 2 weeks if necessary. MAX amlodipine besylate 10 mg/valsartan 320 mg
Amlodipine 5 mg TabletC08CA01000T1001XXBHypertension5 mg once daily. Max: 10 mg once daily
Amlodipine besylate 10mg, valsartan 160mg, hydrochlorothiazide 12.5mg tabletC09DX01941T1001XXA/KKTreatment of essential hypertension. This fixed combination drug is not indicated for the initial therapy of hypertension.One tablet daily i) A patient whose blood pressure is not adequately controlled on dual therapy with amlodipine besylate/valsartan/HCTZ. ii) For convenience, patients receiving valsartan, amlodipine and HCTZ from seperate tablets may be switched to amlodipine besylate/valsartan/HCTZ containing the same component dosses. Dosage may be increased after 2 weeks. The maximum antihypertensive effect of amlodipine besylate/valsartan/HCTZ is reached within 2 weeks of change in dose. The maximum recommended dose of amlodipine besylate/valsartan/HCTZ is 10/320/25 mg. It can be taken with or without food. It is recommended to take it with some water.
Amlodipine besylate 10mg, valsartan 160mg, hydrochlorothiazide 25mg tabletC09DX01941T1002XXA/KKTreatment of essential hypertension. This fixed combination drug is not indicated for the initial therapy of hypertension.One tablet daily i) A patient whose blood pressure is not adequately controlled on dual therapy with amlodipine besylate/valsartan/HCTZ. ii) For convenience, patients receiving valsartan, amlodipine and HCTZ from seperate tablets may be switched to amlodipine besylate/valsartan/HCTZ containing the same component dosses. Dosage may be increased after 2 weeks. The maximum antihypertensive effect of amlodipine besylate/valsartan/HCTZ is reached within 2 weeks of change in dose. The maximum recommended dose of amlodipine besylate/valsartan/HCTZ is 10/320/25 mg. It can be taken with or without food. It is recommended to take it with some water.
Amlodipine besylate 5mg,valsartan 160mg,hydrochlorothiazide 12.5mg tabletC09DX01941T1004XXA/KKTreatment of essential hypertension. This fixed combination drug is not indicated for the initial therapy of hypertension.One tablet daily i) A patient whose blood pressure is not adequately controlled on dual therapy with amlodipine besylate/valsartan/HCTZ. ii) For convenience, patients receiving valsartan, amlodipine and HCTZ from seperate tablets may be switched to amlodipine besylate/valsartan/HCTZ containing the same component dosses. Dosage may be increased after 2 weeks. The maximum antihypertensive effect of amlodipine besylate/valsartan/HCTZ is reached within 2 weeks of change in dose. The maximum recommended dose of amlodipine besylate/valsartan/HCTZ is 10/320/25 mg. It can be taken with or without food. It is recommended to take it with some water.
Amlodipine Camsylate 5 mg and Losartan Potassium 100 mg TabletC09DB06935T1002XXA/KKTreatment of essential hypertension in adults patients whose blood pressure is not adequately controlled on either monotherapyAmlodipine 5mg/losartan 50mg OR amlodipine 5mg/losartan 100mg orally once daily. MAXIMUM DOSE: amlodipine 5mg/losartan 100mg. No dosage adjustment in mild renal impairment. Not recommended in moderate to severe renal impairment or in patients on dialysis. Not recommended in patients who require lower dose of losartan (25mg). Not recommended in patients < 18 years as safety and efficacy is not established in this group
Amlodipine Camsylate 5 mg and Losartan Potassium 50 mg TabletC09DB06935T1001XXA/KKTreatment of essential hypertension in adults patients whose blood pressure is not adequately controlled on either monotherapyAmlodipine 5mg/losartan 50mg OR amlodipine 5mg/losartan 100mg orally once daily. MAXIMUM DOSE: amlodipine 5mg/losartan 100mg. No dosage adjustment in mild renal impairment. Not recommended in moderate to severe renal impairment or in patients on dialysis. Not recommended in patients who require lower dose of losartan (25mg). Not recommended in patients < 18 years as safety and efficacy is not established in this group
Ammonium Bicarbonate, Tincture Ipecac, etc MixtureR05CA04900L2101XXCCoughAdults, the elderly and children over 12 years: 10- 20ml, repeated after 4 hours if required. Not more than 4 doses to be taken in any 24 hours.
Amorolfine 5 % Nail LacquerD01AE16110L5001XXA*Fungal nail infectionsApply to affected nail once or sometimes twice a week after filling and cleansing, allow to dry, treat finger nail for 6 months, toe nail for 9 - 12 months (review at intervals of 3 months)
Amoxicillin & Clavulanate 228 mg/5 ml SyrupJ01CR02961F2102XXA/KKInfections caused by susceptible organismsMild to Moderate infection: 25mg/kg/day (based on Amoxicillin dose) in 2 divided dose. Severe infection: 45mg/kg/day (based on Amoxicillin dose) in 2 divided dose
Amoxicillin 1 g & Clavulanate 200 mg InjectionJ01CR02961P4002XXAInfections caused by susceptible organisms. Respiratory tract, skin, soft tissue, GUT infection, septicaemia, peritonitis, post-operative infection & osteomyelitisCHILD less than 3 months: 30mg/kg 12 hourly. 3 months - 12 years: 30mg/kg 6 - 8 hourly. ADULT: 1.2 g by IV or intermittent infusion 6 - 8 hourly
Amoxicillin 250 mg CapsuleJ01CA04012C1001XXBInfections caused by susceptible strains of gram positive and gram negative organismsADULT: 250 - 500 mg 3 times daily. CHILD: 20 - 40 mg/kg/day in divided doses 8 hourly
Amoxicillin 500 mg & Clavulanate 125 mg TabletJ01CR02961T1002XXA/KKInfections due to beta-lactamase producing strain where amoxicillin alone is not appropriate. Respiratory tract, skin, soft tissue, GUT infection, septicaemia, peritonitis, post-operative infection & osteomyelitisADULT & CHILD more than 12 years: Mild to moderate infections: 625 mg twice daily.
Amoxicillin 500 mg and Clavulanate 100 mg InjectionJ01CR02961P4001XXAInfections caused by susceptible organisms. Respiratory tract, skin, soft tissue, GUT infection, septicaemia, peritonitis, post-operative infection and osteomyelitisCHILD less than 3 months: 30mg/kg 12 hourly. 3 months - 12 years: 30 mg/kg 6 - 8 hourly. ADULT: 1.2 g by IV or intermittent infusion 6 - 8 hourly
Amoxicillin 500 mg CapsuleJ01CA04012C1002XXBInfections caused by susceptible strains of gram positive and gram negative organismsADULT: 250 - 500 mg 3 times daily. CHILD: 20 - 40 mg/kg/day in divided doses 8 hourly
Amoxicillin Trihydrate 125 mg/5 ml SyrupJ01CA04012F1001XXBInfections caused by susceptible strains of gram positive and gram negative organismsCHILD less than 10 years: 125 - 250 mg 8 hourly. CHILD less than 20 kg: 20 - 40 mg/kg/day in 3 - 4 divided doses
Amphotericin B 0.15% Eye DropsS01A000801D2002XXAFungal infection of the cornea1 drop hourly or 2 hourly
Amphotericin B 0.25% Eye DropsS01A000801D2003XXAFungal infection of the cornea1 drop hourly or 2 hourly
Amphotericin B 50 mg InjectionJ02AA01801P4001XXASystemic fungal infectionsADULT: 0.25 mg/kg/day by IV infusion, gradually increase if tolerated to 1 mg/kg/day. Maximum in severe cases: 1.5 mg/kg daily or on alternate days. For neonates, lower doses are recommended
Ampicillin Sodium & Sulbactam Sodium 250 mg/5 ml SuspensionJ01CR01961F2101XXATreatment of susceptible bacterial infectionsADULT: (1-) 2-6g daily CHILDREN: (25-) 50-100mg/kg daily PREMATURE AND NEWBORNS: 25-50mg/kg daily
Ampicillin Sodium & Sulbactam Sodium 375 mg TabletJ01CR01961T1001XXA/KKTreatment of susceptible bacterial infectionsADULT: 375-750mg twice daily CHILDREN AND INFANTS: 25-50mg/kg/day in 2 divided doses, if ≥ 30kg use an adult dose
Ampicillin Sodium 1g & Sulbactam Sodium 500mg InjectionJ01CR01961P4002XXATreatment of susceptible bacterial infectionsADULT: 1.5 - 12 g/day in divided doses 6 - 8 hourly. Maximum: 4 g Sulbactam. CHILD: 150-300 mg/kg/day 6 - 8 hourly. Prophylaxis of surgical infections: 1.5 - 3 g at induction of anaesthesia. May be repeated 6 - 8 hourly. NEONATES: First week of life, 75mg/kg/day in divided doses every 12 hour
Ampicillin Sodium 500 mg & Sulbactam Sodium 250 mg InjectionJ01CR01961P4001XXATreatment of susceptible bacterial infectionsADULT: 1.5 - 12 g/day in divided doses 6 - 8 hourly. Maximum: 4 g Sulbactam per day. CHILD: 150-300mg/kg/day 6 - 8 hourly. Prophylaxis: 1.5 -3 g at induction of anaesthesia. May be repeated 6 - 8 hourly
Ampicillin Sodium 500 mg InjectionJ01CA01520P4001XXBTreatment of susceptible bacterial infections (non beta-lactamase-producing organisms); meningitis250 - 500 mg IM/IV every 4 - 6 hours. Maximum: 400 mg/kg/day. Meningitis: 2 g 6 hourly. CHILD: 150 mg/kg/daily IV in divided doses. Usual children dose less than 10 years, half adult dose
Ampicillin Trihydrate 125 mg/5 ml SuspensionJ01CA01012F2101XXBTreatment of susceptible bacterial infections (non beta-lactamase-producing organisms)CHILD: 50 - 100 mg/kg/day 4 times daily. Under 1 year: 62.5 - 125 mg 4 times daily, 1 - 10 years: 125 - 250 mg 4 times daily
Anastrozole 1 mg TabletL02BG03000T1001XXA*Treatment of hormone responsive metastatic or locally advanced breast cancer after failure of tamoxifen1 mg daily
Anidulafungin 100mg InjectionJ02AX06000P3001XXA*Treatment of invasive candidiasis, including candidemia in adults when intolerance or resistance to Amphotericin B or FluconazoleLoading dose of 200 mg on day 1, then 100 mg once daily thereafter for at least 14 days after the last positive culture.
Antazoline HCl, Tetrahydrozoline HCl and Benzalkonium Cloride Eye DropsS01GA52110D2001XXA/KKHay fever, conjunctivitis, allergic conjunctivitis, vernal keratoconjunctivitis and eczematosaADULT : Instill 1 drop, 3 - 4 times daily, into the lower eyelid. CHILD 2 - 12 years : Instill 1 drop daily or twice daily
Anti RhD Gamma Globulin 250 mcg/2 ml Injection (500 units=100 mcg)J06BB01000P3001XXBPrevention of Rh(D) sensitisation by IM injection to rhesus-negative woman after delivery of rhesus-positive infant50 - 100 mcg within 72 hours after incompatible blood transfusion: 25 mcg (125 units) per ml transfused blood, up to 1000 mcg
Antilymphocyte/Antithymocyte Immunoglobulin (from Horse) InjectionL04AA03000P3001XXA*i) To be used when conventional anti-rejection therapy is not successful ii) Treatment of aplastic anaemia not responding to oxymethalone after 3 months, in which there is persistent pancytopenia with repeated attacks of septicaemia and bleeding. iii) Severe aplastic anaemia with the following parameters: a) Granulocyte less than 0.5x109/L b) Platelet less than 20x109/L c) Reticulocyte less than 20x109/L iv) As a conditioning regime prior to transplant. v) Graft-versus-host disease treatment10 - 30 mg/kg body weight daily. Slow IV infusion (over at least 4 hours) diluted in 250 - 500 ml Normal Saline. For Graft versus host disease treatment:40 mg/kg/day
Antirabies Immunoglobulin (Human) 300 iu/2mlJ06BB05000P3001XXBTreatment of rabies, post-exposure20 iu/kg; half by IM and half by infiltration around the wound
Antithymocyte Immunoglobulin (from rabbit) InjectionL04AA04000P3001XXA*i)Prophylaxis of acute graft rejection ii)Treatment of acute graft rejection iii)Prophylaxis of acute and chronic graft versus host disease iv)Treatment of steroid-resistant, acute graft versus host disease v)Treatment of aplastic anemiai)1.0 - 1.5 mg/kg/day for 2 - 9 days after transplantation of a kidney, pancreas or liver, for 2 - 5 days after heart transplantation ii)1.5 mg/kg/day for 3 - 14 days iii)2.5 - 5.0 mg/kg/day for 4 days iv)2.5 - 5.0 mg/kg/day for 5 days v)2.5 - 3.5 mg/kg/day for 5 days
Antivenene Cobra InjectionJ06AA03000P3002XXBTreatment of patients who exhibit manifestations of systemic envenoming following a bite by Cobra (Naja kaouthia).Initial dose of 100ml of reconstituted antivenene given by slow intravenous infusion (2ml/min). Subsequent dose can be given every 12 hours according to the clinical symptoms. As product may differ from batches and manufacturer, it is strongly recommended to refer to the product insert on dosing recommendation.
Antivenene Pit Viper InjectionJ06AA03000P3001XXBTreatment of patients who exhibit manifestations of systemic envenoming following a bite by Malayan Pit Viper (Calloselasma rhodostoma).Initial dose of 30ml of reconstituted antivenene given by slow intravenous infusion (2ml/min). Subsequent dose can be given every 6 hours according to the clinical symptoms. As product may differ from batches and manufacturer, it is strongly recommended to refer to the product insert on dosing recommendation.
Antivenene Serum (Sea snake) 1000 units InjectionJ06AA03000P3003XXBTreatment of patients who exhibit manifestations of systemic envenoming following a bite by sea snake.1000 units by IV infusion over 1/2 to 1 hour. In severe cases 3000 -10000 units may be required
Antivenene Serum Snake polyvalent InjectionJ06AA03000P3004XXBTreatment of patients who exhibit manifestations of systemic envenoming following a bite by Indian Cobra (Naja naja),Common Krait (Bungarus caeruleus), Russell's Viper (Daboia russelli) and Saw-scaled Viper (Echis carinatus)Recommended initial dose is 20ml by intravenous infusion. The injection should be given very slowly as 5 minutes by direct slow intravenous route or 1hour by infusion. If symptoms continue, further doses are administered as required until symptoms completely disappear
Aprepitant 125 mg CapsuleA04AD12000C1002XXA*In combination with other antiemetic agents for prevention of delayed nausea and vomiting associated with initial and repeat course of highly emetogenic chemotherapy125 mg 1 hour prior to chemotherapy on Day 1. To be given as part of a 3-day regimen that includes a corticosteroid and a 5-HT3 antagonist
Aprepitant 80 mg CapsuleA04AD12000C1001XXA*In combination with other antiemetic agents for prevention of delayed nausea and vomitting associated with initial and repeat course of highly emetogenic chemotherapy80 mg once daily in the morning on Days 2 and Day 3. To be given as part of a 3-day regimen that includes a corticosteroid & a 5-HT3 antagonist
Aprotinin 10,000 KIU/ml InjectionB02AB01000P3001XXA*Only for Open Heart Surgery (extracorporeal circulation)All patients should receive a 1 ml IV test dose at least 10 minutes prior to loading dose. Initially 2 million KIU bolus followed by 2 million KIU in heart-lung machine followed by a slow infusion of 500,000 KIU/hr until end of surgery. CHILD: 20,000 KIU/kg/day
Aqueous CreamD02AX00000G1001XXC+Dry skinAs a soap or apply to the skin as an emollient cream
Aripiprazole 10mg TabletN05AX12000T1001XXA*i) Treatment of acute episodes of schizophrenia and for maintenance of clinical improvement during continuation therapy. ii) Treatment of acute manic episodes associated with bipolar I disorderSchizophrenia: 10 or 15 mg/day. Maintenance dose: 15 mg/day. Bipolar mania: Starting dose: 15 or 30 mg/day. Dose adjustment should occur at intervals of not less than 24 hour
Aripiprazole 15mg TabletN05AX12000T1002XXA*i) Treatment of acute episodes of schizophrenia and for maintenance of clinical improvement during continuation therapy. ii) Treatment of acute manic episodes associated with bipolar I disorderSchizophrenia: 10 or 15 mg/day. Maintenance dose: 15 mg/day. Bipolar mania: Starting dose: 15 or 30 mg/day. Dose adjustment should occur at intervals of not less than 24 hour
Arsenic Trioxide 1 mg/ml InjectionL01XX27550P3001XXA*Relapsed acute promyelocytic leukaemia (APML). To be prescribed by consultant haematologist onlyInduction : 0.15 mg/kg/day IV until bone marrow remission. Total induction dose ≤ 60 doses. Consolidation : 0.15 mg/kg/day IV for 25 doses in 5 weeks (5 days per week, followed by 2 days interruption; treatment should begin 3-6 weeks after completion of induction therapy).
Artemether 20mg + Lumefantrine 120mgP01BE52981T1001XXBAcute uncomplicated falciparum malariaADULT and CHILD over 12 years weighing over 35 kg : 4 tablets as a single dose at the time of initial diagnosis, again 4 tablets after 8 hours and then 4 tablets twice daily (morning and evening) on each of the following two days (total course comprises 24 tablets). INFANT and CHILD weighing 5 kg to less than 35 kg : A 6 dose regimen with 1 to 3 tablets per dose, depending on bodyweight
Artesunate 100 mg and Mefloquine HCI 220 mg TabletP01BF02000T1002XXATreatment of acute uncomplicated Plasmodium falciparummalaria, resulting either from P. falciparum mono-infection or mixed infection with P. vivax.Weight 5-8kg, Age 6-11 months, Dose: One tablet 25/55mg OD x 3 days Weight : 9-17kg, Age 1-6 years, Dose : Two tablet 25/55mg OD x 3 days Weight :18-29kg, Age 7-12 years, Dose :One tablet 100/220mg OD x 3 days Weight ≥30kg, Age ≥13 years, Dose:Two tablet 100/220mg OD x 3 days
Artesunate 25 mg and Mefloquine HCI 55 mg TabletP01BF02000T1001XXATreatment of acute uncomplicated Plasmodium falciparummalaria, resulting either from P. falciparum mono-infection or mixed infection with P. vivax.Weight 5-8kg, Age 6-11 months, Dose: One tablet 25/55mg OD x 3 days Weight : 9-17kg, Age 1-6 years, Dose : Two tablet 25/55mg OD x 3 days Weight :18-29kg, Age 7-12 years, Dose :One tablet 100/220mg OD x 3 days Weight ≥30kg, Age ≥13 years, Dose:Two tablet 100/220mg OD x 3 days
Artesunate 60 mg InjectionP01BE03000P3001XXATreatment of severe malaria caused by Plasmodium falciparum in adults and children2.4mg of artesunate/kg body weight, by intravenous (IV) or intramuscular (IM) injection, at 0, 12 and 24 hours, then once daily until oral treatment can be substituted. For adults and children with severe malaria or who are unable to tolerate oral medicines, artesunate 2.4 mg/kg body weight IV or IM given on admission (time = 0), then at 12 hrs and 24 hrs, then once a day for 5-7 days is the recommended treatment.
Ascorbic Acid 100 mg TabletA11GA01000T1002XXC+Vitamin C deficiencyADULT: 100-250 mg once or twice daily CHILD: 100 mg three times daily for one week followed by 100mg daily until symptoms abate.
Ascorbic Acid 500 mg TabletA11GA01000T1003XXC+Vitamin C deficiencyADULT: 100-250 mg once or twice daily CHILD: 100 mg three times daily for one week followed by 100mg daily until symptoms abate.
Ascorbic Acid 500 mg/2 ml InjectionA11GA01000P3001XXBFor prevention and treatment of scurvyTherapeutic: Not less than 250 mg daily in divided doses
Atenolol 100 mg TabletC07AB03000T1002XXBHypertension, angina pectoris, myocardial infarction and arrhythmiasHypertension and arrythmias; 50 - 100 mg daily, Angina; 100 mg daily, Myocardial infarction; individualised
Atenolol 50 mg TabletC07AB03000T1001XXBHypertension, angina pectoris, myocardial infarction and arrhythmiasHypertension and arrythmias; 50 - 100 mg daily, Angina; 100 mg daily, Myocardial infarction; individualised
Atomoxetine HCl 10 mg CapsuleN06BA09110C1001XXA*Attention deficit hyperactivity disorder (ADHD) in children 6 years and older who do not respond to methylphenidate or who have intolerable effects or have tics. Diagnosis should be made according to DSM IV criteria or the guidelines in ICD-10CHILD and ADOLESCENTS up to 70 kg: Initially 0.5 mg/kg/day for at least 7 days, then increased according to response. Maintenance: 1.2 mg/kg/day. ADULTS and ADOLESCENTS more than 70 kg: Initially 40 mg/day for at least 7 days then increased according to response. Maintenance: 80 mg/day. Max 100 mg/ day
Atomoxetine HCl 18 mg CapsuleN06BA09110C1002XXA*Attention deficit hyperactivity disorder (ADHD) in children 6 years and older who do not respond to methylphenidate or who have intolerable effects or have tics. Diagnosis should be made according to DSM IV criteria or the guidelines in ICD-10CHILD and ADOLESCENTS up to 70 kg: Initially 0.5 mg/kg/day for at least 7 days, then increased according to response. Maintenance: 1.2 mg/kg/day. ADULTS and ADOLESCENTS more than 70 kg: Initially 40 mg/day for at least 7 days then increased according to response. Maintenance: 80 mg/day. Max 100 mg/ day
Atomoxetine HCl 25 mg CapsuleN06BA09110C1003XXA*Attention deficit hyperactivity disorder (ADHD) in children 6 years and older who do not respond to methylphenidate or who have intolerable effects or have tics. Diagnosis should be made according to DSM IV criteria or the guidelines in ICD-10CHILD and ADOLESCENTS up to 70 kg: Initially 0.5 mg/kg/day for at least 7 days, then increased according to response. Maintenance: 1.2 mg/kg/day. ADULTS and ADOLESCENTS more than 70 kg: Initially 40 mg/day for at least 7 days then increased according to response. Maintenance: 80 mg/day. Max 100 mg/ day
Atomoxetine HCl 40 mg CapsuleN06BA09110C1004XXA*Attention deficit hyperactivity disorder (ADHD) in children 6 years and older who do not respond to methylphenidate or who have intolerable effects or have tics. Diagnosis should be made according to DSM IV criteria or the guidelines in ICD-10CHILD and ADOLESCENTS up to 70 kg: Initially 0.5 mg/kg/day for at least 7 days, then increased according to response. Maintenance: 1.2 mg/kg/day. ADULTS and ADOLESCENTS more than 70 kg: Initially 40 mg/day for at least 7 days then increased according to response. Maintenance: 80 mg/day. Max 100 mg/ day
Atomoxetine HCl 60mg CapsuleN06BA09110C1005XXA*Attention deficit hyperactivity disorder (ADHD) in children 6 years and older who do not respond to methylphenidate or who have intolerable effects or have tics. Diagnosis should be made according to DSM IV criteria or the guidelines in ICD-10CHILD and ADOLESCENTS up to 70 kg: Initially 0.5 mg/kg/day for at least 7 days, then increased according to response. Maintenance: 1.2 mg/kg/day. ADULTS and ADOLESCENTS more than 70 kg: Initially 40 mg/day for at least 7 days then increased according to response. Maintenance: 80 mg/day. Max 100 mg/ day
Atorvastatin 20 mg TabletC10AA05000T1002XXA*Hypercholesterolaemia and coronary heart disease intolerant or not responsive to other forms of therapy10 mg once daily. Maximum: 80 mg daily
Atorvastatin 40 mg TabletC10AA05000T1001XXA*Hypercholesterolaemia and coronary heart disease intolerant or not responsive to other forms of therapy10 mg once daily. Maximum: 80 mg daily
Atorvastatin 80 mg TabletC10AA05000T1004XXA*Hypercholesterolaemia and coronary heart disease intolerant or not responsive to other forms of therapy10 mg once daily. Maximum: 80 mg daily
Atosiban 7.5 mg/ml InjectionG02CX01122P3001XXA*To delay imminent preterm birth in pregnant women with i)Regular uterine contractions of at least 30 seconds duration at a rate of ≥ 4 per 30 minutes ii) A cervical dilation of 1 to 3 cm (0 - 3 nulliparas) and effacement of ≥ 50% iii) Age ≥ 18 years iv) A gestational age from 28 until 33 completed weeks v) A normal foetal heart rate.Initial intravenous bolus dose of 6.75mg (using 7.5mg/ml solution for injection). Immediately followed by a continuous high dose infusion (loading infusion 300 mcg/min using 7.5mg/ml concentrate for solution for infusion) during three hours, followed by lower infusion of 100mcg/min up to 45 hours. Duration of treatment should not exceed 48 hours. Total dose given during a full course should not exceed 330mg of the active substance.
Atracurium Besylate 10 mg /ml in 2.5 ml InjectionM03AC04197P3001XXA*Muscle relaxant in general anaesthesia, Endotracheal intubation, Aid controlled ventilation.Adult & childn >2 mth 0.3-0.6 mg/kg IV. Endotracheal intubation dose: 0.5-0.6 mg/kg. Supplementary dose: 0.1-0.2 mg/kg as required. Continuous infusion rates of 0.3-0.6 mg/kg/hr to maintain neuromuscular block during long surgical procedure.
Atracurium Besylate 10 mg /ml in 5 ml InjectionM03AC04197P3002XXA*Muscle relaxant in general anaesthesia, Endotracheal intubation, Aid controlled ventilation.Adult & childn >2 mth 0.3-0.6 mg/kg IV. Endotracheal intubation dose: 0.5-0.6 mg/kg. Supplementary dose: 0.1-0.2 mg/kg as required. Continuous infusion rates of 0.3-0.6 mg/kg/hr to maintain neuromuscular block during long surgical procedure.
Atropine Sulphate 0.3%, Cocaine HCl 1.7%, Adrenaline Acid Tartrate 0.03% Mydriatic InjectionS01F000183P3001XXASubconjunctival injection to dilate pupils resistant to topical mydriatics1 - 2 drops
Atropine Sulphate 1% Eye DropsS01FA01183D2001XXBDetermination of refraction, strabismus, iritis and iridocyclitis, after extra or intracapsular extraction of lensPREOPERATIVE MYDRIASIS : one drop of a 1% solution supplemented with one drop of 2.5 or 10% phenylephrine prior to surgery. ANTERIOR UVEITIS or POSTOPERATIVE MYDRIASIS : one drop of a 1% or 2% solution up to 3 times a day
Atropine Sulphate 1mg/ml InjectionA03BA01183P3001XXBi) Reduce vagal inhibition,salivary and bronchiol secretion in anaesthesia ii) Reversal of excessive bradycardia iii) Reversal of effect of competitive muscle relaxants iv) Overdosage with other compounds having muscarinic action v) Organophosphate poisoningi) Adult: 300-600 mcg IM/SC 30-60 minutes before anaesthesia. Alternatively, 300-600 mcg IV immediately before induction of anaesthesia. Child: >20 kg: 300-600 mcg; 12-16 kg: 300 mcg; 7-9 kg: 200 mcg; >3 kg: 100 mcg. Doses to be given via IM/SC admin 30-60 minutes before anaesthesia.ii) Adult: 500 mcg every 3-5 minutes. Total: 3 mg. Max Dosage: 0.04 mg/kg body weight.iii) Adult 0.6-1.2 mg before or with anticholinesterase iv) Adult: 0.6-1 mg IV/IM/SC, repeated every 2 hr. v) Adult: 2 mg IV/IM, every 10-30 minutes until muscarinic effects disappear or atropine toxicity appears. In severe cases, dose can be given as often as every 5 minutes. In moderate to severe poisoning, a state of atropinisation is maintained for at least 2 days and continued for as long as symptoms are present. Child: 20 mcg/kg given every 5-10 minutes.
Azacitidine Powder for suspension for injection 100mg/vialL01BC07000P4001XXA*First line therapy for intermediate-2 and high risk MDS, CMMOL with 10-29% blasts with no transplant option and elderly AML with 20-30% blasts and multilineage dysplasia.Recommended starting dose for the first treatment cycle, for all patients regardless of baseline haematology laboratory values, is 75mg/m2 of body surface area. Injected subcutaneously. Daily for 7 days, followed by a rest period of 21 days (28 day treatment cycle)
Azathioprine 50 mg TabletL04AX01000T1001XXAi) Prophylaxis of rejection in organ and tissue transplant ii) Auto-immune diseases iii) Rheumatoid arthritisi) Adult: 1-5 mg/kg/day. Adjust dose according to clinical response and haematological tolerance. Dose may also be given via IV administration. ii) Adult: 1-3 mg/kg/day. Discontinue treatment if there is no improvement after 12 week. iii) Adult: Initially, 1 mg/kg/day given in 1-2 divided doses for 6-8 week, may increase by 0.5 mg/kg every 4 week until response or up to 2.5 mg/kg/day. Maintenance: Reduce dose gradually to achieve the lowest effective dose.
Azelaic Acid 20% CreamD10AX03000G1001XXA*Acne vulgarisApply twice daily (sensitive skin, once daily for 1st week). Treatment should not exceed 6 months
Azithromycin 200 mg/5 ml GranulesJ01FA10011F1001XXA*Treatment of complicated respiratory tract infections not responding to standard macrolidesCHILD 36 - 45 kg: 400 mg, 26 - 35 kg: 300mg, 15 - 25 kg 200 mg, less than 15 kg: 10 mg/kg. To be taken daily for 3 days or to be taken as a single dose on day 1, then half the daily dose on days 2 - 5
Azithromycin 250 mg TabletJ01FA10011T1001XXA*i) Treatment of complicated respiratory tract infection not responding to standard macrolides ii) Adult treatment of uncomplicated genital infections due to Chlamydia trichomatis or susceptible Neisseria gonorrhoea iii) Prophylaxis against Mycobacterium avium complex in patients with advanced HIVi) 500 mg daily for 3 days ii) 1 g as a single dose iii) 1 g weekly
Azithromycin 500 mg InjectionJ01FA10011P4001XXA*Only for treatment of severe atypical pneumonia500 mg IV as a single daily dose for a minimum of two days followed by 500 mg oral dose as a single daily dose to complete a 7 - 10 days course
Bacampicillin 400 mg TabletJ01CA06000T1001XXBInfections caused by ampicillin-sensitive gram positive& gram negative microorganismsADULT: 400 mg twice daily. Severe infection: 800 mg twice daily. CHILD more than 25 kg: 12.5 - 25 mg/kg 12 hourly
Baclofen 10 mg TabletM03BX01000T1001XXBSpasticity of the skeletal muscleADULT: 5 mg 3 times daily. Max: 80 mg daily. CHILD: 0.75 - 2 mg/kg daily (more than 10 years, maximum: 2.5 mg/kg daily)
Balanced Salt SolutionB05CB10907L5001XXAFor irrigation during ocular surgeryIrrigate as directed
Balanced Salt Solution PLUS (fortified with sodium bicarbonate, glucose & glutathione)B05CB10905L5001XXAFor irrigation during intraocular surgery especially in patients with poor cornea endothelium and poorly controlled diabetesIrrigate as directed
Barium Sulphate SuspensionV08BA01183L8001XXBFor x-ray examination of the alimentary tract: i) Oesophagus ii) Stomach and duodenum iii) Coloni) Up to 150 ml of a 50% - 200% suspension orally ii) Up to 300 ml of a 30% - 200% suspension orally iii) Up to 2 litre of a 30% - 200% suspension orally
Basiliximab 20 mg InjectionL04AC02000P3001XXA*Prophylaxis of acute organ rejection in de novo renal transplantation.ADULT & CHILD 2 years and above & 35 kg or more:20 mg /dose. 2 years or more but less than 35kg:10 mg/dose. First dose given within 2 hours before start of transplantation and second dose 4th day after transplant
BCG 81 mg/3 mlL03AX03000P3001XXA*Superficial bladder cancer81 mg intravesically once weekly for 6 weeks, followed by treatments at 3, 6, 12, 18, and 24 months after initial treatment
BCG Vaccine Freeze-Dried InjectionJ07AN01000P4001XXC+For the prevention of tuberculosis0.1 ml by intradermal injection. INFANT under 12 months: 0.05 ml
Beclomethasone Dipropionate 100 mcg/dose InhalerR03BA01133A2101XXBProphylaxis of asthma especially if not fully controlled by bronchodilatorsAdults: The usual maintenance dose is one to two inhalations (200-400 mcg) twice daily.If needed,the dose can be increased up to 1600 mcg/day divided in two to four doses : Children 6-12 years old: One inhalation (200 mcg) two times daily and dose may be increased up to 800 mcg/day in divided two to four doses if necessary.
Beclomethasone dipropionate 100mcg and formoterol fumarate dehydrate 6mcg pressurized inhalation solutionR03AK07986A2101XXA/KKRegular treatment of asthma where use of a combination product (inhaled corticosteroid and long-acting beta2 agonist) is appropriate in: i.Patients not adequately controlled with inhaled corticosteroids and ?as needed? inhaled short-acting beta2 agonist or ii.Patients already adequately controlled on both inhaled corticosteroids and long-acting beta2-agonistsDose recommended for patients 18 years and above. One or two inhalations twice daily. The maximum daily dose is 4 inhalations daily. No need to adjust dose in elderly patients. There are no data available for use in patients with hepatic or renal impairment.
Beclomethasone Dipropionate 200 mcg/dose InhalerR03BA01133A2102XXA/KKProphylaxis of asthma especially if not fully controlled by bronchodilatorsADULT : 1 - 2 puff twice daily. May increase to 2 puff 2 - 4 times daily CHILD : 1 puff twice daily. May increase to 1 puff 2 - 4 times daily
Beclomethasone Dipropionate 50 mcg/dose Nasal SprayR01AD01133A4101XXA/KKProphylaxis and treatment of perennial and seasonal allergic rhinitis and vasomotor rhinitisADULT and CHILD over 6 years : Apply 100 mcg (2 sprays) into each nostril twice daily or 50 mcg (1 spray) into each nostril 3 - 4 times/day. Maximum 400 mcg daily (8 sprays). When symptoms controlled, reduce dose to 50 mcg (1 spray) into each nostril twice daily
Benzalkonium 0.01% CreamD08AJ01000G1001XXBPrevention and treatment of nappy rashWash and dry baby's bottom. Apply by spreading the cream evenly paying particular attention to the fold of the skin, after every nappy change
Benzalkonium Chloride Disinfectant SolutionV07AV00100L9908XXCLow level disinfectant suitable for general cleaning and disinfection of hard surfaceCleaning purposes: Dilute 1 in 10. Disinfection, use undiluted
Benzathine Penicillin 2.4 MIU (1.8 g) InjectionJ01CE08702P4001XXBi) Treatment of mild to moderately severe infections due to Penicillin G-sensitive organisms ii) Treatment of syphillisi) ADULT: 1.2 mega units IM ii) For syphillis: 2.4 mega units weekly for 1 - 3 weeks
Benzhexol 2 mg TabletN04AA01110T1001XXBi) Parkinson's disease ii) Drug induced parkinsonism iii) DystoniasADULT: Initially 1 mg daily, increase gradually. Maintenance: 5 - 15 mg daily in 3 - 4 divided doses. (Max 15mg/day)
Benzoic Acid Compound Half Strength (Paed) OintmentD01AE12952G5001XXCTinea infections of the skinApply sparingly to affected area once or twice daily
Benzoic Acid Compound OintmentD01AE12952G5002XXCTinea infections of thickened skin of palms and solesApply sparingly to affected area once or twice daily
Benzoin Compound TinctureD08AX00000L5001XXCInfected skin, lesions, cuts, abrasions, wounds and burnsApply undiluted to the skin 1 or 2 times daily. Duration of therapy, may be weeks to months depending on the infection being treated
Benzoyl Peroxide 10% GelD10AE01241G3002XXBMild to moderate acne vulgarisApply 1-2 times daily preferably after washing with soap and water
Benzoyl Peroxide 5% GelD10AE01241G3001XXBMild to moderate acne vulgarisApply 1-2 times daily preferably after washing with soap and water
Benzydamine HCl 0.15% SolutionA01AD02110M2001XXBFor relief of painful condition of the oral cavityUsed as a 30 seconds gargle or rinse, undiluted. ADULT 15 ml. CHILD less 12 years 5-15 ml. Uninterrupted treatment should not be more than 7 days
Benzydamine Hydrochloride 3.0 mg/ml throat sprayA01AD02110A4201XXA*Temporary relief of painful conditions of the mouth and throat including tonsillitis, sore throat, radiation mucositis, aphthous ulcers, pharyngitis, swelling, redness, inflammatory conditions, post-orosurgical and periodontal procedures. (For pediatric and otorhinolaringology use. Restrict to patients who are not able to gargle)ADULTS and CHILDREN OVER 12 YEARS: 2-4 sprays (1-2mg) directly onto the sore/inflamed area and swallow gently. Repeat every 1 1/2 to 3 hours as necessary. CHILDREN 6-12 YEARS: 2 sprays (1mg) directly onto sore/ inflamed area and swallow gently. Repeat every 11/2 to 3 hours as necessary. CHILDREN UNDER 6 YEARS: Not recommended. Uninterrupted treatment should not exceed seven days, unless under medical supervision
Benzyl Benzoate 12.5 % Emulsion (Child)P03AX01252L2001XXCScabies and pediculosis, for child under 2 yearsAfter bath, apply over the whole body, neck down and leave on for 24 hours then wash off. Reapply for another 24 hours, the first repeat application should be within 5 days of the initial application, a third application may be required in some cases
Benzyl Benzoate 25 % Emulsion (Adult)P03AX01000L2002XXC+Scabies and pediculosisAfter bath, apply over the whole body, neck down and leave on for 24 hours then wash off. Reapply for another 24 hours, the first repeat application should be within 5 days of the initial application, a third application may be required in some cases
Benzylpenicillin 1 mega unit (600 mg) InjectionJ01CE01702P4001XXBi) Infections caused by susceptible organisms ii) Infective endocarditisi) Adult: 600mg - 3600mg (1 - 6 mega units) daily, divided into 4 to 6 doses. Higher doses (24 mega units) in divided doses may be given in serious infections such as meningitis. Child 1 month to 12 years old: 100mg/kg/day in 4 divided doses, not exceeding 4g/day; Infants 1 -4 weeks: 75mg/kg/day in 3 divided doses; Newborn Infants: 50mg/kg/day in 2 divided doses ii)7.2 to 12g (12 - 20 mega units) maybe given daily in divided doses
Benzylpenicillin 10,000 units/ml Eye DropsS01AA14702D2002XXBEye infection1-2 drops every 15 minutes or accordingly to needs of the patient
Benzylpenicillin 2,500 units/ml (1.5 mg/ml) Eye DropsS01AA14702D2001XXBEye infection1-2 drops every 15 minutes or accordingly to needs of the patient
Benzylpenicillin 5 mega units (3 g) InjectionJ01CE01702P4002XXBi) Infections caused by susceptible organisms ii) Infective endocarditisi) ADULT: 600 - 1200 mg IM 4 times daily, increased if necessary in more serious infections. CHILD: 50 - 100 mg/kg body weight daily IV in 2 - 4 divided doses ii) ADULT: 7.2 g daily by slow IV infusion in 6 divided doses
Beractant Intratracheal Suspension (200 mg phospholipids in 8 ml vial)R07AA02000L8001XXA*Treatment of newborn baby with birth weight of 700 g or greater undergoing mechanical ventilation for respiratory distress syndrome, whose heart rate and arterial oxygenation are continuously monitored100 mg/kg (4 ml/kg) body weight intratracheally up to 4 doses in 1st 48 hr. Doses should not be given more frequently than 6 hrly. To be administered as soon as possible.
Betahistine Dihydrochloride 16 mg TabletN07CA01110T1002XXA/KKVertigo, tinnitus and hearing loss associated with Meniere's diseaseGiven in doses of 8 to 16 mg orally 3 times daily (total 24 to 48 mg/day) preferably with food. CHILD not recommended
Betahistine Dihydrochloride 24 mg TabletN07CA01110T1003XXA*Vertigo, tinnitus and hearing loss associated with Meniere's disease24-48mg in divided doses daily
Betahistine Dihydrochloride 8 mg TabletN07CA01110T1001XXA/KKVertigo, tinnitus and hearing loss associated with Meniere's diseaseGiven in doses of 8 to 16 mg orally 3 times daily (total 24 to 48 mg/day) preferably with food. CHILD not recommended
Betamethasone 0.5 mg TabletH02AB01000T1001XXASuppression of inflammatory and allergic disorders, congenital adrenal hyperplasia, cerebral oedema0.5 - 9 mg daily in divided doses. CHILD: 0.5 - 7.5 mg/m2/day divided every 6 - 12 hours
Betamethasone 17-Valerate 0.01-0.05% CreamD07AC01256G1001XXBEczemas, prurigo nodularis, limited psoriasis in appropriate in sitesApply sparingly to affected area 2 - 3 times daily then reduced to once daily when improvement occurs
Betamethasone 17-Valerate 0.01-0.05% OintmentD07AC01256G5001XXBEczema, prurigo nodularis, limited psoriasis in appropriate in sitesApply sparingly to affected area 2 - 3 times daily then reduced to once daily when improvement occurs
Betamethasone 17-Valerate 0.1% CreamD07AC01256G1002XXAEczemas, prurigo nodularis, psoriasis (excluding widespread plaque psoriasis)Apply sparingly to affected area 2 - 3 times daily then reduced to once daily when improvement occurs
Betamethasone 17-Valerate 0.1% OintmentD07AC01256G5002XXAEczema, prurigo nodularis, psoriasis (excluding widespread plaque psoriasis)A small quantity is applied lightly to the affected area two or three times daily until improvement by applying once a day or even less often. Occlusion of the area under treatment with plastic film may be used to enhance the corticosteroid activity in the more resistant lesions. Overnight occlusion only is usually adequate to bring about a satisfactory response in such cases thereafter, improvement can usually be maintained by regular application without occlusion
Betamethasone Disodium Phoshate 0.1% Ear DropsS03BA03162D1001XXBNon-infected inflammatory conditionsApply 2 - 3 drops every 2 - 3 hours, reduce frequency when relief obtained
Betamethasone Disodium Phoshate 0.5% Ear DropsS03BA03162D1002XXBNon-infected inflammatory conditionsApply 2 - 3 drops every 2 - 3 hours, reduce frequency when relief obtained
Betamethasone Disodium Phosphate 0.1% Eye DropsS01BA06162D2001XXANon-infected inflammatory conditions of the eyes1 - 2 drops every 1 - 2 hours until controlled then reduce frequency
Betamethasone Disodium Phosphate 0.1% Eye OintmentS01BA06162G5101XXANon-infected inflammatory conditions of the eyes2 - 4 times daily or at night when used with eye drops
Betamethasone Disodium Phosphate and Neomycin Sulphate 0.5% Ear DropsS03CA06991D1001XXBAllergic dermatosis in the earApply 2 - 3 drops 3 - 4 times daily, reduce frequency when relief obtained
Betamethasone Disodium Phosphate and Neomycin Sulphate Eye DropsS01CA05991D2001XXAInfected inflammatory conditions of the eyes2 - 3 drops every 2 - 3 hours
Betamethasone Sodium Phosphate 4 mg/ml InjectionH02AB01162P3001XXBPre-operative and in serious trauma or illness, shock, as adjunctive therapy in rheumatoid disorders, ocular, dermatologic and respiratory allergic and inflammatory statesUsual intravenous doses are up to 9 mg/day of the sodium phosphate salt only. CHILD: IM: 0.5 - 7.7 mg base/m2/day divided every 6 - 12 hours. ADOLESCENT and ADULT, IM: 0.6 - 9 mg divided every 12 - 24 hours
Betaxolol 0.25% Eye SuspensionS01ED02110D2001XXAChronic open-angle glaucoma, ocular hypertensionOne to two drops in the affected eye(s) twice daily
Bicalutamide 50 mg TabletL02BB03000T1001XXA*Advanced prostate cancer in combination with LHRH analogue therapy or surgical castration.50 mg once daily. (morning or evening), with or without food. Take on the same time each day. Adult: When used with gonadorelin analogue: Usual dose: 50 mg once daily. May be started with or at least 3 days before starting gonadorelin analogue therapy.
Bimatoprost 0.03% Ophthalmic SolutionS01EE03000D2001XXA*Lowering of intraocular pressure in patients with open-angle glaucoma and ocular hypertension who are intolerant of other intraocular pressure lowering medications or insufficiently responsive to another intraocular pressure lowering medication1 drop in affected eye(s) once daily at evening
Bisacodyl 10 mg SuppositoryA06AB02000S2002XXCi) Constipation ii) Bowel preparation for radiological procedures and surgeryi) ADULT and CHILD over 10 years: 10 mg, CHILD less than 10 years 5 mg insert rectally ii) ADULT 10-20 mg, CHILD over 4 years 5 mg the following morning before procedures insert rectally
Bisacodyl 5 mg SuppositoryA06AB02000S2001XXCi) Constipation ii) Bowel preparation for radiological procedures and surgeryi) ADULT and CHILD over 10 years: 10 mg, CHILD less than 10 years 5 mg insert rectally ii) ADULT 10-20 mg, CHILD over 4 years 5 mg the following morning before procedures insert rectally
Bisacodyl 5 mg TabletA06AB02000T1001XXCi) Constipation ii) Bowel preparation for radiological procedures and surgeryi) ADULT and CHILD over 10 years 5-10 mg, CHILD 4-10 years 5 mg. To be taken at night for effect on the following morning ii) ADULT 10-20 mg the night before procedures, CHILD over 4 years 5 mg the night before procedures
Bismuth Subgallate and Benzyl Benzoate SuppositoryC05AX02931S2001XXCFor relief of pruritus, burning and soreness in patients with haemorrhoids and perianal conditionsInsert 1 suppository night and morning after bowel movements; do not use for longer than 7 days
Bismuth Subnitrate, Iodoform and Liquid Paraffin PasteR01AX30984G6001XXBAs a mild antiseptic for wounds and abscesses. Sterile gauze impregnated with paste for packing cavities after otorhinological surgeryAs directed for local application
Bisoprolol Fumarate 2.5 mg TabletC07AB07000T1001XXBTreatment of stable moderate to severe congestive cardiac failure in addition to ACEI's and diuretics1.25 mg once daily to 5 - 10 mg daily
Bisoprolol Fumarate 5 mg TabletC07AB07000T1002XXBTreatment of stable moderate to severe congestive cardiac failure in addition to ACEI's and diuretics1.25 mg once daily to 5 - 10 mg daily
Bleomycin HCl 15 mg InjectionL01DC01110P4001XXASquamous cell carcinoma, germ cell tumours, lymphomas. Routes: SC, IM, IV (either as bolus or as infusion over 24 hours), intra-arterial, intra-pleural15 - 30 mg weekly in divided doses or 10 - 20 mg/m2 once or twice weekly or 10 mg/m2 slow bolus in 15 minutes D1 and D15. Total dosage:should not exceed 300 mg. CHILD: 10 - 15 mg/m2 over 6 hours every 3 - 4 weeks
Boric Acid with Spirit 2% w/v Ear DropsS02AA03000D1001XXCPerforated eardrum3 drops instilled into affected ear 3 - 4 times daily
Bortezomib 3.5 mg InjectionL01XX32000P3001XXA*Treatment of multiple myeloma in patient who have received at least one prior therapy1.3 mg/ m2/dose given as IV bolus injection twice weekly for two weeks (days 1, 4, 8, and 11) followed by a 10- day rest period (days 12-21). At least 3 days should elapse between consecutive doses of bortezomib
Bosentan 125 mg tabletC02KX01000T1001XXA*For the treatment of pulmonary arterial hypertension (PAH) in patients with WHO Class III or IV symptoms, to improve exercise ability and decrease the rate of clinical worsening (To be used by those who are trained and specialized in treating and managing PAH)Initially 62.5 mg bd for 4 weeks, then increase to the maintenance dose of 125 mg bd
Brimonidine Tartrate 0.15% OphthalmicS01EA05123D2001XXA*Lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension1 drop in the affected eye(s) 3 times daily
Bromazepam 3 mg TabletN05BA08000T1002XXAAnxiety disordersAdult: Initially, 6-18 mg daily in divided doses. Doses up to 60 mg daily have been used. Elderly: Max initial dose: 3 mg daily
Bromhexine HCl 4 mg/2 ml InjectionR05CB02110P3001XXASecretolytic therapy in acute and chronic bronchopulmonary diseases associated with abnormal mucous secretion and impaired mucous transport4 to 8 mg SC, IM or IV 2 - 3 times daily (maximum 24mg/ day). Elderly: Max initial dose: 3 mg daily.
Bromhexine HCl 4 mg/5 ml ElixirR05CB02110L1001XXBSecretolytic therapy in acute and chronic bronchopulmonary diseases associated with abnormal mucous secretion and impaired mucous transport1) Adults :10 ml three times a day.Can increase up to 15 ml four times a day. 2)Children 5 to 12 years : 5 ml four times a day 3)Children 2 to 5 years: 5 ml two times a day
Bromhexine HCl 8 mg TabletR05CB02110T1001XXBSecretolytic therapy in acute and chronic bronchopulmonary diseases associated with abnormal mucous secretion and impaired mucous transportADULT and CHILD more than 12 years : 8 mg 3 times daily, 6 - 12 years : 4 mg 3 times daily, 2 - 6 years : 4 mg 2 times daily
Bromocriptine Mesilate 10 mg TabletG02CB01196T1003XXA/KKi) Hypogonadism or Galactorrhoea ii) Acromegalyi) Initially 1 - 1.25 mg at bedtime increased gradually, usual dose: 7.5 mg daily in divided doses. Max 30 mg daily ii) 1.25 - 2.5 mg at bedtime for 3 days and may be increased by 1.25 - 2.5 mg every 3 - 7 days up to 30 mg a day in divided doses
Bromocriptine Mesilate 2.5 mg TabletG02CB01196T1001XXA/KKi) Hypogonadism or Galactorrhoea ii) Acromegalyi) Initially 1 - 1.25 mg at bedtime increased gradually, usual dose: 7.5 mg daily in divided doses. Max 30 mg daily ii) 1.25 - 2.5 mg at bedtime for 3 days and may be increased by 1.25 - 2.5 mg every 3 - 7 days up to 30 mg a day in divided doses
Bromocriptine Mesilate 5 mg TabletG02CB01196T1002XXA/KKi) Hypogonadism or Galactorrhoea ii) Acromegalyi) Initially 1 - 1.25 mg at bedtime increased gradually, usual dose: 7.5 mg daily in divided doses. Max 30 mg daily ii) 1.25 - 2.5 mg at bedtime for 3 days and may be increased by 1.25 - 2.5 mg every 3 - 7 days up to 30 mg a day in divided doses
Budesonide 1 mg/2 ml Nebuliser SolutionR03BA02000A3002XXBMaintenance treatment of asthma as prophylactic therapy especially if not fully controlled by bronchodilatorsADULT : Initially 1 - 2 mg twice daily. CHILD 3 months - 12 years of age : 500 mcg - 1 mg. Maintenance dose : half of the above doses
Budesonide 100 mcg/dose IInhalerR03BA02000A2101XXBMaintenance treatment of asthma as prophylactic therapy especially if not fully controlled by bronchodilatorsADULT : 200 - 1600 mcg daily in 2 - 4 divided doses. Maintenance with twice daily dosing. CHILD more than 7 years 200 - 800 mcg, 2 - 7 years 200 - 400 mcg. To be taken orally in 2 - 4 divided doses
Budesonide 160 mcg and Formoterol 4.5 mcg InhalationR03AKO7989A2101XXA/KKi)Regular treatment of asthma where use of a combination (inhaled corticosteroid & long-acting β2-agonist) is appropriate. ii) Symptomatic treatment of patients with severe COPD (FEV1<50% predicted normal) & a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators.Asthma Maintenance therapy Adult ≥18 yr 160 mcg to 320 mcg bd. Some patients may require up to a max of 640 mcg bd. Adolescent 12-17 yr 160 mcg to 320 mcg bd. Childn 6-11 yr 160 mcg bd, <6 yr Not recommended. Maintenance & relief Adult ≥18 yr 320 mcg/day either as 160 mcg bd or 320 mcg either morning or evening. For some patients a maintenance dose of 320 mcg bd may be appropriate. Patients should take 160 mcg additional inhalation as needed in response to symptoms. If symptoms persist after a few minutes, an additional inhalation should be taken. Not more than 960 mcg should be taken on any single occasion. A total daily dose of more than 1280 mcg is not normally needed, however a total daily dose of up to 1920 mcg could be used for a limited period. Patients using more than 1280 mcg daily should seek medical advice, should be reassessed & their maintenance therapy reconsidered. Childn & adolescent <18 yr Not recommended. COPD Adult ≥18 yr 320 mcg bd.
Budesonide 200 mcg/dose InhalationR03BA02000A2102XXBMaintenance treatment of asthma as prophylactic therapy especially if not fully controlled by bronchodilatorsADULT : 200 - 1600 mcg daily in 2 - 4 divided doses. Maintenance with twice daily dosing. CHILD more than 7 years 200 - 800 mcg, 2 - 7 years 200 - 400 mcg. To be taken orally in 2 - 4 divided doses
Budesonide 320 mcg and Formoterol 9 mcg InhalationR03AK07989A2102XXA/KKi) Regular treatment of asthma where use of a combination (inhaled corticosteroid & long-acting β2-agonist) is appropriate. ii) Symptomatic treatment of patients with severe COPD (FEV1<50% predicted normal) & a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators.Asthma; Maintenance therapy: Adult ≥18 yr 160 mcg to 320 mcg bd. Some patients may require up to a max of 640 mcg bd. Adolescent 12-17 yr 160 mcg to 320 mcg bd. Childn 6-11 yr 160 mcg bd, <6 yr Not recommended. Maintenance & relief: Adult ≥18 yr 320 mcg/day either as 160 mcg bd or 320 mcg either morning or evening. For some patients a maintenance dose of 320 mcg bd may be appropriate. Patients should take 160 mcg additional inhalation as needed in response to symptoms. If symptoms persist after a few minutes, an additional inhalation should be taken. Not more than 960 mcg should be taken on any single occasion. A total daily dose of more than 1280 mcg is not normally needed, however a total daily dose of up to 1920 mcg could be used for a limited period. Patients using more than 1280 mcg daily should seek medical advice, should be reassessed & their maintenance therapy reconsidered. Children & adolescent less than 18 yr: Not recommended. COPD; Adult more than or equal to 18 yr: 320 mcg bd.
Budesonide 500 mcg/2 ml Nebuliser SolutionR03BA02000A3001XXBMaintenance treatment of asthma as prophylactic therapy especially if not fully controlled by bronchodilatorsADULT : Initially 1 - 2 mg twice daily. CHILD 3 months - 12 years of age : 500 mcg - 1 mg. Maintenance dose : half of the above doses
Budesonide 64mcg Nasal SprayR01AD05000A4103XXASeasonal allergic, perennial rhinitis and nasal polyposisADULT and CHILD 6 years and older. Rhinitis : 2 spray into each nostril once daily in the morning or 1 spray into each nostril twice daily. Nasal polyps : 2 spray twice daily
Bumetanide 0.5 mg/ml InjectionC03CA02000P3001XXA*Oedema used in furosemide allergic patientIV injection: 1 - 2 mg repeated after 20 mins. IV infusion: 2 - 5 mg over 30 - 60 mins
Bumetanide 1 mg TabletC03CA02000T1001XXA*Oedema used in furosemide allergic patient1 mg in the early evening. Up to 5 mg daily in severe cases
Bupivacaine 0.125% Epidural InjectionN01BB01110P3004XXAEpidural analgesia for postoperative pain relief.Infuse at 6 - 15 ml/hour. Not to exceed 2 mg/kg in a single dose.
Bupivacaine 0.5 % Heavy InjectionN01BB01110P3003XXAUsed for spinal anaesthesiaADULT: 2 - 4 ml. Not to exceed 2 mg/kg in a single dose
Bupivacaine 0.5 % InjectionN01BB01110P3002XXBFor peripheral sympathetic nerve and epidural (excluding caudal) anaesthesia and obstetrics anaesthesiaRegional nerve block or epidural block: 15 - 30 ml. Nerve block of finger or toe: 2 - 6 ml. Maximum: 2 mg/kg body weight in any 4 hours period, equivalent to 25 - 30 ml in adults of average weight
Bupivacaine 0.5 % with Adrenaline 1:200,000 InjectionN01BB51975P3001XXBRegional nerve block or epidural block.10 - 40 ml (0.25 %) or maximum : 2 mg/kg body weight in any 4 hours period, equivalent to 25 - 30 ml of 0.5% solution
Buprenorphine 10mcg/hr transdermal patchN02AE01110M7001XXA*Treatment of non-malignant pain of moderate intensity when an opioid is necessary for obtaining adequate analgesia. Not suitable for the treatment of acute pain. Restrictions: For elderly patients or patients with comorbidities/difficult to swallowOnce weekly transdermal patch/for hospital use only. Patient aged 18 years and over. Initial dose: 5 mcg/hr For elderly: Renal impairment. No special dose adjustments necessary in patients with renal impairment Hepatic impairment Patients with hepatic insufficiency should be carefully monitored during the treatment with buprenorphine patch. Alternate therapy should be considered. Patch should be used with cautions in severe hepatic impairment patient
Buprenorphine 5mcg/hr transdermal patchN02AE01110M7003XXA*Treatment of non-malignant pain of moderate intensity when an opioid is necessary for obtaining adequate analgesia. Not suitable for the treatment of acute pain. Restrictions: For elderly patients or patients with comorbidities/difficult to swallowOnce weekly transdermal patch/for hospital use only. Patient aged 18 years and over. Initial dose: 5 mcg/hr For elderly: Renal impairment. No special dose adjustments necessary in patients with renal impairment Hepatic impairment Patients with hepatic insufficiency should be carefully monitored during the treatment with buprenorphine patch. Alternate therapy should be considered. Patch should be used with cautions in severe hepatic impairment patient
Busulfan 2 mg TabletL01AB01000T1001XXAi) Chronic myeloid leukaemia (CML) and other myeloproliferative diseases ii) Haemopoietic stem cell transplant (HSCT)- refer to specific protocolsi) ADULT: Initial: 2 - 4 mg daily. Maintenance: 0.5 - 2 mg daily. Stop when white blood cell less than 20 x 109/L. CHILD: 60 mcg/kg body weight daily ii) CHILD: Induction 60 mcg/kg body weight daily (maximum 4 mg) if leucocytes more than 20,000/mm3 and platelets more than 100,000/mm3. Maintenance 10 - 30mcg/kg (maximum 2 mg daily)
Busulfan 6 mg/ml InjectionL01AB01000P3001XXA*For use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic stem cell transplantation (HSCT) for chronic myelogenous leukemia in selected cases with high risk of liver toxicity and intolerance to oral busulfan. To be prescribed by paediatric oncologist and consultant haematologist trained in transplant only.0.8 mg/kg of ideal body weight or actual body weight, whichever is lower via central venous catheter as a 2-hour infusion on the basis of every 6 hours for 4 days, for a total of 16 doses. For obese or severely obese patients, IV Busulfan should be administered based on adjusted ideal body weight
Cabergoline 0.5 mg TabletG02CB03000T1001XXA*i) Treatment of hyperprolactinaemic disorders ii) Prevention of puerperal lactation and suppression of lactation in HIV infected mothers onlyi)0.5mg per week given in 1 or 2 (one-helf of one 0.5mg tablet) doses per week ii) HIV mothers only : Prevent lactation 2 tab first day after delivery. Interruption of laction : 0.25mg 12 hourly for 2 days
Calamine CreamD04AX00000G1001XXC+Soothes and relieves nappy rashes, prickly heat, minor skin irritations, insect bites and sunburn, Pruritic skin conditions.Apply to the affected area as required, 1-3 times daily
Calamine LotionD04AX00000L8001XXC+Soothes and relieves nappy rashes, prickly heat, minor skin irritations, insect bites and sunburn, Pruritic skin conditions.Apply to the skin as required and allow to dry, 1-3 times daily
Calamine with 0.25 - 0.5% Menthol LotionD04AX00952L6001XXCSoothes and relieves nappy rashes, prickly heat, minor skin irritations, insect bites and sunburn, Pruritic skin conditions.Apply to the skin as required and allow to dry, 1 - 3 times daily
Calamine with 0.5% Phenol CreamD04AX00952G1001XXCFor use as a mild astringentApply to the affected area as required
Calamine with 2 - 6% Precipitated Sulphur LotionD04AX00952L6002XXCAcne vulgarisApply to the skin as required and allow to dry, 1 - 3 times daily
Calcipotriol 50 mcg/g CreamD05AX02000G1001XXA*Only for the treatment of Psoriasis VulgarisADULT Apply to the affected skin lesions twice daily. Maintenance therapy may be achieved with less frequent application. The weekly dose should not exceed 100 g. CHILD over 6 years, apply twice daily. 6-12 years maximum 50gm weekly, over 12 years maximum 75gm weekly
Calcipotriol 50 mcg/g OintmentD05AX02000G5001XXA*Only for the treatment of Psoriasis VulgarisADULT Apply to the affected skin lesions twice daily. Maintenance therapy may be achieved with less frequent application. The weekly dose should not exceed 100 g. CHILD over 6 years, apply twice daily. 6-12 years maximum 50gm weekly, over 12 years maximum 75gm weekly
Calcipotriol 50 mcg/ml Scalp SolutionD05AX02000L9901XXA*Only for the treatment of Psoriasis VulgarisApply to scalp twice daily. Maximum 60 mL weekly.
Calcipotriol Hydrate 50 mcg/g & Betamethasone Dipropionate 0.5 mg/g OintmentD05AX52952G5001XXA*Resistant plaque psoriasisApply once daily up to 4 weeks with maximum weekly dose of 100g and maximum treatment area 30% of body surface
Calcipotriol monohydrate 50 mcg/g and Betamethasone dipropionate 0.5 mg/g GelD05AX52952G3001XXA*Topical treatment of scalp and non-scalp plaque psoriasis vulgaris in adultsShould be applied to affected areas once daily. The recommended treatment period is 4 weeks for scalp areas and 8 weeks for ?non-scalp areas. The body surface area treated with calcipotriol containing products should not exceed 30% and maximum dose should not exceed 15g or 100g/ week
Calcitonin (synthetic Salmon) 100 IU InjectionH05BA01000P3002XXA*Acute hypercalcaemia5-10 IU per kg body weight in 500mL physiological saline daily by i.v. infusion over at least 6 hours or by slow i.v. injection in 2-4 divided doses spread over the day. Mimsgateway Adjunct in hypercalcaemia Adult: SC/IM: 4 u/kg 12 hrly, may increase after 1-2 days to 8 u/kg 12 hrly to max 8 u/kg 6 hrly after 2 days. Alternatively, 100 u every 6-8 hr, increased after 1-2 days to max 400 u every 6-8 hr. Emergency treatment of hypercalcaemia Adult: Up to 10 u/kg in 500 mL of sodium chloride 0.9% by slow IV infusion over at least 6 hr. Renal impairment: Dosage adjustment needed. Parenteral
Calcitonin (Synthetic Salmon) 200 IU Nasal SprayH05BA01000A4101XXA*Osteoporosis200 units daily
Calcitonin (Synthetic Salmon) 50 IU InjectionH05BA01000P3001XXA*Acute hypercalcaemia5-10 IU per kg body weight in 500mL physiological saline daily by i.v. infusion over at least 6 hours or by slow i.v. injection in 2-4 divided doses spread over the day. (Package insert) Mimsgateway Adjunct in hypercalcaemia Adult: SC/IM: 4 u/kg 12 hrly, may increase after 1-2 days to 8 u/kg 12 hrly to max 8 u/kg 6 hrly after 2 days. Alternatively, 100 u every 6-8 hr, increased after 1-2 days to max 400 u every 6-8 hr. Emergency treatment of hypercalcaemia Adult: Up to 10 u/kg in 500 mL of sodium chloride 0.9% by slow IV infusion over at least 6 hr. Renal impairment: Dosage adjustment needed. Parenteral
Calcitriol 0.25 mcg CapsuleA11CC04000C1001XXA/KKi)Established postmenopausal osteoporosis ii) Renal osteodystrophy in patients on haemodialysis iii)Hypoparathyroidism and rickets iv)Secondary hyperparathyroidism in renal failure"i) 0.25 mcg 2 times daily ii) Initial dose 0.25 mcg. In patients with normal or only slightly reduced serum calcium levels, doses of 0.25 mcg every other day is sufficient iii) 0.25 mcg/day given in the morning iv) ADULT and CHILD 3 years and older : Initially 0.25 mcg/ml. CHILD less than 3 years : 10 to 15 ng/kg/day "
Calcitriol 1 mcg/ml InjectionA11CC04000P3001XXA*Management of hypocalcaemia and/or secondary hyperparathyroidism in patients undergoing chronic renal dialysisInitially dose, depending on severity, 1 mcg (0.02 mg/kg) to 2 mcg 3 times weekly, approximately every other day
Calcitriol 2 mcg/ml InjectionA11CC04000P3002XXA*Management of hypocalcaemia and/or secondary hyperparathyroidism in patients undergoing chronic renal dialysisInitially dose, depending on severity, 1 mg (0.02 mg/kg) to 2 mg 3 times weekly, approximately every other day
Calcium Carbonate 500 mg CapsuleA12AA04121C1001XXA/KKi) Elemental calcium supplementation ii) Phosphate binder in chronic renal failure patientsADULT:Typical oral doses of calcium carbonate range from aboyt 3gm to 7gm daily in divided dose. US National Foundation suggest the calcium-based phosphate binder should not exceed 1.5gm daily in those with kidney failure. CHILD (12-18 years old): 1.25gm 3 or 4 times daily with or before meals and adjusted as necessary.
Calcium Carbonate 500 mg TabletA12AA04121T1001XXA/KKTo be used only for elemental calcium supplementation and phosphate binding activity in patients with chronic renal failureInitial 2.5 g daily and increased up to 17 g daily
Calcium Chloride Dihydrate, Sodium Chloride, Magnesium Chloride Hexahydrate, Sodium Acetate Trihydrate,Potassium Chloride, and Malic Acid SolutionB05BB01905P6002XXAReplacement of extracellular fluid losses in the case of isotonic dehydration, where acidosis is present or imminent.The maximum infusion rate depends on the needs of the patient in fluid replacement and electrolytes, patient?s weight, clinical condition, and biological status. Adults, elderly, adolescents:500ml-3L/24hr. Babies, children: 20ml to 100ml/kg/24 hr.
Calcium Disodium Edetate 200 mg InjectionV03AB03999P3001XXALead PoisoningIM (Lead encephalopathy): 1000 mg/m(2)/day IM in divided equal doses 8 to 12 hours apart, for 5 days. Therapy is interrupted for 2 to 4 days, and followed by an additional 5-day course of therapy, if indicated. Do not exceed the recommended daily dosage. IV: 1000 mg/m(2)/day administered IV over 8 to 12 hours for 5 days. Therapy is interrupted for 2 to 4 days, and followed by an additional 5-day course of therapy, if indicated.
Calcium Gluconate 10% InjectionA12AA03000P3001XXBi)Acute hypocalcaemia ii)Hypocalcaemic tetany iii)Cardiac resuscitationi) 1-2 g (2.25-4.5 mmol). CHILD 50 mg/kg ii) ADULT 1g (2.2 mmol) by slow IV injection followed by continuous infusion of 4 g (8.8 mmol) daily iii) IV or intracardiac injection, 10 ml
Calcium Lactate 300 mg TabletA12AA05125T1001XXCFor prophylaxis of calcium deficiency and treatment of chronic hypocalcaemiaADULT 1-5 g daily in divided doses
Calcium Polystyrene Sulphonate PowderV03AE01999F2101XXAHyperkalemia resulting from acute or chronic renal failure15 - 30g daily in 2-3 divided doses. Each dose should be suspended in 30 - 50ml of water and administered orally
Capecitabine 150 mg TabletL01BC06000T1002XXA*i) Metastatic breast cancer in elderly and poor performance status patients and refractory to taxanes. ii) Metastatic colon cancer, first line in elderly and poor performance status patients. iii) Colon cancer, adjuvant therapy for stage III (Duke's Stage C) following surgery. iv) First line treatment of patients with advanced gastric cancer in combination with a platinum-based regimeni) & ii) 1250 mg/m2 twice daily (morning and evening) for 2 weeks, every 21 days. iii) Recommended for a total of 24 weeks (8 cycles of 2 weeks of drug administration and 1 week rest period. Iv) In combination with a platinum on day 1, give capecitabine 1250 mg/m2 twice daily for 14 days. Repeated every 3 weeks for 8 cycles or optimum number of cycles
Capecitabine 500 mg TabletL01BC06000T1001XXA*i)Metastatic breast cancer in elderly and poor performance status patients and refractory to taxanes ii) Metastatic colon cancer, first line in elderly and poor performance status patients iii) Colon cancer, adjuvant therapy for stage III (Duke's Stage C) following surgery iv) First line treatment of patients with advanced gastric cancer in combination with a platinum-based regimeni) & ii) 1250 mg/m2 twice daily (morning and evening) for 2 weeks, every 21 days iii) Recommended for a total of 24 weeks (8 cycles of 2 weeks of drug administration and 1 week rest period iv) In combination with a platinum on day 1, give capecitabine 1250 mg/m2 twice daily for 14 days. Repeated every 3 weeks for 8 cycles or optimum number of cycles
Captopril 25 mg TabletC09AA01000T1002XXBi) Hypertension ii) Congestive heart failure iii) Post-myocardial infarction iv) Diabetic nephropathyi) Initially 12.5 mg twice daily. Maintenance: 25-50 mg 2 - 3 times daily, may be increased to maximum 450 mg/day in divided doses ii) Initially 6.25 - 12.5 mg 3 times daily, increase after several days to 25 - 50 mg 3 times daily iii) Start 3 days after MI Initially 6.25 mg daily, gradually increased to 37.5 mg daily in divided doses. May increase after several week to 150 mg/day in divided doses if needed and tolerated iv)75 - 100 mg daily in divided dose.
Carbachol 0.01% Intraocular SolutionS01EB02100D2001XXAFor intraocular use for miosis during surgeryInstill no more than 0.5 ml gently into the anterior chamber
Carbamazepine 100 mg/5 ml (2% w/v) SyrupN03AF01000L9001XXAEpilepsyADULT: Initially, 100-200 mg once or twice daily gradually increased by increments of 100-200 mg every 2 week. Maintenance: 0.8-1.2 g daily in divided doses. CHILD: 10-15 years: 0.6-1 g daily; 5-10 years: 400-600 mg daily; 1-5 years: 200-400 mg daily; less than or equal to 1 year: 100-200 mg daily. Alternatively, 10-20 mg/kg body weight daily in divided doses. Max: Adult: 1.6 g daily
Carbamazepine 200 mg CR TabletN03AF01000T5001XXAEpilepsyADULT: Initial, 200 mg twice daily for the first week, may increase dosage by 200 mg/day at weekly intervals until optimal response is obtained. Maximum 1.6 g/day. CHILD: usual maximum dosage 1000 mg/day in children 12-15 years of age, 1200 mg/day in patients above 15 years of age
Carbamazepine 200 mg TabletN03AF01000T1001XXBi) Epilepsy ii) Trigeminal neuralgiai) ADULT: 100 - 200 mg 1 - 3 times daily increased gradually to usual dose of 0.8 - 1.2 g daily in divided doses. CHILD: Up to 1 year: 100 - 200 mg daily; 1 - 5 yrs: 200 - 400 mg daily; 5 - 10 years: 400 - 600 mg daily; 10 - 15 years: 0.6 - 1 g daily ii) The initial dosage of 200 to 400mg should be slowly raised daily until freedom from pain is achieved (normally at 200mg 3 to 4 times daily). The dosage should then be gradually reduced to the lowest possible maintenance level. In elderly patients, an initial dose of 100mg twice daily is recommended.
Carbamazepine 400 mg CR TabletN03AF01000T5002XXAEpilepsyADULT: Initial, 200 mg twice daily for the first week, may increase dosage by 200 mg/day at weekly intervals until optimal response is obtained. Maximum 1.6 g/day. CHILD: usual maximum dosage 1000 mg/day in children 12-15 years of age, 1200 mg/day in patients above 15 years of age
Carbamide (Urea) 10 % CreamD02AE01000G1001XXBContact irritant dermatitis, infantile eczemas, acute and chronic allergic eczemas, icthyosis, hyperkeratoticApply sparingly and rub into affected area 2 - 3 times daily and when required after cleansing skin
Carbetocin 100 mcg/ ml InjectionH01BB03000P2001XXA*Prevention of uterine atony and postpartum hemorrhage following elective cesarean section under epidural or spinal anaesthesiaA single IV dose of 100mcg (1ml) is adminitered by bolus injection, slowly over 1minute, only when delivery of the infant has been completed by caesarean section under epidural or spinal anaesthesia, before or after delivery of the placenta.
Carbimazole 5 mg TabletH03BB01000T1001XXBHyperthyroidismADULT: Initially, 10-60mg daily in divided doses given 8 hourly. Maintenance: 5 to 20mg daily. CHILDREN > 6 years: Initially 15mg daily in divided doses. CHILDREN 1-6 years: Initially 7.5mg daily in divided doses
Carboplatin 150 mg InjectionL01XA02000P4001XXA*Adult solid tumours, paediatric tumours. Salvage therapy for lymphoma360 - 400 mg/m2 BSA, by IV infusion over 15 mins to 1 hour on Day 1 every 4 weeks. Alternatively, prescription may be based on Area Under Curve (AUC) calculations. CHILD: 500-600 mg/m2 over 1 hour once every 3 weeks. Salvage regimes in lymphomas - refer to specific protocols. Starting dose in renal impairment, please refer to product insert.
Carboplatin 450 mg InjectionL01XA02000P4002XXA*Adult solid tumours, paediatric tumours. Salvage therapy for lymphoma360 - 400 mg/m2 BSA, by IV infusion over 15 mins to 1 hour on Day 1 every 4 weeks. Alternatively, prescription may be based on Area Under Curve (AUC) calculations. CHILD: 500-600 mg/m2 over 1 hour once every 3 weeks. Salvage regimes in lymphomas - refer to specific protocols. Starting dose in renal impairment, please refer to product insert.
Carboprost Tromethamine 250 mcg InjectionG02AD04999P3001XXA*Postpartum haemorrhage refractory to oxytocinInitially 250 mcg deep IM inj. The dose may be repeated at intervals of 15-90 min if necessary. Max total dose: 2 mg.
Cardioplegia solution containing Potassium Chloride, Magnesium chloride & Procaine HCl InjectionB05XA16934P3001XXA*For myocardial preservation(prevent myocardial damage) during cardiac surgeryDilute 20 ml to 1 L of Ringer solution (cooled to 2-8 °C prior to use). Initial rapid instillation into aortic root at 300 ml/m² body surface area/min for 3 minutes. Should myocardial activity persist or recur instill at 300ml/m² body surface area/min for 2 minutes
Carvedilol 25 mg TabletC07AG02000T1002XXA/KKTreatment of stable moderate to severe congestive cardiac failure in addition to ACEI's and diuretics3.125 mg twice daily for 2 weeks, then 6.25 mg twice daily for 2 weeks, then 12.5 mg twice daily for 2 weeks then 25 mg twice daily (titrated up to the highest tolerated level). Max: <85 kg: 25 mg bid; >85 kg: 50 mg bid.
Carvedilol 6.25 mg TabletC07AG02000T1001XXA/KKTreatment of stable moderate to severe congestive cardiac failure in addition to ACEI's and diuretics3.125 mg twice daily for 2 weeks, then 6.25 mg twice daily for 2 weeks, then 12.5 mg twice daily for 2 weeks then 25 mg twice daily (titrated up to the highest tolerated level). Max: <85 kg: 25 mg bid; >85 kg: 50 mg bid.
Caspofungin Acetate 50 mg InjectionJ02AX04122P4001XXA*i) Confirmed systemic fungal infection in patients who are refractory or intolerant to other fungal therapies. ii) For pediatric patient (12 month and older) for the following indications : a) Empirical therapy for presumed fungal infections in febrile, neutropenic patients b) Treatment of invasive candidiasis, including candidemia and the following Candida infections ; intra-abdominal abscesses, peritonitis and pleural space infections c) Treatment of esophageal candidiasis d) Treatment of invasive Aspergillosis in patients who are refractory to or intolerant of others therapy (eg : Amphotericin B)i) Invasive aspergillosis & invasive candidiasis: ADULT: Initially, 70 mg infused over 1 hour followed by subsequent doses of 50 mg/day. Oesophageal candidiasis: ADULT: 50 mg by slow IV infusion over approximately 1 hour ii) For all indications, a loading dose of 70mg/m2 on D1 followed by maintenance dose of 50mg/m2 od.
Caspofungin Acetate 70 mg InjectionJ02AX04122P4002XXA*For adult and pediatric patient (12 month and older) for the following indications: a) Treatment of invasive candidiasis, including candidemia and the following Candida infections ; intra-abdominal abscesses, peritonitis and pleural space infections b) Treatment of invasive Aspergillosis in patients who are refractory to or intolerant of others therapy (eg : Amphotericin B) c) Treatment of esophageal candidiasis (need to follow the current indications)i) Invasive aspergillosis & invasive candidiasis: ADULT: Initially, 70 mg infused over 1 hour followed by subsequent doses of 50 mg/day. Oesophageal candidiasis: ADULT: 50 mg by slow IV infusion over approximately 1 hour daily ii) Child (12months to 17 years) : For all indication) A single 70mg/m2 loading dose (not to exceed an actual dose of 70mg) by slow IV infusion over 1hour; followed by 50mg/m2 (not to exceed an actual dose of 70mg)
Cefaclor 125 mg/5 ml SuspensionJ01DC04000F2101XXAInfections caused by susceptible organisms including Staphylococcus aureus and H. influenzae, treatment of sinusitis and infections involving the respiratory tract, skin and skin structure, bone and joint, and urinary tractCHILD:>1 mth: 20 mg/kg daily in 3 divided doses, increased to 40 mg/kg daily if necessary, <1 yr: 62.5 mg tid, 1-5 yr: 125 mg tid, >5 yr: 250 mg tid. Maximum: 1 g daily
Cefaclor 375 mg MR TabletJ01DC04010T5001XXAi) Adult pharyngitis, tonsillitis, skin& soft tissue infections ii) Bronchitis iii) Pneumonia iv) Lower UTIi) 375 mg twice daily ii) 375 mg or 500 mg twice daily iii) 750mg twice daily iv) 375mg twice daily or 500 mg once daily
Cefaclor 500 mg CapsuleJ01DC04000C1002XXAInfections caused by susceptible organisms including Staphylococcus aureus and H. influenzae, treatment of sinusitis and infections involving the respiratory tract, skin and skin structure, bone and joint, and urinary tractADULT: 250 mg 3 times daily for 10 days. For severe infections, double the dosage. Maximum: 4 g daily. CHILD:>1 mth: 20 mg/kg daily in 3 divided doses, increased to 40 mg/kg daily if necessary, <1 yr: 62.5 mg tid, 1-5 yr: 125 mg tid, >5 yr: 250 mg tid . Maximum: 1 g daily
Cefazolin Sodium 1 g InjectionJ01DB04520P3001XXAInfection caused by cefazolin-sensitive microorganism, infection of the respiratory tract, urogenital tract, skin and soft tissue, bile duct, bones and joint, endocarditis, systemic septic infection, peri-operative/ surgical prophylaxisADULT: Uncomplicated infections: 500 - 1000 mg 2 - 3 times daily. Moderately severe and severe infections: 500 - 1000 mg 3 - 4 times daily. Severe life-threatening infections: 1 - 1.5 g 4 times daily. Rarely, dose up to 12 g daily. CHILDREN >1 month: 25-50mg/kg/day in 3-4 divided dose
Cefepime 1 g InjectionJ01DE01110P4002XXA*Febrile neutropenia, septicaemia, lower respiratory tract infection, urinary tract infection, skin and skin structure infections, gynaecologic and intra-abdominal infectionsADULT: 1 - 2 g twice daily for most infections. For severe infections including febrile neutropenia: 2 g 3 times daily. CHILD:2 mth - 16 yr: ≤40 kg: 50 mg/kg every 8-12 hr for 7-10 days
Cefepime 500 mg InjectionJ01DE01110P4001XXA*Febrile neutropenia, septicaemia, lower respiratory tract infection, urinary tract infection, skin and skin structure infections, gynaecologic and intra-abdominal infectionsADULT: 1 - 2 g twice daily for most infections. For severe infections including febrile neutropenia: 2 g 3 times daily. CHILD: 2 mth - 16 yr: ≤40 kg: 50 mg/kg every 8-12 hr for 7-10 days
Cefoperazone Sodium 1 g InjectionJ01DD12520P4002XXAInfections due to gram-negative bacteriaADULT: 1 - 2 g twice daily IM or IV. By IV, adult dose may be doubled. Maximum: 16 g daily in divided doses. CHILD & INFANT: 50 - 200 mg/kg/day in 2 - 4 divided doses. NEONATE less than 8 days: 50 - 200 mg/kg/day 12 hourly
Cefoperazone Sodium 2 g InjectionJ01DD12520P4003XXAInfections due to gram-negative bacteriaADULT: 1 - 2 g twice daily IM or IV. By IV, adult dose may be doubled. Maximum: 16 g daily in divided doses. CHILD & INFANT: 50 - 200 mg/kg/day in 2 - 4 divided doses. NEONATE less than 8 days: 50 - 200 mg/kg/day 12 hourly
Cefoperazone Sodium 500 mg & Sulbactam Sodium 500 mg InjectionJ01DD62000P4001XXAi) Treatment of infections due to multi-drug resistance pathogens producing B-lactamase ii) Treatment of infections caused by Acinetobacter speciesADULT: 1 - 2 g twice daily. In severe or refractory infections the daily dosage of sulbactam/cefoperazone may be increased up to 8g (4g cefopreazone activity) CHILD: 40 - 80 mg/kg/day in 2 to 4 equally divided doses; in serious or refractory infections, may increase to 160mg/kg/d in 2 - 4 equally divided doses.
Cefoperazone Sodium 500 mg InjectionJ01DD12520P4001XXAInfections due to gram-negative bacteriaADULT: 1 - 2 g twice daily IM or IV. By IV, adult dose may be doubled. Maximum: 16 g daily in divided doses. CHILD & INFANT: 50 - 200 mg/kg/day in 2 - 4 divided doses. NEONATE less than 8 days: 50 - 200 mg/kg/day 12 hourly
Cefotaxime 1 g InjectionJ01DD01520P4002XXAInfections due to gram-negative bacteriaADULT: 1 g 12 hourly (up to 12 g/day in severe cases). CHILD: 50 - 180 mg/kg/day in 4 - 6 divided doses
Cefotaxime 500 mg InjectionJ01DD01520P4001XXAInfections due to gram-negative bacteriaADULT: 1 g 12 hourly (up to 12 g/day in severe cases). CHILD: 50 - 180 mg/kg/day in 4 - 6 divided doses
Ceftaroline Fosamil 600mg Powder for concentrate for solution for infusionJ01D102000P4001XXA*Treatment of complicated skin and soft tissue infections (cSSTI) in adults Restriction: Restricted for only complicated SSTI in patients who are unable to tolerate or not responding to vancomycin.600mg administered every 12 hours by intravenous infusion over 60 minutes for 5-14 days. Dose adjustment in renal impairment: - CrCl > 30 to ≤50 ml/min : 400mg every 12 hours - CrCl < 30ml/min is not recommended
Ceftazidime 1 g InjectionJ01DD02520P4003XXASevere gram negative bacterial infectionsADULT: 1 g 8 hourly or 2 g 12 hourly. In severe infections: 2 g 8 hourly. CHILD: 25 - 150 mg/kg/day in 2 - 3 divided doses
Ceftazidime 2 g InjectionJ01DD02520P4004XXASevere gram negative bacterial infectionsADULT: 1 g 8 hourly or 2 g 12 hourly. In severe infections: 2 g 8 hourly. CHILD: 25 - 150 mg/kg/day in 2 - 3 divided doses
Ceftazidime 250 mg InjectionJ01DD02520P4001XXASevere gram negative bacterial infectionsADULT: 1 g 8 hourly or 2 g 12 hourly. In severe infections: 2 g 8 hourly. CHILD: 25 - 150 mg/kg/day in 2 - 3 divided doses
Ceftazidime 500 mg InjectionJ01DD02520P4002XXASevere gram negative bacterial infectionsADULT: 1 g 8 hourly or 2 g 12 hourly. In severe infections: 2 g 8 hourly. CHILD: 25 - 150 mg/kg/day in 2 - 3 divided doses
Ceftriaxone 0.25 g InjectionJ01DD04520P4001XXA/KKi) Gonorrhoea ii) Chancroidi) 250 mg by deep IM injection ii) single IM injection 250 mg only. For severe infection up to 100 mg/kg/day
Ceftriaxone 0.5 g InjectionJ01DD04520P4002XXAInfections caused by susceptible organismsADULT: 1 - 2 g once daily. Severe infection: 4 g daily at 12 hour intervals. INFANT & CHILD, 3 weeks - 12 years: 20 - 80 mg/kg body weight daily. CHILD with body weight 50 kg or more: adult dose. NEONATE up to 2 weeks: 20 - 50 mg/kg body weight daily, not to exceed 50 mg/kg
Ceftriaxone 1g InjectionJ01DD04520P4003XXAInfections caused by susceptible organismsADULT: 1 - 2 g once daily. Severe infection: 4 g daily at 12 hour intervals. INFANT & CHILD, 3 weeks - 12 years: 20 - 80 mg/kg body weight daily. CHILD with body weight 50 kg or more: adult dose. NEONATE up to 2 weeks: 20 - 50 mg/kg body weight daily, not to exceed 50 mg/kg
Cefuroxime Axetil 125 mg TabletJ01DC02233T1001XXA/KKUpper and lower respiratory tract, genito-urinary tract, skin & soft tissue and urinary tract infections (UTI)ADULT: 250 mg twice daily ;UTI: 125 mg twice daily. CHILD:30 mg/kg/day in 2 divided doses, up to 500 mg daily
Cefuroxime Axetil 125 mg/5 ml SuspensionJ01DC02233F2101XXAInfections caused by susceptible organisms30 mg/kg/day in 2 divided doses, up to 500 mg daily.
Cefuroxime Axetil 250 mg TabletJ01DC02233T1002XXA/KKUpper and lower respiratory tract, genito-urinary tract, skin & soft tissue and urinary tract infections (UTI)ADULT: 250 mg twice daily ;UTI: 125 mg twice daily. CHILD:30 mg/kg/day in 2 divided doses, up to 500 mg daily
Cefuroxime Sodium 1.5 g InjectionJ01DC02520P4003XXAInfections caused by susceptible organisms, surgical prophylaxisADULT: 750 mg every 6 - 8 hours as IM or IV. Severe infections: 1.5 g every 6 - 8 hours as IV. CHILD: 30 - 100 mg/kg/day in 3 - 4 divided doses or 2-3 divided doses in neonates. Surgical prophylaxis: 1.5 g IV
Cefuroxime Sodium 250 mg InjectionJ01DC02520P4001XXAInfections caused by susceptible organisms, surgical prophylaxisADULT: 750 mg every 6 - 8 hours as IM or IV. Severe infections: 1.5 g every 6 - 8 hours as IV. CHILD: 30 - 100 mg/kg/day in 3 - 4 divided doses or 2-3 divided doses in neonates. Surgical prophylaxis: 1.5 g IV
Cefuroxime Sodium 750 mg InjectionJ01DC02520P4002XXAInfections caused by susceptible organisms, surgical prophylaxisADULT: 750 mg every 6 - 8 hours as IM or IV. Severe infections: 1.5 g every 6 - 8 hours as IV. CHILD: 30 - 100 mg/kg/day in 3 - 4 divided doses or 2-3 divided doses in neonates. Surgical prophylaxis: 1.5 g IV
Celecoxib 200 mg CapsuleM01AH01000C1001XXAi) Osteoarthritis ii) Rheumatoid Arthritis iii) Acute pain iv) Ankylosing Spondylitisi) ADULTS: 200 mg once daily. May increase to 200 mg bid, if necessary. CHILD not recommended ii) 100mg twice daily, increased if necessary to 200 mg 2 times daily; CHILD not recommended iii) 400mg as a single dose on first day followed by 200mg once daily on subsequent days iv) Initial, 200 mg once daily or 100 mg twice daily; if no effect after 6 weeks, may increase to max. 400 mg daily in 1-2 divided doses. If no response following 2 weeks of treatment with 400 mg/day, consider discontinuation and alternative treatment
Celecoxib 400 mg CapsuleM01AH01000C1002XXA*i) Osteoarthritis ii) Rheumatoid Arthritis iii) Acute pain iv) Ankylosing Spondylitisi) ADULTS: 200 mg once daily. CHILD not recommended ii) 100 mg twice daily, increased if necessary to 200 mg 2 times daily; CHILD not recommended iii) 400 mg as a single dose on first day followed by 200 mg once daily on subsequent days iv) Initial, 200 mg once daily or 100 mg twice daily; if no effect after 6 weeks, may increase to max. 400 mg daily in 1-2 divided doses. If no response following 2 weeks of treatment with 400 mg/day, consider discontinuation and alternative treatment
Cephalexin Monohydrate 125 mg/5 ml SyrupJ01DB01010F2101XXBRespiratory tract infections, ear, nose and throat infections, urinary tract infections, obstetric and gynaecologic infectionsCHILD: 25 - 100 mg/kg/day every 6 hourly. Maximum: 4 g daily
Cephalexin Monohydrate 250 mg CapsuleJ01DB01010C1001XXBi) Respiratory tract infection, urinary tract infection ii) Complicated, recurrent or chronic infections, bronchitis iii) Pneumoniai) 250 mg 6 hourly ii) 250 - 500 mg 6 hourly iii) 1 - 1.5 g 3 times daily or 4 times daily. Maximum: 6 g/day Child: 25-100 mg/kg daily in divided doses. Max: 4 g daily.
Cephalexin Monohydrate 250 mg TabletJ01DB01010T1001XXBi) Respiratory tract infection, urinary tract infection ii) Complicated, recurrent or chronic infections, bronchitis iii) Pneumoniai) 250 mg 6 hourly ii) 250 - 500 mg 6 hourly iii) 1 - 1.5 g 3 times daily or 4 times daily. Maximum: 6 g/day Child: 25-100 mg/kg daily in divided doses. Max: 4 g daily.
Cephalexin Monohydrate 500 mg CapsuleJ01DB01010C1002XXBi) Respiratory tract infection, urinary tract infection ii) Complicated, recurrent or chronic infections, bronchitis iii) Pneumoniai) 250 mg 6 hourly ii) 250 - 500 mg 6 hourly iii) 1 - 1.5 g 3 times daily or 4 times daily. Maximum: 6 g/day
Cephalexin Monohydrate 500 mg TabletJ01DB01010T1002XXBi) Respiratory tract infection, urinary tract infection ii) Complicated, recurrent or chronic infections, bronchitis iii) Pneumoniai) 250 mg 6 hourly ii) 250 - 500 mg 6 hourly iii) 1 - 1.5 g 3 times daily or 4 times daily. Maximum: 6 g/day Child: 25-100 mg/kg daily in divided doses. Max: 4 g daily.
Cetirizine HCl 10 mg TabletR06AE07110T1001XXA/KKUrticaria, allergic dermatoses (insect bites, atopic eczema), perennial rhinitis, allergic rhinitisADULT and CHILD over 6 years:10 mg daily or 5 mg twice daily. Child 2-6 years: 5 mg once daily or 2.5 mg twice daily
Cetrimide 1-2% Lotion.D08AJ04000L6001XXC+As shampoo and cleansing agentApply to affected area
Cetrorelix 0.25 mg InjectionH01CC02122P4001XXA*Prevention of premature ovulation in patients undergoing a controlled ovarian stimulation, followed by oocyte pick-up and assisted reproductive techniquesGiven by SC 0.25 mg/day, given either in the morning beginning on the day 5 or 6 of ovarian stimulation or in the evening beginning on day 5, and continued until ovulation induction
Cetuximab 5 mg/ml Solution for InfusionL01XC06000P5002XXA*For neo-adjuvant treatment of KRAS wild type metastatic colorectal cancer with the aim of liver resection with the following conditions: i) The primary colorectal tumour has been resected or is potentially resected. ii)The metastatic disease is confined to the liver and is unresectable iii) The patient is fit enough to undergo surgery to resect the primary colorectal tumour and to undergo liver surgery if the metastases become resectable after treatment with cetuximab. iv)The treatment is limited to 16 weeksAdministered once a week. The very first dose is 400mg cetuximab per m2 body surface area with a recommended infusion period of 120 minutes. All subsequent weekly doses are 250mg per m2 body surface area each with a recommended infusion period of 60 minutes. The maximum infusion rate must not exceed 10mg/min.
Charcoal, Activated 250 mg TabletA07BA01000T1001XXCi) Diarrhoea and food poisoning ii) Reduce absorption of drugs, plant, inorganic poison and chemicals in poisoning casesi) ADULT 0.5-1 g given 3-4 times daily. CHILD half adult dose. ii) Need to be dissolved in liquid (slurry consistency). ADULT and CHILD over 12 years: initial 30-100 g or 1-2 g/kg; repeat initial dose as soon as possible or 20-50 g every 2-6 hours. CHILD over 1-12 years, 25-50 g or 1-2 g/kg; may repeat half the initial dose every 2-6 hour as needed. CHILD to 1 year of age, 1 g/kg; may repeat half the initial dose every 2-6 hours as needed. For maximum efficacy administer within 1 hour after ingestion of toxic compound
Charcoal, Activated 50 g GranulesA07BA01000F1001XXAEmergency treatment of acute oral poisoning and drug overdoseADULT:Acute poisoning: 50 - 100g in suspension. Severe poisoning: 50 - 100g as an initial dose followed by 20g every 4 - 6 hours. CHILDREN: 1g/kg/dose
Chloral Hydrate 200 mg/5 ml MixtureN05CC01010L2101XXBPreoperative sedationADULT : 0.5 - 1 g (max 2 g) with plenty of water at bedtime. CHILD : Neonate: 30-50 mg/kg; up to 100 mg/kg may be used with respiratory monitoring. 1 mth-12 yr: 30-50 mg/kg (max: 1 g); up to 100 mg/kg (max: 2 g) may be used; 12-18 yr: 1-2 g. Doses to be taken 45-60 minutes before procedure. May be given rectally if oral route is not available.
Chlorambucil 2 mg TabletL01AA02000T1001XXALow grade lymphoma, chronic lymphocytic leukaemia. Ovarian cancerGeneral : Initial :0.1 -0.2 mg/kg body weight daily for 4 - 8 weeks maintanance : given either by reduced daily dosage or intermittent course of treatment. Chronic Lymphocytic Leukaemia: initial : 0.15mg/kg/day untill total leukocyte count has fallen to 10,000peruL, then resumed treatment untill 4 weeks after the end of the first course then continued at a dosage 0.1mg/kg/day.
Chloramphenicol 0.5% Eye DropsS01AA01000D2001XXCBroad spectrum antibiotic in superficial eye infectionsInstill 1 drop of a 0.5% solution every 2 hr. Increase dosage interval upon improvement. To continue treatment for at least 48 hr after complete healing
Chloramphenicol 1% Eye OintmentS01AA01000G5101XXCTreatment of ocular infections involving the conjunctiva and/or cornea caused by chloramphenicol susceptible organismsADULT and CHILD : Apply to the conjunctiva, a thin strip (approximately 1 cm) of ointment every 3 hours or more frequently
Chloramphenicol 125 mg/5 ml SuspensionJ01BA01126L8001XXBTyphoid fever, salmonella infections, meningitis, cholera, anaerobic and rickettsial infectionsCHILD: 25 - 50 mg/kg/day in 4 divided doses. Severe infections, premature& full-term infants less than 2 weeks: 25mg/kg/day in divided doses. Full-term infants more than 2 weeks: up to 50mg/kg/day in divided doses
Chloramphenicol 250 mg CapsuleJ01BA01126C1001XXBTreatment of typhoid, paratyphoid fevers, bronchopneumonia and enteric infectionADULT: 500 mg 4 times daily or 50 mg/kg/day in 4 divided doses. Maximum dose: 4 g/day. CHILD: 25 - 100 mg/kg/day in 4 divided doses
Chloramphenicol 5% w/v Ear DropsS02AA01000D1001XXCAcute otitis media, otitis externa with perforationApply 2 - 3 drops into the ear 2 - 3 times daily. Not to be used for long term
Chloramphenicol Sodium Succinate 1 g InjectionJ01BA01520P4001XXBTreatment of typhoid, paratyphoid fevers, bronchopneumonia and enteric infectionAdult:50 to 100 mg/kg/day in 4 divided doses. Premature and full-term neonates: 25 mg/kg/day in 4 divided doses. Full-term infants >2 wk: 50 mg/kg/day in 4 divided doses. Children: 50-100 mg/kg/day in 4 divided doses
Chlorhexidine Gluconate 0.2 % MouthwashR02AA05137M2001XXCAs a gargleRinse mouth with 10 ml for about 1 minute twice daily
Chlorhexidine Gluconate 2% in Alcohol 70% SolutionD08AC52137L9902XXCUse as disinfectant in central venous catheter care bundleSkin Preparation:Use Chlorhexidine Gluconate 2% in Isopropyl Alcohol 70% and allow to dry. Catheter acces:Apply to catheter ports or hubs prior to accessing the line for administering fluids or injections
Chlorhexidine Gluconate 4% ScrubD08AC02137M9901XXC+Surgical hand scrub/disinfection, pre-op skin preparationSurgical hand disinfection: Apply 5ml to clean hands and forearms for 1 min. Rinse and repeat with another 5ml for a further 2 mins and then rinse and dry. General skin disinfection: Apply appropriate quantity to wet area and scrub for 1 min. Rinse thoroughly & dry
Chlorhexidine Gluconate 5% SolutionD08AC02137L9901XXC+i) Preoperative skin disinfection ii) Wounds or burns iii) Emergency disinfection of instrumentsi) & iii) 1 : 10 in 70 % Alcohol ii) 1 : 100
Chlorhexidine Gluconate 5% Solution 1:10 in 70% alcohol with lanolin as emollientD08AC52137L9901XXC+To be used undiluted for hand and skin disinfectionsPre-op surgical hand disinfection: Spread 5ml throughly over both hands and forearms, rubbing vigorously. When dry apply a further 5ml and repeat procedure. Antiseptic hand disinfection on the ward: Spread 3ml throughly over the hands and wrist rubbing vigorously until dry. Disinfection of patient's skin: Prior to surgery, apply to a sterile swab and rub thoroughly over the operation site for a minimum of 2 mins
Chlorinated Lime PowderV07AV00000F9901XXCAntiseptic and disinfectantsNot applicable
Chlorinated Lime Solution & Buffered Acetate SolutionD08A000999G9901XXCWound or ulcerApply to affected areas undiluted as a cleansing agent
Chloroquine Phosphate 250 mg Tablet (150 mg Chloroquine base)P01BA01162T1001XXCTreatment of malaria - acute attackADULT 600 mg base stat, 300 mg 6 - 8 hours later and a further 300 mg on each of 2 following days. CHILD 3 - 4 years : 150 mg base stat, 75 mg 6 hours later, then 75 mg daily for 2 days. CHILD 5 - 8 years : 300 mg stat, 150 mg 6 hours later, then 150 mg daily for 2 days
Chlorpheniramine Maleate 10 mg/ml InjectionR06AB04253P3001XXBAllergic conditions10 - 20 mg IM or SC, repeated if required. Not to exceed 40 mg in 24 hours. 10 - 20 mg over 1 minute by slow IV
Chlorpheniramine Maleate 2 mg/5 ml SyrupR06AB04253L9001XXCSymptomatic treatment of allergic conditions responsive to antihistamineCHILD 1 - 2 years : 1 mg twice daily, 2 - 5 years : 1 mg every 4 - 6 hours (maximum 6 mg daily), 6 - 12 years : 2 mg every 4 - 6 hours (maximum 12 mg daily)
Chlorpheniramine Maleate 4 mg TabletR06AB04253T1001XXCSymptomatic treatment of allergic conditions responsive to antihistaminesADULT : 4 mg every 4 - 6 hours. Maximum 24 mg daily. CHILD 1 - 2 years : 1 mg twice daily, 2 - 5 years : 1 mg every 4 - 6 hours (maximum 6 mg daily), 6 - 12 years : 2 mg every 4 - 6 hours (maximum 12 mg daily)
Chlorpromazine HCl 100 mg TabletN05AA01110T1002XXBPsychosis mania and agitationADULT : Initial dose - 25 mg 3 times daily according to response up to 1 g daily. PAEDIATRIC: Up to 5 years: 0.5 mg/kg body weight every 4 - 6 hours (Maximum 40 mg daily). CHILD 6 - 12 years: A third to half adult dose (Maximum 75 mg daily)
Chlorpromazine HCl 25 mg TabletN05AA01110T1001XXBPsychosis mania and agitationADULT : Initial dose - 25 mg 3 times daily according to response up to 1 g daily. PAEDIATRIC: Up to 5 years: 0.5 mg/kg body weight every 4 - 6 hours (Maximum 40 mg daily). CHILD 6 - 12 years: A third to half adult dose (Maximum 75 mg daily)
Chlortetracycline 1% Eye OintmentS01AA02000G5101XXBEye infections requiring a broad spectrum antibioticApply thin strip (approximately 1 cm) to the conjuctiva 2 to 4 hourly or more frequently.
Chlortetracycline 1-3 % CreamD06AA02000G1001XXBBacterial skin infectionsApply directly to affected area twice daily as required for 1 - 2 weeks
Cholera VaccineJ07AE01000P3001XXBImmunisation of choleraProphylactic ADULT: First dose of 0.5 ml SC/IM followed after 1 - 4 weeks by a second dose of 1 ml. CHILD: 1 - 5 years: 0.1 ml (1st dose), 0.3 ml (2nd dose). CHILD; 5 - 10 years: 0.3 ml (1st dose), 0.5ml (2nd dose). Booster: For optimum long-term protection, a booster dose is recommended for adults after 2 years. Children 2-6 years should receive a booster dose after 6 months.
Cholestyramine Resin 4 GC10AC01000M4001XXAi) Hypercholesterolemia ii) Familial hypercholesterolemia - heterozygous iii) Generalized atherosclerosis iv) Diarrhoea due to bile acid malabsorption v) Pruritus of skin associated with partial biliary obstructionHypercholesterolemia: Adjunct: initial, 4 g orally 1-2 times daily, maintenance, 8 to 16 g in divided doses, max 24 g daily CHILD: 50 - 150 mg/ kg 6 - 8 hourly oral
Choline Salicylate 8.7%, Cetylkonium Chloride 0.01% Dental GelN02BA03900G3001XXBFor relief of the pain and discomfort in mouth ulcers and sores, infant teething and denture irritationApply to area 4 times daily
Choriogonadotropin Alfa 250 mcg/0.5 ml Injection in Prefilled SyringeG03GA01000P5001XXA*i)Women undergoing superovulation prior to assisted reproductive techniques such as in-vitro fertilization (IVF) ii)Anovulatory or oligo-ovulatory women250 mcg 24-48 hour after the last administration of an FSH or hMG preparation, when optimal stimulation of follicular growth is achieved.
Chorionic Gonadotrophin Human (HCG) 5000 IU InjectionG03GA01000P4001XXA*i)Treatment of infertile women to induce ovulation ii) As a luteal support in controlled ovarian hyperstimulation cyclesi) & ii)Induction of ovulation: 5000 - 10,000 units one day following last dose of menotropin. Up to 3 repeat injections of 5000 units each may be given within the following 9 days to prevent insufficiency corpus luteum
Ciclesonide 160mcg InhalerR03BA08000A2101XXA*Prophylactic treatment of asthma in adults, adolescents and children over 6 years (follow current indication) Not meant for 6 yo)For adults and adolescents over 12 years of age with mild to moderate asthma is 160 to 640mcg per day: severe asthma dose may be increased to 1280mcg per day.
Ciclosporin 100 mg CapsuleL04AD01000C1002XXA*Only for: i) Patients in whom donor specific transplantation cannot be carried out and in young children to minimise side-effects of steroids ii) Follow-up cases of bone marrow transplant iii) Patients with severe rheumatoid arthritis not responding to other second line drugs iv) Patients with idiopathic nephrotic syndrome who are steroid toxic or poor response to cyclophosphamide v) Severe aplastic anemia, pure red cell aplasia vi) Cases of recalcitrant psoriasis and atopic eczema vii) Treatment of chronic ocular inflammatory disorders/uveitisi & ii) Initially 12.5 - 15 mg/kg/day, beginning on the day before transplant. Maintenance approx 12.5 mg/kg/day for 3 - 6 months before being tapered off to zero by 1 year of transplantation iii) 3 mg/kg/day in 2 divided doses for first 6 weeks. May increased gradually to maximum 5 mg/kg. Treatment withdrawn if no response after 3 months iv) ADULT: 5 mg/kg/day in 2 divided doses. CHILD: 6 mg/kg/day in 2 divided doses. Patients with permitted levels of kidney failure, the starting dose must not more than 2.5 mg/kg/day v) 12 mg/kg/day. vi) 2.5 mg/kg/day in 2 divided doses increasing if there is no improvement after 4 weeks by 0.5 -1 mg/kg/month up to maximum 5 mg/kg/day vii) 5 mg/kg/day in 2 divided doses, may increase to 7 mg/kg/day in resistant cases. Maintenance: Less than 5 mg/kg/day especially during remission
Ciclosporin 100 mg/ml Drink SolutionL04AD01000L5002XXA*Only for : i) Patients in whom donor specific transplantation cannot be carried out and in young children to minimise side-effects of steroids ii) Follow-up cases of bone marrow transplant iii) Patients with severe Rheumatoid arthritis not responding to other second line drugs iv) Patients with idiopathic nephrotic syndrome who are steroid toxic or poor response to cyclophosphamide v) Severe aplastic anaemia, pure red cell aplasia vi) Cases of recalcitrant psoriasis and atopic eczemai & ii) Initially 12.5 - 15 mg/kg/day, beginning on the day before transplant. Maintenance approx 12.5 mg/kg/day for 3 - 6 months before being tapered off to zero by 1 year of transplantation iii) 3 mg/kg/day in 2 divided doses for first 6 weeks. May increased gradually to maximum 5 mg/kg. Treatment withdrawn if no response after 3 months iv) ADULT: 5 mg/kg/day in 2 divided doses. CHILD: 6 mg/kg/day in 2 divided doses. Patients with permitted levels of kidney failure, the starting dose must not more than 2.5 mg/kg/day v) 12 mg/kg/day vi) 2.5 mg/kg/day in 2 divided doses increasing if there is no improvement after 4 weeks by 0.5 -1 mg/kg/month up to maximum 5 mg/kg/day
Ciclosporin 25 mg CapsuleL04AD01000C1001XXA*Only for: i) Patients in whom donor specific transplantation cannot be carried out and in young children to minimise side-effects of steroids ii) Follow-up cases of bone marrow transplant iii) Patients with severe rheumatoid arthritis not responding to other second line drugs iv) Patients with idiopathic nephrotic syndrome who are steroid toxic or poor response to cyclophosphamide v) Severe aplastic anemia, pure red cell aplasia vi) Cases of recalcitrant psoriasis and atopic eczema vii) Treatment of chronic ocular inflammatory disorders/uveitisi & ii) Initially 12.5 - 15 mg/kg/day, beginning on the day before transplant. Maintenance approx 12.5 mg/kg/day for 3 - 6 months before being tapered off to zero by 1 year of transplantation iii) 3 mg/kg/day in 2 divided doses for first 6 weeks. May increased gradually to maximum 5 mg/kg. Treatment withdrawn if no response after 3 months iv) ADULT: 5 mg/kg/day in 2 divided doses. CHILD: 6 mg/kg/day in 2 divided doses. Patients with permitted levels of kidney failure, the starting dose must not more than 2.5 mg/kg/day v) 12 mg/kg/day vi) 2.5 mg/kg/day in 2 divided doses increasing if there is no improvement after 4 weeks by 0.5 -1 mg/kg/month up to maximum 5 mg/kg/day vii) 5 mg/kg/day in 2 divided doses, may increase to 7 mg/kg/day in resistant cases. Maintenance: Less than 5 mg/kg/day especially during remission
Ciclosporin 50 mg/ml InjectionL04AD01000P3001XXA*i) Post bone marrow transplant ii) Solid organ transplanti) 3 - 5 mg/kg/day until tolerate orally ii) 2 - 3 mg/kg/day for recipients who are unable to take orally
Cilostazol 100 mg TabletB01AC00000T1002XXA*Improvement of the maximal and pain-free walking distances in patients with intermittent claudication, who do not have rest pain and who do not have evidence of peripheral tissue necrosis.100 mg twice daily
Cimicifuga Racemosa Rhizome Extract 20 mg TabletHG03WA5001T1001XXATraditionally used for the relief of hot flushes, sweating, restlessness associated with menopause20 mg twice daily
Cinnarizine 25 mg TabletN07CA02000T1001XXBVestibular disordersOne tablet 3 times daily
Ciprofloxacin 100 mg/50 ml InjectionJ01MA02125P3001XXATreatment of infections due to susceptible bacterial strainsADULT: the dosage range is 100-400mg twice daily Gonorrhoea: 100mg single dose Upper and Lower Urinary Tract Infection: 100mg bd Upper and Lower Respiratory Tract Infection: 200mg bd-400mg twice daily Cystic Fibrosis with psuedomonal Lower RTI: 400mg bd Others: 200-400mg bd inhalation Anthrax: 400mg bd
Ciprofloxacin 200 mg/100 ml InjectionJ01MA02125P3002XXATreatment of infections due to susceptible bacterial strainsSuggest to rephrase ADULT: the dosage range is 100-400mg twice daily Gonorrhoea: 100mg single dose Upper and Lower Urinary Tract Infection: 100mg bd Upper and Lower Respiratory Tract Infection: 200mg bd-400mg twice daily Cystic Fibrosis with psuedomonal Lower RTI: 400mg bd Others: 200-400mg bd inhalation Anthrax: 400mg bd
Ciprofloxacin 250 mg TabletJ01MA02110T1001XXATreatment of infections due to susceptible bacterial strainsADULT: 125-750 mg twice daily. Acute gonorrhoea: a single dose of 250 mg
Ciprofloxacin 500 mg TabletJ01MA02110T1002XXATreatment of infections due to susceptible bacterial strainsADULT: 125-750 mg twice daily. Acute gonorrhoea: a single dose of 250 mg
Ciprofloxacin HCl 0.3% Ophthalmic SolutionS01AX13110D2001XXA*Treatment of bacterial infections caused by susceptible strains in i) corneal ulcers ii) bacterial conjunctivitisi) 2 drops every 15 minutes for the first 6 hours, then 2 drops every 30 minutes for the rest of the first day. Second day : 2 drops every hour. Subsequent days (3rd - 14th day) : 2 drops every 4 hours. Treatment may be continued after 14 days if corneal re-epithelialization has not occured ii) 1 - 2 drops every 2 hours into the conjunctival sac while awake for 2 days and 1-2 drops every 4 hours while awake for the next 5 days
Cisatracurium Besylate 2 mg/ml InjectionM03AC11197P3001XXA*As an adjunct to general anaesthesia to facilitate endotracheal intubation, to provide skeletal muscle relaxation during surgery and to facilitate mechanical ventilation. Restricted to patients with lung problem such as asthma.Administered as bolus intravenous injection. May be administered as infusion in ICU patients at a rate of 3mcg/kg/min. Adult dose: a) Induction: 0.15mg/kg over 5-10 secs, b) Maintenance: 0.03 mg/kg. Children 2-12 years: a) Induction: 0.1 mg/kg over 5-10 secs, b) Maintenance: 0.02 mg/kg
Cisplatin 10 mg InjectionL01XA01000P3001XXAGerm cell tumours, ovarian tumours, adult solid tumours, lymphomasGerm cell tumours: 20 mg/m2 daily for 5 days every 3 weeks for 3 - 4 courses. Ovarian tumours: 75 mg/m2 once every 3 weeks as part of combination therapy with paclitaxel or 50-60mg/m2 IV once every 3 weeks as a single agent. Baseline creatinine clearance, pretreatment hydration and forced diuresis are mandatory. CHILD: 100mg/m2 over 6 hours once every 3 weeks. Lymphomas: Refer to protocols CHILD: 100mg/m2 over 6 hours once every 3 weeks. Lymphomas: Refer to protocols
Cisplatin 50 mg InjectionL01XA01000P3002XXAGerm cell tumours, ovarian tumours, adult solid tumours, lymphomasGerm cell tumours: 20 mg/m2 daily for 5 days every 3 weeks for 3 - 4 courses. Ovarian tumours: 75 mg/m2 once every 3 weeks as part of combination therapy or 100 mg/m2 IV once every 3 weeks as a single agent. Baseline creatinine clearance, pretreatment hydration and forced diuresis are mandatory. CHILD: 100mg/m2 over 6 hours once every 3 weeks. Lymphomas: Refer to protocols CHILD: 100mg/m2 over 6 hours once every 3 weeks. Lymphomas: Refer to protocols
Clarithromycin 250 mg TabletJ01FA09000T1001XXA*Only for i) treatment of complicated respiratory tract infection not responding to standard macrolides ii) eradication of Helicobacter pylori infectioni) 250 - 500 mg twice daily. Up to 6 - 14 days ii) 500 mg twice daily with omeprazole & amoxicillin. Up to 2 weeks
Clarithromycin 500 mg InjectionJ01FA09000P3001XXA*Only for treatment of complicated respiratory tract infection not responding to standard macrolidesSusceptible infections Adult: 500 mg bid for 2-5 days. Dose to be infused over 60 minutes in a 0.2% solution; revert to oral therapy whenever possible. Child: 1 mth-12 yr: 7.5 mg/kg every 12 hr. Dose to be given via infusion into proximal vein. Dosage Recommendation CrCl (ml/min)<30 : Half the dosage or double dosing interval
Clarithromycin Granules 125 mg/5 mlJ01FA09000F1001XXA*Treatment of complicated respiratory tract infections not responding to standard macrolidesCHILD: 8 - 12 years: 30 - 40 kg 10 mL, 4 - 8 years: 20 - 29 kg 7.5 mL, 2 - 4 years: 12 - 19 kg 5 mL, 1 - 2 years: 8 - 11 kg 2.5 mL, less than 8 kg: 7.5 mg/kg. To be given twice daily. Maximum dose: 1g/day
Clindamycin HCl 300 mg CapsuleJ01FF01110C1001XXA*i) Skin and soft tissue infections, bone& joint infections ii) Cerebral toxoplasmosis iii) Children less than 8 years old:Treatment and prophylaxis of malaria in combination with quinine, as an alternative to doxyclinei) ADULT: 150 - 300 mg every 6 hours; up to 450 mg every 6 hours in severe infections; Max: 1.8g/day CHILD: 3 - 6 mg/kg every 6 hours. Children weighing <10 kg should receive at least 37.5 mg every 8 hr. ii) 600 mg 6 hourly for 6 weeks iii) 10mg/kg twice a day, in combination with quinine. The combination to be given for 7 days
Clindamycin Phosphate 150 mg/ml InjectionJ01FF01162P3001XXA*i) Skin and soft tissue infections, bone & joint infections ii) Cerebral toxoplasmosisi) ADULT: 0.6 - 2.7 g daily (in 2 - 4 divided doses); up to 4.8 g daily; CHILD over 1 month, 20 - 40 mg/kg/day or 350 mg/m2/day in 3 - 4 divided doses ii) 1200 mg every 6 hours for 3 weeks followed by 300 mg orally every 6 hours for another 3 weeks
Clobazam 10 mg tabletN05BA09000T1001XXA*As adjunctive therapy in patients with epilepsy not adequately stabilised with their basic medication.The initial dose in adults and adolescents >15 yr should be low (5 to15mg daily), if necessary, increased gradually to a maximum daily dose of about 80mg. Doses of up to 30mg may be taken as a single dose in the evening. The initial dose in children from 3 to15 yr is normally 5mg. A maintenance dose of 0.3 to 1.0mg/kg body weight daily is usually sufficient.
Clobetasol Propionate 0.05% CreamD07AD01133G1001XXAShort term treatment only of more resistant dermatoses eg. psoriasis, recalcitrant eczemas, lichen planus, discoid lupus erythematosus and other conditions which do not respond satisfactorily to less potent steroidsApply sparingly once or twice daily, changing to lower potency therapy as soon as condition is controlled. For mild to moderate use maximum for 2 weeks. For moderate to severe maximum duration 4 consecutive weeks. Max: 50 g/week
Clobetasol Propionate 0.05% OintmentD07AD01133G5001XXAShort term treatment only of more resistant dermatoses eg. psoriasis, recalcitrant eczemas, lichen planus, discoid lupus erythematosus and other conditions which do not respond satisfactorily to less potent steroidsApply sparingly once or twice daily, changing to lower potency therapy as soon as condition is controlled. For mild to moderate use maximum for 2 weeks. For moderate to severe maximum duration 4 consecutive weeks. Max:50 g/week
Clobetasone Butyrate 0.05% CreamD07AB01255G1001XXA/KKEczema and dermatitis of all typesApply up to four times daily until condition improves, then reduce frequency
Clobetasone Butyrate 0.05% OintmentD07AB01255G5001XXAEczema and dermatitis of all typesApply up to four times daily until condition improves, then reduce frequency
Clodronate 800 mg TabletM05BA02011T1011XXA*Treatment of hypercalcaemia due to malignancy2 tablets in single or two divided doses
Clofazimine 100 mg CapsuleJ04BA01000C1002XXBi) Previously untreated leprosy patients ii) Leprosy patients resistant to sulphones iii) Suppression of lepra reactionsi) ADULT: 100 mg each other day or 50 mg daily with 100mg Dapsone & 300mg once a month with 600mg rifampicin under supervision. Maximum: 200 mg/day. CHILD: 10-14 yr: 50mg clofazimine on alternate days with 50mg dapsone & 150 mg clofazimine with 450 mg rifampicin once a month.Maximum: 100 mg/day. ii) 100 mg daily iii) 200-300mg usually effective. Treatment with minimum suppression dose continued for at least 6 months
Clofazimine 50 mg CapsuleJ04BA01000C1001XXBi) Previously untreated leprosy patients ii) Leprosy patients resistant to sulphones iii) Suppression of lepra reactionsi) ADULT: 100 mg each other day or 50 mg daily with 100mg Dapsone & 300mg once a month with 600mg rifampicin under supervision. Maximum: 200 mg/day. CHILD: 10-14 yr: 50mg clofazimine on alternate days with 50mg dapsone & 150 mg clofazimine with 450 mg rifampicin once a month.Maximum: 100 mg/day. ii) 100 mg daily iii) 200-300mg usually effective. Treatment with minimum suppression dose continued for at least 6 months
Clomiphene Citrate 50mg TabletG03GB02136T1001XXAAnovulatory infertility50 mg daily from 2nd - 6th or 5th - 9th day of menstrual cycle. Increase dose gradually by increments of 50 mg if there is no response until a dosage of 200 mg daily is achieved (starting as early as 30 days afer the previous course). Further treatment may not be recommended if pregnancy has not occurred after a total of 6 treatment cycles.
Clomipramine HCI 25 mg TabletN06AA04110T1001XXADepression, obsessive-compulsive disorder.Initially 10 mg daily, increased gradually as necessary to 30 - 150 mg daily in divided doses or as a single dose at bedtime; max 250 mg daily. ELDERLY initially 10 mg daily increased carefully over approximately 10 days to 30 - 75 mg daily;Child: ≥10 yr: Initially, 25 mg daily, increased gradually over 2 wk. Max: 3 mg/kg/day or 100 mg daily, whichever is smaller. Give in divided doses. Once titrated, dose may be given as a single dose at bedtime.
Clonazepam 0.5 mg TabletN03AE01000T1001XXBi) Epilepsy ii) Non-epileptic myoclonusi) & ii) ADULT: Initial dose should not exceed 1.5mg/day divided into 3 doses, may be increased in increments of 0.5mg every 3 days until seizures are controlled. Maintenance dose: 3-6mg/day. Maximum: 20mg/day. CHILD up to 10 years: initial dose 0.01-0.03 mg/kg/day in 2-3 divided doses, increased by no more than 0.25-0.5mg every third day, maximum 0.2mg/kg/day. CHILD 10-16 years: initial dose 1-1.5mg/day in 2-3 divided dose, may be increased by 0.25-0.5mg every third day until individual maintenance dose of 3-6mg/day is reached.
Clonazepam 2 mg TabletN03AE01000T1002XXBi) Epilepsy ii) Non-epileptic myoclonusi) & ii) ADULT: Initial dose should not exceed 1.5mg/day divided into 3 doses, may be increased in increments of 0.5mg every 3 days until seizures are controlled. Maintenance dose: 3-6mg/day. Maximum: 20mg/day. CHILD up to 10 years: initial dose 0.01-0.03 mg/kg/day in 2-3 divided doses, increased by no more than 0.25-0.5mg every third day, maximum 0.2mg/kg/day. CHILD 10-16 years: initial dose 1-1.5mg/day in 2-3 divided dose, may be increased by 0.25-0.5mg every third day until individual maintenance dose of 3-6mg/day is reached.
Clonidine HCl 0.025 mg TabletN02CX02110T1001XXARapid opiod detoxification combination use with naltrexoneRapid detoxification in 4-5 days (use with naltrexone): 6 mcg/kg ORALLY divided in 3 doses 6 to 8 hours apart the first day, increasing to 11 mcg/kg divided in 3 doses given day two, tapering to 0.6 mcg/kg the third day. Rapid opioid detoxification for 7 days ( use with naltrexone) : 0.1 to 0.2 mg every 4 hours as needed
Clopidogrel 75 mg TabletB01AC04192T1001XXA*Prevention of myocardial infarct, stroke or established peripheral arterial disease. As second/third line treatment in patients who are sensitive to acetylsalicylic acid & intolerant to ticlopidine75 mg once daily
Clostridium Botulinum Toxin Type A 100 unitsM03AX01000P4001XXA*i) Focal dystonias ii) Hemifacial spasm iii) Spasticity including cerebral palsy20 - 200 units 3 months once
Clostridium Botulinum Type A toxin haemagglutinin complex 300 units/vial powder for injectionM03AX01000P4003XXA*i) Focal dystonias ii) Hemifacial spasm iii) Spasticity including cerebral palsyInitially 20 U/kg divided between both calf muscles. May be titrated 10-30 U/kg up to max of not >1000 U/patient. Should only be used in children > 2 years of age. Repeat injections given not less than 3 months from previous injection.
Clostridium botulinum Type A toxin haemagglutinin complex 500U/vial powder for injectionM03AX01000P4002XXA*i) Focal dystonias ii) Hemifacial spasm iii) Spasticity including cerebral palsyInitially 20 U/kg divided between both calf muscles. May be titrated 10-30 U/kg up to max of not >1000 U/patient. Should only be used in children > 2 years of age. Repeat injections given not less than 3 months from previous injection.
Clotrimazole 1% CreamD01AC01000G1001XXBCutaneous candidiasis, Tinea corporis, Tinea cruris, Tinea pedis and Tinea versicolorRub in gently onto affected and surrounding skin 2 or 3 times daily continuing for about 2 weeks beyond the dissapearance of all symptoms
Clotrimazole 1% Ear DropS02AA00000D1002XXBOtomycosis; concomitant therapy with antibiotics and corticosteroid ear drops4 to 5 drops 3 to 4 times daily
Clotrimazole 1% SolutionD01AC01000L6001XXACutaneous candidiasis, tinea orporis, tinea cruris, tinea pedis and tinea versicolorApply gently onto affected and surrounding skin area 2 or 3 times daily continuing for 2-4 weeks
Clotrimazole 200 mg Vaginal TabletG01AF02000S1002XXBVaginal candidiasis200 mg once daily, preferably at bedtime for three consecutive days
Clotrimazole 500 mg Vaginal TabletG01AF02000S1003XXBVaginal candidiasis500 mg as a single one-time dose
Cloxacillin Sodium 125 mg/5 ml SuspensionJ01CF02520L8001XXBTreatment of susceptible bacterial infections, notably penicillinase-producing staphylococciChild: 50-100 mg/kg in divided doses every 6 hr
Cloxacillin Sodium 250 mg CapsuleJ01CF02520C1001XXBTreatment of susceptible bacterial infections, notably penicillinase-producing staphylococciADULT: 250 - 500 mg every 6 hours. Child: 50-100 mg/kg in divided doses every 6 hr.
Cloxacillin Sodium 250 mg InjectionJ01CF02520P4001XXBTreatment of susceptible bacterial infections, notably penicillinase-producing staphylococci infectionsADULT: 250 to 500 mg every 6 hours depending on type and severity of infection. CHILD less than 20 kg: 25 to 50 mg/kg/day in equally divided doses every 6 hours
Cloxacillin Sodium 500 mg CapsuleJ01CF02520C1002XXBTreatment of susceptible bacterial infections, notably penicillinase-producing staphylococciADULT: 250 - 500 mg every 6 hours. CHILD: 2 - 10 years: 250 mg 4 times daily; less than 2 years: 125 mg 4 times daily
Cloxacillin Sodium 500 mg InjectionJ01CF02520P4002XXBTreatment of susceptible bacterial infections, notably penicillinase-producing staphylococci infectionsADULT: 250 to 500 mg every 6 hours depending on type and severity of infection. CHILD less than 20 kg: 25 to 50 mg/kg/day in equally divided doses every 6 hours
Clozapine 100 mg TabletN05AH02000T1002XXATreatment of resistant schizophreniaInitial dose : 12.5 mg ( once or twice ) daily, increase slowly in steps of 25 - 50 mg up to 300 mg daily within 2 - 3 weeks. Maximum 900 mg/day
Clozapine 25 mg TabletN05AH02000T1001XXATreatment of resistant schizophreniaInitial dose : 12.5 mg ( once or twice ) daily, increase slowly in steps of 25 - 50 mg up to 300 mg daily within 2 - 3 weeks. Maximum 900 mg/day
Coal Tar 1- 6 % in Betamethasone 17 - Valerate 0.01 % OintmentD05AA00946G5003XXBDandruff, seborrhoeic dermatitis, atopic dermatitis, eczema and psoriasisApply to the affected areas sparingly 1-2 times daily
Coal Tar 1-9% OintmentD05AA00000G5001XXBDandruff, seborrhoeic dermatitis, atopic dermatitis, eczema and psoriasis. Used as a mild astringent for the skin, as a soothing and protective application in eczema and as a protective to slight excoriationApply sparingly to the affected area 1-3 times daily starting with low strength preparations
Coal Tar 20% SolutionD05AA00000L5201XXBDandruff, seborrhoeic dermatitis, atopic dermatitis, eczema and psoriasisUse 100 ml in a bath
Coal Tar and Salicylic Acid (various concentrations) OintmentD05AA00946G5002XXBDandruff, seborrhoeic dermatitis, atopic dermatitis, eczema and psoriasisApply to the affected areas
Cocaine 10% SolutionN01BC01110L5001XXBTo produce local anaesthesia or vasoconstriction during endoscopic nasal surgery, turbinectomy septoplasty, polypectomy etcMaximum total dose recommended for application to the nasal mucosa in healthy adult is 1.5 to 2 mg/kg of a 10% cocaine solution
Cocois Co. OintmentD05AA00946G5001XXBScalp psoriasis and severe seborrhoeic dermatitisRub a small amount into the scalp gently
Colchicine 0.5 mg TabletM04AC01000T1001XXBi) Acute gout and prophylaxis of recurrent gout. ii) Leucocytoclastic Vasculitis either cutaneous or systemic involvement, Behcet's syndrome, Urticarial vasculitis, Systemic sclerosis, Sweet's syndrome and severe recalcitrant aphthous stomatitisi) Initial dose, 0.5-1.2 mg, then 0.5-0.6 mg every hour until relief of pain is obtained or vomiting or diarrhoea occurs (Maximum : 8 mg). The course should not be repeated within 3 days. Prevention of attacks during initial treatment with allopurinol or uricosuric drugs: 0.5 mg 1-3 times daily. ii) 0.5 mg 1-3 times daily depends on disease and severity, up to a maximum of 3 mg/day
Colloidal Bismuth Subcitrate 120 mg TabletA02BX05136T1001XXAEradication therapy for Helicobacter Pylori in combination with antibiotics and antisecretory drugs240 mg twice daily for 1-2 weeks
Compound Sodium Lactate (Hartmanns Solution)B05XA30125P6001XXCReplacement of extracellular losses of fluid and electrolytes, as an alkaliniser agent100-1000 ml by IV or according to the needs of the patient
Conjugated estrogens 0.3 mg TabletG03CA57000T1003XXAi) Osteoporosis associated with oestrogen deficiency ii) Female hypoestrogenism iii) Vasomotor symptoms associated with oestrogen deficiency iv)atrophic vaginitis and urethritisi) 0.3 - 0.625 mg daily ii) 0.3- 1.25mg daily for 3weeks, then off for 1 week iii) & iv) 0.3mg-1.25mg daily
Conjugated Estrogens 0.625 mg & Medroxyprogesterone Acetate 2.5 mg TabletG03FA12295T1002XXAManagement of moderate to severe vasomotor symptoms associated with menopause, prevention and management of postmenopausal osteoporosis, atropic vaginitis and atropic urethritis in post menopausal woman with intact uterus1 tablet daily
Conjugated Oestrogens 0.625 mg TabletG03CA57000T1001XXAi) Osteoporosis associated with oestrogen deficiency ii) Female hypoestrogenism iii) Vasomotor symptoms associated with oestrogen deficiency iv)atrophic vaginitis and urethritisi) 0.3 - 0.625 mg daily ii) 0.3- 1.25mg daily for 3weeks, then off for 1 week iii) & iv) 0.3mg-1.25mg daily
Conjugated Oestrogens 0.625 mg/g CreamG03CA57000G1001XXAAtrophic vaginitis and post menopausal atrophic urethritisIntravaginally or topically 0.5-2g daily depending on severity of condition. Administration should be cyclic, with 3 weeks on conjugated estrogens and one week off. Estrogens should be used for the shortest duration possible when treating atrophic vaginitis. Every 3 to 6 months attempts should be made to taper or discontinue therapy and conjugated estrogens should be titrated to give the lowest possible dosage to control symptoms
Continuous Ambulatory Peritoneal Dialysis (CAPD) Solution containing 2.3% glucose (Calcium 1.75mmol/L) & (Calcium 1.25mmol/L)B05DB00908H2504XXBFor chronic renal diseases requiring dialysis and acute therapy-resistance renal failure eg. prior to transfer to a dialysis centreDose depending on clinical cases
Continuous Ambulatory Peritoneal Dialysis Solution containing 1.5% DextroseB05DB00908H2501XXBFor chronic renal diseases requiring dialysis and acute therapy-resistance renal failure eg. prior to transfer to a dialysis centreDose depending on clinical cases
Continuous Ambulatory Peritoneal Dialysis Solution containing 2.5% DextroseB05DB00908H2502XXBFor chronic renal diseases requiring dialysis and acute therapy-resistance renal failure eg. prior to transfer to a dialysis centreDose depending on clinical cases
Continuous Ambulatory Peritoneal Dialysis Solution containing 4.25% DextroseB05DB00908H2503XXBFor chronic renal diseases requiring dialysis and acute therapy-resistance renal failure eg. prior to transfer to a dialysis centreDose depending on clinical cases
Copper 250 mm2 Intrauterine DeviceG02BA02000M9001XXBIntrauterine contraceptionOne unit intrauterine device to be inserted into the uterine cavity on the last day of the menstrual flow or in the first days afterwards. It is advised that the Multiload Cu 250 devices are replaced every 3 years
Copper 375 mm2 Intrauterine DeviceG02BA02000M9002XXBContraceptionOne unit intrauterine device to be inserted into the uterine cavity on the last day of the menstrual flow or in the first days afterwards. It is advised that the Multiload Cu 375 devices are replaced every 5 years
Copper Sulphate CrystalD08A000183F9901XXCWoundsThe tip of the crystal should be moistened by dipping in water and applied carefully to the lesion
Corifollitropin Alfa 100mcg/0.5ml solution for injectionG03GA09000P5001XXA*Controlled Ovarian Stimulation (COS) in combination with a GnRH antagonist for the development of multiple follicles in woman participating in an Assisted Reproductive Technology (ART) program Restriction: As second line treatment alternative to other recombinant FSHWomen with Body Weight ≤60 kg: A single dose of 100 mcg should be administered. Women with Body Weight >60 kg: A single dose of 150 mcg should be administered. Details : Refer to Product Information
Corifollitropin Alfa 150mcg/0.5ml solution for injectionG03GA09000P5002XXA*Controlled Ovarian Stimulation (COS) in combination with a GnRH antagonist for the development of multiple follicles in woman participating in an Assisted Reproductive Technology (ART) program Restriction: As second line treatment alternative to other recombinant FSHWomen with Body Weight ≤60 kg: A single dose of 100 mcg should be administered. Women with Body Weight >60 kg: A single dose of 150 mcg should be administered. Details : Refer to Product Information
Cortisone Acetate 5 mg TabletH02AB10122T1002XXBFor salt losing congenital adrenal hyperplasia in newborn and paediatric patients20-30 mg/m2 daily. Doses may be divided with two-thirds in the morning and one-third late in the afternoon
Crotamiton 10 % CreamP03A000000G1001XXA/KKi) Pruritus ii) Scabies iii) Insect bite reactionsi) and iii) Massage into affected area until the medication is completely absorbed. Repeat as needed. Apply 2 or 3 times daily ii) Apply to the whole body from below the chin. 2nd application is applied 24 hr later. May need to use once daily for up to 5 days.
Cyanocobalamin 0.1 mg InjectionB03BA01000P3001XXBi) Prophylaxis of anaemia ii) Uncomplicated pernicious anaemia or Vitamin B12 malabsorptioni) Prophylaxis of anaemia: 250-1000 mcg IM every month ii) Uncomplicated pernicious anaemia or Vitamin B12 malabsorption: Initial 100 mcg daily for 5-10 days followed by 100-200 mcg monthly until complete remission is achieved. Maintenance: 100 mcg monthly. CHILD 30-50 mcg daily for 2 or more weeks (to a total dose of 1-5mg). Maintenance: 100 mcg monthly to sustain remission
Cyanocobalamin 1 mg InjectionB03BA01000P3002XXBi) Prophylaxis of anaemia associated with Vitamin B12 deficiency ii) Uncomplicated pernicious anaemia or Vitamin B12 malabsorptioni) Prophylaxis of anaemia: 250-1000 mcg IM every month ii) Uncomplicated pernicious anaemia or Vitamin B12 malabsorption: Initial 100 mcg daily for 5-10 days followed by 100-200 mcg monthly until complete remission is achieved. Maintenance: 100 mcg monthly. CHILD 30-50 mcg daily for 2 or more weeks (to a total dose of 1-5mg).
Cyanocobalamin 50 mcg TabletB03BA01000T1002XXBVitamin B12 deficiency of dietary originADULT 50-150 mcg daily. CHILD 50-105 mcg daily in 1-3 divided doses
Cyclopentolate 0.2% with Phenylephrine 1% Eye DropsS01GA55990D2001XXADilating agent for premature babies1 drop every 5 - 10 minutes; not exceeding three times to produce rapid mydriasis. Observe infants closely for at least 30 minutes
Cyclopentolate 0.5% Eye DropsS01FA04000D2001XXAMydriasis and cycloplegia1 to 2 drops of 0.5% to 2% solution in eye(s); may repeat after 5 to 10 minutes if needed. Small INFANT : single instillation of 1 drop of 0.5% solution in the eye; apply pressure to nasolacrimal sac for 2 to 3 minutes; observe infant closely for at least 30 minutes for signs or symptoms of systemic absorption
Cyclopentolate 1% Eye DropsS01FA04000D2002XXAMydriasis and cycloplegia1 - 2 drops several times a day. Refractory procedures, ADULT : 1 drop of 0.5% solution. CHILD 6 - 12 years : 1 drop of 1% solution. CHILD less than 6 years : 1 - 2 drops of 1% solution
Cyclophosphamide 1 g InjectionL01AA01000P4002XXAi) Solid tumours (adult and paediatric), leukaemia, non-Hodgkin's lymphoma, multiple myeloma ii) Severe lupus nephritis (Class III and IV) iii) Other systemic vasculitis iv) Systemic lupus erythematosus, rheumatoid arthritis, polyarteritis nodosa, wegener granulomatosis v) Pemphigus vulgarisi) ADULT: 600 - 750 mg/m2 IV once every 3 weeks as part of combination regime. CHILD: Dose variable depending on disease and protocol. Range 600 mg/m2 to 2 g/m2 infusion over 1 hour to 6 hours (lower doses can be given as bolus). Care with pre and post-hydration. Mesna to be given with doses more than 1 g/m2. Higher doses are used in haematopoetic stem cell transplant-refer to specific protocols ii) 750 mg/m2 BSA monthly for 18 months iii) 750 mg/m2 BSA monthly for 6 months. Dose can be adjusted up to 1,000 mg/m2 BSA to achieve adequate leucocyte suppression iv) 500 - 1000 mg intravenously (Regime varies according to indication). Starting dose may be given fortnightly then at monthly intervals followed by 3 monthly intervals v) 500 mg infusion on the 2nd day of the dexamethasone-cyclophosphamide pulsed regime, the cycle is repeated every 4 weeks up to 6 cycles or till remission followed by oral cyclophosphamide
Cyclophosphamide 200 mg InjectionL01AA01000P4001XXAi) Solid tumours (adult and paediatric), leukaemia, non-Hodgkin's lymphoma, multiple myeloma ii) Severe lupus nephritis (Class III and IV) iii) Other systemic vasculitis iv) Systemic lupus erythematosus, rheumatoid arthritis, polyarteritis nodosa, wegener granulomatosis v) Pemphigus vulgarisi) ADULT: 600 - 750 mg/m2 IV once every 3 weeks as part of combination regime. CHILD: Dose variable depending on disease and protocol. Range 600 mg/m2 to 2 g/m2 infusion over 1 hour to 6 hours (lower doses can be given as bolus). Care with pre and post-hydration. Mesna to be given with doses more than 1 g/m2. Higher doses are used in haematopoetic stem cell transplant-refer to specific protocols ii) 750 mg/m2 BSA monthly for 18 months iii) 750 mg/m2 BSA monthly for 6 months. Dose can be adjusted up to 1,000 mg/m2 BSA to achieve adequate leucocyte suppression iv) 500 - 1000 mg intravenously (Regime varies according to indication). Starting dose may be given fortnightly then at monthly intervals followed by 3 monthly intervals v) 500 mg infusion on the 2nd day of the dexamethasone-cyclophosphamide pulsed regime, the cycle is repeated every 4 weeks up to 6 cycles or till remission followed by oral cyclophosphamide
Cyclophosphamide 50 mg TabletL01AA01000T1001XXAi) Solid tumours, leukaemia, lymphoma, autoimmune disorders, autoimmune bullous diseases, connective tissue disease, pyoderma gangrenosum ii) For severe lupus nephritis (Class III & IV), systemic vasculitis and steroid resistant/dependent nephrotic syndrome iii) Systemic lupus erythematosus (SLE), rheumatoid arthritis, polyarteritis nodosa, wegener granulomatosisi) ADULT: 50 - 100 mg/day. Monitor full blood count (FBC), liver function, urine microscopy and renal function. CHILD, up to 1 year: 10 - 20 mg daily, 1 - 5 years: 30 - 50 mg daily, 6 - 12 years: 50 - 100 mg daily ii) 2 mg/kg/day for 3 - 4 months iii) 1 - 1.5 mg/kg/day orally in divided doses
Cycloserine 250 mg CapsuleJ04AB01000C1001XXA*Multi-Drug Resistance Tuberculosis treatment failure. (For respiratory physicians)ADULT: Initial: 250 mg every 12 hours for 14 days, then administer 0.5 - 1 g daily in 2 divided doses for 18 - 24 months (maximum daily dose: 1 g). CHILD: 2-12 yr: 5 mg/kg bid; 12-18 yr: 250 mg bid for 2 wk then adjusted to a max dose of 1 g daily
Cyproterone Acetate 2 mg & Ethinyloestradiol 0.035 mg TabletG03HB01954T1001XXA*Androgen dependent diseases in women1 tablet daily for 21 days on the first day of the cycle, followed by 7 tab free days. Starting on day 2 to 5 is allowed, but during the first cycle a barrier method is recommended for the first 7days of tablet taking.
Cyproterone Acetate 50 mg TabletG03HA01122T1001XXA*Carcinoma of prostatei) After orchidectomy, 100 mg once daily or twice daily ii) If used together with LHRH agonists, the initial dose is 100 mg twice daily for 5 to 7 days before the start of LHRH agonist, then 100 mg twice daily for 3 to 4 weeks together with the LHRH agonist
Cytarabine 1 g InjectionL01BC01000P4004XXAi) Central nervous system lymphoma ii) Meningeal leukemia iii) Non Hodgkin's Lymphoma iv) High dose cytarabine as conditioning to cytoreduce the disease before stem cell transplant for relapsed or refractory leukemia v) As salvage for acute lymphocytic leukemia vi) As salvage for acute myeloid leukemia vii) As palliative chemotherapy in elderly acute myeloid leukemia/ myelodysplastic syndromeStandard doses 100 - 200 mg/m2 daily over 5 - 10 days. Higher doses for intensification/consolidation: 1000 - 3000 mg/m2 daily over 3 - 5 days depending on specific protocols. CHILD: Dose variable depending on disease and protocol. Range from 100 mg/m2 to 3 g/m2 twice daily. May be given as SC, IV bolus or infusion. Intrathecal dose: Less than 1 year: 15 mg, 1 - 2 years: 20 mg, 2 - 3 years: 25 mg, more than 3 years: 30 mg. (ENSURE THAT PREPARATION IS SUITABLE FOR INTRATHECAL USE)
Cytarabine 100 mg InjectionL01BC01000P4002XXAi) Central nervous system lymphoma ii) Meningeal leukemia iii) Non Hodgkin's Lymphoma iv) High dose cytarabine as conditioning to cytoreduce the disease before stem cell transplant for relapsed or refractory leukemia v) As salvage for acute lymphocytic leukemia vi) As salvage for acute myeloid leukemia vii) As palliative chemotherapy in elderly acute myeloid leukemia/ myelodysplastic syndromeStandard doses 100 - 200 mg/m2 daily over 5 - 10 days. Higher doses for intensification/consolidation: 1000 - 3000 mg/m2 daily over 3 - 5 days depending on specific protocols. CHILD: Dose variable depending on disease and protocol. Range from 100 mg/m2 to 3 g/m2 twice daily. May be given as SC, IV bolus or infusion. Intrathecal dose: Less than 1 year: 15 mg, 1 - 2 years: 20 mg, 2 - 3 years: 25 mg, more than 3 years: 30 mg. (ENSURE THAT PREPARATION IS SUITABLE FOR INTRATHECAL USE)
Cytarabine 500 mg InjectionL01BC01000P4003XXAi) Central nervous system lymphoma ii) Meningeal leukemia iii) Non Hodgkin's Lymphoma iv) High dose cytarabine as conditioning to cytoreduce the disease before stem cell transplant for relapsed or refractory leukemia v) As salvage for acute lymphocytic leukemia vi) As salvage for acute myeloid leukemia vii) As palliative chemotherapy in elderly acute myeloid leukemia/ myelodysplastic syndromeStandard doses 100 - 200 mg/m2 daily over 5 - 10 days. Higher doses for intensification/consolidation: 1000 - 3000 mg/m2 daily over 3 - 5 days depending on specific protocols. CHILD: Dose variable depending on disease and protocol. Range from 100 mg/m2 to 3 g/m2 twice daily. May be given as SC, IV bolus or infusion. Intrathecal dose: Less than 1 year: 15 mg, 1 - 2 years: 20 mg, 2 - 3 years: 25 mg, more than 3 years: 30 mg. (ENSURE THAT PREPARATION IS SUITABLE FOR INTRATHECAL USE)
Dabigatran Etexilate 110 mg CapsuleB01AE07999C1002XXA*i) Prevention of venous thromboembolic events in patients who have undergone total knee replacement or total hip replacement surgery ii) Reduction of the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (AF)i) Following total knee replacement: Initially ADULT 110mg (ELDERLY, 75 mg) within 1- 4 hours after surgery, then 220 mg (ELDERLY, 150 mg) once daily thereafter for 6-10 days Following total hip replacement: Initially ADULT 110 mg (ELDERLY, 75 mg) within 1- 4 hours after surgery, then 220 mg (ELDERLY, 150 mg) once daily thereafter for 28-35 days ii) Recommended daily dose is 300mg taken orally as 150mg hard capsule twice daily. Therapy should be continued lifelong. Patients aged 80 years and above should be treated with a dose of 220mg daily , taken orally as one 110mg capsule twice daily. Special patient population for Renal Impairment : Renal function should be assessed by calculating the creatinine clearance (CrCl) prior to initiation of treatment with Dabigatran to exclude patients for treatment with severe renal impairment (i.e. CrCl < 30 ml/min)
Dabigatran Etexilate 75 mg CapsuleB01AE07999C1001XXA*Prevention of venous thromboembolic events in patients who have undergone total knee replacement or total hip replacement surgeryFollowing total knee replacement: Initially ADULT 110 mg (ELDERLY, 75 mg) within 1- 4 hours after surgery, then 220 mg (ELDERLY, 150 mg) once daily thereafter for 6-10 days Following total hip replacement: Initially ADULT 110 mg (ELDERLY, 75 mg) within 1- 4 hours after surgery, then 220 mg (ELDERLY, 150 mg) once daily thereafter for 28-35 days
Dabigatran Etexilate150 mg CapsuleB01AE07999C1003XXA*Reduction of the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (AF)Recommended daily dose is 300mg taken orally as 150mg hard capsule twice daily. Therapy should be continued lifelong. Patients aged 80 years and above should be treated with a dose of 220mg daily , taken orally as one 110mg capsule twice daily. Special patient population for Renal Impairment : Renal function should be assessed by calculating the creatinine clearance (CrCl) prior to initiation of treatment with Dabigatran to exclude patients for treatment with severe renal impairment (i.e. CrCl < 30 ml/min).
Dacarbazine 100 mg InjectionL01AX04000P4001XXA*i) Malignant melanoma, sarcomas, neuroblastomas and other childhood solid tumours ii) Hodgkin's Diseasei) 250 mg/m2 for 5 days, may be repeated every 3 weeks ii) 375 mg/m2 IV every 2 weeks
Danazol 100 mg CapsuleG03XA01000C1001XXA/KKi)Endometriosis and gynaecomastia ii)Menorrhagia iii)Prophylaxis of hereditary angioedemai)200 - 800 mg daily for max of 9 months ii)200 mg daily for 12 weeks ii)400 mg daily. Reduce to 200 mg daily after 2 months attack free period
Danazol 200 mg CapsuleG03XA01000C1002XXA/KKi)Endometriosis and gynaecomastia ii)Menorrhagia iii)Prophylaxis of hereditary angioedemai)200 - 800 mg daily for max of 9 months ii)200 mg daily for 12 weeks ii)400 mg daily. Reduce to 200 mg daily after 2 months attack free period
Dapsone 100 mg TabletJ04BA02000T1001XXBi)Leprosy ii) Dermatitis herpetiformisi) ADULT: 6 - 10 mg/kg weekly/ 1.4mg/kg daily (around 50 - 100 mg daily). CHILD: 1 - 2 mg/kg/day. Maximum: 100 mg/day ii) ADULT: 50 - 300 mg daily
Daunorubicin HCl 20 mg InjectionL01DB02110P4001XXA*i) Acute myeloblastic leukaemia (AML) ii) Acute lymphoblastic leukemia (ALL)i) 45 - 60 mg/m2 IV daily for 3 - 5 days ii) 25 - 45 mg/m2 once a week for first 4 weeks during induction phase. Caution: Total cumulative dose of daunorubicin and doxorubicin must not exceed 500 mg/m2 due to risk of cardiotoxicity. CHILD: 30-45 mg/m2/dose infusion over 6 hours. Schedule depends on protocol. Need to check cardiac function closely by echocardiography every cumulative dose of 100mg/m2 to max. 360 mg/m2
Decitabine 50 mg InjectionL01BC08000P3001XXA*Myelodysplastic syndromes (MDS) including: Previously treated and untreated de novo and secondary MDS of all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and Intermediate-1, Intermediate-2, and High-Risk International Prognostic Scoring System (IPSS) groups15 mg/m2 by continuous IV infusion over 3 hours repeated every 8 hours for 3 days. Repeat this treatment cycle every 6 weeks for a minimum of 4 cycles. However, complete or partial response may take longer than 4 cycles. Treatment may be continued as long as there is continued
Deferasirox 125 mg Dispersible TabletV03AC03000T4001XXA*Treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adult and pediatric patients aged 2 years and aboveInitial 20 mg/kg/day. Starting dose can also be based on transfusion rate and existing iron burden. Max is 30 mg/kg/day
Deferasirox 500 mg Dispersible TabletV03AC03000T4002XXA*Treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adult and pediatric patients aged 2 years and aboveInitial 20 mg/kg/day. Starting dose can also be based on transfusion rate and existing iron burden. Max is 30 mg/kg/day
Deferiprone 500 mg TabletV03AC02000T1001XXA*Treatment of iron overload in patients with thalassemia major for whom desferrioxamine therapy is contraindicated or inadequate. Add on therapy to desferrioxamine for thalassemia patients with cardiac complication25 mg/kg 3 times a day for total daily dose of 75 mg/kg. Doses greater 100 mg/kg are not recommended
Desferrioxamine B Methanesulphonate 0.5 g InjectionV03AC01196P3001XXAi) Acute iron poisoning in children ii) Investigation and treatment of haemochromatosis iii) Diagnosis and treatment of aluminium toxicity in patients with renal failure and dialysis iv) Chronic iron toxicity or overloadi) 2 g by IM immediately and 5 g by mouth after gastric lavage ii) 0.5 - 1.5 g by IM injection daily iii) Diagnosis: 5 mg per kg by slow intravenous infusion during the last hour of haemodialysis. Treatment: 5 mg per kg once a week by slow intravenous infusion during the last hour of dialysis iv) 30 - 50 mg/kg
Desflurane LiquidN01AB07000L5001XXAi) Induction and maintenance of anaesthesia in adult ii) Maintenance of anaesthesia in infants & childrenADULT: Induction , initially 3% in oxygen or nitrous oxide/oxygen and increased by 0.5%-1% every 2-3 breaths or as tolerated (up to 11%), until loss of consciousness. Maintenance: 2.5%-8.5% with or without concomitant nitrous oxide CHILD: maintenance, inhaled in concentrations of 5.2%-10% with or without concomitant nitrous oxide
Desloratadine 5 mg TabletR06AX27000T1001XXA*Allergic rhinitis and chronic idiopathic urticariaADULT & CHILD more than 12 years : 5 mg once daily. CHILD: 6-11 yr: 2.5 mg; 1-5 yr: 1.25 mg; 6-11 mth: 1 mg. Doses to be taken once daily
Desmopressin 0.1 mg TabletH01BA02122T1001XXAi)Central diabetes insipidus ii)Primary nocturnal enuresis iii)Treatment of nocturia associated with nocturnal polyuria in adulti)ADULT and CHILD : 0.1-0.2mg 3 times daily, up to 0.1-1.2mg daily ii) ADULT & Child≥5 yr 0.2-0.4mg at night iii)Initially 0.1 mg at night. May be increased to 0.2 mg and then to 0.4 mg by means of weekly increase
Desmopressin 0.2 mg TabletH01BA02122T1002XXAi)Central diabetes insipidus ii)Primary nocturnal enuresis iii)Treatment of nocturia associated with nocturnal polyuria in adulti)ADULT and CHILD : 0.1-0.2mg 3 times daily, up to 0.1-1.2mg daily ii) ADULT & Child≥5 yr 0.2-0.4mg at night iii)Initially 0.1 mg at night. May be increased to 0.2 mg and then to 0.4 mg by means of weekly increase
Desmopressin 100 mcg/ml Nasal SprayH01BA02122A4101XXAi) Diabetes Insipidus ii) Primary nocturnal enuresisi) ADULT : 10 - 20 mcg 1-2 times daily. CHILD: 5 - 10mcg 1-2 times daily ii) 10-40 mcg nocte
Desmopressin Acetate 4 mcg/ml InjectionH01BA02122P3001XXADiabetes insipidusADULT : 1 - 4 mcg IV daily. CHILD :0.4 mcg daily
Desogestrel 0.075 mg TabletG03AC09000T1001XXA*Contraception. Only for women who should not take combined oral contraceptives (COCs) eg Obese, smoker, migraine, breast feedingTablets must be taken in the order directed on the package every day at about the same time with some liquid as needed. One tablet is to be taken daily for 28 consecutive days. Each subsequent pack is started immediately after finishing the previous pack.
Desogestrel 150 mcg & Ethinylestradiol 20 mcg TabletG03AA09954T1002XXA/KKOral contraceptionOne tablet daily for 21 days starting on 1st day of menses followed by 7 tablet-free days.
Desogestrel 150 mcg & Ethinylestradiol 30 mcg TabletG03AB05954T1001XXC+Contraception1 tablet daily for 21 days, subsequent courses repeated after 7 day interval (during which withdrawal bleeding occurs)
Desvenlafaxine Succinate 50 mg Extended Release TabletN06AX23999T5002XXA*Major depressionRecommended dose is 50mg once daily, with or without food.
Dexamethasone 0.5 mg TabletH02AB02000T1001XXACroup, septic shock, cerebral oedema and respiratory distress syndrome including status asthmaticus0.5 - 9 mg daily, depending upon the disease being treated. Up to 15 mg daily in severe disease
Dexamethasone and Neomycin Sulphate and Polymyxin B Eye OintmentS01CA01990G5101XXATreatment of ocular inflammation when concurrent use of an antimicrobial is judged necessaryApply 1 - 1.5 cm 3 - 4 times daily, may be used adjunctively with drops at bedtime
Dexamethasone and Neomycin Sulphate and Polymyxin B Sulphate Ophthalmic SuspensionS01CA01990D2001XXATreatment of ocular inflammation when concurrent use of an antimicrobial is judged necessary1 - 2 drops hourly for severe cases and 4 - 6 hourly for mild infection
Dexamethasone Sodium Phosphate 0.1% Eye DropsS01BA01162D2001XXAAcute steroid responsive inflammatory and allergic conditions1 - 2 drops 4 - 6 times a day
Dexamethasone Sodium Phosphate 4 mg/ml InjectionH02AB02162P3001XXBCroup, septic shock, cerebral oedema and respiratory distress syndrome including status asthmaticusInitially 0.5 - 9 mg IM, IV or infusion daily, depending upon the disease being treated
Dexchlorpheniramine Maleate 2 mg TabletR06AB02253T1001XXBSymptomatic treatment of allergic rhinitis and allergic dermatosesADULT : 2 mg 3 times daily. CHILD : 1 - 12 years : 2 mg 3 times daily
Dexchlorpheniramine Maleate 2 mg/5 ml SyrupR06AB02253L9001XXBSymptomatic treatment of allergic rhinitisCHILD 2 - 5 years : 0.5 mg every 4 - 6 hours; 6 - 11 years : 1 mg every 4 - 6 hours
Dexmedetomidine HCl 100 mcg/ml InjectionN05CM18110P4001XXA*i) Sedation of intubated and mechanically ventilated ICU patients. For use only by specialist anaesthetist ii) For sedation of non-intubated patients prior to and/or during surgical and other proceduresi) Not to be infused for more than 24 hours, 1 mcg/kg over 10 minutes as loading dose. Maintenance dose: 0.2 - 0.7 mcg/kg/hr ii) Not to be infused for more than 24 hours, 1 mcg/kg over 10 minutes as loading dose. Maintenance dose: 0.2 - 0.7 mcg/kg/hr
Dextran 40 InjectionB05AA05000P6001XXA*Condition associated with peripheral local slowing of the blood flow, prophylaxis of post surgical thromboembolic diseaseInitially 500-1000 ml by infusion, further doses are given according to the patient's condition
Dextrose 10% InjectionB05BA03000P6002XXBFor parenteral replenishment of fluid and minimal carbohydrate calories as required by the clinical condition of the patientAccording to the needs of the patient
Dextrose 20% InjectionB05BA03000P6003XXBFor parenteral replenishment of fluid and minimal carbohydrate calories as required by the clinical condition of the patientAccording to the needs of the patient
Dextrose 30% InjectionB05BA03000P3004XXBFor parenteral replenishment of fluid and minimal carbohydrate calories as required by the clinical condition of the patientAccording to the needs of the patient
Dextrose 5% InjectionB05BA03000P6001XXBFor parenteral replenishment of fluid and minimal carbohydrate calories as required by the clinical condition of the patientAccording to the needs of the patient
Dextrose 50% InjectionB05BA03000P3005XXBFor parenteral replenishment of fluid and minimal carbohydrate calories as required by the clinical condition of the patientAccording to the needs of the patient
Dextrose PowderV04CA02000F2101XXBUse as a diagnostic agent for diabetes75 g stat
Diatrizoate Meglumine and Sodium Amidotrizoate SolutionV08AA01254L9901XXAi) Contrast medium for the radiological examination of the gastrointestinal tract (primarily in cases in which barium sulphate is contraindicated) ii) Computerised tomography in abdominal region iii) Treatment of Mecolinium ileusi) ADULT and CHILD more than 10 year, ORALLY: 60 -100 ml RECTALLY, contrast medium should be diluted with 3-4 times its volume of water. ORALLY: CHILD less than 10 years,: 15- 30 ml NEWBORN, INFANT contrast medium should be diluted with 3 times its volume of water. RECTALLY: CHILD more than 5 years, contrast medium should be diluted with 4-5 times its volume of water. Younger patients a dilution with 5 times its volume is recommended ii) Adult, orally, 25-77 mL in 1000 mL tap water 15-30 minutes prior to imaging
Diazepam 2 mg TabletN05BA01000T1001XXBi) Muscle spasm of varied aetiology, including tetanus ii) Anxiety disordersi) ADULT: 2-10 mg 3-4 times daily. CHILD 6 months and older: 0.12 - 0.8 mg/kg daily in divided doses, every 6-8 hours ii) ADULT : 2 mg 3 times daily, increased in severe anxiety to 15 - 30 mg daily in divided doses. ELDERLY (or delibitated) half adult dose. CHILD (night terrors), 1 - 5 mg at bedtime
Diazepam 5 mg Rectal SolutionN05BA01000G2001XXCStatus epilepticus, skeletal muscle spasmStatus epilepticus - ADULT: 0.5 mg/kg repeated after 12 hours if necessary. CHILD (febrile convulsions, prolonged or recurrent): 0.5 mg/kg (maximum 10 mg), repeated if necessary. Not recommended for children below 2 years
Diazepam 5 mg TabletN05BA01000T1002XXBi) Muscle spasm of varied aetiology, including tetanus ii) Anxiety disordersi) ADULT: 2-10 mg 3-4 times daily. CHILD 6 months and older: 0.12 - 0.8 mg/kg daily in divided doses, every 6-8 hours ii) ADULT : 2 mg 3 times daily, increased in severe anxiety to 15 - 30 mg daily in divided doses. ELDERLY (or delibitated) half adult dose. CHILD (night terrors), 1 - 5 mg at bedtime
Diazepam 5 mg/ml InjectionN05BA01000P3001XXBi) Status epilepticus ii) Skeletal muscle spasm iii) Anxiety disordersi) Status epilepticus, by slow IV: 5-10 every 10-15 minute (rate not more than 5 mg/min), to a total dose of 30 mg, may repeat in 2 hour if needed. Infants 30 days to 5 years, 0.05-0.3 mg/kg/dose given over 2-3 minutes, every 15-30 minutes to a total dose of 5 mg, repeat in 2-4 hours if necessary. CHILD more than 5 years, 1 mg by slow IV, every 2-5 minutes, maximum 10 mg, repeat in 2-4 hours if necessary ii) Skeletal muscle spasm, by slow IV or IM, 5-10 mg repeated if necessary in 3-4 hours. CHILD (tetanus): 30 days - 5 years, 1-2 mg IM or IV slowly every 3-4 hours as needed. 5 years and above, 5-10 mg IM or IV slowly every 3-4 hours if needed iii) Anxiety disorders, 2-10 mg by slow IV (not more than 5 mg/min). Repeat if necessary every 3-4 hours
Diclofenac 1% GelM02AA15520G3001XXAPost-traumatic inflammation of the tendons,ligaments & joints. Localised forms of soft tissue rheumatism and degenerative rheumatismApply 3 - 4 times daily and gently rubbed in
Diclofenac 12.5 mg SuppositoryM01AB05520S2001XXAPain and inflammation in rheumatic disease and juvenile arthritisADULT: 75 - 150 mg daily in divided doses. CHILD 1-12 years, 12.5- 25 mg daily
Diclofenac 25 mg SuppositoryM01AB05520S2002XXAPain and inflammation in rheumatic disease and juvenile arthritisADULT: 75 - 150 mg daily in divided doses. CHILD 1-12 years, 12.5- 25 mg daily
Diclofenac 50 mg TabletM01AB05520T1001XXBPain and inflammation in rheumatic diseaseADULTS: Initial dose of 150 mg daily. Mild or long term: 75 - 150 mg daily in 2 to 3 divided doses after food. Maximum 200mg/day. PAEDS more than 6 months : 1 - 3 mg/kg body weight daily in divided doses. Maximum 3mg/kg/day (Max 150mg/day).
Diclofenac Sodium 50 mg SuppositoryM01AB05520S2003XXAPain and inflammation in rheumatic disease and juvenile arthritisADULTS: 75 - 150 mg daily in divided doses. Maximum 150mg/day. PAEDS more than 6 months : 1 - 3 mg/kg body weight daily in divided doses. Maximum 3mg/kg/day (Max 150mg/day).
Diclofenac Sodium 75 mg/3 ml InjectionM01AB05520P3001XXAPain and inflammation in rheumatic diseaseIM 75 mg once daily (2 times daily in severe cases) for not more than 2 days. Max 150mg/day. Not suitable for children.
Didanosine 100 mg Tablet (ddI)J05AF02000T1002XXA*HIV infection, in combination with other antiretroviralsADULT less than 60 kg: 125 mg twice daily or 250 mg once daily; more than 60 kg: 400 mg once daily or 200 mg twice daily. CHILD: 2 weeks to less than 3 months: 50mg/m2 twice daily; 3-8 months: 100mg/m2 twice daily
Didanosine 2 g Oral Solution (ddI)J05AF02000F2101XXA*HIV infection, in combination with other antiretroviralsADULT less than 60 kg: 125 mg twice daily or 250 mg once daily; more than 60 kg: 400 mg once daily or 200 mg twice daily. CHILD: 2 weeks to less than 3 months: 50mg/m2 twice daily; 3-8 months: 100mg/m2 twice daily
Didanosine 25 mg Tablet (ddI)J05AF02000T1001XXA*HIV infection, in combination with other antiretroviralsADULT less than 60 kg: 125 mg twice daily or 250 mg once daily; more than 60 kg: 400 mg once daily or 200 mg twice daily. CHILD: 2 weeks to less than 3 months: 50mg/m2 twice daily; 3-8 months: 100mg/m2 twice daily
Didanosine 250 mg Enteric Coated CapsuleJ05AF02000C1001XXA*HIV infection, in combination with other antiretroviralsADULT less than 60 kg: 250 mg once daily; 60 kg or greater: 400 mg once daily. Dose may varies if taken in combination with tenofovir
Didanosine 400 mg Enteric Coated CapsuleJ05AF02000C1002XXA*HIV infection, in combination with other antiretroviralsADULT less than 60 kg: 250 mg once daily; 60 kg or greater: 400 mg once daily. Dose may varies if taken in combination with tenofovir
Dienogest 2mg tabletG03DB08000T1001XXA/KKTreatment of endometriosisOne tablet daily. Treatment can be started on any day of menstrual cycle. Tablets must be taken continously without regard to vaginal bleeding.
Diethylcarbamazine Citrate 50 mg TabletP02CB02136T1001XXBi) Bancrofti filariasis, onchocerciasis, loasis, creeping eruption ii) Ascariasis iii) Tropical eosinophiliai) 1 mg/kg on the first day and increased gradually over 3 days to 6 mg/kg daily in divided doses. This dosage is maintained for 21 days. ii) 13 mg/kg once daily for 7 days. CHILD : 6 - 10 mg/kg 3 times daily for 7 days iii) 6 mg/kg/day in 3 divided doses for 21 days
Digoxin 0.25 mg TabletC01AA05000T1001XXBHeart failure , with atrial fibrillation, supraventricular arrhythmias (particularly, atrial fibrillation)Rapid digitalisation: 0.75 -1.5 mg in divided doses over 24 hours; less urgent digitalisation, 250 mcg-500 mcg daily (higher dose may be divided). Maintenance : 62.5mg -500 mcg daily (higher dose may be divided) according to renal function and , in atrial fibrillation, on heart rate response; usual range, 125-250 mcg daily (lower dose may be appropriate in elderly)
Digoxin 250 mcg/ml InjectionC01AA05000P3001XXAHeart failure with atrial fibrillation, supraventricular arrhythmias (particularly atrial fibrillation)Rapid digitilisation: ADULT & CHILD over 10 years, initially 0.75 - 1.5 mg, followed by 250 mcg 6 hourly until digitilisation is complete
Digoxin 50 mcg/ml ElixirC01AA05000L1001XXBHeart failure, supraventricular arrhythmias (particularly atrial fibrillation)Rapid digitalization, give in divided doses; PREMATURE: 20-30 mcg/kg; FULLTERM: 25-35 mcg/kg; CHILD 1-2 years : 35 to 60 mcg/kg; CHILD 2-5 years: 30-40 mcg/kg; CHILD 5-10 years: 20- 35 mcg/kg; CHILD over 10 years: 10-15 mcg/kg. For daily maintenance doses or for gradual digitalization, give 20% to 30% of oral digitalizing dose for premature infants or 25% to 35% of oral digitalizing dose for all other pediatric patients
Digoxin 62.5 mcg TabletC01AA05000T1002XXBHeart failure, with atrial fibrillation, supraventricular arrhythmias (particularly, atrial fibrillation)Rapid digitalisation: 1-1.5 mg in divided doses over 24 hours; less urgent digitalisation, 250 mcg-500 mcg daily (higher dose may be divided). Maintenance: 62.5 - 500 mcg dailly (higher dose may be divided) according to renal fuction, and in atrial fibrillation, on heart-response; usual range :125 - 250 mcg daily (lower doses may be appropriate in the elderly)
Dihydrocodeine Tartrate 30 mg TabletN02AA08123T1001XXBFor the control of moderate to severe chronic painADULT: 30 - 60 mg every 4 - 6 hours. PAED, over 4 yrs: 0.5 - 1 mg/kg body weight every 4-6 hours
Dihydroergocristine or Co-dergocrine Mesilate 1 mg TabletC04AE01196T1001XXA/KKAdjunct in elderly with mild to moderate dementia, prevention of migraine and vascular headache3-6 mg daily in divided doses
Diltiazem HCl 30 mg TabletC08DB01110T1001XXBTreatment of angina pectoris in the following cases: i) inadequate response or intolerance to beta-blockers and Isosorbide Dinitrate ii) contraindication to beta-blockers iii) coronary artery spasmInitially 30mg tds, may increase to 60mg tds (elderly initially twice daily; increased if necessary to 360 mg daily.
Dimercaprol 50 mg/ml InjectionV03AB09000P3001XXBPoisoning by antimony, arsenic, bismuth, gold, mercury, possibly thallium; adjunct (with calcium disodium edetate) in lead poisoningBy IM: 2.5 - 3 mg/kg every 4 hours for 2 days, 2 - 4 times on the third day, then 1 - 2 times daily for 10 days or until recovery. For ophthalmic use : instillation of 50 mg/ml oily solution in conjunctival sac, within 5 minutes of contamination
Dinoprostone (Prostagladin E2) 3 mg Vaginal TabletG02AD02000S1001XXAInduction of labour3 mg vaginal tablet to be inserted high into the posterior formix. A second 3 mg tablet may be inserted after 6-8 hours if labour is not established. Max 6 mg
Diosmin 450 mg and Hesperidin 50 mg TabletC05CA53931T1001XXA/KKi) Haemorrhoids ii) Chronic venous insufficiencyi) Acute attack: 6 tablets daily for the first 4 days, then 4 tablets daily in 2 divided doses for 3 days and 2 tablets thereafter. Chronic: 2 tablets daily ii) 2 tab daily with meals
Diphenhydramine HCl 14 mg/5 ml and Ammonium Chloride 135 mg/5 ml Oral SolutionR06AA52110L2101XXCCoughADULT : 5 - 10 ml 2 - 3 times daily. CHILD : 2.5 - 5 ml 2 - 3 times daily (not to be used in children less than 2 years of age)
Diphenhydramine HCl 7 mg/5 ml and Ammonium Chloride 67.5 mg/5 ml oral solutionR06AA52110L9003XXCCoughADULT : 5 - 10 ml 2 - 3 times daily. CHILD : 2.5 - 5 ml 2 - 3 times daily
Diphenhydramine hydrochloride 10 mg/5 ml Oral solutionR06AA02110L1001XXCCough and allergic rhinitisAllergic rhinitis :1) Adults & Children over 12 years of age : 25 to 50 mg 3 to 4 times a day 2) Children 6 to 12 years of age: 10 mg 3 to 4 times a day 3) Children 1 to 6 years of age: 5 mg 3 to 4 times a day. Maximum daily dosage <300 mg (adults and children) Cough and cold : 1)Adults: 25 mg every 4 hrs. Not to exceed 150 mg in 24 hours 2) Children (6 to 12years): 12.5 mg every 4 hours. Not to exceed 75 mg in 24 hours 3) Children (2 to 6 years): 6.25 mg every 4 hours. Not to exceed 25 mg in 24 hours
Diphenoxylate with Atropine Sulphate TabletA07DA01922T1001XXBAcute diarrhoeaADULT initially 4 tablet followed by 2 tablet 4 times daily until diarrhoea is controlled
Diphtheria and Tetanus Vaccine InjectionJ07AM51963P3001XXC+Immunisation against diphtheria and tetanusProphylactic: 2 or 3 doses by deep SC or IM injection, 0.5 or 1 ml. Each second dose at 4 - 6 weeks then 4 - 6 months. Booster at 4 - 6 years
Diphtheria Antitoxin InjectionJ07AF01000P3001XXBDiphtheriaTherapeutic: 10,000 - 30,000 units by IM or IV. Increase to 40,000 - 100,000 units in severe cases. Doses up to 30,000 units may be given IM
Diphtheria, Pertussis, Tetanus and Conjugated Haemophilus Type B 10 mcg VaccineJ07AG52000P3001XXCImmunisation of children against Haemophilus Type B infections, diphtheria, tetanus and pertussis0.5 ml given by IM
Diphtheria, Pertussis, Tetanus and Hepatitis B VaccineJ07CA05963P3001XXC+Active immunisation against diphtheria, tetanus, pertussis and hepatitis B in infants from 6 weeks onwardsPrimary vaccination: 3 doses of 0.5 ml each within the first 6 months of life. Administer each dose at intervals of at least 4 weeks. A booster dose can be administered in the second year of life
Diphtheria, Pertussis, Tetanus Vaccine InjectionJ07AJ52963P3001XXCProphylactic immunisation against diphtheria, pertussis and tetanusBy deep SC or IM injection: 3 doses each of 0.5 or 1 ml with intervals of 6 - 8 weeks and 4 - 6 months respectively between the doses. Booster 1 and 5 years after primary immunisation
Diptheria, Tetanus, Acellular Pertussis, Inactivated Polio Virus, Haemophilus Influenza Type B (DTaP-IPV-HiB) Vaccine Injection (Single Dose)J07CA06963P3001XXC+Immunisation of children against Diphtheria, Tetanus, Acellular Pertussis, Polio and Haemophilus Influenza Type B infectionPrimary : 0.5 ml by IM at 1 - 2 months intervals Booster : Second year of life
Dipyridamole 75 mg TabletB01AC07000T1001XXBAs an adjunct to oral anticoagulation/ antiplatelet therapy in the prophylaxis of cerebrovascular events75-150 mg 3 times daily to be taken 1 hour before meals
Distigmine Bromide 5 mg TabletN07AA03320T1001XXAi) Myasthenia gravis ii) Prevention and treatment of post-operative intestinal atony, urinary retention and neurogenic bladderi) ADULT : 5 mg daily 30 minutes before breakfast. Increase at intervals of 3 - 4 days if necessary to maximum of 20 mg daily. CHILD : Up to 10 mg daily according to age ii) Urinary retention : 5 mg daily 30 minutes before breakfast. Neurogenic bladder : 5 mg daily or on alternate days 30 minutes before breakfast
Dithranol 0.1 - 5% in Vaseline/ OintmentD05AC01000G5001XXAShort contact treatment for plaque psoriasis and alopecia areataFor application to skin or scalp. 0.1-0.5% suitable for overnight treatment. 1-2% for max 1 hour.
Dithranol 1 % in Lassars PasteD05AC01000G6001XXATreatment of quiescent or chronic psoriasis of the skin, scalp and alopecia areataApply liberally and carefully to the lesions with a suitable applicator. A dressing may be applied
Dobutamine 12.5 mg/ml InjectionC01CA07110P3001XXAHypotension and heart failureInitial 0.5-1 mcg/kg/min by IV, maintenance 2.5-10mcg/kg/min. Frequently,doses up to 20mcg/kg/min are required for adequate hemodynamic improvement. On rare occasions,infusion rates up to 40mcg/kg/min
Docetaxel 40mg/ml InjectionL01CD02000P3002XXA*i) Adjuvant treatment of patients with high risk node-positive breast cancer in combination with doxorubicin and cyclophosphamide ii) Breast cancer, locally advanced or metastatic, not previously on cytotoxic therapy, in combination with doxorubicin iii) First line therapy in non small cell lung cancer in stage 3- 4 and performance status 0-1, in combination with cisplatin iv) Inoperable locally advanced squamous cell carcinoma of head and neck, in combination with cisplatin and 5-FU for induction treatment v) Prostate cancer, in combination with prednisolonei) 75 mg/m2 IV over 1 hour after doxorubicin 50 mg/m2 and cyclophosphamide 500 mg/m2 every 3 weeks for 6 cycles ii) 75 mg/m2 IV over 1 hour every 3 week in combination with doxorubicin 50 mg/m2 iii) Administer IV over 1 hour every 3 weeks. Chemotherapy-naive patients 75 mg/m2 immediately followed by 75 mg/m2 cisplatin over 30-60 mins or carboplatin (AUC 6 mg/mL/min) over 30-60 minutes. Monotherapy of non small cell lung cancer (NSCLC) after failure of prior platinum-based chemotherapy 75 mg/m2 iv) 75 mg/m2 as a 1 hour infusion followed by cisplatin 75 mg/m2 over 1 hour, on day one, followed by 5-fluorouracil as a continuous infusion at 750 mg/m2 per day for five days. This regimen is administered every 3 weeks for 4 cycles.
Domperidone 1 mg/ml SuspensionA03FA03000L8001XXBNausea, vomiting, dyspepsia, gastro-esophageal refluxChronic dyspepsia : CHILD 2.5 mL/10 kg body weight 3 times daily and once more in the evening if necessary. Dosage may be doubled in adults & childs over 1 year. Acute and subacute conditions (particularly nausea and vomiting). CHILD: 5 mL/10 kg bodyweight. All to be taken 3-4 times daily
Domperidone 10 mg TabletA03FA03253T1001XXBNausea, vomiting, dyspepsia, gastro-esophageal refluxChronic dyspepsia ADULT 10 mg 3 times daily. Acute and subacute conditions (particularly nausea and vomiting):ADULT 20 mg 3-4 times daily
Donepezil HCl 10 mg TabletN06DA02110T1002XXATreatment of mild to moderate dementia in Alzheimer's disease, as well as in patients with severe Alzheimer's disease. [psychiatrists and neurologists only]5 - 10 mg once daily at bedtime. Maximum 10 mg daily
Donepezil HCl 5 mg TabletN06DA02110T1001XXATreatment of mild to moderate dementia in Alzheimer's disease, as well as in patients with severe Alzheimer's disease. [psychiatrists and neurologists only]5 - 10 mg once daily at bedtime. Maximum 10 mg daily
Donepezil Hydrochloride 10mg Orodispersible TabletN06DA02110T4002XXA*Treatment of mild to moderate dementia in Alzheimer's disease, as well as in patients with severe Alzheimer's disease. [psychiatrists and neurologists only]Initiated at 5mg/day (one a day dosing), should be maintained for at least 1 month in order to allow the earliest clinical responses and to allow steady state concentration to be achieved. The maximum recommended daily dose is 10 mg.
Donepezil Hydrochloride 5mg Orodispersible TabletN06DA02110T4001XXA*Treatment of mild to moderate dementia in Alzheimer's disease, as well as in patients with severe Alzheimer's disease. [psychiatrists and neurologists only]Initiated at 5mg/day (one a day dosing), should be maintained for at least 1 month in order to allow the earliest clinical responses and to allow steady state concentration to be achieved. The maximum recommended daily dose is 10 mg.
Dopamine HCl 40 mg/ml InjectionC01CA04110P3001XXBNon-hypovolemic hypotensionInitial dose 2-5  mcg/kg/min with incremental changes of 5-10 mcg/kg/min at 10-15 minutes intervals until adequate response is noted. Most patients are maintained at less than 20 mcg/kg/min. If dosage exceeds 50 mcg/kg/min, assess renal function frequently
Doripenem Monohydrate 500 mg InjectionJ01DH04000P4001XXA*Ventilator-associated pneumonia (VAP) patients at risk or involving multidrug resistant pathogens especially Pseudomonas aeruginosa infections500mg every 8 hours as a one hour infusion for 5 to 14 days according to severity, site of infection and the patient's clinical response.
Dorzolamide HCl 2% Ophthalmic SolutionS01EC03110D2001XXA*All glaucoma patients where beta-blockers are contraindicated and when intraocular pressure is not well controlled by other drugsMonotherapy : 1 drop 3 times daily. Adjunctive therapy with an ophthalmic beta-blocker : 1 drop 2 times daily. When substituting for another ophthalmic antiglaucoma agent with this product, discontinue the other agent after proper dosing on one day and start Trusopt on the next day. If more than 1 topical ophthalmic drug is used, the drugs should be administered at least 10 mins apart
Dothiepin HCl 25 mg CapsuleN06AA16110C1001XXADepression of any aetiologyInitially 75 mg (ELDERLY 50-75 mg) daily in divided doses or single dose at bedtime, increased gradually as necessary to 150 mg daily (ELDERLY 75 mg may be sufficient), up to 225 mg daily in some circumstances. CHILD is not recommended
Dothiepin HCl 75 mg TabletN06AA16110T1001XXADepression of any aetiologyInitially 75 mg (ELDERLY 50-75 mg) daily in divided doses or single dose at bedtime, increased gradually as necessary to 150 mg daily (ELDERLY 75 mg may be sufficient), up to 225 mg daily in some circumstances. CHILD is not recommended
Doxazosin Mesilate 4 mg CR TabletC02CA04196T5001XXA*Benign Prostatic Hyperplasia4 mg once daily to maximum 8mg/day
Doxorubicin HCl 10 mg InjectionL01DB01110P4001XXAi) Solid tumours, leukaemia, non-Hodgkin's lymphoma ii) Leukaemia (ALL induction) iii) Multiple myelomai) 30 - 75 mg/m2 IV as a single dose at 21 day intervals ii) 25 - 45 mg/m2 once a week for the first 4 weeks during induction or re-induction phase (refer to specific protocol. Caution: Total cumulative dose of doxorubicin must not exceed 550 mg/m2 due to risk of cardiotoxicity. CHILD: 30 mg/m2/dose over 6 - 24 hours for 1 - 2 days. Need to check cardiac function closely by echocardiography every cumulative dose of 100 mg/m2 to maximum 360 mg/m2 iii) 9 mg/m2 over 24 hours infusion for 4 days at monthly intervals
Doxorubicin HCl 50 mg InjectionL01DB01110P4002XXAi) Solid tumours, leukaemia, non-Hodgkin's lymphoma ii) Leukaemia (ALL induction) iii) Multiple myelomai) 30 - 75 mg/m2 IV as a single dose at 21 day intervals ii) 25 - 45 mg/m2 once a week for the first 4 weeks during induction or re-induction phase (refer to specific protocol. Caution: Total cumulative dose of doxorubicin must not exceed 550 mg/m2 due to risk of cardiotoxicity. CHILD: 30 mg/m2/dose over 6 - 24 hours for 1 - 2 days. Need to check cardiac function closely by echocardiography every cumulative dose of 100 mg/m2 to maximum 360 mg/m2 iii) 9 mg/m2 over 24 hours infusion for 4 days at monthly intervals
Doxycycline 100 mg CapsuleJ01AA02000C1001XXBInfections due to susceptible organismsADULT: 200 mg on the first day followed by 100 mg daily. Severe infections: 200 mg daily
Doxycycline 100 mg TabletJ01AA02000T1001XXBInfections due to susceptible organismsADULT: 200 mg on the first day followed by 100 mg daily. Severe infections: 200 mg daily
D-Penicillamine 0.25 g CapsuleM01CC01000C1001XXAi) Treatment of severe lead poisoning, it is used as adjunctive treatment following initial treatment with another chelating agent. May also be used as sole therapy in the treatment of asymptomatic patients with moderately elevated blood concentrations ii) Wilson's Disease: to aid in elimination of copper ionsi) Heavy metal poisoning: 900mg-1800mg daily. Duration of treatment is dictated by the urinary heavy metal excretion. Simultaneous oral vitamin B6 replacement with at least 40mg daily is essential ii) Wilson's disease: 0.25g - 1.5g daily on an incremental basis. Maximal daily dose: 2g. Maintenance dose: 0.75g - 1g daily
Duloxetine 30 mg CapsuleN06AX21110C1001XXA*Major depressive disorder, diabetic peripheral neuropathic painADULT: 60 mg once daily up to a maximum dose of 120mg/day (in divided doses) CHILD and ADOLESCENT under 18 years not recommended
Duloxetine 60 mg CapsuleN06AX21110C1002XXA*Major depression, diabetic peripheral neuropathic painADULT: 60 mg once daily up to a maximum dose of 120mg/day (in divided doses) CHILD and ADOLESCENT under 18 years not recommended
Dutasteride 0.5 mg CapsuleG04CB02000C1001XXA*Benign prostatic hyperplasia in men with an enlarged prostate gland0.5 mg daily
Dutasteride 0.5mg and Tamsulosin 0.4mg CapsuleG04CA52953C1001XXA*Combination therapy for the treatment of moderate to severe symptoms of BPH with: i) Large prostate (>30g) ii) Poor risk or not fit for surgery iii)Those who are awaiting their turn for surgeryOne capsule daily
Dydrogesterone 10 mg TabletG03DB01110T1001XXA/KKi) Dysmenorrhoea ii) Endometriosis iii) Dysfunctional uterine bleeding (to arrest and to prevent bleeding) iv) Threatened abortion v) Habitual abortion vi) Post menopausal complaints (hormone replacement therapy in combination with oestrogen)i) 10 mg bd from day 5 - 25 of cycle ii) 10 mg bd - tds from day 5 - 25 of the cycle or continuously iii) To arrest bleeding :10 mg bd with an oestrogen once daily for 5 - 7 days, To prevent bleeding : 10 mg bd with an oestrogen once daily from day 11 - 25 of the cycle iv) 40 mg at once, then 10mg 8hrly until symptoms remit v) 10 mg bd until 20th week of pregnancy vi) 10-20 mg daily during last 12-14 days of each cycle
Edrophonium Chloride 10 mg/ml InjectionN07AA00100P3001XXBi) For reversal of neuromuscular block ii) Diagnosis of myasthenia gravisi) Intravenous injection on over several minutes, 500 - 700 mcg/kg (after or with atropine sulphate 600 mcg) ii) Intravenous injection 2 mg followed by 8 mg if no response occurs within 30 seconds. CHILD: 20 mcg followed by 80 mcg/kg after 30 seconds
Efavirenz 100 mg CapsuleJ05AG03000C1002XXA*Combination therapy for HIV infections with a protease inhibitor and or Nucleoside Reverse Transcriptase Inhibitors (NRTIs)ADULT: 600 mg once daily. ADOLESCENT & CHILD less than 17 years, more than 40 kg: 600 mg once daily, 32.5 - less than 40 kg: 400 mg once daily, 25 - less than 32.5 kg: 350 mg once daily, 20 - less than 25 kg: 300 mg once daily, 15 - less than 20 kg: 250 mg once daily, 13 - less than 15 kg: 200 mg once daily. No studies in children less than 3 years or less than 13 kg. Tablet formulation unsuitable for children less than 40 kg
Efavirenz 200 mg CapsuleJ05AG03000C1003XXA*Combination therapy for HIV infections with a protease inhibitor and or Nucleoside Reverse Transcriptase Inhibitors (NRTIs)ADULT: 600 mg once daily. ADOLESCENT & CHILD less than 17 years, more than 40 kg: 600 mg once daily, 32.5 - less than 40 kg: 400 mg once daily, 25 - less than 32.5 kg: 350 mg once daily, 20 - less than 25 kg: 300 mg once daily, 15 - less than 20 kg: 250 mg once daily, 13 - less than 15 kg: 200 mg once daily. No studies in children less than 3 years or less than 13 kg. Tablet formulation unsuitable for children less than 40 kg
Efavirenz 50 mg CapsuleJ05AG03000C1001XXA*Combination therapy for HIV infections with a protease inhibitor and or Nucleoside Reverse Transcriptase Inhibitors (NRTIs)ADULT: 600 mg once daily. ADOLESCENT & CHILD less than 17 years, more than 40 kg: 600 mg once daily, 32.5 - less than 40 kg: 400 mg once daily, 25 - less than 32.5 kg: 350 mg once daily, 20 - less than 25 kg: 300 mg once daily, 15 - less than 20 kg: 250 mg once daily, 13 - less than 15 kg: 200 mg once daily. No studies in children less than 3 years or less than 13 kg. Tablet formulation unsuitable for children less than 40 kg
Efavirenz 600 mg TabletJ05AG03000T1001XXA/KKCombination therapy for HIV infections with a protease inhibitor and or Nucleoside Reverse Transcriptase Inhibitors (NRTIs)ADULT: 600 mg once daily. ADOLESCENT & CHILD less than 17 years, more than 40 kg: 600 mg once daily, 32.5 - less than 40 kg: 400 mg once daily, 25 - less than 32.5 kg: 350 mg once daily, 20 - less than 25 kg: 300 mg once daily, 15 - less than 20 kg: 250 mg once daily, 13 - less than 15 kg: 200 mg once daily. No studies in children less than 3 years or less than 13 kg. Tablet formulation unsuitable for children less than 40 kg
Eltrombopag Olamine 25 mg Film-coated TabletB02BX05999T1001XXA*Short term use in idiopathic thrombocytopenic purpura patients as bridging therapy for splenectomy or surgery and in cases of severe bleeding.Individualised dosage based on the patient's platelet count. Adult Initially 50 mg once daily. East Asian patient 25 mg once daily. Then, adjust dose to maintain platelet count ≥50,000/microliter. Max: 75 mg daily.
Emulsificants OintmentD02AC00952G5001XXCXerosis and ichthyosisUse as a soap and emollient
Enalapril 10 mg TabletC09AA02253T1002XXBi) Hypertension ii) Congestive heart failurei) Initially 5 mg daily, (ELDERLY 2.5 mg once daily), usual maintenance dose 10 - 20 mg daily. Maximum: 40 mg/day in 1 - 2 divided doses ii) Initially 2.5 mg daily, usual maintenance dose 20 mg daily in 1 - 2 divided doses; maximum: 40 mg/day
Enalapril 20 mg TabletC09AA02253T1003XXBi) Hypertension ii) Congestive heart failurei) Initially 5 mg daily, (ELDERLY 2.5 mg once daily), usual maintenance dose 10 - 20 mg daily. Maximum: 40 mg/day in 1 - 2 divided doses ii) Initially 2.5 mg daily, usual maintenance dose 20 mg daily in 1 - 2 divided doses; maximum: 40 mg/day
Enalapril 5 mg TabletC09AA02253T1001XXBi) Hypertension ii) Congestive heart failurei) Initially 5 mg daily, (ELDERLY 2.5 mg once daily), usual maintenance dose 10 - 20 mg daily. Maximum: 40 mg/day in 1 - 2 divided doses ii) Initially 2.5 mg daily, usual maintenance dose 20 mg daily in 1 - 2 divided doses; maximum: 40 mg/day
Enoxaparin Sodium 20 mg InjectionB01AB05520P5001XXA*i) Prevention of Deep Vein Thrombosis(DVT) especially in perioperative and high risk surgical cases ii) Treatment of DVT iii) Unstable angina and non Q wave Myocardial Infarctioni) Prophylaxis fo DVT especially in surgical patients: moderate risk, 20 mg SC approximately 2 hours before surgery then 20 mg every 24 hours for minimum 7 - 10 days, high risk (eg orthopaedic surgery, medical patients, 40mg every 24 hours for at least 6 days until patient ambulant, max 14 days. ii) Treatment of DVT or pulmonary embolism, 1.5 mg/kg every 24 hours, usually for 5 days and until adequate oral anticoagulation established. iii) Unstable angina and non-ST-segment-elevation myocardial infarction 1 mg/kg every 12 hours, usually for 2 - 8 days
Enoxaparin Sodium 40 mg InjectionB01AB05520P5002XXA*i) Prevention of Deep Vein Thrombosis(DVT) especially in perioperative and high risk surgical cases ii) Treatment of DVT iii) Unstable angina and non Q wave Myocardial Infarctioni) Prophylaxis for DVT especially in surgical patients: moderate risk, 20 mg SC approximately 2 hours before surgery then 20 mg every 24 hours for minimum 7 - 10 days, high risk (eg orthopaedic surgery, medical patients, 40mg every 24 hours for at least 6 days until patient ambulant, max 14 days. ii) Treatment of DVT or pulmonary embolism, 1.5 mg/kg every 24 hours, usually for 5 days and until adequate oral anticoagulation established. iii) Unstable angina and non-ST-segment-elevation myocardial infarction 1 mg/kg every 12 hours, usually for 2 - 8 days
Enoxaparin Sodium 60 mg InjectionB01AB05520P5003XXA*i) Prevention of Deep Vein Thrombosis(DVT) especially in perioperative and high risk surgical cases ii) Treatment of DVT iii) Unstable angina and non Q wave Myocardial Infarctioni) Prophylaxis fo DVT especially in surgical patients: moderate risk, 20 mg SC approximately 2 hours before surgery then 20 mg every 24 hours for minimum 7 - 10 days, high risk (eg orthopaedic surgery, medical patients, 40mg every 24 hours for at least 6 days until patient ambulant, max 14 days. ii) Treatment of DVT or pulmonary embolism, 1.5 mg/kg every 24 hours, usually for 5 days and until adequate oral anticoagulation established. iii) Unstable angina and non-ST-segment-elevation myocardial infarction 1 mg/kg every 12 hours, usually for 2 - 8 days
Entacapone 200 mg TabletN04BX02000T1001XXAParkinson's Disease. An adjunct to standard levodopa/benserazide or levodopa/carbidopa for use in patients with parkinson's disease and end of dose motor fluctuations, who cannot be stabilised on those combinations200 mg to be taken with each daily dose of levodopa/dopa-decarboxylase inhibitor. Max 2g daily. May be taken with or without food
Entecavir 0.5 mg TabletJ05AF10000T1001XXA*First line treatment of Chronic Hepatitis B in patients who satisfy the criteria for treatment and require long-term therapy or have a very high baseline viral load0.5-1mg once daily. Renal Dose Adjustment: 0.5-1mg every 48hours (30-49ml/min); 0.5-1mg every 72hours (10-29ml/min); 0.5mg-1mg every 5-7 days (<10ml/min; HD or CAPD).
Eperisone HCl 50 mg TabletM03BX09110T1001XXAMyotonic symptoms associated with cervical syndrome, periarthritis of shoulder and lumbago spastic paralysis50 mg 3 times daily
Ephedrine 0.5% w/v Nasal DropsR01AA03110D6001XXA/KKDecongestion of the upper respiratory tract2 drops 3 times daily. Maximum use for 1 week
Ephedrine HCl 30 mg/ml InjectionR03CA02110P3001XXBTreatment of bronchial spasm in asthma, adjunct to correct haemodynamic imbalances and treat hypotension in epidural and spinal anaesthesiaBy IM, SC or IV. Severe, acute bronchospasm : 12.5-25 mg. Further dosage should be determine by patient response. When used as a pressor agent : ADULT 25 - 50 mg SC/IM. If necessary, a second IM dose of 50 mg or an IV dose of 25 mg may be given. Direct IV injection, 10 - 25 mg may be given slowly. Maximum parenteral ADULT dose : 150 mg in 24 hours. CHILD : 3 mg/kg or 100 mg/m2 SC or IV daily, in 4 - 6 divided doses
Epirubicin 10 mg InjectionL01DB03110P4001XXA*Breast cancer, Non-Hodgkin's lymphoma, Leukaemia (ALL induction), gastric cancer, ovarian canceri) 75 - 90mg/m2 body area injected IV in 3 - 5 min, repeated at 21 day intervals.Higher doses up to 135mg/m2 as single agent and 120mg/m2 as combination (effective in treatment of breast cancer) CHILD: 50 mg/m2 over 6 hours. Schedule depends on protocol.
Epirubicin 50 mg InjectionL01DB03110P4002XXA*Breast cancer, Non-Hodgkin's lymphoma, Leukaemia (ALL induction), gastric cancer, ovarian canceri) 75 - 90mg/m2 body area injected IV in 3 - 5 min, repeated at 21 day intervals.Higher doses up to 135mg/m2 as single agent and 120mg/m2 as combination (effective in treatment of breast cancer) CHILD: 50 mg/m2 over 6 hours. Schedule depends on protocol.
Erlotinib 100 mg TabletL01XE03110T1003XXA*i) As monotherapy for maintenance treatment in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with stable disease after 4 cycles of standard platinum-based first-line chemotherapy. ii) For the treatment of patients with locally advanced or metastatic NSCLC after failure of at least one prior chemotherapy regimen. Restricted to non-smoker, female, epidermal growth factor receptor (EGFR) positive and Asian patients only150 mg taken at least one hour before or two hours after the ingestion of food once daily. Reduce in steps of 50 mg when necessary. Continue treatment until disease progression or unacceptable toxicity occurs. May require dose modifications when coadministered with strong CYP3A4 inhibitors or inducers; or in cigarette smoking patients.
Erlotinib 150 mg TabletL01XE03110T1002XXA*i) As monotherapy for maintenance treatment in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with stable disease after 4 cycles of standard platinum-based first-line chemotherapy. ii) For the treatment of patients with locally advanced or metastatic NSCLC after failure of at least one prior chemotherapy regimen. Restricted to non-smoker, female, epidermal growth factor receptor (EGFR) positive and Asian patients only.150 mg taken at least one hour before or two hours after the ingestion of food once daily. Reduce in steps of 50 mg when necessary. Continue treatment until disease progression or unacceptable toxicity occurs. May require dose modifications when coadministered with strong CYP3A4 inhibitors or inducers; or in cigarette smoking patients.
Ertapenem 1 g InjectionJ01DH03520P4001XXA*i) Patient with confirm ESBL producing gram-negative infection. ii) Empiric treatment for severe community acquired pneumonia or other infections when Pseudomonas aeruginosa is not suspected.ADULT: 1 g once daily. CHILD 3 month to 12 years: 15 mg/kg twice daily. Not to exceed 1 g/ day
Erythromycin Ethylsuccinate 200 mg/5 ml SuspensionJ01FA01238F2101XXBTreatment of susceptible bacterial infectionsChild: 30-50 mg/kg daily, increased to twice the usual dose in severe cases. 2-8 yr: 1 g daily in divided doses; <2 yr: 500 mg daily in divided doses.
Erythromycin Ethylsuccinate 400 mg TabletJ01FA01238T1001XXBTreatment of susceptible bacterial infectionsAdult 400 mg 6 hrly or 800 mg 12 hrly. Max: 4 g/day. Childn 30-50 mg/kg in divided doses. Childn 2-8 yr 1 g/day in divided doses in severe cases. Infant & childn ≤2 yr 500 mg/day in divided doses.
Erythromycin Ethylsuccinate 400 mg/5 ml SuspensionJ01FA01238F2102XXBTreatment of susceptible bacterial infectionsChild: 30-50 mg/kg daily, increased to twice the usual dose in severe cases. 2-8 yr: 1 g daily in divided doses; <2 yr: 500 mg daily in divided doses.
Erythromycin Lactobionate 500 mg InjectionJ01FA01129P3001XXA*Only for treatment of i) certain forms of meningitis ii) septicaemia not responding to usual antibiotics iii) mycoplasma pneumonia iv) infection with gram-positive organisms (e.g. tetanus, streptococcal infection) associated with Penicillin allergy, only when oral erythromycin cannot be givenAdult & Child: 25 - 50mg/kg /day infusion every 6 hours. Maximum: 4 g/day.
Erythromycin Stearate 250 mg TabletJ01FA01258T1001XXBInfections due to susceptible organismChild: 30-50 mg/kg daily, increased to twice the usual dose in severe cases. 2-8 yr: 1 g daily in divided doses; <2 yr: 500 mg daily in divided doses.
Erythropoietin Human Recombinant 10,000 IU/ml InjectionB03XA01000P5005XXA*i) Treatment of anaemia associated with chronic renal failure. Dialysis patients who are haemoglobin less than 8 g or exhibiting symptoms of anaemia although haemoglobin more than 8 g and pre-transplant cases ii) Anaemia in cancer (non-myeloid malignancies) with concomitant chemotherapyi) ADULT by IV injection over 1-5 minutes, initially 50 units/kg 3 times weekly adjusted according to response in step of 25 units/kg 3 times weekly at interval of at least 4 weeks. CHILD initially as for adult. Maintenance, bodyweight under 10 kg usually 75-150 units/kg 3 times weekly, bodyweight 10-30 kg usually 60-150 units/kg 3 times weekly, bodyweight over 30 kg usually 30-100 units/kg 3 times weekly ii) ADULT by SC injection (max. 1 ml per injection site), initially 150 units/kg 3 times weekly, increased if appropriate rise in haemoglobin not achieved after 4 weeks to 300 units/kg 3 times weekly. Discontinue if inadequate response after 4 weeks at higher dose
Erythropoietin Human Recombinant 1000 IU/0.5ml InjectionB03XA01000P5001XXA*i) Treatment of anaemia associated with chronic renal failure. Dialysis patients who are haemoglobin less than 8 g or exhibiting symptoms of anaemia although haemoglobin more than 8 g and pre-transplant cases ii) Anaemia in cancer (non-myeloid malignancies) with concomitant chemotherapyi) ADULT by IV injection over 1-5 minutes, initially 50 units/kg 3 times weekly adjusted according to response in step of 25 units/kg 3 times weekly at interval of at least 4 weeks. CHILD initially as for adult. Maintenance, bodyweight under 10 kg usually 75-150 units/kg 3 times weekly, bodyweight 10-30 kg usually 60-150 units/kg 3 times weekly, bodyweight over 30 kg usually 30-100 units/kg 3 times weekly ii) ADULT by SC injection (max. 1 ml per injection site), initially 150 units/kg 3 times weekly, increased if appropriate rise in haemoglobin not achieved after 4 weeks to 300 units/kg 3 times weekly. Discontinue if inadequate response after 4 weeks at higher dose
Erythropoietin Human Recombinant 3000 IU/0.3ml InjectionB03XA01000P5003XXA*i) Treatment of anaemia associated with chronic renal failure. Dialysis patients who are haemoglobin less than 8 g or exhibiting symptoms of anaemia although haemoglobin more than 8 g and pre-transplant cases ii) Anaemia in cancer (non-myeloid malignancies) with concomitant chemotherapyi) ADULT by IV injection over 1-5 minutes, initially 50 units/kg 3 times weekly adjusted according to response in step of 25 units/kg 3 times weekly at interval of at least 4 weeks. CHILD initially as for adult. Maintenance, bodyweight under 10 kg usually 75-150 units/kg 3 times weekly, bodyweight 10-30 kg usually 60-150 units/kg 3 times weekly, bodyweight over 30 kg usually 30-100 units/kg 3 times weekly ii) ADULT by SC injection (max. 1 ml per injection site), initially 150 units/kg 3 times weekly, increased if appropriate rise in haemoglobin not achieved after 4 weeks to 300 units/kg 3 times weekly. Discontinue if inadequate response after 4 weeks at higher dose
Erythropoietin Human Recombinant 4000 IU/0.4ml InjectionB03XA01000P5004XXAi) Treatment of anaemia associated with chronic renal failure. Dialysis patients who are haemoglobin less than 8 g or exhibiting symptoms of anaemia although haemoglobin more than 8 g and pre-transplant cases ii) Anaemia in cancer (non-myeloid malignancies) with concomitant chemotherapyi) ADULT by IV injection over 1-5 minutes, initially 50 units/kg 3 times weekly adjusted according to response in step of 25 units/kg 3 times weekly at interval of at least 4 weeks. CHILD initially as for adult. Maintenance, bodyweight under 10 kg usually 75-150 units/kg 3 times weekly, bodyweight 10-30 kg usually 60-150 units/kg 3 times weekly, bodyweight over 30 kg usually 30-100 units/kg 3 times weekly ii) ADULT by SC injection (max. 1 ml per injection site), initially 150 units/kg 3 times weekly, increased if appropriate rise in haemoglobin not achieved after 4 weeks to 300 units/kg 3 times weekly. Discontinue if inadequate response after 4 weeks at higher dose
Escitalopram 10 mg TabletN06AB10124T1001XXA*i) Major depression ii) Treatment of panic disorder with or without agoraphobiai) 10 mg once daily; may be increased to max 20 mg daily. ii) Panic disorder with or without agoraphobia :Initially 5 mg for the first week, thereafter increased to 10 mg daily. Max 20 mg daily, ELDERLY initially half the adult dose, lower maintenance dose may be sufficient. CHILD and ADOLESCENT under 18 years not recommended
Esmolol HCl 10 mg/ml InjectionC07AB09110P3001XXA*Tachycardia and hypertension in perioperative periodBy IV infusion usually within range of 50 - 200 mcg/kg/min
Esomeprazole 20 mg TabletA02BC05000T1002XXA*i)Gastro-oesophageal reflux disease ii)H. pylori eradicationi)20mg daily for 4-8 weeks ii)40mg daily for 10 days in combination with amoxicillin 1g twice daily or clarithromycin 500mg twice daily
Esomeprazole 40 mg InjectionA02BC05000P3001XXA*i) Acute erosive/ ulcerative oesophagitis ii) Non -variceal upper gastrointestinal bleedi) 20- 40 mg once daily for 2-5 days ii) 80 mg by IV bolus followed by 8mg/hour infusion for 72 hours
Esomeprazole 40 mg TabletA02BC05000T1001XXA*i)Gastro-oesophageal reflux disease ii)H. pylori eradicationi)20mg daily for 4-8 weeks ii)40mg daily for 10 days in combination with amoxicillin 1g twice daily or clarithromycin 500mg twice daily
Essential Phospholipids 300 mg CapsuleA05BA00924C1001XXA/KKNutritional supplement in liver disordersADULT 1-2 capsules three times daily with meals
Estradiol 1 mg & Estradiol 1 mg with Dydrogesterone 10 mgG03FB08954T1001XXA*Hormone Replacement Therapy for women with disorders due to natural or surgically induced menopause with intact uterus.One tablet daily without pill-free interval, starting with 1 mg of Estradiol for first 14 days, followed by 1mg Estradiol with 10 mg Dydrogestrone daily for the next 14 days
Estradiol 1 mg & Norethisterone Acetate 0.5 mg TabletG03FA01122T1001XXA*Hormone replacement therapy for oestrogen deficiency symptoms in women more than 1 year after menopause and prevention of osteoporosis in post menopausal women1 tablet per day without interruption
Estradiol 1 mg with Dydrogesterone 5 mg TabletG03FB08954T1002XXA*i) Hormone replacement therapy for the relief of symptoms due to oestrogen deficiency ii) Prevention of postmenopausal osteoporosis in women with a uterusOne tablet daily, taken continuously without interruption. Should be used only in postmenopausal women more than 12 month after menopause
Estradiol Valerate 1 mg TabletG03CA03256T1002XXA*Oestrogen replacement therapy - only those who cannot tolerate Premarin1 mg daily continuously or 21 day regimen with 1 week of tablet free interval
Estradiol Valerate 2 mg and Norgestrel 500 mcg with Estradiol Valerate 2 mg TabletG03FB01953T1001XXBPre and post menopausal syndrome, primary and secondary amenorrhea, menstrual irregularities. Deficiency symptoms after oophorectomy or radiological castration for noncarcinomatous diseaseStart on the 5th day of menstrual cycle - 1 tab daily for 21 days then stop for 7 days. If patient forgets dose at usual time, it should be taken within following 12 hours
Etanercept 25 mg InjectionL04AA11000P4001XXA*i)Moderately to severe rheumatoid arthritis as monotherapy or in combination with methotrexate in patients with inadequate response to methotrexate alone. ii)Active polyarticular-course juvenile idiopathic arthritis in children 2-17 years with inadequate response to, or who have proved intolerant of methotrexate. iii)Psoriatic arthritis as monotherapy or in combination with methotrexate in patients inadequate response to methotrexate alone. iv)Active ankylosing spondylitis in adults v)Moderate to severe plaque psoriasis who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or PUVAAdult & geriatric dose: Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis; 50 mg SC once-weekly for once-weekly dosing or 25 mg SC twice weekly (individual doses should be separated by 72 to 96 hours) for twice-weekly dosing. Plaque psoriasis; Initial: 50 mg SC twice weekly, 72 to 96 hours apart; maintain initial dose for 3 months (starting doses of 25 or 50 mg once weekly have also been used successfully). Maintenance dose: 50 mg SC once weekly. Paediatric dose (2 to 17 years): Juvenile idiopathic arthritis; 0.8 mg/kg (max. 25 mg/dose) SC once weekly for once-weekly dosing or 0.4 mg/kg (max. 25 mg/dose) SC twice weekly (individual doses should be separated by 72 to 96 hours) for twice-weekly dosing.
Etanercept 50 mg InjectionL04AB01000P4002XXA*i) Moderately to severe rheumatoid arthritis as monotherapy or in combination with methotrexate in patients with inadequate response to methotrexate alone. ii) Active polyarticular-course juvenile idiopathic arthritis in children 2-17 years with inadequate response to, or who have proved intolerant of methotrexate. iii) Psoriatic arthritis as monotherapy or in combination with methotrexate in patients inadequate response to methotrexate alone. iv) Active ankylosing spondylitis in adults v) Moderate to severe plaque psoriasis who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or PUVAAdult & geriatric dose: Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis; 50 mg SC once-weekly for once-weekly dosing or 25 mg SC twice weekly (individual doses should be separated by 72 to 96 hours) for twice-weekly dosing. Plaque psoriasis; Initial: 50 mg SC twice weekly, 72 to 96 hours apart; maintain initial dose for 3 months (starting doses of 25 or 50 mg once weekly have also been used successfully). Maintenance dose: 50 mg SC once weekly. Paediatric dose (2 to 17 years): Juvenile idiopathic arthritis; 0.8 mg/kg (max. 25 mg/dose) SC once weekly for once-weekly dosing or 0.4 mg/kg (max. 25 mg/dose) SC twice weekly (individual doses should be separated by 72 to 96 hours) for twice-weekly dosing.
Ethambutol HCl 200 mg TabletJ04AK02110T1001XXBTuberculosisAdult: 15-25mg/kg daily (max 1200mg) or 50mg/kg biweekly (max2000mg). Children: 15-25mg/kg daily or 50 mg/kg twice weekly.
Ethambutol HCl 400 mg TabletJ04AK02110T1002XXBTuberculosisAdult: 15-25mg/kg daily (max 1200mg) or 50mg/kg biweekly (max2000mg). Children: 15-25mg/kg daily or 50 mg/kg twice weekly.
Ether SolventN01AA01000L9901XXCTo remove adhesive plaster from the skinDose depending on the route and procedure
Ethinylestradiol 20 mcg & Drospirenone 3 mg TabletG03AA12954T1002XXA*i)Oral contraception ii)Treatment of acne vulgaris in women seeking oral contraception. iii) Treatment of symptoms of premenstrual dysphoric disorder (PMDD) in women who choose to use an oral contraceptive as their method of contraception.1 tab daily for 28 consecutive days starting on 1st day of menstrual bleeding.
Ethinylestradiol 20 mcg & Gestodene 75 mcg TabletG03AA10954T1001XXA/KKOral contraception1 tablet to be taken daily for 21 executive days starting on the first day of menses. Each subsequent pack is started after a 7 days tablet free interval.
Ethinylestradiol 20 mcg & Levonorgestrel 100 mcg TabletG03AA07954T1002XXA/KKi)Prevention of pregnancy ii)Treatment of moderate acne vulgaris not controlled by conventional therapy (e.g topical preparations and oral antibiotics) in post-menarchal, premenopausal women more than or 14 years who accept contraception.Beginning on day 1 of cycle, 1 tablet daily for 21 days followed by 7 tablet-free days.
Ethionamide 250 mg TabletJ04AD03000T1001XXA*As second-line therapy in the treatment of Multi Drug Resistant Tuberculosis only in combination with other efficacious agents and only when therapy with isoniazid, rifampicin, or other first-line agents has failed.ADULT: 15-20mg/kg daily, in divided doses if necessary; maximum dose 1g/day. CHILD: 10-20mg/kg in 2-3 divided doses or 15mg/kg/24hrs as a single daily dose.
Ethosuximide 250 mg/5 ml SyrupN03AD01000L9001XXBAbsence seizuresADULT: Initially, 500 mg daily. Increased by 250 mg at intervals of 4-7 days to usual dose of 1-1.5 g daily. Maximum: Up to 2 g, under strict supervision. CHILD: Greater than or equal to 6 years: Same as adult dose; less than 6 years: Initially, 250 mg daily. Increased gradually to usual dose of 20 mg/kg daily. Maximum: Children greater than or equal to 6 years: Same as adult dose; less than 6 years: Up to 1 g
Ethyl Chloride 100ml SprayN01BX01000A4001XXCFor minor surgical procedures including lancing boils, incision and drainage of small abscesses, pain due to athletic injuries and pain due to injection administrationSpray to affected area at a distance of about 30cm until a fine white film is produced
Etomidate 20 mg/10 mg InjectionN01AX07000P3001XXA*Induction of general anaesthesia for haemodynamically unstable patientsAdult: 300 mcg/kg given slowly over 30-60 seconds into a large vein in the arm. Child: Up to 30% more than the standard adult dose. Elderly: 150-200 mcg/kg, subsequently adjusted according to effects.
Etonogestrel 68 mg ImplantG03AC08000P1001XXA/KKContraceptionA single implant inserted subdermally and can be left in place for three years. The implant can be removed at any time but not later than three years after the date of insertion.
Etoposide 100 mg CapsuleL01CB01000C1002XXA*i) For palliative treatment of children with neuroblastoma, germ cell tumour, leukaemia ii) For elderly patients with acute myeloid leukemia and myelodysplasia (palliative)i) 50 mg/m2 in 2 divided doses/day for 21 days. Rest 1 week and restart. Usually for 6 courses ii) 50 mg daily for 21 days every 28 days or 100 mg daily for 14 days every 3 weeks. Doses for indications: refer to specific protocols
Etoposide 100 mg/5 ml InjectionL01CB01000P3001XXA*i) For treatment of children with solid tumours, juvenile myelomonocytic leukemia (JMML) and Langerhan cell histiocytosis ii) Leukaemia, lymphoma iii) Testicular cancer, lung cancer, gestational trophoblastic disease, gastric cancer, sarcomai) CHILD: 60-120 mg/m2/day by IV for 3 - 5 days every 3 - 6 weeks depending on protocols ii) Maintenance or palliative chemotherapy for elderly acute myeloid leukemia, consolidation therapy for acute lymphoblastic leukemia, stem cell mobilization (Refer to protocol) iii) 100 mg/m2 by IV every other day for 3 doses repeated every 3-4 weeks
Etoposide 25 mg CapsuleL01CB01000C1001XXA*i) For palliative treatment of children with neuroblastoma, germ cell tumour, leukaemia ii) For elderly patients with acute myeloid leukemia and myelodysplasia (palliative)i) 50 mg/m2 in 2 divided doses/day for 21 days. Rest 1 week and restart. Usually for 6 courses ii) 50 mg daily for 21 days every 28 days or 100 mg daily for 14 days every 3 weeks. Doses for indications: refer to specific protocols
Etoposide 50mg capsuleL01CB01000C1003XXA*Treatment of small cell lung cancer and malignant lymphomasNormal adult dose is 175mg-200mg daily for 5 consecutive days orally, followed by recession (withdrawal) interval of 3 weeks. Repeat administration as necessary. Increase or reduce dose as appropriate, according to the particular disease or symptoms.
Etoricoxib 120 mg TabletM01AH05000T1002XXA*i)Acute and chronic treatment of signs and symptoms of osteoarthritis (OA) and rheumatoid arthritis (RA) ii)Acute gouty arthritis iii)Acute paini) OA: 60 mg once daily. RA: 90 mg once daily ii & iii) Acute gouty arthritis and acute pain: 120 mg once daily (Given the exposure to COX-2 inhibitors, doctors are advised to use the lowest effective dose for the shortest possible duration of treatment)
Etoricoxib 60 mg TabletM01AH05000T1003XXA*i)Acute and chronic treatment of signs and symptoms of osteoarthritis (OA) and rheumatoid arthritis (RA) ii)Acute gouty arthritis iii)Acute paini) OA: 60 mg once daily. RA: 90 mg once daily ii & iii) Acute gouty arthritis and acute pain: 120 mg once daily (Given the exposure to COX-2 inhibitors, doctors are advised to use the lowest effective dose for the shortest possible duration of treatment)
Etoricoxib 90 mg TabletM01AH05000T1001XXA*i)Acute and chronic treatment of signs and symptoms of osteoarthritis (OA) and rheumatoid arthritis (RA) ii)Acute gouty arthritis iii)Acute paini) OA: 60 mg once daily. RA: 90 mg once daily ii & iii) Acute gouty arthritis and acute pain: 120 mg once daily (Given the exposure to COX-2 inhibitors, doctors are advised to use the lowest effective dose for the shortest possible duration of treatment)
Everolimus 0.25mg tabletL04AA18000T1001XXA*Indicated for the prophylaxis of organ rejection in adult patients at low to moderate immunological risk receiving an allogeneic renal or cardiac transplant in combination with ciclosporin for microemulsion and corticosteroids.An initial dose regimen of 0.75 mg b.i.d., which is recommended for the general kidney and heart transplant population. The daily dose of everolimus should always be given orally in two divided doses (b.i.d.).
Everolimus 0.75mg tabletL04AA18000T1003XXA*Indicated for the prophylaxis of organ rejection in adult patients at low to moderate immunological risk receiving an allogeneic renal or cardiac transplant in combination with ciclosporin for microemulsion and corticosteroids.An initial dose regimen of 0.75 mg b.i.d., which is recommended for the general kidney and heart transplant population. The daily dose of everolimus should always be given orally in two divided doses (b.i.d.).
Exemestane 25 mg TabletL02BG06000T1001XXA*Treatment of post-menopausal women with advanced breast cancer whose disease has progressed following tamoxifen and non-steroidal aromatase inhibitors25 mg once daily
Ezetimibe 10 mg & Simvastatin 20 mg TabletC10BA02000T1001XXA*Primary hypercholesterolemiaUsual starting dose: 10/20 mg/day
Ezetimibe 10 mg TabletC10AX09000T1001XXA*i) Co-administration with statins for patients who have chronic heart disease or are chronic heart disease equivalent or familial hypercholesterolaemia with target LDL-C not achieved by maximum dose of statins ii) Monotherapy in patients with documented biochemical intolerance to statins10 mg once daily. Not recommended for children less than 10 years old
Factor IX InjectionB02BD04000P9901XXAPrevention and control of bleeding in patients with factor IX deficiency due to haemophilia BDose varies according to the patient and the circumstances of the bleeding. i) Mild haemorrhage: initial dose of 30 units/kg body weight. ii) Moderate haemorrhage: initial dose of 50 units/kg iii) Major haemorrhage/surgery: Initial dose of 75 - 100 units/kg. Half of these doses may be repeated after 18-24 hrs if necessary.
Factor IX, Factor II, Factor VII and Factor X In Combination InjectionB02BD01000P4001XXA*i)treatment and perioperative prophylaxis of bleeding in acquired deficiency of the prothrombin complex coagulation factors, such as deficiency caused by treatment with vitamin K antagonists, or in case of overdose of vitamin K antagonists, when rapid correction of the deficiency is required. ii)treatment and perioperative prophylaxis of bleeding in congenital deficiency of any of the vitamin K dependent coagulation factors only if purified specific coagulation factor product is not available.i. Amount and frequency of administration should be calculated on an individual patient basis. Individual dosage requirements can only be identified on the basis of regular determinations of the individual plasma levels of the coagulation factors of interest or on the global tests of the prothrombin complex levels (INR, Quick's test) and a continuous monitoring of the clinical condition of the patient. An approximate calculation is as follows: Required dose (IU) = body weight (kg) x desired factor rise (IU/dl or % of normal) x reciprocal of the estimated recovery, i.e. Factor II = 53 Factor VII = 59 Factor IX = 77 Factor X = 56 As product may differ from one to another, it is strongly advised to refer to the manufacturer (product insert) in regards to dosing calculation.
Factor VIIa (Recombinant) eptacog alfa (activated) 100 KIU (2 mg) InjectionB02BD08000P4005XXA*Treatment of bleeding episodes and prevention of excessive bleeding in connection with surgery in patients with inherited or acquired haemophilia with inhibitors to coagulation factors VIII or IXInitially 4.5 KIU (90 mcg)/kg body weight IV bolus over 2-5 minutes, followed by 3-6 KIU (60-120 mcg)/kg body weight depending on type & severity of haemorrhage or surgery performed. Dosing interval: initially 2-3 hour to obtain haemostasis and until clinically improved. If continued therapy is needed, dose interval can be increased successively to every 4, 6, 8 or 12 hours
Factor VIIa (Recombinant) eptacog alfa (activated) 50 KIU (1 mg) InjectionB02BD08000P4004XXA*Treatment of bleeding episodes and prevention of excessive bleeding in connection with surgery in patients with inherited or acquired haemophilia with inhibitors to coagulation factors VIII or IXInitially 4.5 KIU (90 mcg)/kg body weight IV bolus over 2-5 minutes, followed by 3-6 KIU (60-120 mcg)/kg body weight depending on type & severity of haemorrhage or surgery performed. Dosing interval: initially 2-3 hour to obtain haemostasis and until clinically improved. If continued therapy is needed, dose interval can be increased successively to every 4, 6, 8 or 12 hours
Factor VIII (Human blood coagulation factor) & Von Willebrand factor InjectionB02BD06000P4002XXA*i)The treatment and prophylaxis of haemorrhage or surgical bleeding in Von Willebrand Disease (VWD) when 1-deamino-8-D-arginine vasopressin (desmopressin, DDAVP) treatment alone is ineffective or contraindicated. ii)The treatment and prophylaxis of bleeding associated with factor VIII deficiency due to haemophilia A.i. Von Willebrand Disease: Spontaneous Bleeding Episodes: Initially, factor VIII 12.5-25 IU/kg and ristocetin cofactor 25-50 IU/kg followed by factor VIII 12.5 IU/kg and ristocetin cofactor 25 IU/kg subsequently every 12-24 hrs. Minor Surgery: Factor VIII 30 IU/kg and ristocetin cofactor 60 IU/kg daily. Major Surgery: Initially, factor VIII 30-40 IU/kg and ristocetin cofactor 60-80 IU/kg followed by factor VIII 15-30 IU/kg and ristocetin cofactor 30-60 IU/kg subsequently every 12-24 hrs. Prophylaxis: Factor VIII 12.5-20 IU/kg and ristocetin cofactor 25-40 IU/kg 3 times weekly. ii. Hemophilia A therapy: Minor haemorrage: 10-15 IU/kg every 12-24 hours. Moderate to severe haemorrhage: 15-40 IU/kg every 8 to 24 hours. Minor surgery: Loading dose 20-30 IU/kg, maintenance dose 15-30 IU/kg. Major surgery: Loading dose 40-50 IU/kg, maintenance dose 10-40 IU/kg. Prophylaxis: 25-40 IU/kg three times weekly As product may differ from one to another, it is strongly advised to refer to the manufacturer (product insert) in regards to dosing calculation.
Factor VIII (Recombinant) Octocog Alfa 250 IU InjectionB02BD02000P4001XXA*i)Control and prevention of bleeding episodes in adults and children (0-16 years) with hemophilia A. ii)Surgical prophylaxis in adults and children with hemophilia A. iii)Routine prophylactic treatment to reduce the frequency of bleeding episodes and the risk of joint damage in children with no pre-existing joint damage. Not indicated fot the treatment of von willebrand's disease.The dosage and duration of treatment should be individualised and taking into account the severity of factor VIII deficiency, location and extent of bleeding and patient's clinical condition. Dose can be calculated by using: i. Required dose (IU) = body weight (kg) x desired factor VIII rise (IU/dl or % of normal) x 0.5 (IU/kg) or ii. Expected factor VIII rise (% of normal) = 2 x (dose administered)/ bodyweight (kg) Dose administered should be titrated to patient's clinical response
Factor VIII (Recombinant) Octocog Alfa 500 IU InjectionB02BD02000P4002XXA*i)Control and prevention of bleeding episodes in adults and children (0-16 years) with hemophilia A. ii)Surgical prophylaxis in adults and children with hemophilia A. iii)Routine prophylactic treatment to reduce the frequency of bleeding episodes and the risk of joint damage in children with no pre-existing joint damage. Not indicated for the treatment of von willebrand's disease.The dosage and duration of treatment should be individualised and taking into account the severity of factor VIII deficiency, location and extent of bleeding and patient's clinical condition. Dose can be calculated by using: i. Required dose (IU) = body weight (kg) x desired factor VIII rise (IU/dl or % of normal) x 0.5 (IU/kg) or ii. Expected factor VIII rise (% of normal) = 2 x (dose administered)/ bodyweight (kg) Dose administered should be titrated to patient's clinical response.
Factor VIII Inhibitor Bypassing Activity InjectionB02BD03000P4001XXAi)Treatment and prophylaxis of hemorrhages in hemophilia A and B patients with inhibitors. ii) Treatment and prophylaxis of hemorrhages in non-hemophilic patients who have developed inhibitors to Factors VIII, IX and XI. iii)Treatment of patients with acquired inhibitors to Factors X and XIII. iv)In the combination with Factor VIII concentrate for a long-term therapy to achieve a complete and permanent elimination of the Factor VIII inhibitor so as to allow for regular treatment with Factor VIII concentrate as in patients without inhibitor.As a general guideline, a dose of 50 to 100IU/kg body weight is recommended, not exceeding an individual dose of 100IU/kg bw and a maximum daily dose of 200IU/kg bw.
Factor VIII InjectionB02BD02999P9901XXAPrevention and control of bleeding in patients with factor VIII deficiency due to classical haemophilia ADose varies according to the patient and the circumstances of the bleeding. i) Mild to moderate: Usually a single dose of 10-15units/kg. ii) More serious haemorrhage/minor surgery:Initially 15-25 units/kg followed by 10-15 units/kg every 8 - 12 hours if required iii) Severe haemorrhage/major surgery: Initial : 40 - 50 units/kg followed by 20 - 25 units/kg every 8-12 hrs.
Fat Emulsion 10% for IV Infusion InjectionB05BA02000P6001XXASource of lipid in patients needing IV nutritionDose to be individualised. ADULT usual lipid requirement 2-3 g/kg/day. INFANT 0.5 - 1 g/kg/day
Fat Emulsion 20% for IV Infusion InjectionB05BA02000P6002XXASource of lipid in patients needing IV nutritionDose to be individualised. ADULT usual lipid requirement 2-3 g/kg/day. INFANT 0.5-1 g/kg/day
Felodipine 10 mg TabletC08CA02000T1002XXA/KKHypertensionInitiate at 5 mg once daily. Usual dose, 5 - 10 mg once daily in the morning
Felodipine 5 mg TabletC08CA02000T1001XXA/KKHypertensionInitiate at 5 mg once daily. Usual dose, 5 - 10 mg once daily in the morning
Fenofibrate 145 mg tabletC10AB05000T1002XXA*As second line therapy after failed gemfibrozil in patients: i) Hypercholesterolemia and hypertriglyceridemia alone or combined [type IIa,IIb,III and V dysplipidemias] in patients unresponsive to dietary and other non-pharmacological measures especially when there is evidence of associated risk factors ii) Treatment of secondary hyperlipoproteinemias if hyperlipoprotenemia persists despite effective treatment of underlying disease iii) Dyslipidemia in Type 2 Diabetes Mellitus145mg once daily, with or without food
Fentanyl 12mcg/h Transdermal PatchN02AB03136M7005XXA*As a second line drug in the management of chronic severe cancer pain not responding to non-narcotic analgesic. Not to be used in opiod naive patients.The use is to be restricted to pain specialists, palliative medicine specialists and oncologistsADULT and CHILD over 2 years previously treated with a strong opioid analgesic, initial dose based on previous 24-hour opioid requirement (consult product literature). If necessary dose should be adjusted at 72-hour intervals in steps of 12-25 mcg/hr
Fentanyl 25 mcg/h Transdermal PatchN02AB03136M7001XXA*As a second line drug in the management of chronic cancer pain. The use is to be restricted to pain specialists, palliative medicine specialists and oncologists.Patients who have not previously received a strong opioid analgesic, initial dose , one 25 mcg/hour patch to be replaced after 72 hours. Patients who have received a strong opioid analgesic, initial dose based on previous 24 hours opioid requirement (oral morphine sulphate 90 mg over 24 hours = one 25 mcg/hour patch). Not recommended in children.
Fentanyl 50 mcg/h Transdermal PatchN02AB03136M7002XXA*As a second line drug in the management of chronic cancer pain. The use is to be restricted to pain specialists, palliative medicine specialists and oncologistsPatients who have not previously received a strong opioid analgesic, initial dose , one 25 mcg/hour patch to be replaced after 72 hours. Patients who have received a strong opioid analgesic, initial dose based on previous 24 hours opioid requirement (oral morphine sulphate 90 mg over 24 hours = one 25 mcg/hour patch). Not recommended in children.
Fentanyl Citrate 50 mcg/ml InjectionN01AH01136P3001XXAShort duration analgesia during pre-medication induction and maintenance of anaesthesia, and in the immediate post-operative period.Dose should be individualized according to age, body weight, physical status, underlying pathological conditions and type of surgery and anaesthesia. ADULT: Premedication: IM 50 - 100 mcg, 30 - 60 mins prior to surgery. Adjunct to general anaesthesia: Induction IV 50 - 100mcg, repeat 2 - 3 mins intervals until desired effect is achieved. IV/IM 25 - 50mcg in elderly and poor risk patients. Maintenance: IV/IM 25 - 50mcg. Adjunct to regional anaesthesia: IM/slow IV 50 - 100mcg when additinal analgesia is required. Post-operatively (recovery room): IM 50 - 100mcg for pain control, tachypnoea and emergency delirium. May be repeated in 1- 2 hours as needed. CHILD (2 - 12 years): Induction & maintenance: 2 - 3 mcg/kg.
Ferric Ammonium Citrate 800 mg/10 ml Paediatric MixtureB03AB06136L2101XXCPrevention and treatment of iron-deficiency anaemiasCHILD up to 1 year 5 ml, 1 - 5 years 10 ml, taken well diluted with water
Ferrous controlled release 500 mg, Vitamin B1, Vitamin B2, Vitamin B6, Vitamin B12, Vitamin C, Niacinamide, Calcium Pantothenate, Folic Acid 800 mcg TabletB03AE10903T1001XXA/KKAnemia due to iron deficiency, megaloblastic anemia where there is an associated deficiency of Vitamin C and Vitamin B-complex particularly in pregnancy. In primary health clinic, the indication is restricted to anemia due to iron deficiency in pregnant women ONLY.One tablet daily
Ferrous Fumarate 200 mg TabletB03AA02138T1001XXC+Prevention and treatment of iron-deficiency anaemiasAdult: Usual dose range: Up to 600 mg daily. May increase up to 1.2 g daily if necessary. Child: As syrup containing 140 mg(45 mg iron)/5ml. Preterm neonate: 0.6-2.4 ml/kg daily; up to 6 years old: 2.5-5ml twice daily
Filgrastim (G-CSF) 30 MU/ml InjectionL03AA02000P3001XXA*i) Reduction in the duration of neutropenia and incidence of febrile neutropenia in cytotoxic chemotherapy for malignancy except chronic myeloid leukemia and myelodysplastic syndrome ii) Haemopoeitic stem cell transplantation (HSCT)/stem cell harvestingi) Adult: SC or IV 5 mcg/kg/day. Initiation: 24 - 72 hours after chemotherapy. Duration: Until a clinically adequate neutrophil recovery is achieved (absolute neutrophil count of at least 1 x 109/L on 2 consecutive days) ii) Refer to protocol
Filgrastim 30 MU in 0.5 ml InjectionL03AA02000P5001XXA*i) Reduction in the duration of neutropenia and incidence of febrile neutropenia in cytotoxic chemotherapy for malignancy except chronic myeloid leukemia and myelodysplastic syndrome ii) Haemopoeitic stem cell transplantation (HSCT)/stem cell harvestingi) ADULT: 5 mcg/kg/day by SC or IV. Initiation: 24 - 72 hours after chemotherapy. Duration: Until a clinically adequate neutrophil recovery is achieved (absolute neutrophil count of at least 1 x 109/L on 2 consecutive days) ii) Refer to protocol
Finasteride 5 mg TabletG04CB01000T1001XXA*Treatment and control of benign prostatic hyperplasia5 mg a day as a single dose. Clinical responses occur within 12 weeks - 6 months of initiation of therapy. Long-term administration is recommended for maximal response
Fingolimod 0.5mg CapsuleL04AA27110C1001XXA*Treatment of patients with relapsing forms of multiple sclerosis to reduce the frequency of clinical exacerbations and to delay the accumulation of physical disability0.5mg orally once daily
Flavoxate HCl 100 mg TabletG04BD02110T1001XXAUrinary frequency and incontinence, dysuria, urgency, bladder spasm due to catheterisationADULT: 200 mg 3 times daily. CHILD under 12 years not recommended
Flecainide Acetate 100 mg TabletC01BC04122T1001XXA*i) Sustained monomorphic ventricular tachycardias ii) Preexcited atrial fibrillation associated with Wolff-Parkinson White Syndrome iii) Reciprocating Atrio-Ventricular tachycardias (AVT) associated with Wolff-Parkinson White Syndrome iv) Supraventricular tachycardias due to Intra-Atrio Ventricular Nodul ReentryVentricular arrhythmias: 100 mg twice daily, maximum 400 mg/day (usually reserved for rapid control or in heavily built patients), reduced after 3 - 5 days if possible. Supraventricular arrhythmias: 50 mg twice daily, increased if required to maximum of 150 mg twice daily
Fluconazole 100 mg CapsuleJ02AC01000C1002XXAi) Oropharyngeal candidiasis, atrophic oral candidiasis associated with dentures, other candidal infections of mucosa ii) Tinea pedis, corporis, cruris, versicolor and dermal candidiasis iii) Invasive candidal & cryptococcal infections (including meningitis) iv) Prevention of relapse of cryptococcal meningitis in AIDS patients after completion of primary therapy v) Prevention of fungal infections in immunocompromised patients considered at risk as a consequence of HIV infections or neutropenia following cytotoxic chemotherapy, radiotherapy or bone marrow transplanti) Oropharyngeal candidiasis: 50 - 100 mg daily for 7 - 14 days (Maximum 14 days) except in severely immunocompromised patients, treatment can be continued for longer periods. Atrophic oral candidiasis associated with dentures: 50 mg daily for 14 days. Other candidal infections of mucosa: 50 - 100 mg daily for 14 - 30 days. CHILD: 3 - 6 mg/kg on first day then 3 mg/kg daily (every 72 hours in NEONATE up to 2 weeks old, every 48 hours in NEONATE 2 - 4 weeks old) ii) 50 mg daily for 2 - 4 weeks, maximum 6 weeks iii) 400 mg initially then 200 - 400 mg daily for 6 - 8 weeks. CHILD: 6 - 12 mg/kg daily (every 72 hours in NEONATE up to 2 weeks old, every 48 hours in NEONATE 2 -4 weeks old) iv) 100 - 200 mg daily v) 50 - 400 mg daily. CHILD: 3 - 12 mg/kg daily (every 72 hours in NEONATE up to 2 weeks old, every 48 hours in NEONATE 2 - 4 weeks old)
Fluconazole 2 mg/ml InjectionJ02AC01000P9901XXAi) Oropharyngeal candidiasis, atrophic oral candidiasis associated with dentures, other candidal infections of mucosa ii) Tinea pedis, corporis, cruris, versicolor and dermal candidiasis iii) Invasive candidal& cryptococcal infections (including meningitis) iv) Prevention of relapse of cryptococcal meningitis in AIDS patients after completion of primary therapy v) Prevention of fungal infections in immunocompromised patients considered at risk as a consequence of HIV infections or neutropenia following cytotoxic chemotherapy, radiotherapy or bone marrow transplanti) 50 - 100 mg daily for 7 - 14 days (Maximum 14 days) except in severely immunocompromised patients, treatment can be continued for longer periods. Atrophic oral candidiasis associated with dentures: 50 mg daily for 14 days. Other candidal infections of mucosa: 50 - 100 mg daily for 14 - 30 days. CHILD: 3 - 6 mg/kg on first day then 3 mg/kg daily (every 72 hours in NEONATE up to 2 weeks old, every 48 hours in NEONATE 2 - 4 weeks old) ii) 50 mg daily for 2 - 4 weeks, maximum 6 weeks iii) 400 mg initially then 200 - 400 mg daily for 6 - 8 weeks. CHILD: 6-12 mg/kg daily (every 72 hours in NEONATE up to 2 weeks old, every 48 hours in NEONATE 2 - 4 weeks old) iv) 100 - 200 mg daily v) 50 - 400 mg daily. CHILD: 3 - 12 mg/kg daily (every 72 hours in NEONATE up to 2 weeks old, every 48 hours in NEONATE 2 - 4 weeks old)
Fluconazole 50 mg CapsuleJ02AC01000C1001XXAi) Oropharyngeal candidiasis, atrophic oral candidiasis associated with dentures, other candidal infections of mucosa ii) Tinea pedis, corporis, cruris, versicolor and dermal candidiasis iii) Invasive candidal & cryptococcal infections (including meningitis) iv) Prevention of relapse of cryptococcal meningitis in AIDS patients after completion of primary therapy v) Prevention of fungal infections in immunocompromised patients considered at risk as a consequence of HIV infections or neutropenia following cytotoxic chemotherapy, radiotherapy or bone marrow transplanti) Oropharyngeal candidiasis: 50 - 100 mg daily for 7 - 14 days (Maximum 14 days) except in severely immunocompromised patients, treatment can be continued for longer periods. Atrophic oral candidiasis associated with dentures: 50 mg daily for 14 days. Other candidal infections of mucosa: 50 - 100 mg daily for 14 - 30 days. CHILD: 3 - 6 mg/kg on first day then 3 mg/kg daily (every 72 hours in NEONATE up to 2 weeks old, every 48 hours in NEONATE 2 - 4 weeks old) ii) 50 mg daily for 2 - 4 weeks, maximum 6 weeks iii) 400 mg initially then 200 - 400 mg daily for 6 - 8 weeks. CHILD: 6 - 12 mg/kg daily (every 72 hours in NEONATE up to 2 weeks old, every 48 hours in NEONATE 2 -4 weeks old) iv) 100 - 200 mg daily v) 50 - 400 mg daily. CHILD: 3 - 12 mg/kg daily (every 72 hours in NEONATE up to 2 weeks old, every 48 hours in NEONATE 2 - 4 weeks old)
Flucytosine 2.5 g/250 ml InjectionJ02AX01000P9901XXA*Treatment of systemic fungal infectionADULT: 100 - 200 mg/kg daily in 4 divided doses by IV infusion over 20 - 40 minutes not more than 7 days
Flucytosine 500 mg TabletJ02AX01000T1001XXA*Only for the treatment of fungal meningitisADULT: 50 - 150 mg/kg/day in 4 divided doses
Fludarabine Phosphate 10 mg TabletL01BB05162T1001XXA*B-cell chronic lymphocytic leukemia who have not responded to or whose disease had progressed during or after treatment with at least one standard alkylating-agent containing regimen40 mg /m2 given daily for 5 consecutive days every 28 days. Courses may be repeated every 28 days, usually for up to 6 cycles. Duration of treatment depends on treatment success and tolerability of the drug
Fludarabine Phosphate 50 mg InjectionL01BB05162P4001XXA*B-cell chronic lymphocytic leukaemia who have not responded to or whose disease had progressed during or after treatment with at least one standard alkylating-agent containing regimen25 mg/m2 daily for 5 consecutive days every 28 days. May be administered up to the achievement of a maximal response (usually 6 cycles) and then the drug should be discontinued. Reduce dose by up to 50% in patients with mild to moderate renal impairment (30-70ml/min)
Fludrocortisone Acetate 0.1 mg TabletH02AA02122T1001XXAAs an adjunct to glucocorticoids in the management of primary adrenocortical insufficiency in Addison's disease and treatment of salt-losing adrenogenital syndromeAdrenocorticoid insufficiency (chronic): ADULT 1 tablet daily. Salt-losing adrenogenital syndrome: ADULT 1 - 2 tablets daily. CHILD and INFANT 0.5 - 1 tablet daily
Flumazenil 0.1 mg/ml InjectionV03AB25000P3001XXBi) Diagnosis and/or management of benzodiazepine overdose due to self-poisoning or accidental overdose ii) Reversal of sedation following anaesthesia with benzodiazepinei) Initial, 0.2 mg IV over 30 seconds; if desired level of consciousness not obtained after an additional 30 seconds, give dose of 0.3 mg IV over 30 seconds; further doses of 0.5 mg IV over 30 seconds may be given at 1-minutes intervals if needed to maximum total dose of 3 mg; patients with only partial response to 3 mg may require additional slow titration to a total dose of 5 mg; if no response 5 minutes after receiving total dose of 5 mg, overdose is unlikely to be benzodiazepine and further treatment with flumazenil will not help ii) 0.2 mg IV over 15 seconds; if desired level of consciousness is not obtained after waiting 45 seconds, a second dose of 0.2 mg IV may be given and repeated at 60-seconds intervals as needed (up to a maximum of 4 additional times) to a maximum total dose of 1 mg; most patients respond to doses of 0.6 to 1 mg; in the event of resedation, repeated doses may be given at 20-minutes intervals if needed; for repeat treatment, no more than 1 mg (given as 0.5 mg/minute) should be given at any one time and no more than 3 mg should be given in any one hour
Flunarizine HCl 5 mg CapsuleN07CA03110C1001XXBi) Migraine prophylaxis ii) Maintenance treatment of vestibular disturbances and of cerebral and peripheral disordersi) ADULT: 5 - 10 mg daily preferably at night. ELDERLY more than 65 years: 5 mg at night. Maintenance 5-day treatment at the same daily dose ii) 5 - 10 mg at night. If no improvement after 1 month, discontinue treatment
Fluorescein 1 mg Ophthalmic StripS01JA01520M9901XXBDiagnostic fluorescein angiography or angioscopy of the fundus and of the iris vasculatureMoisten tip with tear fluid from lower fornix, sterile water or ophthalmic solution and gently stroke across the conjunctiva
Fluorescein Sodium 10% in 5 ml InjectionS01JA01520P3001XXADiagnostic fluorescein angiography or angioscopy of the fundus and of the iris vasculature500 mg IV
Fluorometholone 0.1% Ophthalmic SuspensionS01BA07000D2001XXA*Treatment of steroid responsive ocular inflammation1-2 drops qds. During the initial 24-48 hr, dose may be increased to 2 drops 2 hrly.
Fluorouracil 1 g/20 ml InjectionL01BC02000P4002XXA*Cancers of gastro-intestinal tract, breast and pancreas, head and neck. Ophtalmological indication: trabeculectomy500 - 600 mg/m2 IV in combination with other cytotoxic agents, repeated every 3 weeks or 300 - 450 mg/m2 IV slow bolus daily for 5 days in combination with biological response modifiers, repeated every 4 weeks or 3000 - 3750 mg/m2 as a continuous infusion over 5 days in combination with a platinum compound every 3 to 4 weeks
Fluorouracil 100 mg TabletL01BC02000T1001XXAColorectal cancer15 mg/kg (max: 1 g/day), may be given once weekly for maintenance. Max: 1 g/week.
Fluorouracil 50 mg / ml in 5 ml InjectionL01BC02000P4001XXA*Cancers of gastro-intestinal tract, breast and pancreas, head and neck. Ophtalmological indication: trabeculectomyIntravenous Infusion: 15 mg/kg bodyweight (to a maximum of 1 g daily) diluted in 300-500mL of 5% glucose given over a period of 4 hours. 12 mg/kg bodyweight daily for 3 consecutive days. Providing there are no signs of toxic effects, the patient may then be given 6mg/kg I.V. on the 5th, 7th and 9th days. If after the 9th day there is still no sign of toxicity, the patient may be placed on maintenance therapy. Maintenance Therapy: 5 - 10mg/kg bodyweight by I.V. injection once a week.
Fluoxetine HCl 20 mg CapsuleN06AB03110C1001XXAi) Depression ii) Obsessive-compulsive disorderi) 20 mg once daily increased after 3 weeks if necessary, usual dose 20 - 60 mg (ELDERLY 20 - 40 mg) once daily max 80 mg once daily (ELDERLY max 60 mg once daily). ii) Initially 20 mg once daily increased after 2 weeks if necessary, usual dose 20 - 60 mg (ELDERLY 20 - 40 mg) once daily, max 80 mg (ELDERLY max 60 mg) once daily, discontinue if no improvement within 10 weeks. CHILD and ADOLESCENT under 18 years are not recommended
Flupenthixol Decanoate 20mg/ml lnjectionN05AF01135P2001XXBChronic psychosesBy deep IM, initial test dose of 5-20 mg, then after at least 7 days. 20 - 40 mg repeated at intervals of 2 - 4 weeks. Maximum 400 mg weekly. Usual maintenance dose 50 mg every 4 weeks to 300 mg every 2 weeks. ELDERLY, initially quarter to half adult dose. CHILD not recommended. Deep IM recommended. Not for IV use
Fluphenazine Decanoate 25 mg/ml InjectionN05AB02135P3001XXBLong term management of psychotic disordersBy deep IM : Test dose 12.5 mg (6.25 mg in ELDERLY), then after 4-7 days 12.5 mg-100 mg repeated at intervals of 14-35 days, adjusted according to response. CHILD not recommended
Flutamide 250 mg TabletL02BB01000T1001XXA*Metastatic prostatic carcinoma250 mg 3 times daily
Fluticasone Furoate 27.5 mcg/dose Nasal SprayR01AD08139A4101XXA*Treatment of nasal symptoms (rhinorrhea, nasal congestion, nasal itching and sneezing) and ocular symptoms (itching/burning, tearing/watering, and redness of the eye) of seasonal and perennial allergic rhinitis.Adults/Adolescents (≥12 years) : 1-2 sprays (27.5 mcg/spray) in each nostril once daily. Children (2-11 years) : 1-2 sprays (27.5 mcg/spray) in each nostril once daily
Fluticasone Propionate 125 mcg/dose InhalerR03BA05133A2101XXBProphylactic treatment for asthmaADULT and CHILD more than 16 years i) Mild asthma : 100 mcg - 250 mcg twice daily ii) Moderate asthma : 250 - 500 mcg twice daily iii) Severe asthma : 500 mcg - 1000 mcg twice daily. Alternatively, the starting dose of fluticasone dipropionate may be gauged at half the total daily dose of beclomethasone dipropionate or equivalent administered by inhalation. CHILD 4 - 11 years, 50 mcg twice daily (maximum 100 mcg twice daily), CHILD 1-4 years, 50-100mcg microgram twice daily
Fluvoxamine 100 mg TabletN06AB08253T1002XXBDepressionFor depression, initially 50 - 100 mg daily in the evening, increased if necessary to 300 mg daily (over 150 mg in divided doses); usual maintenance dose 100 mg daily. CHILD and ADOLESCENT under 18 years not recommended
Fluvoxamine 50 mg TabletN06AB08253T1001XXBDepressive disorderFor depression, initially 50 - 100 mg daily in the evening, increased if necessary to 300 mg daily (over 150 mg in divided doses); usual maintenance dose 100 mg daily. CHILD and ADOLESCENT under 18 years not recommended
Folic Acid 5 mg TabletB03BB01000T1001XXC+i) For the prevention and treatment of folate deficiency states ii) For the prevention of neural tube defect in the foetusi) ADULT initially 10-20mg mg daily for 14 days or until haematopoietic response obtained. Daily maintenance: 2.5 mg-10mg .CHILD up to 1 year:250 mcg/kg daily; 1 to 5 years:2.5mg/day;6-12 years: 5mg/day ii) 5 mg daily starting before pregnancy and continued through the first trimester
Follitropin Alpha (Recombinant Human FSH) 300 IU/0.5 ml InjectionG03GA05000P3002XXA*i) Infertility treatment in anovulatory women who have been unresponsive to treatment with clomiphene citrate ii) Stimulation of follicular development for intra-uterine cycles iii) Stimulation of follicular development in assisted reproductive technology in the management of infertilityi) 75 - 150 IU daily, should commence within the first 7 days of the menstrual cycle and increased by 37.5 IU or 75 IU at 7 or 14 days interval. Max daily dose 225 IU ii) 150 - 225 IU daily commencing on days 2 or 3 of the cycle. Max daily dose 450 IU
Follitropin Alpha (Recombinant Human FSH) 75 IU InjectionG03GA05000P3001XXA*i) Infertility treatment in anovulatory women who have been unresponsive to treatment with clomiphene citrate ii) Stimulation of follicular development for intra-uterine cycles iii) Stimulation of follicular development in assisted reproductive technology in the management of infertilityi) 75 - 150 IU daily, should commence within the first 7 days of the menstrual cycle and increased by 37.5 IU or 75 IU at 7 or 14 days interval. Max daily dose 225 IU ii) 150 - 225 IU daily commencing on days 2 or 3 of the cycle. Max daily dose 450 IU
Follitropin Beta (Recombinant Human FSH) 300 IU InjectionG03GA06000P3002XXA*Infertility treatment in anovulatory women who have been unresponsive to treatment with clomiphene citrate. Stimulation of follicular development for intra-uterine insemination cycles and assisted reproductive technology in the management of infertility.To be individualized. Give in multiples of 50 IU. Starting dose can be 50 IU - 200 IU daily. It can be a step-up regime or a step-down, depending on the protocol and the ovarian response
Follitropin Beta (Recombinant Human FSH) 50 IU InjectionG03GA06000P3001XXA*Infertility treatment in anovulatory women who have been unresponsive to treatment with clomiphene citrate. Stimulation of follicular development for intra-uterine insemination cycles and assisted reproductive technology in the management of infertility.To be individualized. Give in multiples of 50 IU. Starting dose can be 50 IU - 200 IU daily. It can be a step-up regime or a step-down, depending on the protocol and the ovarian response
Fondaparinux Sodium 12.5 mg/ml Injection in Prefilled SyringeB01AX05520P5002XXA*i) Treatment of acute Deep Vein Thrombosis (DVT). ii) Treatment of Pulmonary Embolism (PE)The recommended dose to be administered by SC injection once daily is: 5mg for body weight less than 50kg, 7.5mg for body weight 50 to 100kg, 10mg for body weight greater than 100kg. Treatment should be continued for at least 5 days and until adequate oral anticoagulation is established (INR 2 to 3). Concomitant treatment with vitamin K antagonists should be initiated as soon as possible, usually within 72 hours. The usual duration of treatment is 5 to 9 days
Fondaparinux Sodium 2.5 mg/0.5 ml InjectionB01AX05520P5001XXA*i) Prevention of venous thromboembolic events (VTE) in orthopedic surgery (e.g. hip fracture, major knee or hip replacement surgery), abdominal surgery in patients at risk of thromboembolic complication. ii) Treatment of unstable angina or non-ST segment elevation myocardial infarction [UA/NSTEMI] in patients for whom urgent invasive management (PCI) is not indicated. iii) Treatment of ST segment elevation myocardial infarction (STEMI) in patients managed with thrombolytics or are not receiving other forms of reperfusion therapyi) 2.5 mg once daily given by SC, administered 6 hr following surgical closure provided homeostasis has been established. Usual duration of therapy is 5 to 9 days; for hip fracture patients, an extended course of up to 24 days is recommended. ii) ADULT more than 18 years: 2.5 mg once daily given by SC, initiated as soon as possible after diagnosis and continued for up to 8 days or until hospital discharge. If patient needs to undergo PCI, unfractionated heparin to be admin as per local practice protocol, taking into account the patient's bleeding risk and time of last dose of fondaparinux. Fondaparinux may be restarted no earlier than 2 hr after sheath removal. iii) ADULT more than 18 years: 2.5 mg once daily; first dose to be given IV (directly through an existing IV line or as infusion in 25 or 50 ml of 0.9% saline over 1-2 min), subsequent doses to be given SC. Treatment to be initiated as soon as diagnosis is made and continued up to a max of 8 days or until hospital discharge, whichever comes earlier. If patient needs to undergo non-primary PCI, unfractionated heparin to be admin as per local practice protocol, taking into account the patient's bleeding risk and time of last dose of fondaparinux. Fondaparinux may be restarted no earlier than 3 hr after sheath removal
Formoterol Fumarate Dihydrate 4.5 mcg /dose InhalerR03AC13138A2101XXA*i) Moderate persistent and severe persistent asthma ii) COPDi) ADULT and ELDERLY : 6 - 12 mcg (1 - 2 puff) once - twice daily, maximum daily dose 8 puff. CHILD over 6 years : 2 puff once - twice daily ii) ADULT and ELDERLY : 2 puff once - twice daily, maximum 4 puff once or twice daily
Formoterol Fumarate Dihydrate 9 mcg/dose TurbuhalerR03AC13138A2102XXA*i) Moderate persistent and severe persistent asthma ii) COPDi) ADULT and ELDERLY : 1 puff once - twice daily, maximum daily dose 4 - 6 puff. CHILD over 6 years : 1 puff once - twice daily, maximum dose : 2 puff daily ii) ADULT and ELDERLY : 1 puff, once - twice daily, maximum dose : 2 - 4 puff daily
Framycetin Sulphate 0.5%, Dexamethasone 0.05% and Gramicidin 0.005% Ear DropsS01CA01991D1001XXA/KKOtitis externaApply 2 - 3 drops 3 to 4 times daily
Frusemide 10 mg/ml InjectionC03CA01000P3001XXBPulmonary oedemaInitially 20 -40 mg IM or slow IV (rate not exceeding 4 mg/min). CHILD: 0.5 - 1.5 mg/kg. Max: 20 mg daily
Frusemide 40 mg TabletC03CA01000T1001XXBPulmonary oedemaADULT: Initial 40 - 80 mg on morning if required, can be increased to a max of 1 g/day in certain cases especially in chronic renal failure. CHILD : 1 - 3 mg/kg daily
Fuller's Earth PowderV03AB00000F2101XXCAdsorbent in pesticide poisoningAdult: 100-150g every 2-4 hours. Child: 1-2g/kg. (100g of Fuller's Earth is mixed with 200ml water. Repeat until Fuller's Earth is seen in stool (normally between 4-6 hours)
Fusafungine 1% Nasal SprayR02AB03000A4101XXALocal antibiotic, anti-inflammatory treatment of infectious and inflammatory syndromes of the respiratory mucosaADULT : 1 oral or 1 nasal inhalation 4 hourly, withdraw if no improvement after 7 days. CHILD : 1 oral or 1 nasal inhalation 6 hourly, withdraw if no improvement after 7 days
Fusidate, Sodium 250 mg TabletJ01XC01520T1001XXA*Treatment of infections caused by susceptible organisms especially Staphylococcal infections including Methicillin Resistant Staphylococcus aureus (MRSA)ADULT: 500 mg 3 times daily, skin and soft tissue infection: 250 - 500 mg twice daily
Fusidic Acid 1% Eye DropsS01AA13000D2001XXAFor staphylococcal infections1 drop in conjunctival sac 12 hourly. To be continued for 2 days after the eye appears normal. On the first day of treatment, may be applied more frequently : 1 drop 4 hourly. Surgical prophylaxis : 1 drop every 12 hours, 24 - 48 hours before operation
Fusidic Acid 2% CreamD06AX01000G1001XXASkin infections caused by staphylococci, streptococci, corynebacterium minutissumun and other sodium fusidate-sensitive organismsApply to affected area 2 - 3 times daily
Fusidic Acid 2% in Betamethasone Valerate 0.1% CreamD07CC01948G1001XXA/KKInflammatory dermatosis where bacterial infection is likely to occur eg atopic eczema, discoid eczema, stasis eczema, seborrhoic dermatitis, contact dermatitis, lichen simplex chronicus, psoriasis, discoid lupus erythematosusUncovered lesion- Apply 2 to 3 times daily. Covered lesions- Less frequent applications may be adequate
Fusidic Acid 50 mg/ml SuspensionJ01XC01000L8001XXA*Treatment of infections caused by staphylococcal especially Methicillin Resistant Staphylococcus aureus (MRSA)ADULT : 15 ml 3 times daily. CHILD 1 - 5 years: 5 ml 3 times daily; 5 - 12 years: 10 ml 3 times daily. INFANT : 1 ml/kg body weight daily in 3 - 4 divided doses
Fusidic Acid 500 mg InjectionJ01XC01520P4001XXA*Treatment of severe staphylococcal infections especially Methicillin Resistant Staphylococcus aureus (MRSA). To be used in combination therapy onlyADULT : 500 mg 3 times daily diluted to 250 - 500 ml infused slowly over 2 hours. Maximum : 2 g daily. CHILD and INFANT : 20 mg/kg/day divided into 3 equal doses infused slowly over 2 - 4 hours
Gabapentin 100 mg TabletN03AX12000T1002XXA*i) Add-on therapy for intractable partial epilepsy, refractory to standard anti-epileptic drugs ii) Treatment of various types of neuropathic pain, both peripheral (which includes diabetic neuropathy, post-herpetic neuralgia, trigeminal neuralgia) in adult more than 18 yearsADULT & CHILD > 12 yrs: 900-3600mg/day. Therapy may be initiated by administering 300mg TDS on day 1, or by titrating the dose as: 300mg once on day 1, 300mg BD on day 2, 300mg TDS on day 3. Thereafter, then dose may be increased in 3 equally divided doses up to max 3600mg/day.CHILD 3-12 yr: Initially 10-15 mg/kg/day in 3 divided dose. Effective dose: CHILD 3 to less than 5 yrs: 40mg/kg/day in 3 divided doses, CHILD 5-12 yrs: 25-35mg/kg/day in 3 divided doses ii) ADULT: 900mg/day in 3 equally divided doses. Max 3600mg/day
Gabapentin 300 mg CapsuleN03AX12000C1001XXA*i) Add-on therapy for intractable partial epilepsy, refractory to standard anti-epileptic drugs ii) Treatment of various types of neuropathic pain, both peripheral (which includes diabetic neuropathy, post-herpetic neuralgia, trigeminal neuralgia) in adult more than 18 yearsADULT & CHILD > 12 yrs: 900-3600mg/day. Therapy may be initiated by administered 300mg TDS on day 1, or by titrating the dose as: 300mg once on day 1, 300mg BD on day 2, 300mg TDS on day 3. Thereafter, may be increased in 3 equally divided doses up to max 3600mg/day.CHILD 3-12 yr: Initially 10-15 mg/kg/day in 3 divided dose. Effective dose: CHILD 3 to less than 5 yrs: 40mg/kg/day in 3 divided doses, CHILD 5-12 yrs: 25-35mg/kg/day in 3 divided doses ii) ADULT: 900mg/day in 3 equally divided doses. Max 3600mg/day
Gabapentin 600 mg TabletN03AX12000T1001XXA*i) Add-on therapy for intractable partial epilepsy, refractory to standard anti-epileptic drugs ii) Treatment of various types of neuropathic pain, both peripheral (which includes diabetic neuropathy, post-herpetic neuralgia, trigeminal neuralgia) in adult over 18 yearsADULT & CHILD > 12 yrs: 900-3600mg/day. Therapy may be initiated by administered 300mg TDS on day 1, or by titrating the dose as: 300mg once on day 1, 300mg BD on day 2, 300mg TDS on day 3. Thereafter, may be increased in 3 equally divided doses up to max 3600mg/day.CHILD 3-12 yr: Initially 10-15 mg/kg/day in 3 divided dose. Effective dose: CHILD 3 to less than 5 yrs: 40mg/kg/day in 3 divided doses, CHILD 5-12 yrs: 25-35mg/kg/day in 3 divided doses ii) ADULT: 900mg/day in 3 equally divided doses. Max 3600mg/day
Gadobutrol 1 mmol/ml injectionV08CA09000P3001XXA*In adults, adolescents and children aged 2 years and older with diagnostic difficulty especially in patients with renal impairment for: i) Contrast enhancement in cranial and spinal magnetic resonance imaging (MRI). ii) Contrast enhanced MRI of liver or kidneys in patients with high suspicion or evidence of having focal lesion to classify these lesions as benign or malignant. iii)Contrast enhancement in Magnetic Resonance Angiography (CE-MRA).A single intravenous injection of 0.1 mmol/kg (equivalent to 0.1 ml/kg body weight). Max: 0.3 mmol/kg (equivalent to 0.3 ml/kg body weight)
Gadodiamide 287mg (0.5 mmol/ml) InjectionV08CA03000P3001XXAContrast medium for cranial and spinal magnetic resonance imaging (MRI) after intravenous administration. The product provides contrast enhancement and facilitates visualisation of abnormal structure or lesions in the CNS0.1 mmol/kg body weight (equivalent to 0.2 ml/kg body weight) up to 100 kg. Above 100 kg body weight 20 ml is usually sufficient to provide diagnostically adequate contrast
Gadopentetate Dimeglumine 469 mg/mlV08CA01000P3001XXAi) Cranial and spinal magnetic resonance imaging ii) Whole body magnetic resonance imagingThe usual dose in adults, children, and neonates is 0.2 mL/kg (0.1 mmol/kg) intravenously. For cranial and spinal imaging, a further dose of 0.2 mL/kg (0.1 mmol/kg) may be given within 30 minutes if necessary; in adults this second dose may be 0.4 mL/kg (0.2 mmol/kg). For whole body imaging in adults and children over 2 years, a dose of 0.4 mL/kg (0.2 mmol/kg) may be needed in some cases to produce adequate contrast and in special circumstances a dose of 0.6 mL/kg (0.3 mmol/kg) may be used in adults
Gadoterate Meglumine (Gadoteric Acid) 0.5 mmol/ ml InjectionV08CA02254P3001XXAHigh risk patients undergoing Magnetic Resonance Imaging for cerebral and spinal disease, diseases of the vertebral column and other whole body pathologyThe recommended dose is 0.1 mmol/kg (equivalent to 0.2 mL/kg in adults, children and infants. In angiography, depending on the results of the examination being performed, a second injection may be administered during the same session if necessary
Gadoxetic acid disodium 0.25 mmol/ml solution for injection (10ml pre-filled syringe)V08CA10520P3001XXA*For use in adults for the enhancement of magnetic resonance imaging (MRI) of focal liver lesions0.1ml/kg body weight (equivalent to 25 µmol per kg body weight). Not recommended for patients younger than 18 years
Gamma Benzene Hexachloride 0.1 % LotionP03AB02100L6001XXCScabiesApply lotion to entire body from neck down for 8 to 12 hours, then rinse
Gamma Benzene Hexachloride 0.1% in Oil SolutionP03AB02100L9901XXCHead liceApply a sufficient quantity of shampoo onto clean, dry hair; generally 1 ounce is sufficient, no more than 2 ounces should be used. Work the shampoo into hair thoroughly and allow to remain on hair for 4 minutes. Add small quantities of water and massage until a good lather forms. Rinse thoroughly and towel dry briskly
Gamma Benzene Hexachloride 1% CreamP03AB02100G1002XXA/KKOnly for scabies in adultScabies Adult: Apply a thin layer of 1% topical preparation onto all skin areas from the neck to toes. Completely wash off from the body with warm water after 8-12 hr.
Ganciclovir Sodium 50 mg/ ml InjectionJ05AB06520P3001XXA*Treatment of cytomegalovirus (CMV) disease in immunocompromised patients, prevention of CMV disease during immunosuppressive therapy following organ transplantationInitial: 5 mg/kg infused over 1 hour 12 hourly for 14 - 21 days (CMV retinitis treatment) or 7 - 14 days (CMV disease prevention). Long term maintenance: 6 mg/kg daily for 5 days/week or 5 mg/kg daily for 7 days/week
Ganirelix 0.25 mg/0.5 ml InjectionH01CC01000P2001XXA*Prevention of premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for assisted reproduction techniqueGiven by SC 0.25 mg once daily, starting on day 6 of ovarian stimulation and continued until ovulation induction
Gefitinib 250 mg tabletL01XE02000T1001XXA*For the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have previously failed chemotherapy, and who have activating mutation of epidermal growth factor receptor (EGFR). Restricted to non-smoker, female, EGFR positive and Asian patients only.250mg tablet once a day, taken with or without food
Gemcitabine HCl 1 g InjectionL01BC05110P4002XXA*i) Locally advanced or metastatic non-small cell lung cancer ii) Locally advanced or metastatic pancreatic cancer iii) In combination with carboplatin in the treatment of patients with recurrent epithelial ovarian carcinoma, who have relapsed more than six months, following platinum-based therapy iv) In combination with paclitaxel for treatment of patients with metastatic breast cancer who have relapsed following adjuvant/ neoadjuvant chemotherapy. Prior chemotherapy should have included an anthracycline unless clinically contraindicatedi) Alone or with cisplatin: 1000 mg/m2 day 1 & 8 every 3 weeks or 1000 mg/m2 day 1, day 8, day 15 every 4 weeks ii) Initially 1000 mg/m2 weekly for 7 weeks followed by 1 week rest. Subsequent cycles 1000 mg/ m2 weekly for 3 weeks followed by 1 week rest iii) Gemcitabine 1000 mg/m2 as 30 minutes IV infusion day 1 & 8 of each 21-day cycle followed by carboplatin on day 1 to attain a target AUC of 4 mg/ml/minute iv) 1250 mg/m2 on days 1 and 8 of each 21-day cycle with paclitaxel 175 mg/m2 given as a 3-hour infusion before gemcitabine on day 1 of each 21-day cycle
Gemcitabine HCl 200 mg InjectionL01BC05110P4001XXA*i) Locally advanced or metastatic non-small cell lung cancer ii) Locally advanced or metastatic pancreatic cancer iii) In combination with carboplatin in the treatment of patients with recurrent epithelial ovarian carcinoma, who have relapsed more than six months, following platinum-based therapy iv) In combination with Paclitaxel, for treatment of patients with metastatic breast cancer who have relapsed following adjuvant/ neoadjuvant chemotherapy. Prior chemotherapy should have included an anthracycline unless clinically contraindicatedi) Alone or with cisplatin: 1000 mg/m2 day 1 & 8 every 3 weeks or 1000 mg/m2 day 1, day 8, day 15 every 4 weeks ii) Initially 1000 mg/m2 weekly for 7 weeks followed by 1 week rest. Subsequent cycles 1000 mg/ m2 weekly for 3 weeks followed by 1 week rest iii) Gemcitabine 1000 mg/m2 as 30 minutes IV infusion day 1 & 8 of each 21-day cycle followed by carboplatin on day 1 to attain a target AUC of 4 mg/ml/minute iv) 1250 mg/m2 on days 1 and 8 of each 21-day cycle, with paclitaxel 175 mg/m2 given as a 3-hour infusion before gemcitabine on day 1 of each 21-day cycle
Gemeprost (Prostagladin E1 Synthetic Analogue) 1 mg PessaryG02AD03000S1001XXAInducing abortion in the first trimesterCervical dilatation: 1 pessary 3 hourly before surgery to a max of 5 pessaries over 24 hours
Gemfibrozil 300 mg CapsuleC10AB04000C1001XXA/KKTreatment of hyperlipoprotinaemias (TYPES IIA, IIB, III, IV, V)ADULT: 1200 mg/day in 2 divided doses, 30 minutes before breakfast and dinner. Dose range from 0.9-1.5 g daily
Gentamicin 0.1% CreamD06AX07183G1001XXA*For localised infectionsApply 2 - 3 times daily
Gentamicin 0.3% Eye DropsS01AA11183D2001XXA/KKBroad spectrum antibiotic in superficial eye infections and also for Pseudomonas aeruginosa1 - 2 drops every 4 hours, in severe infection dosage may be increased up to 2 drops every hour
Gentamicin 0.3% Eye OintmentS01AA11183G5101XXA/KKConjunctivitis, blepharitis, blepharo-conjunctivitis, keratitis, keratoconjunctivitis, episcleritis, dacrocystitis, corneal ulcers, styes and infected eye socketApply into the conjunctival sac 3 - 4 times daily
Gentamicin 3% Fortified Eye DropsS01AA11183D2002XXABroad spectrum antibiotic in superficial eye infections and also for Pseudomonas aeruginosaDose according to the needs of the patient
Gentamicin 7.5 mg BeadsJ01GB03183P1001XXATreatment of chronic osteomyelitis of post-traumatic, post-operative or hematogenous origin7.5 - 22.5 mg chains to fill affected cavity
Gentamicin Sulphate 10 mg/ml InjectionJ01GB03183P3002XXBInfections due to susceptible organismsADULT: 3 - 5 mg/kg/day 8 hourly IM or IV. CHILD up to 2 weeks: 3mg/kg every 12 hours; 2 weeks - 12 years: 2 mg/kg 8 hourly
Gentamicin Sulphate 40 mg/ml InjectionJ01GB03183P3003XXBInfections due to susceptible organismsADULT: 3 - 5 mg/kg/day 8 hourly IM or IV. CHILD up to 2 weeks: 3mg/kg every 12 hours; 2 weeks - 12 years: 2 mg/kg 8 hourly
Gentamicin Sulphate and Betamethasone Disodium Phosphate Eye DropsS01CA05990D2001XXA/KKInflammatory and allergic conditions involving superficial eye structures and when bacterial infection is present : conjunctivitis, blepharitis, keratitis, episcleritis, dacryocystitis, hordeolum, meibomianitis, injuries involving anterior segment of the eye2 drops 3 - 4 times daily
Gentamicin Sulphate and Betamethasone Disodium Phosphate Eye OintmentS01CA05990G5101XXAInflammatory and allergic conditions involving superficial eye structures and when bacterial infection is present : conjunctivitis, blepharitis, keratitis, episcleritis, dacryocystitis, hordeolum, meibomianitis, injuries involving anterior segment of the eyeThin coating of ointment 3 - 4 times daily
Glibenclamide 5 mg TabletA10BB01000T1001XXBDiabetes mellitus type 2. Restriction : Use only in patient under 65 years oldRange: 2.5 - 15 mg daily (with or immediately after breakfast). Initially 2.5 mg daily increasing by 2.5 mg required for metabolic control. Max: 20mg daily.
Gliclazide 30 mg Modified Release TabletA10BB09000T5002XXBDiabetes mellitus type 2Initially, 30mg daily at breakfast time, may increase in successive steps to 60, 90 or 120mg daily at 1 month intervals. Max daily dose: 120mg
Gliclazide 60 mg Modified Release TabletA10BB09000T5001XXBDiabetes mellitus type 2Initially, 30mg daily at breakfast time, may increase in successive steps to 60, 90 or 120mg daily at 1 month intervals (except in patients whose blood glucose level was not reduced after 2 weeks of treatment). Max daily dose: 120mg
Gliclazide 80 mg TabletA10BB09000T1001XXBDiabetes mellitus type 2Initially 40-80mg daily. A single dose should not exceed 160mg and when higher doses are required, a twice daily split dosage is advised and should be divided. Maximum daily dose: 320mg. For elderly, starting dose should be 40mg twice daily.
Glucagon (Lyophilised) 1 mg/ml InjectionH04AA01000P4001XXBManagement of hypoglycaemiaAdult, children > 20kg: 1mg by SC, IM or IV. Children < 20kg : 0.5mg. If patient does not respond within 10 minutes, administer IV glucose. Repeat in 20 minutes if necessary.
Glutaraldehyde Solution 2%V07AV00000L9905XXA2% formulation - High level disinfection for heat sensitive equipments such as endoscopes20 minutes or more immersion is recommended for endoscopes before the session and between patients after thorough cleaning based on manufacturer recommendation
GlycerinA06AX01000L5001XXC+As a lubricant and osmotic dehydrating agentApply to area when required
Glycerin 25% and Sodium Chloride 15% EnemaA06AG20921G2001XXC+Constipation1 enema as required
Glyceryl Trinitrate 0.5 mg Sublingual TabletC01DA02221T1001XXCProphylaxis and treatment of angina and left ventricular failure0.5-1 mg sublingually may be repeated every 5 minutes until relief is obtained. Seek physician if the pain persists after a total of 3 tablets in a 15 minutes period.
Glyceryl Trinitrate 5 mg/ml InjectionC01DA02221P3001XXAProphylaxis and treatment of angina, left ventricular failure. Not for direct IV injection.Initial 5 mcg/min delivered via infusion pump. Subsequent titration must be adjusted to clinical situation with dose increment becoming more cautious as partial response is seen.
Glyceryl Trinitrate Aerosol Spray 400mcg (metered dose)C01DA02221A1001XXBProphylaxis and treatment of angina and left ventricular failureAt the onset of an attack, one or two metered sprays should be administered on or under the tongue. A spray maybe repeated approximately every 5 minutes as needed. No more than 3 metered sprays are recommended within 15 minute period. If chest pain persists after a total of 3 sprays, prompt medical attention is recommended. Aerosol may be used prophylactically 5 to 10 minutes before engaging in activities that might precipitate an acute attack
Glycine 1.5% Irrigating SolutionB05CX03000H3001XXABladder irrigation during genitourinary surgeryThe dosage depends on the extent of the procedure and its duration
Glycopyrrolate 200 mcg/ml InjectionA03AB02320P3001XXA*i) To reduce secretions (respiratory tract) for certain types of surgery ii) Reversal of neuromuscular block in patients where atropine is contraindicatedi) Pre-op: 4 mcg/kg via IM administration 30-60 mins before procedure. Intraoperative: 0.1 mg via IV administration, repeat at 2-3 min intervals when needed. Max: 400 mcg/dose. ii) 0.2 mg by IV for each 1 mg of neostigmine or 5 mg pyridostigmine
Golimumab 50mg (0.5ml) solution for injection in a pre-filled syringeL04AB06000P5001XXA*i) Rheumatoid arthritis (RA): In combination with methotrexate (MTX), is indicated for: - The treatment of moderate to severe active rheumatoid arthritis in adult patients when the response to DMARD therapy including MTX has been inadequate. - The treatment of active, severe and progressive rheumatoid arthritis in adult patients not previously treated with MTX. ii) Psoriatic arthritis (PsA): Golimumab alone or in combination with MTX, is indicated for: The treatment of active psoriatic arthritis in adult patients when the response to previous DMARD therapy has been inadequate. iii) Ankylosing spondylitis (AS): Golimumab(used alone) is indicated for: The treatment of active ankylosing spondylitis in adult patients when the response to conventional therapy has been inadequate.i) Rheumatoid arthritis 50mg given as a subcutaneous injection once a month, on the same date each month. ii)Psoriatic arthritis 50mg given as a subcutaneous injection once a month, on the same date each month. iii) Ankylosing spondylitis 50mg given as a subcutaneous injection once a month, on the same date each month.
Goserelin 10.8 mg Depot InjectionL02AE03000P2002XXAProstate cancer,endometriosis,leiomyoma uteri and assissted reproduction,breast cancer in premenopausal and perimenopausal women suitable for hormonal manipulationOne 10.8mg depot injected subcutaneously into the anterior abdominal wall, every 12 weeks.
Goserelin 3.6 mg Depot InjectionL02AE03000P2001XXAProstate cancer,endometriosis,leiomyoma uteri and assissted reproduction,breast cancer in premenopausal and perimenopausal women suitable for hormonal manipulation3.6 mg depot injection every 28 days
Granisetron HCl 1 mg TabletA04AA02110T1001XXAPrevention and treatment of nausea and vomiting associated with chemotherapy and radiotherapyADULT 1 mg twice daily or 2 mg once daily with the first dose to be administered within 1 hour prior to cytostatic therapy and can be given for up to 1 week following radiotherapy. Maximum 9 mg/day
Granisetron HCl 1 mg/ml InjectionA04AA02110P3001XXAi) Prevention and treatment of nausea and vomiting associated with chemotherapy and radiotherapy ii) Post-operative nausea and vomitingi) ADULT 1-3 mg as an IV bolus not not less than 30 seconds; maximum 9 mg/day. CHILD over 2 years; single dose of 10-40 mcg/kg as an IV infusion; maximum 3 mg/day ii) ADULT 1 mg by slow IV injection over 30 seconds prior to induction of anaesthesia
Griseofulvin (Ultramicrosize 125 mg = 250 mg Microsize) TabletD01BA01000T1001XXBDermatophyte infections of the skin, scalp, hair and nails, where topical therapy has failed or inappropriateADULT: 500 mg daily up to 1 g daily in divided doses, 2-8 wk in hair and skin infections, 6 mth in fingernail infections and 12 mth or more for toenail infections. CHILD: 10 mg/kg daily in divided doses or as a single dose
Haemodialysis Concentrate with AcetateB05ZA00908H1001XXAFor acute renal failure, chronic renal failure, overhydration, intoxication, adjustment of acid-base and electrolyte balanceDose depending on clinical cases
Haemodialysis Concentrate with BicarbonateB05ZA00908H1002XXAFor acute renal failure, chronic renal failure, overhydration, intoxication, adjustment of acid-base and electrolyte balanceDose depending on clinical cases
Haemophilus Influenza Type B Conjugate Vaccine Injection (Single Dose)J07AG01000P4001XXCImmunisation of infants against Haemophilus Influenzae Type B0.5 ml IM
Haloperidol 1.5 mg TabletN05AD01000T1001XXBSchizophrenia and other psychosesAdult: 0.5-5 mg bid/tid, may increase up to 100 mg daily in severe or resistant cases. Usual maintenance: 3-10 mg daily. Child: >3 yr: Initially, 25-50 mcg/kg daily in 2 divided doses, increased gradually if necessary. Max: 10 mg/day.
Haloperidol 5 mg TabletN05AD01000T1002XXBSchizophrenia and other psychosesAdult: 0.5-5 mg bid/tid, may increase up to 100 mg daily in severe or resistant cases. Usual maintenance: 3-10 mg daily. Child: >3 yr: Initially, 25-50 mcg/kg daily in 2 divided doses, increased gradually if necessary. Max: 10 mg/day.
Haloperidol 5 mg/ml InjectionN05AD01000P3001XXBAcute psychoses and maniaADULT: IM or IV , 2 mg - 10 mg then every 4 - 8 hours according to response to total maximum 18 mg daily. Use in child is not recommended
Heparin 1000 units/ml InjectionB01AB01520P3001XXBi) Prophylaxis and treatment of venous thrombosis and pulmonary embolism. ii) Treatment of myocardial infarction and arterial embolism. iii) Prevention of clotting in arterial and heart surgery and for prevention of cerebral thrombosisi) By IV injection, loading dose of 5000 units (10,000 units in severe pulmonary embolism) followed by continuous infusion of 15-25 units/kg/hr. By SC injection (for DVT) of 15,000 units every 12 hours (laboratory monitoring on daily basis essential to adjust dose). Small adult or child, lower loading dose then, 15-25 units/kg/hr by IV infusion, or 250 units/kg every 12 hours by SC injection. ii) As i), for unstable angina and acute peripheral arterial occlusion. iii) Prophylaxis in general surgery, by SC injection, 5000 units 2 hour before surgery, then every 8-12 hours for 7 days or until patient is ambulant, during pregnancy (with monitoring), 5000-10000 units every 12 hours. An adjusted dose regimen may be used for major orthopaedic surgery or low molecular weight heparin may be selected
Heparin 5000 units/ml InjectionB01AB01520P3002XXBi) Prophylaxis and treatment of venous thrombosis and pulmonary embolism. ii) Treatment of myocardial infarction and arterial embolism. iii) Prevention of clotting in arterial and heart surgery and for prevention of cerebral thrombosisi) By IV injection, loading dose of 5000 units (10,000 units in severe pulmonary embolism) followed by continuous infusion of 15-25 units/kg/hr. By SC injection (for DVT) of 15,000 units every 12 hours (laboratory monitoring on daily basis essential to adjust dose). Small adult or child, lower loading dose then, 15-25 units/kg/hr by IV infusion, or 250 units/kg every 12 hours by SC injection. ii) As i), for unstable angina and acute peripheral arterial occlusion. iii) Prophylaxis in general surgery, by SC injection, 5000 units 2 hour before surgery, then every 8-12 hours for 7 days or until patient is ambulant, during pregnancy (with monitoring), 5000-10000 units every 12 hours. An adjusted dose regimen may be used for major orthopaedic surgery or low molecular weight heparin may be selected
Heparin Sodium 50 units in Sodium Chloride InjectionB01AB01930P3001XXBTo maintain patency of peripheral venous cathetersFlush with 5 ml (50 units) every 4 hours or as required
Hepatitis A, Inactivated Vaccine 160 antigen units InjectionJ07BC02000P5001XXAVaccination against hepatitis A especially in those at risk of exposure to hepatitis A virus such as: i) Visitors ii) Chronic hepatitis B and C patient iii) Those requiring vaccination against hepatitis A0.5 ml per injection. ADULT and CHILD more than 15 years: A single primary dose followed by a booster dose 6 - 12 months later. CHILD 2 - 15 years: A single primary dose followed by a booster dose 6 - 12 months later
Hepatitis B Immunoglobulin (Human) InjectionJ06BB04000P3001XXAi) For post-exposure prophylaxis of hepatitis B ii) Prophylaxis against recurrence of hepatitis B infection in chronic hepatitis B post liver transplantationi) Adults: Recommended Dose: 1000-2000 IU IM and if necessary, the dose should be increased or repeated. Children: Inject 32-48 IU/kg of body weight, should be administered within 7 days after exposure to HBsAg (preferably within 48 hrs). Neonates: Recommended Initial Dose: 100-200 IU. The 1st dose should be administered within 5 days after birth (preferably within 48 hrs) and booster dose should be 32-48 IU/kg body weight. The booster dose should be administered between 2 and 3 months after the 1st administration. ii) Different regimens depending on hepatitis B virus (HBV) DNA positivity
Hepatitis B Vaccine InjectionJ07BC01000P4001XXC+Immunisation against infections caused by Hepatitis B virusADULTS over 20 years: 10 mcg/dose. ADOLESCENT 11 - 19 years: 5 mcg/dose. NEWBORN and CHILD up to 10 years: 2.5 mcg/dose. INFANTS born to HBsAg positive mothers: 3 doses of 0.5 ml each. Second dose to be given after 1 month and booster dose after 6 months
Homatropine 2% Eye DropsS01FA05330D2003XXBi) Mydriasis and cycloplegia for refraction ii) Treatment of anterior segment inflammationi) Adult: Instill 1 or 2 drops of 2% solution immediately before the procedure, repeat at 5-10-minute intervals if necessary. Child: Instill 1 drop of 2% soln immediately before the procedure, repeat at 10-min intervals if necessary. ii) Adult: Instill 1-2 drops of 2% bd-tds up to every 3-4 hr as needed. Child: 3 mth- 2 yr: instill 1 drop of 0.5% soln once daily or on alternate days. >2 yr: instill 1 drop of 1% or 2% soln bd.
Human Albumin InjectionB05AA01000P3001XXBi) Acute hypovolemic shock ii) Hypoproteinaemia iii) Neonatal hyperbilirubinaemiai) ADULT 25 g. CHILD 0.6 g/kg body weight ii) Maximum daily dose is 2g iii) 1 g/kg before exchange transfusion. Dose is given at rate of 1 ml of 25% solution per minute
Human Normal Globulin InjectionJ06BA02000P3001XXAi) Hypogammaglobulinaemia and other deficiency states ii) Severe refractory idiopathic thrombocytopenia purpura (platelet less than 20,000) with internal bleeding, particularly central nervous system iii) Septicaemia in immunocompromised patients or patients not responding to antibiotics iv) Chronic lymphocytic leukaemia not responding to conventional therapyi) 50 mg/kg body weight daily for 5 days, then 25 - 50 mg/kg weekly for maintenance according to the severity of the condition ii) 400 mg/kg daily for 5 days with a further dose of 400 mg/kg as required iii) Septicaemia in immunocompromised patients or patients not responding to antibiotics iv) 250 mg/kg per month Dose varies depending on brand used
Human Papillomavirus (Types 16, 18) Vaccine InjectionJ07BM02000P3001XXC+For the prevention of cervical cancer due to papilloma virus. To be used as part of the public health program onlyGiven by IM into deltoid region. ADULT and CHILD 10 - 25 years, 3 doses of 0.5 mL, at 0, 1 and 6 months
Human Papillomavirus (Types 6, 11, 16, 18) Vaccine InjectionJ07BM01000P3001XXC+For the prevention of cervical cancer due to papilloma virus. To be used as part of the public health program onlyGiven by IM into deltoid region or higher anterolateral thigh. ADULT and CHILD 9 - 26 years, 3 doses of 0.5 mL, at 0, 2 and 6 months
Hydralazine HCl 20 mg InjectionC02DB02110P3001XXBHypertensive crisis in pregnancyi) Slow IV injection, ADULT: 5-10 mg diluted with 10ml sodium chloride 0.9%. May be repeated after 20-30 minutes if necessary. ii) IV infusion 200-300 mcg/minutes. Maintenance dose 50-150 mcg/minutes
Hydrochlorothiazide 25 mg TabletC03AA03000T1001XXBDiuretic, hypertensionADULT: Diuretics; 25-200 mg daily. Hypertension 12.5-25 mg daily CHILD: Oedema and hypertension; Adjunct; 1 to 2 mg/kg ORALLY daily in single or two divided doses; Children 2-12 years old MAX dose, not to exceed 100 mg ORALLY daily; Infants less than 6 months old, may require doses up to 3 mg/kg ORALLY daily in two divided doses, Infants up to 2 yrs old: MAX dose, not to exceed 37.5 mg ORALLY daily
Hydrochlorothiazide 50 mg TabletC03AA03000T1002XXBDiuretic, hypertensionADULT: Diuretics; 25-200 mg daily. Hypertension 12.5-25 mg daily CHILD: Oedema and hypertension; Adjunct; 1 to 2 mg/kg ORALLY daily in single or two divided doses; Children 2-12 years old MAX dose, not to exceed 100 mg ORALLY daily; Infants less than 6 months old, may require doses up to 3 mg/kg ORALLY daily in two divided doses, Infants up to 2 yrs old: MAX dose, not to exceed 37.5 mg ORALLY daily
Hydrocortisone 1% & Neomycin 0.5% CreamD07CA01952G1001XXBInflammatory and pruritic manifestations of corticosteroid responsive dermatosesApply to affected part 2-3 times daily (occasionally may cause sensitisation to Neomycin)
Hydrocortisone 1% CreamD07AA02000G1001XXBInflammatory and pruritic manifestations of corticosteroid responsive dermatosesApply sparingly to affected area 2 - 3 times daily until condition improve, then reduce frequency
Hydrocortisone 1% OintmentD07AA02000G5001XXBInflammatory and pruritic manifestations of corticosteroid responsive dermatosesApply sparingly to affected area 2 - 3 times daily until condition improve, then reduce frequency
Hydrocortisone 10 mg TabletH02AB09000T1001XXBGlucocorticoid replacement therapy in primary or secondary adrenal insufficiencies and long term management of congenital adrenal hyperplasia in childrenADULT: 20 - 30 mg daily in divided doses. CHILD: 10 - 30 mg daily in divided doses
Hydrocortisone Enema 0.1%A07EA02000G2001XXBAdjunctive treatment for ulcerative colitis and proctitisADULT 100 mg 1-2 times/day for 2-3 weeks. If used for longer than 3 weeks, taper treatment over 2-3 weeks
Hydrocortisone Sodium Succinate 100 mg InjectionH02AB09520P4001XXCConditions responsive to systemic or local glucocorticoid injection therapy especially in emergenciesInitially 100 - 500 mg IV over 30 seconds to more than 10 minutes. Dose may be repeated at intervals of 2, 4 or 6 hours
Hydrogen Peroxide 1.5% Ear DropsS02AA06241D1001XXCTo soften impacted ear waxInstill 1 - 2 drops into the ear as required (leave for a few minutess)
Hydrogen Peroxide 20 volume SolutionD08AX01241L9901XXCSkin disinfection, particularly cleansing and deodorising wounds and ulcersHydrogen Peroxide 6% (=approx. 20 vol) shall be dispensed. For cleansing wounds: 1.5% to 6% solution apply 2-3 times daily or when nescessary. As a mouthwash: rinse the mouth for 2-3 minutes with 15ml of hydrogen peroxide 6% diluted in half a tumblerful of warm water 2-3 times daily. Disinfecting cleaned equipment: immersion for 30 minutes in 6% solution. As ear drop for removal of wax: hydrogen peroxide 6% diluted with 3 parts of water preferably just before use
Hydroxychloroquine Sulphate 200 mg TabletP01BA02183T1001XXAi) SLE and mixed connective tissue disease for skin, joint and serosa ii) Second line therapy for acute rheumatoid arthritisi) Initially 400 mg daily in divided dose. Maintenance : 200 - 400 mg daily ii) ADULT : 400 - 600 mg daily. Maintenance: 200 - 400 mg daily. CHILD : up to 6.5 mg/kg daily (maximum 400mg daily)
Hydroxyethyl Cellulose JellyV07AY00250G4001XXBFor lubricating purposeApply sufficiently for lubricating purpose
Hydroxyethyl Starch 6% InjectionB05AA07000P9901XXBTherapy and prophylaxis of hypovolaemia and shock in connection with surgery trauma, infections and burnsADULT daily dose up to 20 ml/kg/day. Normally 500-1500 ml. The rate of infusion may approach 20 ml/kg/hour in acute haemorrhagic shock, slower rates in burns and septic shock. CHILD under 10 years do not exceed 15 ml /kg/hour.
Hydroxyprogesterone Caproate 250 mg/ml InjectionG03DA03128P2001XXAHabitual and threatened abortion250 - 500 mg once weekly by IM injection
Hydroxyurea 500 mg CapsuleL01XX05000C1001XXAi)Solid tumours ii) Chronic myelocytic leukaemia and myeloproliferative disease iii)Severe psoriasis eg. Extensive plaque psoriasis, erythrodermic psoriasis, pustular psoriasis -as third line therapy.i)Intermittent therapy : 80 mg/kg orally as a single dose every 3rd day. Continuous therapy : 20 - 30 mg/kg orally as a single dose dly. Concomitant therapy with irradiation : 80 mg/kg orally as a single dose every 3rd day.(administration of hydroxyurea should be started at least 7 days before initiation of irradiation and continued during radiotherapy as well). ii)Continuous therapy (20 - 30 mg/kg orally as a single dose daily, therapy should be interrupted if the white blood cell count drops below 2500/mm3, or the platelet count below 100,000/mm3. iii) 500 mg tds.
Hydroxyzine HCl 25 mg TabletN05BB01110T1001XXAAllergic pruritusInitially 25 mg at night, increased if necessary up to 25 mg 3-4 times daily. ADULT and CHILD more than 10 years : 50 - 75 mg; 6 - 10 years: 25 - 50 mg; 1 - 5 years: 12.5 - 25 mg; to be taken daily in divided doses
Hyoscine Hydrobromide 400 mcg/ml InjectionA04AD01330P3001XXBTo reduce oral secretions before surgery200-600 mcg given as SC or IM 60 minutes before induction of anaesthesia. CHILD: 15 mcg/kg
Hyoscine N-Butylbromide 1 mg/ml LiquidA03BB01320L5001XXBGastrointestinal tract and genito-urinary tract spasm, dyskinesia of the biliary systemADULT 40mg 4 times a day. CHILD 6-12 years old: 10mg 3 times a day.
Hyoscine N-Butylbromide 10 mg TabletA03BB01320T1001XXBGastrointestinal tract and genito-urinary tract spasm, dyskinesia of the biliary systemADULT 40mg 4 times a day. CHILD 6-12 years old: 10mg 3 times a day.
Hyoscine N-Butylbromide 20 mg/ml InjectionA03BB01320P3001XXBGastrointestinal tract and genito-urinary tract spasm, dyskinesia of the biliary system20 mg IM/IV repeated after 30 min if needed. Max: 100 mg daily.
Hypromellose 0.3% Eye DropsS01XA20000D2002XXBTear deficiency, ophthalmic lubricant; for relief of dry eyes and eye irritation1 - 2 drops several times a day
Hypromellose 0.3%, Carbomer 980 Ophthalmic GelS01KA02000G3201XXBSymptomatic relief of severe dry eye conditions and as lens lubricant during ophthalmic diagnostic proceduresInstill 1-2 drops in affected eye(s) as needed
Ibandronic Acid 150 mg TabletM05BA06000T1003XXA*Treatment of postmenopausal osteoporosis to reduce the risk of fracture. Review treatment after 2 years and if there is positive response, treatment may be continued up to 5 years and then re-evaluate. Treatment should be stopped if there is no positive response after 5 years. Otherwise, patient needs to be given drug holiday for 1 to 2 years and then continue treatment shall the benefit outweigh the risk.150 mg once monthly
Ibuprofen 200 mg TabletM01AE01000T1001XXBPain and inflammation in rheumatic diseaseDosage: ADULT : 200 - 400 mg 3 times daily after food, maximum 3.2 g daily. CHILD : 30-50 mg/kg body weight daily in divided doses, maximum 2.4g daily. Lowest effective dose for the shortest possible duration.
Ichthammol Glycerin 10% Ear DropsS02AA30000D1001XXCEar wick for otitis externa with oedema2 - 3 drops 3 - 4 times daily and in ear wick for otitis externa
Idarubicin 10 mg InjectionL01DB06110P4002XXA*i) Acute promyelocytic leukaemia ii) Relapse Acute myeloid leukemia (with sibling match) iii) Acute myeloid leukemia, acute lymphoblastic leukemia (salvage therapy)i) Induction phase: 12 mg/m2 IV slow bolus on Days 3, 5 and 7. Consolidation phase, month 1: 12 mg/m2 IV on Days 1 and 2. Repeat monthly for 3 courses ii) 12 mg/m2 D1-3 iii) 12 mg/m2 D1-3 as part of FLAG-IDA regimen. Children: 10mg/m2 IV daily for 3 days
Idarubicin 5 mg InjectionL01DB06110P4001XXA*i) Acute promyelocytic leukaemia ii) Relapse Acute myeloid leukemia (with sibling match) iii) Acute myeloid leukemia, acute lymphoblastic leukemia (salvage therapy)i) Induction phase: 12 mg/m2 IV slow bolus on Days 3, 5 and 7. Consolidation phase, month 1: 12 mg/m2 IV on Days 1 and 2. Repeat monthly for 3 courses ii) 12 mg/m2 D1-3 iii) 12 mg/m2 D1-3 as part of FLAG-IDA regimen. Children: 10mg/m2 IV daily for 3 days
Idursulfase 2 mg/ml InjectionA16AB09000P3001XXA*Hunter syndrome (Mucopolysaccharidosis II, MPS II).0.5 mg/kg of body weight administered every week as an intravenous infusion.
Ifosfamide 1 g InjectionL01AA06000P4001XXA*i) Solid tumours ii) Leukaemia iii) Lymphomai) 1.2 - 2.4 g/m2/day for 3 - 7 days as a 30 - 120 minutes infusion. Alternatively, can also be given as a single high dose, eg. 5 g/m2 in a 24 hour infusion. Cycles may be repeated every 3 - 4 weeks ii) CHILD: 400 - 3000 mg/m2/day for 3 - 5 days according to protocol iii) Refer to protocols
Imatinib Mesylate 100 mg TabletL01XE01196T1001XXA*i) ADULT and CHILD: Philadelphia positive (Ph+) chronic myeloid leukaemia in chronic phase and in early acceleration after failure of interferon therapy ii) Treatment of patients with unresectable and/or metastatic malignant gastrointestinal stromal tumours (GIST) who are positive for CD117/c-kiti) ADULT: Chronic phase chronic myeloid leukemia: 400 mg once daily. Accelerated phase or blast crisis chronic myeloid leukemia: 600 mg once daily. CHILD more than 2 years, chronic and advanced phase chronic myeloid leukemia: 340 mg/m2 daily. Max: 800 mg/day ii) ADULT : 400mg/day
Imatinib Mesylate 400 mg TabletL01XE01196T1002XXA*i) ADULT and CHILD: Philadelphia positive (Ph+) chronic myeloid leukaemia in chronic phase and in early acceleration after failure of interferon therapy ii) Treatment of patients with unresectable and/or metastatic malignant gastrointestinal stromal tumours (GIST) who are positive for CD117/c-kiti) ADULT: Chronic phase chronic myeloid leukemia: 400 mg once daily. Accelerated phase or blast crisis chronic myeloid leukemia: 600 mg once daily. CHILD more than 2 years, chronic and advanced phase chronic myeloid leukemia: 340 mg/m2 daily. Max: 800 mg/day ii) ADULT : 400mg/day
Imiglucerase 400 IU InjectionA16AB02000P4002XXA*Non-neuronopathic (Type 1) or chronic neuronopathic (Type 3) Gaucher disease and who exhibit clinically significant non-neurological manifestations of the disease. The non-neurological manifestations of Gaucher disease include one or more of the following conditions: - anemia, after exclusion of other causes, such as iron deficiency - thrombocytopenia - bone disease, after exclusion of other causes, such as Vitamin D deficiency - hepatomegaly or splenomegalyDosage should be individualized to each patient. Initial dosages range from 2.5 units/kg of body weight 3 times a week to 60 units/kg once every 2 weeks. Administered by intravenous infusion over 1-2 hours.
Imipenem 500 mg and Cilastatin 500 mg InjectionJ01DH51961P4002XXA*Severe infections caused by susceptible pathogens especially useful in infections involving ESBL organisms. Not to be used for prophylaxisBased on type or severity of infection, susceptibility of pathogen(s) and patient condition including body weight and renal function. ADULT: 1 - 2 g/day in 3 - 4 divided doses. Maximum: 4 g/day or 50 mg/kg/day. Infusion rate: less than 500 mg dose: over 20 - 30 minutes, more than 500 mg: dose over 40 - 60 minutes. CHILDREN: ≥ 40kg body weight should receive adult doses. CHILDREN AND INFANTS: <40kg body weight should receive 15mg/kg at six hour intervals. The total daily dose should not exceed 2g.
Imipramine HCI 25 mg TabletN06AA02110T1001XXBDepressionInitially up to 75 mg daily in divided doses increased gradually to 150 - 200 mg (up to 300 mg in hospital patients); up to 150 mg may be given as a single dose at bedtime. ELDERLY initially 10 mg daily; increased gradually to 30 - 50 mg daily; CHILD is not recommended
Imiquimod 5 % w/w CreamD06BB10000G1001XXA*Treatment of external genital and perianal warts or condyloma acuminata in adultsApply to affected area at bedtime for 3 times a week for up to 16 weeks; leave on skin for 6-10 hours
Immunoglobulin Tetanus Human 250 Units/Vial InjectionJ06BB02000P3001XXBPassive immunization against tetanusProphylaxis of tetanus: IM 250 units. Treatment of tetanus: IM 30 - 300 units/kg
Indacaterol Maleate 150 mcg Inhalation CapsuleR03AC18253C9901XXA*Maintenance bronchodilator treatment of airflow obstruction in adult patients with chronic obstructive pulmonary disease (COPD).Once-daily inhalation of the content of one 150/300 microgram capsule. Maximum dose is 300 microgram once-daily.
Indacaterol Maleate 300 mcg Inhalation CapsuleR03AC18253C9902XXA*Maintenance bronchodilator treatment of airflow obstruction in adult patients with chronic obstructive pulmonary disease (COPD).Once-daily inhalation of the content of one 150/300 microgram capsule. Maximum dose is 300 microgram once-daily.
Indinavir Sulfate 400 mg CapsuleJ05AE02183C1001XXA*i) Post-exposure prophylaxis (PEP) among healthcare workers in high-risk HIV occupational exposure ii) For therapy as part of combination antiretroviral treatment on adult HIV patients ie Highly Active Anti-Retroviral Therapy (HAART)ADULT: 800 mg every 8 hours. CHILD (investigational): 500 mg/m2 every 8 hours (patients with smaller body surface area (BSA) may require lower doses of 300 - 400 mg/m2 every 8 hours). Dosage may varies depending on types of combination therapy used.
Indomethacin 100 mg SuppositoryM02AA23000S2001XXBPain and inflammation in rheumatic arthritisAdult: As supp: 100 mg to be inserted at night and repeated in the morning if necessary.
Indomethacin 25 mg CapsuleM01AB01000C1001XXBPain and inflammation in rheumatic disease50 - 200 mg daily in divided doses, with food. Child not recommended.
Infliximab 100 mg InjectionL04AB02000P4001XXA*i) Rheumatoid arthritis (moderate to severe), in combination with methotrexate ii) Ankylosing spondylitis in patients with active disease despite treatment with methotrexate iii) Crohn's Disease in patients who have an inadequate response to conventional therapies. iv) Fistulizing Crohn's Disease in patients who have an inadequate response to conventional therapies v) Ulcerative Colitis in patients who have an inadequate response to conventional therapiesi) Rheumatoid arthritis: ADULT over 18 years old: 3 mg/kg at 0, 2, 6 weeks, then every 8 weeks; May increase to 10 mg/kg or increase dosing frequency to 4 weekly for patients with incomplete response. Discontinue if no response by 12 weeks of initial infusion or after dose adjustment ii) Ankylosing spondylitis: ADULT over 18 years: 5 mg/kg IV over 2 hour given at week 0, 2, and 6 then every 6-8 weeks. Discontinue if no response by 6 weeks of initial infusion. iii), iv) & v)5 mg/kg given as an intravenous infusion over a 2-hour period followed by additional 5 mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 8 weeks thereafter
Influenza Vaccine (Inactivated, trivalent) Injection (containing 3 strains, two type A subtypes, of which one must include pandemic A (H1N1) and one Type B subtype)J07BB02963P3001XXBProphylaxis of influenza for frontliners (KKM staff and essential services personnel) and in high risk groupsCHILD 6-35 months: Single dose of 0.5 ml IM or deep SC; 3-8 years: 1-2 doses of 0.5 ml IM ADULT & CHILD more than 9 years: Single dose of 0.5 ml IM
Influenzae Vaccine (Inactivated,Trivalent) Type A (H1N1) 15 mcg, Type A (H3N2) 15 mcg & Type B 15 mcg Haemagglutinin InjectionJ07BB02963P5002XXBPrevention of influenza and influenza related complications in high risk adult patients, in particular individuals who have chronic cardiovascular, pulmonary, metabolic or renal disease, or who are immunocompromized and elderly patients19 to 59 years: Single dose of 0.1ml 9mcg/strain intradermally. ≥ 60 years: Single dose of 0.1ml 15mcg/strain intradermally
Influenzae Vaccine (Inactivated,Trivalent) Type A (H1N1) 9 mcg, Type A (H3N2) 9 mcg & Type B 9 mcg Haemagglutinin InjectionJ07BB02963P5001XXBPrevention of influenza and influenza related complications in high risk adult patients, in particular individuals who have chronic cardiovascular, pulmonary, metabolic or renal disease, or who are immunocompromized and elderly patients18 to 59 years: Single dose of 0.1ml 9mcg/strain intradermally. ≥ 60 years: Single dose of 0.1ml 15mcg/strain intradermally
Insulin Aspart 100 IU/ml InjectionA10AB05000P3001XXA*Diabetic Type 1 and 2 in patients that still experienced hypoglycaemia with use of human insulinDose to be individualised. The average daily insulin requirement is between 0.5 to 1.0 units/kg body weight
Insulin Aspart 30% and Protaminated Insulin Aspart 70% 100 U/ml InjectionA10AD05000P3001XXA/KKDiabetic type 1 and 2 in patients that still experienced hypoglycaemia with use of human insulinDose to be individualised. The average daily insulin requirement is between 0.5 to 1.0 units/kg body weight
Insulin Detemir 100 IU/ml Injection in Prefilled syringe/cartridgeA10AE05000P5001XXA*i)Type 1 Diabetes patients on basal bolus regimen, whom experience hypoglycemia with conventional insulin, to be used in combination with rapid or short-acting insulin. ii)Type 2 Diabetes patients on oral anti-diabetics and basal insulin regimen or basal bolus insulin regimen whom experience hypoglycemia with conventional basal insulin.Individualized dose given via SC once or twice daily. Initiate at a dose of 10IU or 0.1-0.2IU/kg. For twice daily dosing, the evening dose can be administered either with the evening meal, at bedtime, or 12 hours after the morning dose.
Insulin Glargine 300IU/3ml Prefilled Pen for InjectionA10AE04000P5001XXA/KKi) Diabetes mellitus type I in adults and child over 6 years ii) Diabetes mellitus type II in adultADULT and CHILD over 6 years: individualised dose given by SC, once daily at the same time every day. Adult patients who are insulin naïve may be initiated with 10IU daily.
Insulin Lispro 100 IU/ml Injection in Prefilled syringe/cartridgeA10AB04000P5001XXA*i) As initial therapy in children with Type 1 diabetes ii)Type 1 diabetes patients on basal bolus regimen, not controlled or experience hypoglycaemia with conventional insulin, to be used in combination with long-acting insulin iii)Type 2 diabetes patients on basal bolus or premixed regimen, not controlled or experience hypoglycaemia with conventional insulin, to be used in combination with intermediate-acting insulin or long-acting insulin iv)Patients with diabetes in pregnancy with poor postprandial control or experience hypoglycaemia with conventional short-acting insulinDose to be individualized. The average daily insulin requirement is between 0.5 to 1.0 units/kg body weight, given within 15 minutes before meal.
Insulin Lispro 25% & Insulin Lispro Protamine 75% 100 IU/ml Injection in Prefilled syringe/cartridgeA10AD04000P5001XXA*Patients with Type 2 diabetes whom experience hypoglycemia with the use of human premixed insulin.Dose to be individualized. The average daily insulin requirement is between 0.5 to 1.0 units/kg body weight
Insulin Recombinant Neutral Human short-acting 100 IU/ml Injection in 10ml vialA10AB01000P3001XXBDiabetes mellitusDose to be individualised. The average daily insulin requirement is between 0.3-1.0 units/kg body weight/day. Daily insulin requirement may be higher in patients with insulin resistance, and lower in patients with residual, endogenous insulin production.
Insulin Recombinant Neutral Human Short-acting 1000IU/10ml in Vial for InjectionA10AB01000P5001XXBDiabetes mellitusDose to be individualised. The average daily insulin requirement is between 0.3-1.0 units/kg body weight/day. Daily insulin requirement may be higher in patients with insulin resistance, and lower in patients with residual, endogenous insulin production.
Insulin Recombinant Synthetic Human Intermediate-Acting 1000IU/10ml in Vial for InjectionA10AC01000P3001XXBDiabetes mellitusDose to be individualised. The daily insulin requirement is usually between 0.3 and 1.0IU/kg /day
Insulin Recombinant Synthetic Human Premixed 1000IU/10ml in Vial for InjectionA10AD01000P3001XXBDiabetes mellitusDose to be individualised. The average daily insulin requirement is between 0.3-1.0 units/kg body weight/day. Daily insulin requirement may be higher in patients with insulin resistance, and lower in patients with residual, endogenous insulin production.
Insulin Recombinant Synthetic Human, intermediate-acting 100 IU/ml Penfill and RefillA10AC01000P5001XXBInsulin dependent diabetes mellitus, non insulin dependent diabetes unresponsive to treatment to diet or oral hypoglycaemics, hyperkalaemia to assure proper utilisation of glucose and reduce glucosuria in non diabetic patients receiving parenteral nutritionDose to be individualised. The daily insulin requirement is usually between 0.3 and 1.0IU/kg /day
Insulin Recombinant Synthetic Human, pre-mixed 100 IU/ml Penfill and RefillA10AD01000P5001XXBInsulin dependent diabetes mellitus, non insulin dependent diabetes unresponsive to treatment to diet or oral hypoglycaemics, hyperkalaemia to assure proper utilisation of glucose and reduce glucosuria in non diabetic patients receiving parenteral nutritionDose to be individualised. The average daily insulin requirement is between 0.5-1.0 units/kg body weight
Interferon Alfa - 2a 3 MIU InjectionL03AB04000P3001XXA*For the treatment of i) Hairy cell leukaemia ii) Chronic myelogenous leukaemia iii) AIDS related Kaposi's Sarcoma iv) Chronic hepatitis B v) Chronic hepatitis C vi) Advanced renal cell carcinomai) Initial : 3 MIU SC daily. If intolerant, 1.5 MIU daily or 3 MIU 3 times a week or 1.5 MIU 3 times a week. Maintenance : 1.5-3 MIU SC 3 times a week ii) Patient > 18 years : 3 MIU daily (days 1-3), 6 MIU daily (days 4-6), 9 MIU daily (days 7-84) iii) Patient > 18 years : Initially escalating dose to 18-36 MIU SC/IM for 10-12 weeks. Maintenance: up to 36 MIU 3 times a week iv)2.5-5 MIU/m2 SC 3 times a week for 4-6 months. CHILD: up to 10 MIU/m2 BSA v) Monotherapy : Initial : 3 - 6 MIU SC 3 times a week for 6 months. Maintenance : 3 MIU 3 times a week for an additional 6 months. vi) As an adjunct to cytotoxic chemotherapy: An escalating dose of 3 MIU 3 times a week for 1 week, then 9 MIU 3 times a week for 1 week, then 18 MIU 3 times a week thereafter for 3-12 months SC
Interferon Alfa-2b 18 MIU Multidose Injection PenL03AB05000P5001XXAFor the treatment of i) Hairy cell leukaemia ii) Chronic myelogenous leukaemia iii) AIDS related Kaposi's sarcoma iv) Chronic hepatitis B v) Chronic hepatitis C vi) Advanced renal cell carcinomai) 2 MIU SC or IM 3 times a week ii) Patient more than 18 years: 3 - 9 MIU 3 - 5 times a week or daily depending on response iii) Patient more than 18 years. Initially escalating dose to 18-36 MIU SC/IM for 10-12 weeks. Maintenance: up to 36 MIU 3 times weekly iv) 2.5-5 MIU/m2 SC 3 times weekly for 4-6 month. CHILD: up to 10 MIU/m2 BSA v) 3 MIU for 12 months vi) As an adjunct to cytotoxic chemotherapy: An escalating dose of 3 million IU 3 times/week for 1 week, then 9 million IU 3 times/week for 1 week, then 18 million IU 3 times/week thereafter for 3-12 month SC or IM
Interferon Alfa-2b 30 MIU Multidose Injection PenL03AB05000P5002XXAFor the treatment of i) Hairy cell leukaemia ii) Chronic myelogenous leukaemia iii) AIDS related Kaposi's sarcoma iv) Chronic hepatitis B v) Chronic hepatitis C vi) Advanced renal cell carcinomai) 2 MIU SC or IM 3 times a week ii) Patient more than 18 years: 3 - 9 MIU 3 - 5 times a week or daily depending on response iii) Patient more than 18 years. Initially escalating dose to 18-36 MIU SC/IM for 10-12 weeks. Maintenance: up to 36 MIU 3 times weekly iv) 2.5-5 MIU/m2 SC 3 times weekly for 4-6 month. CHILD: up to 10 MIU/m2 BSA v) 3 MIU for 12 months vi) As an adjunct to cytotoxic chemotherapy: An escalating dose of 3 million IU 3 times/week for 1 week, then 9 million IU 3 times/week for 1 week, then 18 million IU 3 times/week thereafter for 3-12 month SC or IM
Interferon Alpha - 2a 4.5 MIU InjectionL03AB04000P3002XXA*For the treatment of i) Hairy cell leukaemia ii) Chronic myelogenous leukaemia iii) AIDS related Kaposi's Sarcoma iv) Chronic hepatitis B v) Chronic hepatitis C vi) Advanced renal cell carcinomai) 2 MIU SC or IM 3 times a week ii) Patient more than 18 years: 3 - 9 MIU 3 - 5 times a week or daily depending on response iii) Patient more than 18 years. Initially escalating dose to 18-36 MIU SC/IM for 10-12 weeks. Maintenance: up to 36 MIU 3 times weekly iv) 2.5-5 MIU/m2 SC 3 times weekly for 4-6 month. CHILD: up to 10 MIU/m2 BSA v) 3 MIU for 12 months vi) As an adjunct to cytotoxic chemotherapy: An escalating dose of 3 million IU 3 times/week for 1 week, then 9 million IU 3 times/week for 1 week, then 18 million IU 3 times/week thereafter for 3-12 month SC or IM
Interferon Alpha 2b 3 MIU InjectionL03AB05000P3001XXA*For the treatment of i) Hairy cell leukaemia ii) Chronic myelogenous leukaemia iii) AIDS related Kaposi's sarcoma iv) Chronic hepatitis B v) Chronic hepatitis C vi) Advanced renal cell carcinomai) 2 MIU/m2 SC or IM 3 times a week ii) 4 - 5 MIU/m2 SC daily. Treatment must be discontinued after 8 to 12 weeks of treatment if at least a partial haematological remission or a clinically meaningful cytoreduction has not been achieved iii) Patient > 18 years : 30 MIU/m2 SC or IM three times a week until disease progression or maximal response has been achieved after 16 weeks of treatment. iv) 5 MIU daily or 10 MIU three times a week for 16 weeks. CHILD : 3 MIU/m2 three times a week for the first week of therapy followed by dose escalation to 6 MIU/m2 (maximum of 10MIU) three times a week SC for a total duration of 16 to 24 weeks v) 3 MIU SC or IM 3 times a week.
Interferon beta -1b 250mcg (8MIU) InjectionL03AB08000P4001XXA*i)Relapsing-remitting multiple sclerosis (RRMS): Reduction of frequency and degree of severity of clinical relapses in ambulatory patients characterized by at least two attacks of neurological dysfunction over the preceding two year period, followed by complete or incomplete recovery ii)Secondary progressive multiple sclerosis (SPMS):Reduction of frequency and severity of clinical relapses and for slowing the progression of disease0.25 mg (8 MIU) by SC injection every other day
Interferon Beta-1a 22 mcgL03AB07000P5001XXA*Multiple sclerosis of the relapsing remitting type with 2 or more relapses within the last 2 years22 mcg 3 times weekly
Interferon Beta-1a 44 mcgL03AB07000P5002XXA*Multiple sclerosis of the relapsing remitting type with 2 or more relapses within the last 2 years44 mcg 3 times weekly
Iodamide InjectionV08AA03000P3001XXAFor hysterosalpingographyAccording to the procedure and route of administration
Iodine and Potassium Iodide SolutionH03CA00200L9901XXBi) Pre-operative treatment of thyrotoxicosis ii) Thyrotoxicosis crisisi) 1 ml daily in divided doses ii) 2 - 3 ml daily
Iodixanol 320 mg I/ml InjectionV08AB09000P3001XXAX-ray contrast medium for cardioangiography, cerebral angiography, peripheral arteriography, abdominal angiography, uroloraphy, venography, CT enhancement, lumbar, thoracic and cervical myelographyDepending on type of examination
Iohexol InjectionV08AB02000P3001XXAX-ray contrast medium for use in adults and children for cardioangiography, arteriography, urography, phlebography and CT-enhancement. Lumbar, thoracic, cervical myelography and computed tomography of the basal cisterns, following subarachnoid injection. Arthrography, endoscopic retrograde pancreatography (ERCP), herniography, hysterosalpingography, sialography and studies of the gastrointestinal tractDose depending on the route and procedure
Iopamidol 30.62 g in 50 ml InjectionV08AB04000P3001XXAi) Neuroradiology : myeloradiculography, cisternography and ventriculography ii) Angiograph : cerebral arteriography, thoracic aortography, abdominal aortography, angiocardiography, selective visceral arteriography, peripheral arteriography, venography, digital subtraction angiography (DSA), DSA of cerebral arteries, DSA of peripheral arteries, DSA of abdominal arteries iii) Urography : intravenous urography iv) Contrast enhancement in CT Scanning, arthrography, fistulographyFor angiography and cardiac cases- dose depending on the route and procedure. For selected vascular examination - bottles of 30 ml and 100 ml; dose depending on the route and procedure
Iopromide 300mg injectable solution (50ml)V08AB05000P3001XXAi) For angiography, urography, aortography and the visualization of body cavities ii) Contrast enhancement during computerized tomography iii) To check functioning of a dialysis shuntDose depending on the route and procedure
Iopromide 370mg injectable solution (50ml, 100ml)V08AB05000P3002XXAi) For angiography, urography, aortography and the visualization of body cavities ii) Contrast enhancement during computerized tomography iii) To check functioning of a dialysis shuntDose depending on the route and procedure
Ipratropium Bromide 0.0125% Nebulising Solution (125 mcg/ml)R03BB01320A3001XXBOnly for treatment of : i) Patients with ischaemic heart disease who develop extrasystole with salbutamol or terbutaline ii) Patients with chronic bronchitis who have airway obstruction and who do not respond to salbutamol or terbutaline. Reversible airways obstruction, particularly in chronic obstructive pulmonary diseaseADULT : 500 mcg up to 4 times daily. CHILD 5 - 12 years : 125 - 250 mcg up to 4 times daily, 12 years : 250 - 500 mcg up to 4 times daily
Ipratropium Bromide 0.025% Nebulising Solution (250 mcg/ml)R03BB01320A3002XXBOnly for treatment of : i) Patients with ischaemic heart disease who develop extrasystole with salbutamol or terbutaline ii) Patients with chronic bronchitis who have airway obstruction and who do not respond to salbutamol or terbutaline. Reversible airways obstruction, particularly in chronic obstructive pulmonary diseaseADULT : 500 mcg up to 4 times daily. CHILD 5 - 12 years : 125 - 250 mcg up to 4 times daily, 12 years : 250 - 500 mcg up to 4 times daily
Ipratropium Bromide 0.5 mg and Salbutamol 2.5 mg per UDVR03AK04320A3001XXBManagement of reversible bronchospasm associated with obstructive airway diseasesAcute attacks : 1 unit dose vial. In severe cases not relieved by 1 unit dose vial, 2 unit dose vials may require, patient should consult a doctor immediately. Maintenance : 1 unit dose vial 3 - 4 times daily
Ipratropium Bromide 20 mcg and Fenoterol 50 mcg/dose InhalerR03AK03986A2101XXBManagement of symptoms in chronic obstructive airway disorders with reversible bronchospasm such as bronchial asthma and chronic bronchitis with or without emphysemaADULT & CHILD more than 6 years; Acute asthma 2 puffs. Severe cases: if breathing has not noticeably improved after 5 mins, 2 further puffs may be taken. Intermittent and long-term treatment 1-2 puffs for each administration, up to max 8 puffs/day (average: 1-2 puffs three times daily)
Ipratropium Bromide 20 mcg and Salbutamol base 100 mcg/dose InhalationR03AK04320A1001XXBManagement of reversible bronchospasm associated with obstructive airway diseasesADULT and ELDERLY : 2 inhalations 4 times daily. Maximum : 12 inhalations daily. CHILD under 12 years not recommended
Ipratropium Bromide 20 mcg/dose Nebuliser solutionR03BB01320A1001XXBOnly for treatment of : i) Patients with chronic bronchitis who have airway obstruction and who do not respond to Salbutamol or Terbutaline ii) Patients with ischaemic heart disease who develop extrasystole with Salbutamol or Terbutaline20 - 40 mcg 3 - 4 times daily. In the early treatment, up to 80 mcg 3 - 4 times daily. CHILD up to 6 years : 20 mcg 3 times daily, 6 - 12 years : 20 - 40 mcg 3 times daily
Irbesartan 150 mg and Hydrochlorothiazide 12.5 mg TabletC09DA04000T1003XXA/KKHypertension in patients who cannot tolerate ACE inhibitors because of cough1 tablet daily
Irbesartan 150 mg TabletC09CA04000T1001XXA/KKHypertension, diabetic nephropathy (in patients who cannot tolerate ACE inhibitors because of cough)150 mg to 300 mg daily
Irbesartan 300 mg & Hydrochlorothiazide 12.5 mg TabletC09DA04000T1001XXA/KKHypertension in patients who cannot tolerate ACE inhibitors because of cough1 tablet daily
Irbesartan 300 mg TabletC09CA04000T1002XXA/KKHypertension, diabetic nephropathy (in patients who cannot tolerate ACE inhibitors because of cough)150 mg to 300 mg daily
Irinotecan HCl Trihydrate 20 mg/ml InjectionL01XX19110P3002XXA*Only for patients with colorectal cancer who: i) have relapsed within 6 months after the end of adjuvant chemotherapy with 5-fluorouracil-based regime ii) have progressive disease despite 5-fluorouracil chemotherapy for advanced disease iii) good performance status (WHO of 2 or less) The treatment must be given in a tertiary oncology centre or have clearance in writing by an oncologistIn combination therapy (for previously untreated patients): 180 mg/m2 once every 2 weeks as an IV infusion over 90 mins followed by infusion with folinic acid and 5-fluorouracil. In monotherapy (for previously treated patients): 350 mg/m2 administered as an intravenous infusion over 90 minutes period once every 3 weeks
Irinotecan HCl Trihydrate 40 mg/2 ml InjectionL01XX19110P3001XXA*Only for patients with colorectal cancer who: i) have relapsed within 6 months after the end of adjuvant chemotherapy with 5-fluorouracil-based regime ii) have progressive disease despite 5-fluorouracil chemotherapy for advanced disease iii) good performance status (WHO of 2 or less) The treatment must be given in a tertiary oncology centre or have clearance in writing by an oncologistIn combination therapy (for previously untreated patients): 180 mg/m2 once every 2 weeks as an IV infusion over 90 mins followed by infusion with folinic acid and 5-fluorouracil. In monotherapy (for previously treated patients): 350 mg/m2 administered as an intravenous infusion over 90 minutes period once every 3 weeks
Iron Dextran 50 mg Fe/ml InjectionB03AC06000P3001XXBSevere iron deficiency anaemiaAn initial test dose of 0.5 ml should be given over the desired route. For severe iron deficiency anaemia, 1-2 ml daily given by deep IM. Dosage is individualized according to total iron deficit
Iron Sucrose 100 mg/5 ml InjectionB03AC02250P3001XXA/KKDialysis patients on erythropoietin therapy, second and third trimester pregnancy and post partum anaemia patients with iron deficiency: i) who are not responsive to oral iron therapy ii) who may be at risk of allergic reactions to iron dextran injectionIndividualised dosage. ADULT and ELDERLY: Cumulative dose is to be administered in single doses of 100 - 200 mg of iron 2 - 3 times weekly depending on Hb level. By IV drip infusion, slow IV injection or directly into the venous limb of the dialyser. Total cumulative dose: 1000 mg
Isoflurane LiquidN01AB06000L5001XXBi) Induction and ii) Maintenance of anaesthesiai) Induction- Initiate at a concentration of 0.5 % ii) Maintenance- 1 - 2.5 % in oxygen or nitrous oxide mixture. 0.5 - 0.75 % with oxygen and nitrous oxide for Caesarian section
Isoniazid 100 mg TabletJ04AC01000T1001XXBi) Tuberculosis ii)Tuberculous meningitisi) & ii) ADULT 5-8mg/kg daily (Max 300mg) or 15-20mg/kg biweekly (max 1200mg)
Isoniazid 400 mg TabletJ04AC01000T1002XXBi) Tuberculosis ii)Tuberculous meningitisi) & ii) ADULT 5-8mg/kg daily (Max 300mg) or 15-20mg/kg biweekly (max 1200mg)
Isoprenaline HCl 0.2 mg/ml InjectionC01CA02110P3001XXBComplete heart block (third-degree artrioventricular block) not responding to atropine, while waiting for cardiac pacingIf given as IM: Initially 0.2 mg (1 ml of 1:5000 solution), followed by 0.02-1 mg depending on clinical response. If given as SC: 0.2 mg (1 ml of 1:5000 solution), followed by 0.15-0.2 mg depending on clinical response. If given as IV : 1-2 mg in 500 ml of dextrose 5%, infused at a rate of 0.5-2 ml/min while the patient's EKG is being monitored. The dose should be titrated to produce the desired clinical response
Isoprenaline HCl 1 mg/5 ml InjectionC01CA02110P3002XXBComplete heart block (third-degree artrioventricular block) not responding to atropine, while waiting for cardiac pacingIf given as IM: Initially 0.2 mg (1 ml of 1:5000 solution), followed by 0.02-1 mg depending on clinical response. If given as SC: 0.2 mg (1 ml of 1:5000 solution), followed by 0.15-0.2 mg depending on clinical response. If given as IV : 1-2 mg in 500 ml of dextrose 5%, infused at a rate of 0.5-2 ml/min while the patient's EKG is being monitored. The dose should be titrated to produce the desired clinical response
Isosorbide Dinitrate 1 mg/ml InjectionC01DA08221P3001XXATreatment for angina pectoris and left ventricular failure2-10 mg/hour IV infusion after dilution, higher doses up to 20 mg/hour may be required
Isosorbide Dinitrate 10 mg TabletC01DA08221T1001XXBProphylaxis and treatment for: i) Angina ii) Left ventricular failurei) 30 - 120 mg daily in divided doses ii) 40 - 160 mg, up to 240 mg if required
Isosorbide Mononitrate 50 mg SR CapsuleC01DA14221C2001XXAProphylaxis and treatment of angina pectoris50 mg daily
Isosorbide-5-Mononitrate 30 mg SR TabletC01DA14221T5001XXAProphylaxis and treatment of angina pectorisInitiate at 30 mg for 1st 2-4 days to avoid headache. Usual dose: 60 mg once daily, may be increased to 120 mg once daily
Isosorbide-5-Mononitrate 60 mg SR TabletC01DA14221T5002XXAProphylaxis and treatment of angina pectoris60mg once daily, increase to 120 mg daily
Isotretinoin 10 mg CapsuleD10BA01000C1001XXA*Only for treatment of i) Severe nodulo-cystic acne ii) Acne conglobata iii) Acne fulminans iv) Severe acne vulgaris failing conventional treatment.0.5-1 mg/kg of body weight per day (in two divided doses) for 15 to 20 weeks; the maximum recommended dose is 2mg/kg of body weight per day. After about 4 weeks, therefore, dosage for the maintenance treatment should be adjusted within the range 0f 0.1-1mg/kg daily to meet individual need. Treatment usually lasts a total of 16 weeks. There should be an interval of at least 8 weeks before re-starting treatment.
Isotretinoin 20 mg CapsuleD10BA01000C1002XXA*Only for treatment of i) Severe nodulo-cystic acne ii) Acne conglobata iii) Acne fulminans iv) Severe acne vulgaris failing conventional treatment WARNING: THIS DRUG IS TERATOGENIC0.5-1 mg/kg of body weight per day (in two divided doses) for 15 to 20 weeks; the maximum recommended dose is 2mg/kg of body weight per day. After about 4 weeks, therefore, dosage for the maintenance treatment should be adjusted within the range 0f 0.1-1mg/kg daily to meet individual need. Treatment usually lasts a total of 16 weeks. There should be an interval of at least 8 weeks before re-starting treatment.
Itopride HCl 50 mg TabletA03FA00110T1001XXA*Treatment of gastrointestinal symptoms of functional, non-ulcer dyspepsia (chronic gastritis) i.e sensation of bloating, early satiety, upper abdominal pain or discomfort, anorexia, heartburn, nausea and vomiting50 mg 3 times daily before meal
Itraconazole 10 mg/ml Oral SolutionJ02AC02000L9901XXA*Treatment of: i) oral and/or oesophageal candidiasis ii) fluconazole resistant and/or oesophageal candidiasisi) 200 mg daily for 1 week. If no response after 1 week, continue treatment for another week ii) 100 - 200 mg twice daily for 2 weeks. If no response after 2 weeks, continue treatment for another 2 weeks. The 400 mg daily dose should not be used for more than 14 days if there are no signs of improvement
Itraconazole 100 mg CapsuleJ02AC02000C1001XXA*i) Dermatomycosis including pityriasis versicolor ii) Oral candidiasis iii) Palmar tinea manus and plantar tinea pedis iv) Fingernail onychomycosis v) Toenail onychomycosis vi) Vulvovaginal candidiasisi) 200 mg once daily for 7 days ii) 100 mg daily for 15 days iii) 200 mg twice daily for 7 days iv) 200mg twice daily for 1 week/month for 2 months v) 200 mg twice daily for 1 week/month for 3 months vi) 200 mg morning and evening for 1 day or 200 mg once daily for 3 days Dosage (changes for indication iv): iv)
Ivabradine 5 mg TabletC01EB17110T1001XXA*i) Symptomatic treatment of chronic stable angina pectoris in patients with normal sinus rhythm, who have a contraindication or intolerance to beta blockers ii) Treatment of coronary artery disease. Symptomatic treatment of chronic stable angina pectoris in coronary artery disease patients with normal sinus rhythm. Ivabradine is indicated : - in patients unable to tolerate or with a contraindication to the use of beta-blockers - or in combination with beta-blockers in patients inadequately controlled with an optimal beta-blocker dose and whose heart rate is > 60 bpm. Treatment of chronic heart failure. Ivabradine is indicated in chronic heart failure NYHA II to IV class with sinus rhythm and whose heart rate is ≥75bpm, in combination with standard beta-blocker therapy or when beta- blocker therapy is contraindicated or not tolerated.Initial dose 5 mg twice daily. May increase dose after 3-4 weeks to 7.5 mg twice daily depending on response. ELDERLY, initial dose 2.5 mg twice daily and titrate to a maximum of 7.5 mg twice daily
Ivabradine 7.5 mg TabletC01EB17110T1002XXA*i) Symptomatic treatment of chronic stable angina pectoris in patients with normal sinus rhythm, who have a contraindication or intolerance to beta blockers ii) Treatment of coronary artery disease. Symptomatic treatment of chronic stable angina pectoris in coronary artery disease patients with normal sinus rhythm. Ivabradine is indicated : - in patients unable to tolerate or with a contraindication to the use of beta-blockers - or in combination with beta-blockers in patients inadequately controlled with an optimal beta-blocker dose and whose heart rate is > 60 bpm. Treatment of chronic heart failure. Ivabradine is indicated in chronic heart failure NYHA II to IV class with sinus rhythm and whose heart rate is ≥75bpm, in combination with standard beta-blocker therapy or when beta- blocker therapy is contraindicated or not tolerated.Initial dose 5 mg twice daily. May increase dose after 3-4 weeks to 7.5 mg twice daily depending on response. ELDERLY, initial dose 2.5 mg twice daily and titrate to a maximum of 7.5 mg twice daily
Kanamycin 1 g InjectionJ01GB04183P4001XXA*i) Treatment of gonorrhoea and neonatal meningitis ii) Treatment of TB patients who require reserved second line drugs but have no pre-existing renal complicationsi) ADULT: 1 - 2 g daily IM in 1 - 2 equally divided doses. CHILD: 30 - 50 mg/kg/day in 1 - 2 divided doses ii) ADULT: 2 g daily IM in 2 equally divided doses twice a week or 1 g once daily 3 days a week
Ketamine 10 mg/ml InjectionN01AX03110P3001XXBSole anaesthetic for short procedures or induction of anaesthesia in certain types of patients (e.g in shock states)IV Initially, 1-4.5 mg/kg IV, a dose of 2 mg/kg produces anesth for 5-10 mins. IM Initially, 6.5-13 mg/kg IM, a dose of 10 mg/kg produces anesth for 12-25 mins.
Ketamine 50 mg/ml InjectionN01AX03110P3002XXBSole anaesthetic for short procedures or induction of anaesthesia in certain types of patients (e.g in shock states)IV Initially, 1-4.5 mg/kg IV, a dose of 2 mg/kg produces anesthesia for 5-10 mins. IM Initially, 6.5-13 mg/kg IM, a dose of 10 mg/kg produces anesthesia for 12-25 mins.
Ketoconazole 2% ShampooD01AC08000L5201XXAResistant dandruff onlyApply twice weekly for 2 - 4 weeks. Prophylaxis: Once every 1 - 2 weeks
Ketoconazole 200 mg TabletJ02AB02000T1001XXA/KKi) Pityriasis versicolor ii) Systemic mycosis (other skin mycoses) iii) Nail infectionsi) 200 mg with meal once daily for 10 days ii) 200 - 400 mg daily for 4 weeks - 6 months iii) 200 - 400 mg daily for 6 - 12 months.
Ketoprofen 2.5% GelM02AA10000G3001XXAAs a short term treatment for traumatic lesions, sprains, tendinitis, oedema, bruisesApply onto affected areas 2-4 times daily up to 10 days.
Ketoprofen 200 mg Slow Release CapsuleM01AE03000C2002XXA/KKPain and inflammation in rheumatic disease200mg in the morning or evening. Should be taken with food: Take immediately after meals.
Ketoprofen 30 mg Transdermal PlasterM02AA10000M7001XXATreatment of signs & symptoms of arthritis deformans, periarthritis humero-scapularis, tendinitis, peritendinitis, sore muscle, swelling, pain resulting from trauma (eg. contusion, distorsion, sprain).Apply 1 plaster to the affected area twice daily
Ketoprofen 50 mg/ml InjectionM01AE03000P3001XXA*To be used only in treatment of acute inflammatory conditionsBy deep IM into gluteal muscle, 50-100 mg every 4 hours. Maximum 200 mg in 24 hours for up to 3 days. Child not recommended
Ketorolac Tromethamine 0.5% Eye dropsS01BC05239D2001XXAi) Ocular itching due to allergic conjunctivitis ii) Prophylaxis and reduction of inflammation and associated symptoms following ocular surgeryProphylaxis and reduction of inflammation and associated symptoms following ocular surgery: 1 drop 3 times daily starting 24 hours pre-operatively and continuing up to 3 weeks post-operatively.
Ketorolac Tromethamine 30 mg/ml InjectionM01AB15239P3001XXA*Short term management of moderate to severe postoperative painADULT : 60mg as a single dose via IM inj or 30mg as a single IV dose. Alternatively, 30mg every 6 hr via IM or IV admin up to a max of 120mg daily.
Labetalol HCl 100 mg TabletC07AG01110T1001XXBHypertension (including in pregnancy)ADULT: 100 mg (50 mg in elderly) daily with food, increased at intervals of 14 days to usual dose of 200 mg twice daily, up to 800 mg twice daily (3 - 4 divided doses if higher dose). Max: 2.4 g daily
Labetalol HCl 200 mg TabletC07AG01110T1002XXBHypertension (including in pregnancy)ADULT: 100 mg (50 mg in elderly) daily with food, increased at intervals of 14 days to usual dose of 200 mg twice daily, up to 800 mg twice daily (3 - 4 divided doses if higher dose). Max: 2.4 g daily
Labetalol HCl 5 mg/ml InjectionC07AG01110P3001XXBHypertension crisisADULT: 20mg injected slowly for at least 2 min, followed by 40-80mg dose every 10 min, if necessary upto 300 mg. Patient should remain supine during and 3 hr after the procedure.
Lactobacillus acidophilus 100 million viable cells and estriol 0.03mg vaginal tabletG03CC06953T1001XXA/KKi)Atrophic vaginitis due to estrogen deficiency during menopause and post-menopause, or as co-medication to systemic hormone replacement therapy ii)Restoration of the Lactobacillus flora after local and/or systemic treatment with anti-infective agents or chemotherapeutic agentsAtrophic vaginitis : 1 vaginal tablet daily for 6-12 days followed by a maintenance dose of 1 vaginal tablet for 1-2 days per week Restoration therapy: 1-2 vaginal tablet daily for 6-12 days Administration The vaginal tablets should be inserted deeply into the vagina in the evenings before bedtime. ?In cases of a very dry vagina, vaginal tablet can be moistened with 1 or 2 drops of water before insertion into the vagina. ?During menstruation, treatment should be interrupted and resumed afterwards Should not use vaginal douches or rinses during treatment
Lactulose 3.35 g/5 ml LiquidA06AD11000L5001XXC+i) Constipation ii) Hepatic encephalopathyi) ADULT 15 ml twice daily adjusted to patient's need. CHILD 0.5 ml/kg/dose once or twice daily ii) 30-50 ml 3-4 times daily, dose adjusted to produce 2-3 soft stools daily. CHILD 1 ml/kg/dose 3-4 times daily
Lamivudine 10 mg/ml Oral SolutionJ05AF05000L9901XXA*HIV infection in combination with other antiretroviral agentsADULT: 150 mg twice daily or 300 mg once daily. INFANT under 1 month: 2 mg/kg twice daily. CHILD 3 month or over: 4 mg/kg twice daily. Maximum 300 mg daily
Lamivudine 100 mg TabletJ05AF05000T1001XXA*Management of chronic hepatitis B infection associated with evidence of hepatitis B viral replication and active liver inflammationAdult: 100 mg once daily. For patients with concomitant HIV infection: 300 mg once daily or in 2 divided doses. Child: >2 yr: 3 mg/kg once daily. Max: 100 mg/day.
Lamivudine 150 mg TabletJ05AF05000T1002XXA/KKHIV infection in combination with other antiretroviral agentsADULT: 150 mg twice daily or 300 mg once daily. INFANT under 1 month: 2 mg/kg twice daily. CHILD 3 month or over: 4 mg/kg twice daily. Maximum 300 mg daily
Lamotrigine 100 mg TabletN03AX09000T1002XXAi) Adjunctive or monotherapy for partial seizures and generalised tonic-clonic seizures not satisfactorily controlled with other antiepileptic drugs ii) Prevention of mood episodes in adult 18 years and above with bipolar disorder, predominately by preventing depressive episodesi) Up to 200 mg daily in single or divided dosage ii) 25- 200 mg daily
Lamotrigine 25 mg Dispersible/Chewable TabletN03AX09000T2001XXAAdd-on therapy in intractable partial seizures25 mg daily - 50 mg twice daily
Lamotrigine 5 mg Dispersible/Chewable TabletN03AX09000T2002XXAManagement of seizures in children aged 2 - 12 yearsa) Add-on therapy in patients not taking Valproate: week 1 and 2: 2 mg/kg/day twice daily, week 3 and 4: 5 mg/kg/day twice daily. Maintenance: 5 - 15 mg/kg/day twice daily b) Add-on therapy in patients taking Valproate or other anti-epileptic drugs, week 1 and 2: 0.2 mg/kg/day as a single dose (children less than 25 kg may take 5 mg on alternate days), week 3 and 4: 0.5 mg/kg/day as a single dose. Maintenance dose: 1 -5 mg/kg/day once daily or twice daily
Lamotrigine 50 mg TabletN03AX09000T1001XXAi) Adjunctive or monotherapy for partial seizures and generalised tonic-clonic seizures not satisfactorily controlled with other antiepileptic drugs ii) Prevention of mood episodes in adult 18 years and above with bipolar disorder, predominately by preventing depressive episodesi) Up to 200 mg daily in single or divided dosage ii) 25- 200 mg daily
Lansoprazole 30 mg TabletA02BC03000T1001XXA*i) Peptic ulcer disease ii) Reflux oesophagitis iii) Zollinger-Ellison Syndrome iv) For eradication of Helicobacter pylori in combination with antibiotici) 30mg daily in the morning for up to 4 weeks (duodenal ulcer) or up to 8 weeks (gastric ulcer). Maintenance: 15mg/day.ii) 30mg OD in the morning for up to 8 weeks if not healed. Maintenance: 15mg OD. iii) Initially 60mg OM & adjust as required. Daily doses >120mg should be given in 2 divided doses. iv) 30 mg twice daily in combination with any of the 2 antibiotics (clarithromycin 500 mg twice daily , amoxicillin 1 g twice daily or metronidazole 400 mg twice daily) for 1-2 weeks
Lanthanum Carbonate 1000mg Chewable TabletV03AE03130T2004XXA*Phosphate binding agent for the treatment of hyperphosphataemia in dialysis patients with sustained hypercalcaemia of more than three months and secondary hyperparathyroidismInitial: 750 to 1500 mg/day in divided doses with meals, then titrate in increments of 750 mg/day at intervals of 2 to 3 weeks. Maintenance: 1500-3000 mg/day in divided doses. Max: 3750 g/day
Laronidase 2.9 mg/5ml InjectionA16AB05000P3001XXA*Hurler and Hurler-Scheie forms of Mucopolysaccharidosis I (MPS I) and for patients with the Scheie form who have moderate to severe symptoms0.58 mg/kg of body weight administered once-weekly as an intravenous infusion
L-Asparaginase 10,000 IU InjectionL01XX02000P3001XXA*i) Acute lymphoblastic leukemia ii) Non-hodgkin's lymphomai) 5,000 iu/m2 for 10 days during induction, 10,000 iu/m2 also used with high dose methotrexate rescue in consolidation phase of acute lymphoblastic leukemia ii) CHILD: 5,000 - 25,000 iu/m2 per dose depending on protocol
Latanoprost 0.005% and timolol maleate 0.5% eye dropsS01ED51990D2004XXA*For reduction of Intraocular Pressure (IOP) in patients with Open-angle Glaucoma (OAG) and Ocular Hypertension (OH) who are insufficiently responsive to topical beta-blocker.1 drop in the affected eye(s) once daily
Latanoprost 0.005% Eye DropsS01EE01000D2001XXA*Reduction of elevated intraocular pressure in patients with open-angle glaucomaThe recommended dosage is one drop (1.5 µg) in the affected eye(s) once daily in the evening. If more than one topical ophthalmic drug is being used, the drugs should be administered at least five (5) minutes apart
Leflunomide 10 mg TabletL04AA13000T1001XXA*i) Persistent active rheumatoid arthritis ii) Active psoriatic arthritisLoading dose: 100 mg once daily for 3 days. Maintenance: 10-20 mg once daily
Leflunomide 20 mg TabletL04AA13000T1002XXA*i) Persistent active rheumatoid arthritis ii) Active psoriatic arthritisLoading dose: 100 mg once daily for 3 days. Maintenance: 10-20 mg once daily.
Lenalidomide 10 mg CapsuleL04AX04000C1002XXA*In combination with dexamethesone is indicated for the treatment of multiple myeloma patients who have received at least one prior therapyRecommended starting dose: 25 mg once daily on days 1 to 21 of repeated 28 day cycle with dexamethasone 40 mg once daily on days 1 to 4, 9 to 12 and 17 to 20 of each 28 day cycle for the first 4 cycles of therapy, thereafter dexamethasone 40 mg once daily on day 1 to 4 every 28 day cycle
Lenalidomide 15 mg CapsuleL04AX04000C1003XXA*In combination with dexamethesone is indicated for the treatment of multiple myeloma patients who have received at least one prior therapyRecommended starting dose: 25 mg once daily on days 1 to 21 of repeated 28 day cycle with dexamethasone 40 mg once daily on days 1 to 4, 9 to 12 and 17 to 20 of each 28 day cycle for the first 4 cycles of therapy, thereafter dexamethasone 40 mg once daily on day 1 to 4 every 28 day cycle
Lenalidomide 25 mg CapsuleL04AX04000C1004XXA*In combination with dexamethesone is indicated for the treatment of multiple myeloma patients who have received at least one prior therapyRecommended starting dose: 25 mg once daily on days 1 to 21 of repeated 28 day cycle with dexamethasone 40 mg once daily on days 1 to 4, 9 to 12 and 17 to 20 of each 28 day cycle for the first 4 cycles of therapy, thereafter dexamethasone 40 mg once daily on day 1 to 4 every 28 day cycle
Lenalidomide 5 mg CapsuleL04AX04000C1001XXA*In combination with dexamethesone is indicated for the treatment of multiple myeloma patients who have received at least one prior therapyRecommended starting dose: 25 mg once daily on days 1 to 21 of repeated 28 day cycle with dexamethasone 40 mg once daily on days 1 to 4, 9 to 12 and 17 to 20 of each 28 day cycle for the first 4 cycles of therapy, thereafter dexamethasone 40 mg once daily on day 1 to 4 every 28 day cycle
Letrozole 2.5 mg TabletL02BG04000T1001XXA*i) Treatment of hormone responsive metastatic or locally advance breast cancer after failure of tamoxifen ii) Adjunct for node positive postmenopausal women with early breast cancer (positive or unknown oestrogen or positive progesterone receptor status / receptor status) who have received 5 years of adjuvant tamoxifen therapy2.5 mg once daily
Leucovorin Calcium (Calcium Folinate) 15 mg TabletV03AF03390T1001XXATreatment of folic acid antagonist overdose15 mg every 6 hours for the next 48 - 72 hours
Leucovorin Calcium (Calcium Folinate) 3 mg InjectionV03AF03237P3001XXAi) Biochemical modulator for 5-Fluorouracil in the treatment of colorectal cancer ii) As rescue for high dose methotrexate iii) Megaloblastic anaemias due to deficiency of folic acidi) 200mg/m2 by slow IV injection over a minimum 3 minutes, followed by 5-Fluorouracil or 20mg/m2 IV followed by 5-Fluorouracil. In both cases, treatment is repeated daily for 5 days; may repeat at 4-week intervals for 2 courses then 4- to 5-week intervals ii) 15 mg (approximately 10mg/m2) every 6 hours for 10 doses, starting 24 hours after the beginning of the methotrexate infusion iii) Up to 1 mg daily
Leucovorin Calcium (Calcium Folinate) 50 mg InjectionV03AF03237P3002XXAi) Biochemical modulator for 5-Fluorouracil in the treatment of colorectal cancer ii) As rescue for high dose methotrexate iii) Gestational trophoblastic diseasei) 200mg/m2 by slow IV injection over a minimum 3 minutes, followed by 5-Fluorouracil or 20mg/m2 IV followed by 5-Fluorouracil. In both cases, treatment is repeated daily for 5 days; may repeat at 4-week intervals for 2 courses then 4- to 5-week intervals ii) 15 mg (approximately 10mg/m2) every 6 hours for 10 doses, starting 24 hours after the beginning of the methotrexate infusion iii) 6 - 12 mg exactly 30 hours after each dose of methotrexate. In EMA-CO regime for high risk gestational trophoblastic disease, use 30 mg IM
Leuprolide Acetate 11.25 mg InjectionL02AE02122P5002XXA*i) Endometriosis ii) Hormonal therapy in advanced prostate cancer11.25 mg every 3 months
Leuprolide Acetate 3.75 mg InjectionL02AE02122P5001XXA*i) Endometriosis ii) Hormonal therapy in advanced prostate canceri) 3.75 mg monthly for 3 - 6 months ii) 3.75 mg IM or SC injection monthly
Levetiracetam 100 mg/ml InjectionN03AX14000P3001XXA*i) Monotherapy therapy in the treatment of partial onset seizures with or without secondary generalization in patients from age 16 years of age with newly diagnosed epilepsy ii) Adjunctive treatment in partial onset seizures with or without secondary generalization in adults and children from 4 years of age with epilepsy; juvenile myoclonic epilepsy and idiopathic generalized tonic clonic epilepsy from 12 years of age. To be initiated when conventional IV antiepileptic drugs failed to achieve control, or oral form is temporarily not feasible in seizure emergenciesi) ADULTS and ADOLESCENT (from 16 years): Starting dose: 250 mg twice daily, Increase dose to 500 mg twice daily after 2 week. Dose can be further increased by 250 mg twice daily every 2 weeks depending upon the clinical response. Max: 1500 mg twice daily. ii) ADULT more than 18 years and ADOLESCENT (12 to 17 years) more than or equal to 50 kg: Initially 500 mg twice daily may be increased up to 1500 mg twice daily. Dose changes can be made in 500 mg twice daily increments or decrements 2 to 4 weekly. CHILD (4 to 11 years) and ADOLESCENT (12 to 17 years) less than 50 kg : Initially 10 mg/kg twice daily, may be increased up to 30 mg/kg twice daily. Dose changes should not exceed increments or decrements of 10 mg/kg twice daily every 2 weeks. CHILD more than or equal to 50 kg: Adult dose
Levetiracetam 100 mg/ml Oral SolutionN03AX14000L9901XXA*As adjunctive therapy in the treatment of partial onset seizures with or without secondary generalization in adults and children from 4 years of age with epilepsyCHILD: 4-11 years and adolescent (12-17 years) less than 50 kg: Initially 10 mg/kg twice daily, may be increased up to 30 mg/kg twice daily. Dose changes should not exceed increments or decrements of 10 mg/kg two times daily twice weekly
Levetiracetam 250 mg TabletN03AX14000T1001XXA*i) Monotherapy therapy in the treatment of partial onset seizures with or without secondary generalization in patients from age 16 years of age with newly diagnosed epilepsy ii) Adjunctive treatment in partial onset seizures with or without secondary generalization in adults and children from 4 years of age with epilepsy; juvenile myoclonic epilepsy and idiopathic generalized tonic clonic epilepsy from 12 years of agei) Monotherapy ADULTS and ADOLESCENT (from 16 years) : Starting dose: 250 mg twice daily, Increase dose to 500 mg twice daily after 2 week. Dose can be further increased by 250 mg twice daily every 2 week depending upon the clinical response. Max: 1500 mg twice daily. ii) ADULT more than 18 years and ADOLESCENT (12-17 years) more than or equal to 50 kg: Initially 500 mg twice daily may be increased up to 1500 mg twice daily. Dose changes can be made in 500 mg twice daily increments or decrements 2-4 weekly. CHILD (4-11 years) and ADOLESCENT (12-17 years) less than 50 kg : Initially 10 mg/kg twice daily, may be increased up to 30 mg/kg twice daily. Dose changes should not exceed increments or decrements of 10 mg/kg twice daily every 2 weeks. CHILD more than or equal to 50 kg: Adult dose
Levetiracetam 500 mg TabletN03AX14000T1002XXA*i) Monotherapy therapy in the treatment of partial onset seizures with or without secondary generalization in patients from age 16 years of age with newly diagnosed epilepsy ii) Adjunctive treatment in partial onset seizures with or without secondary generalization in adults and children from 4 years of age with epilepsy; juvenile myoclonic epilepsy and idiopathic generalized tonic clonic epilepsy from 12 years of agei) Monotherapy ADULTS and ADOLESCENT (from 16 years) : Starting dose: 250 mg twice daily, Increase dose to 500 mg twice daily after 2 week. Dose can be further increased by 250 mg twice daily every 2 week depending upon the clinical response. Max: 1500 mg twice daily. ii) ADULT more than 18 years and ADOLESCENT (12-17 years) more than or equal to 50 kg: Initially 500 mg twice daily may be increased up to 1500 mg twice daily. Dose changes can be made in 500 mg twice daily increments or decrements 2-4 weekly. CHILD (4-11 years) and ADOLESCENT (12-17 years) less than 50 kg : Initially 10 mg/kg twice daily, may be increased up to 30 mg/kg twice daily. Dose changes should not exceed increments or decrements of 10 mg/kg twice daily every 2 weeks. CHILD more than or equal to 50 kg: Adult dose
Levobupivacaine 5mg/ml InjectionN01BB10110P3001XXAProduction of local or regional anesthesia for surgery and obstetrics, and for postoperative pain managementSurgical anesthesia : Lumber epidural : 10 - 20 ml (50 - 150 mg) , caesarean section : 15 - 30 ml (75 - 150 mg), intrathecal: 3 ml (15 mg), peripheral nerve block : 1 - 40 ml, ilioinguinal/iliohypogastric block. CHILD : 0.25 - 0.5 ml/kg (1.25-2.5 mg/kg)
Levocetirizine Dihydrochloride 5 mg TabletR06AE09110T1001XXA*Symptomatic treatment of allergic rhinitis (including persistent allergic rhinitis) and chronic idopathic urticariaChildren above 6 years and adults: 5 mg orally once daily (Swallow whole, do not chew/crush).
Levodopa 100 mg and Benserazide 25 mg Dispersible TabletN04BA02977T4001XXA*Parkinson's DiseaseInitially 1 cap tds. Max initial dose: 6 caps/day. Patients previously on immediate-release Levodopa/Benserazide preparations: Initially dose should substitute every 100mg of Levodopa with 1 controlled-released cap, given at same dosage frequency as before. Increase every 2-3 days.
Levodopa 100 mg and Carbidopa 25 mg TabletN04BA02000T1001XXBParkinson's diseasePatients not receiving Levodopa before, initially 100 - 125 mg 3 - 4 times daily adjusted according to response. Maintenance: 0.75 - 2 g in divided doses. In patients previously treated with Levodopa the dose should be about 20 - 25% of the dose previously being taken
Levodopa 100 mg, Benserazide 25 mg HBS capsuleN04BA02977C1001XXBParkinson's DiseaseInitial: 100/25 mg 1-2 times/day, increase every 3-4 days until therapeutic effect, optimal dosage: 400/100 mg to 800/200 mg/day divided into 4-6 doses. Dose: 200/50 mg used only when maintenance therapy is reached and not to exceed levodopa 1000-1200 mg/benserazide 250-300 mg per day
Levodopa 100 mg, Carbidopa 25 mg and Entacapone 200 mg TabletN04BA03977T1002XXA*Idiopathic Parkinson's disease100 mg 3 - 4 times daily and subsequently titrated up to 150 mg 3 - 4 times daily as required. Maximum dose of entacapone is 1600 mg/ day (8 tablet)
Levodopa 150 mg, Carbidopa 37.5 mg and Entacapone 200 mg TabletN04BA03977T1003XXA*Idiopathic Parkinson's disease100 mg 3 - 4 times daily and subsequently titrated up to 150 mg 3 - 4 times daily as required. Maximum dose of entacapone is 1600 mg/ day (8 tablet)
Levodopa 200 mg, Benserazide 50 mg TabletN04BA02977T1001XXBParkinson's DiseaseInitial: 100/25 mg 1-2 times/day, increase every 3-4 days until therapeutic effect, optimal dosage: 400/100 mg to 800/200 mg/day divided into 4-6 doses. Dose: 200/50 mg used only when maintenance therapy is reached and not to exceed levodopa 1000-1200 mg/benserazide 250-300 mg per day
Levodopa 200 mg, Carbidopa 50 mg & Entacapone 200 mg TabletN04BA03977T1004XXA*Idiopathic Parkinson?s diseaseThe optimum daily dosage must be determined by careful titration of levodopa in each patient. Maximum daily dose of 200/50/200 mg is 6 tablets per day (due to max dose of carbidopa is 300mg/day).
Levodopa 250 mg and Carbidopa 25 mg TabletN04BA02000T1002XXBParkinson's diseasePatients not receiving Levodopa before, initially 100 - 125 mg 3 - 4 times daily adjusted according to response. Maintenance: 0.75 - 2 g in divided doses. In patients previously treated with Levodopa the dose should be about 20 - 25% of the dose previous being taken
Levodopa 50 mg, Carbidopa 12.5 mg & Entacapone 200 mg TabletN04BA03977T1001XXA*Idiopathic Parkinson?s diseaseThe optimum daily dosage must be determined by careful titration of levodopa in each patient. Maximum dose, for 50/12.5/200 mg is 10 tablets per day. Maximum daily dose of 200/50/200 mg is 7 tablets per day.
Levofloxacin 250 mg TabletJ01MA12000T1001XXA*Community acquired pneumonia500 mg daily for 7 - 14 days
Levofloxacin 500 mg InjectionJ01MA12000P3001XXA*Community Acquired Pneumonia500 mg daily for 7 - 14 days
Levofloxacin 500 mg TabletJ01MA12000T1002XXA*Community acquired pneumonia500 mg daily for 7 - 14 days
Levonorgestrel 1.5 mg TabletG03AC03000T1001XXA*Emergency contraception within 72 hours of unprotected sexual intercourse for the female victim of sexual violence to prevent unwanted pregnancy1.5 mg as a single dose as soon as possible after coitus [preferably within 12 hours but no later than after 72 hours]
Levonorgestrel 150 mcg and Ethinyloestradiol 30 mcg TabletG03AA07954T1001XXC+Contraception1 tablet daily for 21 days from first day of the cycle, followed by 7 tab free days
Levonorgestrel 52 mg Intrauterine SystemG02BA03000P1001XXA*i) Contraception (Initial release rate of 20 mcg/24 hours). ii) Idiopathic menorrhagiai) & ii):One unit intrauterine device to be inserted into the uterine cavity within 7 days of the onset of menstruation or immediately after first trimester abortion. Postpartum insertion should be postponed until 6 weeks after delivery.Can be inserted at any time of amenorrheic woman. One unit IUD is effective for 5 years
Levothyroxine Sodium 100 mcg TabletH03AA01520T1001XXBHypothyroidismStart at low dose and increase at 2-4 weeks interval. Adult: Initially, 50-100 mcg/day may increase by 25-50 mcg at approximately 3 to 4 weeks intervals until the thyroid deficiency is corrected. Maintenance: 100-200 mcg/day. CHILD; 0 - 3 months: 10 - 15 mcg/kg/day; 3 - 6 months: 8 - 10 mcg/kg/day; 6 - 12 months: 6 - 8 mcg/kg/day; 1 - 5 years: 5 - 6 mcg/kg/day; 6 - 12 years: 4 - 5 mcg/kg/day; more than 12 years: 2 -3 mcg/kg/day
Levothyroxine Sodium 25 mcg TabletH03AA01152T1003XXBHypothyroidismStart at low dose and increase at 2-4 weeks interval. Usual recommended dose for i) Treatment of benign euthyroid goitre: 75-200mcg. ii) Prophylaxis of relapse after surgery for euthyroid goitre: 75-200mcg iii) Substitution therapy in hypothyroidism: ADULT Initially, 25-50mcg/day. Maintenance: 100-200mcg/day. CHILDREN Initially 12.5-50mcg/day, Maintenance: 100-150mcg/m2 body surface area iv) Concomitant supplementation during anti-thyroid drug treatment of hyperthyroidism: 50-100mcg v) Suppression therapy in thyroid cancer: 150-300mcg
Levothyroxine Sodium 50 mcg TabletH03AA01520T1002XXBHypothyroidismStart at low dose and increase at 2-4 weeks interval. Usual recommended dose for i) Treatment of benign euthyroid goitre: 75-200mcg. ii) Prophylaxis of relapse after surgery for euthyroid goitre: 75-200mcg iii) Substitution therapy in hypothyroidism: ADULT Initially, 25-50mcg/day. Maintenance: 100-200mcg/day. CHILDREN Initially 12.5-50mcg/day, Maintenance: 100-150mcg/m2 body surface area iv) Concomitant supplementation during anti-thyroid drug treatment of hyperthyroidism: 50-100mcg v) Suppression therapy in thyroid cancer: 150-300mcg
Lidocaine 25mg and Prilocaine 25mg CreamN01BB52974G1001XXAUsed for painless venepunctures, radial artery cannulations before extradural/spinal and other regional blocks in children above 1 year old and adults. Also used in chronic renal failure patients for insertion of A-V fistulas and shunts for haemodialysis.Apply a thick layer under occlusive dressing at least 1 hour before the procedure
Lidocaine Medicated Plaster 5% w/wN01BB02110M6001XXA*Indicated for the symptomatic relief of neuropathic pain associated with previous herpes zoster infection (post-herpetic neuralgia, PHN). Restrictions: i) For elderly patients with polymedication status whom certain treatment was contraindicated or not tolerated. ii)Prescribed by pain specialist only.1 patch /day (Adults & elderly. Cover the painful area once daily for up to 12 hr w/in 24-hr period. Subsequent plaster-free interval: At least 12 hr. Not more than 3 plasters should be used at the same time)
Lignocaine 10 % w/w SprayN01BB02110A4001XXBFor surface anaesthesia in dental practice, in otorhinolaryngology and paracentesisSpray to affected part
Lignocaine 2 % with Adrenaline (1:80,000) InjectionN01BB52974P3001XXBFor local anaesthesia including infiltration, nerve and plexus blocksBy infiltration: 0.5 - 1 ml; not to exceed 7 mg/kg body weight
Lignocaine 2% JellyN01BB02110G4001XXBUse for endotracheal tubes and instruments, painful procedures in the ear, nose and throat, burns, wounds, abrasions, lacerations; catheterisation of the male and female urethra and for symptomatic treatment of cystitis and urethritisApply to affected area 10 mins before catheterization, etc
Lignocaine 2% Viscous SolutionN01BB02110L5001XXAFor post-tonsilectomy, sore throat, dumping syndrome, hiccough, reflux vomiting, painful lesions of the mouth, cardiospasm, instrumentation of the respiratory and digestive tractAs 2% soln: For pain: 300 mg rinsed and ejected for mouth and throat pain; or gargled and swallowed if necessary for pharyngeal pain. Not to be used more frequently than every 3 hr. Max (topical oral soln): 2.4 g/day.
Lignocaine 2% with Chlorhexidine 0.05% GelN01BB52974G3001XXBTo provide local anaesthesia and lubrication during catheterization, exploration by sound and other endourethral operations and examinations, cytoscopy and symptomatic treatment of painful cystitis and urethritisAdult Male Instil 20 mL slowly into the urethra until it reaches external sphincter, proximal to the prostrate. Subsequently, apply compression at the corona for several mins. Fill the length of the urethra w/ the remaining gel. Sounding procedure or cytoscopy Instill 40 mL (in 3-4 portions) into the insertion area then allow 5-10 mins for anaesth to take effect. Adult Female Prior to urological procedure, instill 5-10 mL in small portions to fill the whole urethra & allow anaesth to take effect in 3-5 mins.Childn <12 yr Up to 6 mg/kg.
Lignocaine 4 % SolutionN01BB02110L5002XXBFor anaesthesia of mucous membranes of the oropharyngeal, tracheal and bronchial areas eg. in laryngoscopy and bronchoscopyBronchoscopy, 2 - 3 ml with suitable spray; biopsy in mouth, 3 - 4 ml with suitable spray or swab (with adrenaline if necessary); maximum 7.5 ml
Lignocaine HCl (Lidocaine) 10 mg/ml InjectionC01BB01110P3002XXBVentricular tachycardia and ventricullar fibrillation. To be diluted before use50-100 mg IV as a bolus, repeated after 5 minutes if necessary. Maintenance : 1-4 mg/min by IV infusion under ECG monitoring
Lignocaine HCl (Lidocaine) 2% InjectionN01BB02110P3001XXBLocal anesth by infiltration IV regional anesthesia and nerve block. Emergency management of ventricular arrhythmias particularly after myocardial infarction and cardiac surgeryLocal anesthesia : ADULT Maximum: 100 mg; CHILD Maximum: 3 mg/kg Cardiac arrhythmias : ADULT 50-100 mg IV. Maximum: 200-300 mg/hour; CHILD Loading dose: 0.5-1 mg/kg IV repeated if necessary up to 3-5 mg/kg followed by a continuous infusion of 10-50 mcg/kg/min
Lignocaine HCl (Lidocaine) 20 mg/ml InjectionC01BB01110P3001XXBVentricular tachycardia and ventricullar fibrillation. To be diluted before use50-100 mg IV as a bolus, repeated after 5 minutes if necessary. Maintenance : 1-4 mg/min by IV infusion under ECG monitoring
Lignocaine HCl 1% InjectionN01BB02110P3002XXC+Local or regional anaesthesia for episiotomy repairsAccording to patients weight and nature of procedures, maximum 200mg. For most obstetric procedures, the preparation is diluted to 0.5%, which gives the maximum effect with the least toxicity. [lignocaine 1%, 1 part and normal saline or sterile distilled water, 1 part]
Lignocaine HCl 5% and Phenylephrine HCl 0.5% Nasal SprayN01BB02984A4101XXA*Preparation of nasal mucosa for surgery (eg. Cautery to Little?s area), aid the treatment of acute nose bleeds and removal of foreign bodies from the nose, topical anaesthesia of the pharynx prior to direct or indirect laryngoscopy, topical anaesthesia and local vasoconstriction prior to endoscopy of the upper airwaysAdults and children over 12 years : 5 squirts per nostril. Children: 8 to 12 years 3 squirts per nostril, 4 to 8 years 2 squirts per nostril, 2 to 4 years 1 squirt per nostril. Doses are to be administered once only.
Lignocaine, Aluminium Acetate, Zinc Oxide and Hydrocortisone OintmentC05AX03931G5001XXA/KKAnorectal pain, pruritis, inflammation and irritationApply once or twice daily. Not for prolonged use
Lignocaine, Aluminium Acetate, Zinc Oxide and Hydrocortisone SuppositoryC05AX03931S2001XXBAnorectal pain, pruritis, inflammation and irritation1 suppository to be used once or twice daily. Not for prolonged use
Linagliptin 5 mg tabletA10BH05000T1001XXA*Management of diabetes in patients with renal failure where metformin/sulphonylurea is contraindicated/untolerated and elderly with multiple co morbidities that always experience hypoglycemia with other antidiabetic. Not to be used in diabetic patient whose HBA1c is more than 9%.Adults: 5 mg once daily. When linagliptin is added to metformin, the dose of metformin should be maintained and linagliptin administered concomitantly.
Linezolid 2 mg/ml InjectionJ01XX08000P3001XXA*MRSA patient with severe sepsis requiring intensive care and not clinically responding to vancomycinADULT: 600 mg twice daily for 10 - 14 days. CHILD: 10 mg/kg 3 times daily. PREMATURE NEONATES less than 7 days: 10 mg/kg twice daily
Linezolid 20 mg/ml SuspensionJ01XX08000L8001XXA*MRSA patients with severe sepsis requiring intensive care and not clinically responding to vancomycinCHILD: 10 mg/kg 3 times daily. PREMATURE NEONATES less than 7 days: 10 mg/kg twice daily
Linezolid 600 mg TabletJ01XX08000T1001XXA*MRSA patient with severe sepsis requiring intensive care and not clinically responding to vancomycin.ADULT: Above 12 years 600 mg every 12 hours for 10-14 days. CHILD :10 mg/kg 3 times daily. PREMATURE NEONATES less than 7 days: 10 mg/kg twice daily
Liquid ParaffinA06AA01000L5001XXCConstipationADULT 10-30 ml daily at night but should not be taken immediately before going to bed. CHILD not recommended
Lithium Carbonate 300 mg TabletN05AN01121T1001XXAi) Prophylaxis and treatment of acute mania and hypomania episodes ii)Prophylaxis of manic depression in bipolar illness or bipolar depression and recurrent depressionDose depends on the preparation used. Doses should be adjusted to produce a serum-lithium concentration of 0.4-1 mmol/l.
Loperamide 2 mg CapsuleA07DA03110C1001XXBAdjunct to rehydration in acute diarrhoea in adult also in chronic diarrhoea in adultAcute diarrhoea: ADULT: 4 mg stat, followed by 2 mg after each unformed stool (up to 5 days). Usual 6- 8 mg daily. Max: 16 mg daily. Chronic diarrhoea: Initially 4-8 mg daily in divided doses, adjust according to response. Max: 16 mg daily
Lopinavir 200 mg and Ritonavir 50 mg TabletJ05AE06964T1001XXA*As second line protease inhibitor if intolerant to indinavir/ ritonavir as part of HAART regimenAdult: (Therapy-naive patients) 400/100 mg bd or 800/200 mg once daily; (Therapy-experienced patients): 400/100 mg bd. Concomitant therapy (efavirenz, nevirapine, amprenavir, fosamprenavir or nelfinavir) 400/100 mg bd. Children >40 kg or w/ BSA >1.4 m2 as adult dose.
Lopinavir/Ritonavir Oral SolutionJ05AE06964L9901XXAManagement of patients with asymptomatic and symptomatic (early or advanced) HIV Infection with CD4 cell counts <50 cubic mmTab Adult Therapy-naive patients 400/100 mg bd or 800/200 mg once daily. Therapy-experienced patients 400/100 mg bd. Concomitant therapy (efavirenz, nevirapine, amprenavir, fosamprenavir or nelfinavir) 400/100 mg bd. Can be used w/ no dose adjustment. Childn >40 kg or w/ BSA >1.4 m2 Adult dose. Oral Soln Childn 6 mth-12 yr, 15-40 kg 10/2.5 mg/kg bd; 7 to <15 kg 12/3 mg/kg bd. Max: 5 mL bd in childn >40 kg. W/ efavirenz or nevirapine 15-45 kg 11/2.75 mg/kg bd; 7 to <15 kg 13/3.25 mg/kg.
Loratadine 1 mg/ml SyrupR06AX13000L9001XXAAllergic rhinitis, chronic urticaria and other allergic dermatological disordersADULT and CHILD over 6 years : 10 mg once daily. CHILD 2 - 6 years: 5 mg once daily
Loratadine 10 mg TabletR06AX13000T1001XXBAllergic rhinitis and allergic dermatosesADULT and CHILD over 6 years 10 mg once daily. CHILD 2 - 6 years: 5 mg once daily
Loratadine 5 mg and Pseudoephedrine Sulphate 120 mg TabletR01BA52988T1001XXA/KKFor treatment of allergic rhinitis and allergic dermatosesADULT and CHILD over 12 years 1 tablet twice daily
Lorazepam 1 mg TabletN05BA06000T1001XXA/KKi) Severe anxiety ii) Insomniai) 1 - 4 mg increase to 10 mg daily in divided doses. ELDERLY (or delibitated) half adult dose ii) 1 - 2 mg at bedtime Not recommended in children
Losartan 50 mg TabletC09CA01500T1001XXA/KKPatients intolerant of ACE inhibitors, only in the treatment of i) Hypertensive patient with left ventricular hypertrophy ii) Hypertension in diabetics with proteinuria or nephropathyHypertension: Usual starting and maintenance dose: 50 mg once daily. Maximum increasing the dose to 100 mg once daily. Patients with intravascular volume-depletion starting dose of 25 mg once daily. Renal protection in Type 2 diabetic patients with proteinuria and hypertension, starting dose: 50 mg once daily, may be increased to 100 mg once daily based on blood pressure response
Losartan Potassium 100 mg & Hydrochlorothiazide 25 mg TabletC09DA01935T1004XXA*Hypertension in patients who cannot tolerate ACE inhibitors because of cough, hypertensive patient with left ventricular hypertrophyFixed dose combination is not indicated for initial therapy. i. Usual starting & maintenance dose: 1 tab of losartan & HCTZ 50/12.5 mg once daily. May be increased to 2 tab of losartan & HCTZ 50/12.5 mg or 1 tab of losartan & HCTZ 100/25mg once daily if blood pressure remain uncontrolled after about 3 weeks of combination therapy with losartan & HCTZ 50/12.5mg. Max: 1 tab of losartan & HCTZ 100/25mg once daily or 2 tab of Losartan & HCTZ 50/12.5 mg once daily. ii. Usual starting dose: 50 mg losartan once daily, may be titrated with a combination of losartan 50mg & HCTZ 12.5 mg, maybe substituted with losartan 100mg & HCTZ 12.5mg, followed by losartan 100 mg & HCTZ 25 mg once daily.
Losartan Potassium 100 mg and Hydrochlorothiazide 12.5 mg TabletC09DA01935T1003XXA*Hypertension in patients who cannot tolerate ACE inhibitors because of cough, hypertensive patient with left ventricular hypertrophyFixed dose combination is not indicated for initial therapy. i. Usual starting & maintenance dose: 1 tab of losartan & HCTZ 50/12.5 mg once daily. May be increased to 2 tab of losartan & HCTZ 50/12.5 mg or 1 tab of losartan & HCTZ 100/25mg once daily if blood pressure remain uncontrolled after about 3 weeks of combination therapy with losartan & HCTZ 50/12.5mg. Max: 1 tab of losartan & HCTZ 100/25mg once daily or 2 tab of Losartan & HCTZ 50/12.5 mg once daily. ii. Usual starting dose: 50 mg losartan once daily, may be titrated with a combination of losartan 50mg & HCTZ 12.5 mg, maybe substituted with losartan 100mg & HCTZ 12.5mg, followed by losartan 100 mg & HCTZ 25 mg once daily.
Losartan Potassium 100 mg TabletC09CA01500T1002XXA/KKPatients intolerant of ACE inhibitors, only in the treatment of: i) Hypertensive patient with left ventricular hypertrophy ii)Hypertension in diabetics with proteinuria or nephropathyUsual starting dose: 50 mg once daily. May be increased to 100 mg once daily.
Losartan Potassium 50 mg and Hydrochlorothiazide 12.5 mg TabletC09DA01935T1001XXA/KKHypertension in patients who cannot tolerate ACE inhibitors because of cough, hypertensive patient with left ventricular hypertrophy1 tablet once daily, may increase to maximum dose losartan 100 mg/ hydrochlorothiazide 25 mg once daily
Magnesium Sulphate 45% PasteD11AX05183G6001XXCInflammatory skin conditions such as boils and carbunclesApply under dressing
Magnesium Sulphate 50% InjectionB05XA05183P3001XXCi)Treatment and prophylaxis of acute hypomagnesaemia ii) Prevention and treatment of life-threatening seizures in the treatment of toxemias of pregnancy (pre-eclampsia and eclampsia)i)Mild hypomagnesemia (ADULT): 1gm magnesium sulphate (8mEq) IM every 6 hours for 4 doses. Severe hypomagnesemia (ADULT): 0.25 g/kg IM over 4 hours. Alternative dose of 5g may be given by slow intravenous infusion over 3 hours ii) Toxemia of pregnancy: An initial intravenous dose of 4gm of magnesium sulphate is recommended. Followed by an intramuscular dose of 4-5gm into each buttock. This may be followed by a dose of 4-5gm into alternate buttocks every 4 hours as needed. Alternatively, the initial dose IV dose may be followed by an infusion of 1-2gm/hr
Magnesium Trisilicate MixtureA02AA10912L2101XXCHeartburn, dyspepsia10-20 ml 3-4 times daily before meals
Magnesium Trisilicate TabletA02AA10912T1001XXCHeartburn, dyspepsiaADULT 1-2 tablet to be chewed up to 6 times a day before meals. CHILD over 6 years one tablet to be taken 3-4 times a day
Magnesium, Aluminium Hydroxide and Simethicone SuspensionV07AB00900L8001XXCAs a buffering agent for reconstituting didanosine powder for oral administration so as to prevent acid degradation of didanosine which is used for the treatment of paediatric patients (more than 6 months old) with symptomatic HIV infectionDDI should be mixed with water and diluted with the appropriate dose of antacids to a final concentration of 10 mg per ml
Malathion 1 % ShampooP03AX03000L5201XXC+Lice infestationWet hair, apply shampoo and work up lather. Leave for 15 minutes and rinse, comb. Repeat if necessary after 7 - 9 days
Mannitol 10% Injection (10 g/100 ml)B05BC01000P3001XXACerebral oedema0.25- 2 g/kg IV of a 15% to 25% solution over 30-60 minutes. Safety and efficacy not established in children under 12 years of age
Mannitol 20% Injection (20 g/100 ml)B05BC01000P3002XXACerebral oedema0.25- 2 g/kg IV of a 15% to 25% solution over 30-60 minutes. Safety and efficacy not established in children under 12 years of age
Measles and Rubella Virus Vaccine Live, Attenuated (Freeze-dried) 10 doses/vialJ07BD52963P4002XXCFor active immunization against measles and rubella in infants, children, adolescents and young adults at risk. Immunization of susceptible non-pregnant adolescent and adult females is indicated if certain precautions are observed. The vaccine can be safely and effectively given simultaneously with DTP, DT, TT, Td, BCG, Polio Vaccine (OPV and IPV), Haemophilus influenza type B, Hepatitis B, Yellow fever vaccine and vitamin A supplementation.The vaccine should be reconstituted only with the diluent supplied (sterile water for injection) using a sterile syringe and needle. With gentle shaking the dried cake is easily dissolved. After reconstitution the vaccines should be used immediately. A single dose of 0.5ml should be administered by deep SC injection into the anterolateral aspect of upper thigh in infants and upper arm in older children. If the vaccines is not used immediately then it should be stored in the dark at 20C and 80C for no longer than 6 hours.
Measle's Vaccine Injection (10 doses)J07BD01000P4001XXC+Prophylaxis against measles and to prevent development of infection (if given within 72 hours of contact)By SC or IM injection, 0.5 ml as a single dose at 12 - 15 months of age
Measles, Mumps and Rubella (MMR) Vaccine Injection (Single Dose)J07BD52963P4001XXC+For immunisation of children against measles, mumps and rubellaSubcutaneous or by intramuscular injection, 0.5 ml
Mebeverine HCl 135 mg TabletA03AA04110T1002XXBIrritable bowel syndrome135 mg 3 times daily
Meclozine HCl 25 mg and Pyridoxine 50 mg TabletR06AE55919T1001XXBNausea and vomiting of pregnancy1 - 2 tablet 2 - 3 times daily in severe cases
Mecobalamin 500 mcg TabletM09AX00000T1001XXBPeripheral neuropathies1 tablet 3 times daily. The dosage should be adjusted according to age of patient and severity of symptoms
Medroxyprogesterone Acetate 10 mg TabletG03DA02122T1002XXBi) Secondary amenorrhoea ii) Abnormal uterine bleeding due to hormonal imbalancei) 5-10 mg daily for 5-10 days started anytime during cycle ii) 5-10 mg daily for 5-10 days on day 16-21 of menstrual cycle. Optimum secretory transformation 10 mg daily for 10 days from day 16 of the cycle
Medroxyprogesterone Acetate 100 mg TabletL02AB02122T1002XXABreast carcinoma, endometrial carcinoma, renal carcinoma200-500 mg orally daily
Medroxyprogesterone Acetate 5 mg TabletG03DA02122T1001XXBi) Secondary amenorrhoea ii) Abnormal uterine bleeding due to hormonal imbalancei) 5-10 mg daily for 5-10 days started anytime during cycle ii) 5-10 mg daily for 5-10 days on day 16-21 of menstrual cycle. Optimum secretory transformation 10 mg daily for 10 days from day 16 of the cycle
Medroxyprogesterone Acetate 50 mg/ml InjectionG03AC06122P3001XXBPrevention of pregnancy and to provide long term contraception150mg to be administered once every 3 month
Medroxyprogesterone Acetate 500 mg TabletL02AB02122T1001XXABreast carcinoma, endometrial carcinoma, renal carcinoma200-500 mg orally daily
Mefenamic Acid 250 mg CapsuleM01AG01000C1001XXBMild to moderate painADULT: 250 - 500 mg 3 times daily after meals. CHILD over 6 months: 6.5 - 25 mg/kg daily 3 - 4 times daily for not longer than 7 days except in juvenile arthritis
Mefenamic Acid 250 mg TabletM01AG01000T1001XXBMild to moderate painADULT: 250 - 500 mg 3 times daily after meals. CHILD over 6 months: 6.5 - 25 mg/kg daily 3 - 4 times daily for not longer than 7 days except in juvenile arthritis
Mefloquine HCl 250 mg TabletP01BC02110T1001XXA*For multi-drug resistant cases of malaria onlyTreatment of malaria : ADULT and CHILD 25 mg/kg usually given over 2-3 days. Prophylaxis of malaria : ADULT 250 mg once a week. CHILD over 5 kg : 5 mg/kg once a week; prophylaxis should start 1-3 weeks before departure and continue for 4 weeks after last exposure
Meloxicam 7.5 mg TabletM01AC06000T1001XXA/KKOnly for patients not responding to other NSAIDs in the treatment of i) painful osteoarthritis ii) rheumatoid arthritisi) initially 7.5 mg daily. May be increased to 15 mg daily ii) initially 15 mg daily. May be reduced to 7.5 mg daily. Maximum 15 mg daily. Child under 12 years not recommended
Melphalan 2 mg TabletL01AA03000T1001XXAi) Multiple myeloma ii) Neuroblastoma, rhabdomyosarcoma iii) Recurrent neuroblastoma (palliative)i) 8 - 10 mg/m2 for 4 days every 4 weeks ii) 10 - 35 mg/m2 once every month For dose regimes, refer to protocols
Melphalan 50 mg InjectionL01AA03000P4001XXBHigh dose conditioning therapy for stem cell transplantation in multiple myeloma200 mg/ m2 IV infusions in divided doses for Day 1 to day 3 followed by IV infusions of autologous stem cells
Memantine HCI 10 mg TabletN06DX01110T1001XXA*As monotherapy or as adjunctive therapy with cholinesterase inhibitors for the symptomatic treatment of patients with moderate to severe Alzheimer?s disease.Adult Initially 5 mg/day on the 1st week, 5mg twice a day on the 2nd week, then 15 mg/day (10mg in the morning and 5mg in the evening) on the 3rd week. From the 4th week on, continue treatment with maintenance dose of 20 mg/day (10mg twice a day). Max: 20 mg/day.
Memantine HCl 20 mg TabletN06DX01110T1002XXA*As monotherapy or as adjunctive therapy with cholinesterase inhibitors for the symptomatic treatment of patients with moderate to severe Alzheimer?s disease.Adult Initially 5 mg/day on the 1st week, 5mg twice a day on the 2nd week, then 15 mg/day (10mg in the morning and 5mg in the evening) on the 3rd week. From the 4th week on, continue treatment with maintenance dose of 20 mg/day (10mg twice a day). Max: 20 mg/day.
Meningococcal A, C, Y, W 135 Vaccine InjectionJ07AH04000P4001XXBImmunisation against meningococcal diseases caused by Neisseria meningitis Group A, Group C, Group Y or Group W-135Prophylaxis: 0.5 ml intramuscular injection.
Menotrophin 150 IU Injection (Follicle Stimulating Hormone 150 IU and Luteinizing Hormone 150 IU)G03GA02954P4002XXA*Treatment of infertility where clomifene has fail or stimulation of follicle growth as part of an assisted reproductive technology (ART)SC or IM injection according to patients response
Menotrophin 75 IU Injection (Follicle Stimulating Hormone 75 IU and Luteinizing Hormone 75 IU)G03GA02954P4001XXA*Treatment of infertility where clomifene has fail or stimulation of follicle growth as part of an assisted reproductive technology (ART)SC or IM Injection according to patient's response
Menotrophin, Highly Purified 75 IU Injection (Follicle Stimulating Hormone 75 IU and Luteinizing Hormone 75 IU)G03GA02954P4003XXA*Anovulation in women who have been unresponsive to treatment with clomiphene citrate or stimulation of follicle growth as part of an assisted reproductive technology (ART)The recommended initial dose of MENOPUR is 75-150 IU daily. The subsequent dosing should be adjusted according to individual patient response. Adjustments in dose should not be made more frequently than every 7 days. The recommended dose increment is 37.5 IU per adjustment and should not exceed 75 IU. The maximum daily dose should not be higher than 225 IU.
Menthol 1.6% in Industrial Methylated Spirit InhalationR01AX30000A9901XXCDecongestion of the upper respiratory tractAs directed for local use
Mepivacaine HCl 2% with Adrenaline (1:100,000) InjectionN01BB53974P3001XXBFor local anaesthesia including infiltration and nerve blocksAdult: Single site in the jaw: 36 mg (1.8ml). Entire oral cavity: 180 mg (9 ml). Max: 400 mg (20 ml) per single dental procedure
Mepivacaine HCl 3% InjectionN01BB03110P3001XXBFor dental local anaesthesia including infiltration and nerve blocks on patients in whom adrenalin might be contraindicatedAdult: Single site in the jaw: 54 mg (1.8 ml). Entire oral cavity: 270 mg (9 ml). Max: 400 mg (13.3 ml) per single dental procedure
Mercaptopurine 50 mg TabletL01BB02000T1001XXAi) Langerhan's cell histocytosis ii) Acute lymphoblastic leukaemia iii) Acute promyelocytic leukaemia APML (maintenance)"Leukaemia adults: 2.5mg/kg or 80-00mg/m2 p.o per day, given as a single dose. To be increased at the end of 4 weeks, If necessary, up to 5mg/kg p.o per day. Maintainance dosage are 1.5mg/kg -2.5mg/kg p.o per day Children age 5 and older: Induction: 2.5mg/kg/day p.o once daily. Maintanance dose: 1.5mg/kg -2.5mg.kg p.o once daily or 70-100mg/m2 p.o once daily."
Meropenem 1 g InjectionJ01DH02000P4002XXA*i. Emperical treatment for presume infections in patients (adult and children) with febrile neutropenia, used as monotherapy or in combination with anti-virals or antifungal agent ii. Septicaemia iii. Serious infections in renal impaired patientsADULT: 0.5g - 1g 8 hourly CHILD: (aged 3 months and over): 10-40mg/kg 8 hourly, if body weight over 50kg, adult dosage should be used
Meropenem 500 mg InjectionJ01DH02000P4001XXA*i. Emperical treatment for presume infections in patients (adult and children) with febrile neutropenia, used as monotherapy or in combination with anti-virals or antifungal agent ii. Septicaemia iii. Serious infections in renal impaired patientsADULT: 0.5g - 1g 8 hourly CHILD: (aged 3 months and over): 10-40mg/kg 8 hourly, if body weight over 50kg, adult dosage should be used
Mesalazine 1 g SuppositoryA07EC02259S2002XXAInflammatory bowel disease of ulcerative colitis and Crohn's disease. Only for patients who cannot tolerate or do not respond to SulfasalazineUlcerative colitis : 1 g suppository insert rectally once daily at bedtime. The dose may be increased to 500 mg 3 times daily if the response is inadequate after 2 weeks of therapy. To achieve maximum benefit, it is recommended that the suppository be retained in the rectum for a minimum of 1 to 3 hours or longer. The usual course of therapy, depending upon response, may last from 3 to 6 weeks. CHILD not recommended
Mesalazine 250 mg SuppositoryA07EC02259S2001XXAInflammatory bowel disease of ulcerative colitis and Crohn's disease. Only for patients who cannot tolerate or do not respond to SulfasalazineUlcerative colitis : 1 g suppository insert rectally once daily at bedtime. The dose may be increased to 500 mg 3 times daily if the response is inadequate after 2 weeks of therapy. To achieve maximum benefit, it is recommended that the suppository be retained in the rectum for a minimum of 1 to 3 hours or longer. The usual course of therapy, depending upon response, may last from 3 to 6 weeks. CHILD not recommended
Mesalazine 250 mg TabletA07EC02259T1001XXAInflammatory bowel disease of ulcerative colitis and Crohn's disease. Only for patients who cannot tolerate or do not respond to SulfasalazineADULT: 250 - 500 mg 3 - 4 times daily for 3 - 6 weeks. CHILD up 2 years with Crohn's disease: 20 - 30 mg/daily in divided doses
Mesalazine 500 mg TabletA07EC02259T1002XXAInflammatory bowel disease of ulcerative colitis and Crohn's disease. Only for patients who cannot tolerate or do not respond to SulfasalazineADULT: 250 - 500 mg 3 - 4 times daily for 3 - 6 weeks. CHILD up 2 years with Crohn's disease: 20 - 30 mg/daily in divided doses
Mesalazine 500mg MR TabletA07EC02259T5001XXAi) Ulcerative colitis; acute and maintenance ii) Active Crohn's disease iii) Maintenance therapy for patients with Crohn's disease in remission induced by surgery or medicationADULT Acute :1g mesalazine 4 times/day or according to physician's instruction. Maintenance : (i) Ulcerative Colitis- 500mg mesalazine 3 times/day r according to physician's instruction. (ii) Chrohn's disease- 1g mesalazine 4 times/day or according to physician's instruction CHILDREN OVER 2 YEARS OF AGE; 20-30mg mesalazine per kg body weight daily, in divided doses or according to physician's instruction
Mesalazine 6.67% w/w EnemaA07EC02259G2001XXAInflammatory bowel disease of ulcerative colitis and Crohn's disease. Only for patients who cannot tolerate or do not respond to Sulfasalazine60 ml (4g) at bedtime, retained overnight, approximately 8 hours
Mesna 100 mg/ml InjectionV03AF01520P3001XXAFor prevention of urotoxic effects of oxazaphosphorines e.g. ifosfamide and cyclophosphamideIV injection at a dosage of 20% of the corresponding oxazaphosphorine dose at the times 0 hour (concurrently with the oxazaphosphorine), 4 hours and 8 hours thereafter. CHILD: Dose given at greater frequency (e.g. 6 times) and a shorter intervals (e.g. 3 hours)
Metformin 500 mg and Glibenclamide 2.5 mg TabletA10BD02926T1001XXBAs second-line therapy when diet, exercise and initial treatment with sulphonylurea or metformin do not result in adequate glycemic control in patients with type 2 diabetes mellitusInitial dose:1.25 mg/250 mg ORALLY once daily; titrate in increments of 1.25 mg/250 mg per day every 2 weeks,2.5 mg/500 mg to 5 mg/500 mg ORALLY twice daily; titrate in increments of 5 mg/500 mg up to MAX 20 mg/2000 mg once daily
Metformin 500 mg and Glibenclamide 5 mg TabletA10BD02926T1002XXBAs second-line therapy when diet, exercise and initial treatment with sulphonylurea or metformin do not result in adequate glycemic control in patients with type 2 diabetes mellitusInitial dose:1.25 mg/250 mg ORALLY once daily; titrate in increments of 1.25 mg/250 mg per day every 2 weeks,2.5 mg/500 mg to 5 mg/500 mg ORALLY twice daily; titrate in increments of 5 mg/500 mg up to MAX 20 mg/2000 mg once daily
Metformin HCl 500 mg Extended Release TabletA10BA02110T5001XXA/KKDiabetes mellitus who experienced gastrointestinal side effects with normal metformin500 mg once daily. Maximum dose 2000 mg once daily with evening meal
Metformin HCl 500 mg TabletA10BA02110T1001XXBDiabetes mellitusInitial: 500mg orally twice daily with food. Maintenance: Titrate in 500mg increments weekly, doses up to 2000 mg daily may be divided into 2 equal doses.
Metformin HCl 750 mg Extended Release TabletA10BA02110T5003XXA/KKDiabetes mellitus who experienced gastrointestinal side effects with normal metformin500 mg once daily. Maximum dose 2000 mg once daily with evening meal
Methadone 5mg/ml SyrupN07BC02110L9001XXA/KKDetoxification treatment of narcotic addictionInitial 10-20mg per day, increasing by 10-20mg per day until there are no signs of withdrawal or intoxication. Usual dose 40-60mg/day
Methotrexate 2.5 mg TabletL01BA01000T1001XXAi) Acute lymphoblastic leukaemia and acute promyelocytic leukemia (maintenance) ii) Extensive plaque psoriasis, erythrodermic psoriasis, pustular psoriasis, Reiter's syndrome, connective tissue diseasei) ADULT: 20 mg/m2 weekly. CHILD: 20 - 30 mg/m2 weekly according to protocol ii) Relapsed acute lymphoblastic leukaemia (ALL): 100 mg/m2/day for 5 days 6 weekly according to protocol iii) Dose used by dermatologist: 5 - 25 mg weekly. Liver biopsy after cumulative dose of 1.5 gram and repeat liver biopsy with additional gram received. Maximum cumulative dose is 4 gram. Monitor full blood count (FBC), renal and liver function iv) Rheumatoid arthritis, psoriatic arthropathy: dose used by rheumatologist: 2.5 mg/week orally starting dose, increasing to 7.5 - 20 mg/weekly
Methotrexate 50 mg InjectionL01BA01520P3001XXAi) Solid tumours ii) Gestational trophoblastic disease iii) Acute leukaemia/lymphomas iv) Rheumatoid arthritis, psoriatic arthropathy, severe/erythrodermic psoriasisi) 50 mg/m2 once every 2 - 3 weeks in combination with other drugs ii) 50 mg IV Day 1, 3, 5, 9 every 3 weeks. For high risk gestational trophoblastic disease, use 100 mg/m2 as part of EMA-CO regime iii) High dose regimes: 500 - 3000 mg/m2 per dose may be used, employing the 500 mg preparations. CHILD: Central nervous system prophylaxis for acute leukaemia 2 gm/m2 over 24 hours with folinic acid rescue, 3 doses for B-cell lineage. 4 doses for T-lineage all every 3 weeks. Relapse acute lymphoblastic leukaemia (ALL): 1 gm/m2 over 36 hours with folinic acid rescue every 3 weeks for 9 doses, maintenance: 50 mg/m2 every 2 weeks. B-cell lymphoma: 3 gm/m2 over 3 hours with folinic acid rescue for three doses. Methotrexate level monitoring recommended when using high dose regimens. The 500 mg strength is not for intrathecal (IT) use. Dosage for intrathecal treatment and prophylaxis in leukaemia: less than 1 year: 5 mg, 1 - 2 years: 7.5 mg, 2 - 3 years: 10 mg, more than 3 years: 12.5 mg. IT preparation must be clearly stated/verified. ENSURE THAT PREPARATION IS SUITABLE FOR INTRATHECAL USE iv) Dose used by rheumatologist: 10 - 15 mg IM injection or oral weekly. Dose used by dermatologist: 10 - 25 mg IM injection weekly
Methotrexate 500 mg/20 ml InjectionL01BA01520P3002XXAi) Solid tumours ii) Gestational trophoblastic disease iii) Acute leukaemias, lymphomasi) 50 mg/m2 once every 3 weeks in combination with other drugs (for this dose, use the 50 mg preparation) ii) 50 mg IV Day 1, 3, 5, 9 every 3 weeks. For high risk gestational trophoblastic disease, use 100 mg/m2 as part of EMA-CO regime iii) High dose regimes: 500 - 3000 mg/m2 per dose may be used, employing the 500 mg preparations. CHILD: Central nervous system prophylaxis for acute leukaemia 2 gm/m2 over 24 hours with folinic acid rescue, 3 doses for B-cell lineage. 4 doses for T-lineage all every 3 weeks. Relapse acute lymphoblastic leukaemia (ALL): 1 gm/m2 over 36 hours with folinic acid rescue every 3 weeks for 9 doses, maintenance: 50 mg/m2 every 2 weeks. B-cell lymphoma: 3 gm/m2 over 3 hours with folinic acid rescue for three doses. Methotrexate level monitoring recommended when using high dose regimens. THE 500 MG STRENGTH IS NOT FOR INTRATHECAL USE
Methoxsalen 1% LotionD05AD02000L6001XXARepigmenting agent in vitiligo in conjuction with controlled doses of UVA or sunlightApply 0.1% lotion to area to be exposed to the UVA light ( need to dilute the 1% lotion to 0.1% lotion, otherwise the skin will burn)
Methoxsalen 10 mg CapsuleD05BA02000C1001XXAProtection before exposure to sunlight, psoriasis and vitiligo0.2 - 0.6 mg/kg/body weight. For repigmentation of larger lesions (greater than 6 cm sq): 20 mg/day 2 hours before exposure. Take with food or milk
Methoxy Polyethylene Glycol-epoetin Beta 100 mcg/0.3 ml Injection in Prefilled SyringeB03XA03000P5001XXA*Treatment of anaemia associated with chronic renal failure in the following circumstances: i)Patients who require 2 or more subcutaneous erythropoietin injections per week and need to travel to obtain the injections. ii)Patients who are on high doses of subcutaneous erythropoietin injections eg. 6000 units or more per time and require more than 1 injection of conventional erythropoietin per time. iii)Patients who require 2 or more erythropoietin injections per week and where compliance is an issue.Non Erythropoiesis Stimulating Agent (ESA)-treated patients : 0.6 mcg/kg, once every two weeks (IV or SC). When the Hb is >11g/dl, administration can be reduced to once monthly using the dose equal to twice the previous two weekly dose. ESA-treated patients : 120-360 mcg once monthly or 60-180 mcg every two weeks.
Methoxy Polyethylene Glycol-epoetin Beta 120 mcg/0.3 ml Injection in Prefilled SyringeB03XA03000P5005XXA*Treatment of anaemia associated with chronic renal failure in the following circumstances: i)Patients who require 2 or more subcutaneous erythropoietin injections per week and need to travel to obtain the injections. ii)Patients who are on high doses of subcutaneous erythropoietin injections eg. 6000 units or more per time and require more than 1 injection of conventional erythropoietin per time. iii)Patients who require 2 or more erythropoietin injections per week and where compliance is an issue.Non Erythropoiesis Stimulating Agent (ESA)-treated patients : 0.6 mcg/kg, once every two weeks (IV or SC). When the Hb is >11g/dl, administration can be reduced to once monthly using the dose equal to twice the previous two weekly dose. ESA-treated patients : 120-360 mcg once monthly or 60-180 mcg every two weeks.
Methoxy Polyethylene Glycol-epoetin Beta 150 mcg/0.3 ml Injection in Prefilled SyringeB03XA03000P5006XXA*Treatment of anaemia associated with chronic renal failure in the following circumstances: i)Patients who require 2 or more subcutaneous erythropoietin injections per week and need to travel to obtain the injections. ii)Patients who are on high doses of subcutaneous erythropoietin injections eg. 6000 units or more per time and require more than 1 injection of conventional erythropoietin per time. iii)Patients who require 2 or more erythropoietin injections per week and where compliance is an issueNon Erythropoiesis Stimulating Agent (ESA)-treated patients : 0.6 mcg/kg, once every two weeks (IV or SC). When the Hb is >11g/dl, administration can be reduced to once monthly using the dose equal to twice the previous two weekly dose. ESA-treated patients : 120-360 mcg once monthly or 60-180 mcg every two weeks
Methoxy Polyethylene Glycol-epoetin Beta 200 mcg/0.3 ml Injection in Prefilled SyringeB03XA03000P5007XXA*Treatment of anaemia associated with chronic renal failure in the following circumstances: i)Patients who require 2 or more subcutaneous erythropoietin injections per week and need to travel to obtain the injections. ii)Patients who are on high doses of subcutaneous erythropoietin injections eg. 6000 units or more per time and require more than 1 injection of conventional erythropoietin per time. iii)Patients who require 2 or more erythropoietin injections per week and where compliance is an issue.Non Erythropoiesis Stimulating Agent (ESA)-treated patients : 0.6 mcg/kg, once every two weeks (IV or SC). When the Hb is >11g/dl, administration can be reduced to once monthly using the dose equal to twice the previous two weekly dose. ESA-treated patients : 120-360 mcg once monthly or 60-180 mcg every two weeks.
Methoxy Polyethylene Glycol-epoetin Beta 50 mcg/0.3 ml Injection in Prefilled SyringeB03XA03000P5002XXA*Treatment of anaemia associated with chronic renal failure in the following circumstances: i)Patients who require 2 or more subcutaneous erythropoietin injections per week and need to travel to obtain the injections. ii)Patients who are on high doses of subcutaneous erythropoietin injections eg. 6000 units or more per time and require more than 1 injection of conventional erythropoietin per time. iii)Patients who require 2 or more erythropoietin injections per week and where compliance is an issue.Non Erythropoiesis Stimulating Agent (ESA)-treated patients : 0.6 mcg/kg, once every two weeks (IV or SC). When the Hb is >11g/dl, administration can be reduced to once monthly using the dose equal to twice the previous two weekly dose. ESA-treated patients : 120-360 mcg once monthly or 60-180 mcg every two weeks
Methoxy Polyethylene Glycol-epoetin Beta 75 mcg/0.3 ml Injection in Prefilled SyringeB03XA03000P5004XXA*Treatment of anaemia associated with chronic renal failure in the following circumstances: i)Patients who require 2 or more subcutaneous erythropoietin injections per week and need to travel to obtain the injections. ii)Patients who are on high doses of subcutaneous erythropoietin injections eg. 6000 units or more per time and require more than 1 injection of conventional erythropoietin per time. iii)Patients who require 2 or more erythropoietin injections per week and where compliance is an issueNon Erythropoiesis Stimulating Agent (ESA)-treated patients : 0.6 mcg/kg, once every two weeks (IV or SC). When the Hb is >11g/dl, administration can be reduced to once monthly using the dose equal to twice the previous two weekly dose. ESA-treated patients : 120-360 mcg once monthly or 60-180 mcg every two weeks
Methyl Salicylate 25% OintmentM02AC00260G5001XXC+Relief of minor aches and pains of muscles and joints associated with simple backache, arthritis and rheumatic conditions.To be massage well to the affected area, 3 - 4 times daily.
Methylcellulose 1% with 50 mg Vitamin C Eye DropsS01XA00990D2001XXBTo be used only for i) Post-operative cases with dry eye ii) Unconscious patients in critical care unit (CCU) with exposure keratitis1 to 4 times daily depending on severity of cases
Methyldopa 250 mg TabletC02AB01110T1001XXBHypertensionAdult: 250 mg 2 - 3 times daily, gradually increased at intervals of 2 or more days, maximum; 3 g/day. Elderly: initially 125 mg twice daily, increased gradually, maximum; 2 g daily. Child: Initially, 10 mg/kg or 300 mg/m2 daily in 2-4 divided doses; increase as necessary. Max: 65 mg/kg, 2 g/m2 or 3 g daily, whichever is least.
Methylene Blue 1% InjectionV03AB17100P3001XXBFor treatment of idiopathic and drug-induced methaemoglobinemiaAdult and children: 1 to 2 mg/kg (0.1 to 0.2 mL/kg of a 1% solution) IV very slowly over 5 minutes. This dosage can be repeated if necessary after one hour.
Methylphenidate HCl 10 mg TabletN06BA04110T1001XXAAttention deficit hyperactivity disorder (ADHD)CHILD over 6 years, initially 5 mg 1 - 2 times daily, increased if necessary at weekly intervals by 5 - 10 mg daily to maximum of 60 mg daily in divided doses; discontinue if no response after 1 month, also suspend periodically to assess child's condition (usually finally discontinued during or after puberty)
Methylphenidate HCl 18 mg Extended-release TabletN06BA04110T5002XXA*Attention deficit hyperactivity disorder (ADHD)CHILD over 6 years: Individualize dosage, to be taken once daily in the morning. Dose may be adjusted in increments to a maximum of 54 mg/day, at weekly interval. Patient new to methylphenidate: starting dose 18 mg once daily; adults 18mg or 36mg once daily. Patient currently using methylphenidate: 18 - 36 mg. Maximum 54 mg/day. Discontinue if no response after 1 month
Methylphenidate HCl 20 mg LA CapsuleN06BA04110C2003XXA*Attention deficit hyperactivity disorder (ADHD)20 mg once daily to be taken in the morning. Dosage be adjusted in increments to a maximum of 60 mg/day
Methylphenidate HCl 36 mg Extended-release TabletN06BA04110T5003XXA*Attention deficit hyperactivity disorder (ADHD)CHILD over 6 years: Individualize dosage, to be taken once daily in the morning. Dose may be adjusted in increments to a maximum of 54 mg/day, at weekly interval. Patient new to methylphenidate: starting dose 18 mg once daily; adults 18mg or 36mg once daily. Patient currently using methylphenidate: 18 - 36 mg. Maximum 54 mg/day. Discontinue if no response after 1 month
Methylphenidate HCl 40mg LA CapsuleN06BA04110C2002XXA*Attention deficit hyperactivity disorder (ADHD)20 mg once daily to be taken in the morning. Dosage be adjusted in increments to a maximum of 60 mg/day
Methylprednisolone Acetate 40mg injectionH02AB04134P3001XXA*i) Intramuscular administration: anti-inflammatory treatment, treatment of hematological and oncological disorders, endocrine disorders ii) Intrasynovial, periarticular, intrabursal or soft tissue administration: Indicated as adjunctive therapy for short term administration in : Synovitis of osteoarthritis, rheumatoid arthritis, acute and subacute bursitis, acute gouty arthritis, epicondylitis, acute nonspecific tenosynovitis, post-traumatic osteoarthritis iii) Intralesional use in alopecia areata, discoid lupus erythematosus; keloids, localized hypertrophic, infiltrated inflammatory lesions of granuloma annulare, lichen planus, psoriatic plaques, lichen simplex chronicus (neurodermatitis) *Restricted to patients experiencing side effects with triamcinolone acetonidei. Intramuscular route a) Asthma: may be used in place of a short burst of oral steroids in vomiting or non-adherent patients. The recommended dose is 80- 120mg intramuscularly as a one-dose b) Adrenogenital syndrome: 40mg every two weeks c) Rheumatoid arthritis (maintenance): 40-120mg weekly d) Dermatologic lesions (acute severe dermatitis, chronic contact dermatitis, seborrheic dermatitis): 40-120mg weekly for 1-4 weeks ii. Intraarticular route Recommended dose is 4 to 80 milligrams, depending upon the size of the joint. Injections may be repeated at intervals of 1 to 5 or more weeks in chronic cases iii.Intralesional route 20 to 60 milligrams methylprednisolone acetate injected into the lesion
Methylprednisolone Sodium Succinate 0.5 g InjectionH02AB04520P4001XXASuppression of inflammatory and allergic disorders, cerebral oedema, immunosuppression treatment of haematological and oncological disorders, treatment of shock states and endocrine disorders15 - 30 mg/kg daily. Large doses may be repeated 4 - 6 hourly for up to 48 hours
Methylprednisolone Sodium Succinate 1 g InjectionH02AB04520P4002XXASuppression of inflammatory and allergic disorders, cerebral oedema, immunosuppression treatment of haematological and oncological disorders, treatment of shock states and endocrine disorders15 - 30 mg/kg daily. Large doses may be repeated 4 - 6 hourly for up to 48 hours
Metoclopramide HCl 1 mg/ml SyrupA03FA01110L9001XXBi) Dyspepsia, flatulence, hiatus hernia, peptic ulceration, reflux oesophagitis, gastritis, duodenitis, cholelithiasis, nausea, vomiting ii) Promote bowel transit during diagnostic proceduresi) CHILD over 5 years: 2.5 - 5 ml 3 times daily. 3 - 5 years 2 ml 2 - 3 times daily. 1 - 3 years: 1 ml 2 - 3 times daily. Under 1 year: 1 ml 2 times daily ii) Single dose given 10 minutes before examination. CHILD over 5 years: 2.5 - 5 ml. Between 3 - 5 years: 2 ml. Under 1 year: 1 ml
Metoclopramide HCl 10 mg TabletA03FA01110T1001XXBi) Dyspepsia, flatulence, hiatus hernia, peptic ulceration, reflux oesophagitis, gastritis, duodenitis, cholelithiasis, nausea, vomiting ii) Promote bowel transit during diagnostic proceduresi) ADULT over 20 years: 10 mg 3 times daily. ADULT between 12 - 20 years: 5 mg 3 times daily. CHILD under 12 years: 0.12 mg/kg/dose 6 - 12 hourly ii) Single dose 5 - 10 minutes before examination; ADULT and CHILD over 15 years: 10 - 20 mg; CHILD less than 15 years: 0.12 mg/kg/dose 6 - 12 hourly
Metoclopramide HCl 5 mg/ml InjectionA03FA01110P3001XXBi) Dyspepsia, flatulence, hiatus hernia, peptic ulceration, reflux oesophagitis, gastritis, duodenitis, cholelithiasis, nausea, vomiting ii) Promote bowel transit during diagnostic proceduresi) ADULT over 20 years: 10 mg 3 times daily. ADULT between 12 - 20 years: 5 mg 3 times daily. CHILD under 12 years: 0.12 mg/kg/dose 6 - 12 hourly ii) Single dose 5 - 10 minutes before examination; ADULT and CHILD over 15 years: 10 - 20 mg; CHILD less than 15 years: 0.12 mg/kg/dose 6 - 12 hourly
Metolazone 2.5 mg TabletC03BA08000T1002XXA*Oedema in congestive cardiac failure, nephrotic syndrome and impaired renal functionAdult: 5-10 mg daily, increased if necessary to 20 mg daily. Max: 80 mg in 24 hr. Elderly: Initially, 2.5 mg/day or every other day. Should be taken with food. Take after breakfast.
Metoprolol Tartrate 100 mg TabletC07AB02123T1002XXBHypertension, angina, myocardial infarction, arrhythmiasHypertension: Initially 100 mg to maximum 400 mg daily, Angina: 50 mg - 100 mg in 2 - 3 times daily. Myocardial infarction: 200 mg daily in divided doses. Arrythmias: 50 mg - 300 mg in 2 - 3 times daily
Metoprolol Tartrate 50 mg TabletC07AB02123T1001XXBHypertension, angina, myocardial infarction, arrhythmiasHypertension: Initially 100 mg to maximum 400 mg daily, Angina: 50 mg - 100 mg in 2 - 3 times daily. Myocardial infarction: 200 mg daily in divided doses. Arrythmias: 50 mg - 300 mg in 2 - 3 times daily
Metronidazole 0.5 g SuppositoryP01AB01000S2001XXBAnaerobic infectionAnaerobic infections Adult: As a 1-g suppository 8 hrly for 3 days, then 12 hrly. Substitute oral therapy as soon as possible. May be unsuitable for initiating therapy in severe infections. Child: <1 yr: 125 mg; 1-5 yr: 250 mg; 5-10 yr: 500 mg. All doses to be given 8 hrly for 3 days, then 12 hrly thereafter. May be unsuitable for initiating therapy in severe infections. Prophylaxis of postoperative anaerobic bacterial infections Adult: 1 g 8 hrly starting 2 hr before surgery.
Metronidazole 200 mg TabletP01AB01000T1001XXBAnaerobic infectionAnaerobic bacterial infections Adult: Initially, 800 mg followed by 400 mg 8 hly for about 7 days. Other recommended doses: 500 mg 8 hrly or 7.5 mg/kg 6 hrly (max: 4 g in 24 hr). Child: 7.5 mg/kg 8 hrly. Elderly: Use lower end of adult dose recommendations. Do not admin as a single dose. Prophylaxis of postoperative anaerobic bacterial infections Adult: 400 mg by mouth 8 hrly in the 24 hr prior to surgery followed postoperatively by IV or rectal admin until oral therapy is possible. Other sources recommend that oral doses be initiated only 2 hr prior to surgery and that number of doses for all admin routes be limited to a total of 4. Elderly: Dose reduction may be necessary. Tab: Should be taken with food.
Metronidazole 200 mg/5 ml SuspensionP01AB01000L8001XXBAnaerobic infectionCHILD: 7.5 mg/kg 3 times daily for 7 days
Metronidazole 500 mg/100 ml InjectionJ01XD01000P9901XXAAnaerobic infectionsADULT: 500 mg IV infusion 8 hourly. CHILD: 7.5 mg/kg body weight every 8 hours. Neonates: 15mg/kg LD, followed by 7.5mg/kg every 12 hourly. 1 month to 18 years: 7.5mg/kg (maximum 500mg) every 8 hours.
Miconazole 2% CreamD01AC02221G1001XXBi) Fungal infections: Tinea pedis, Tinea corporis, Tinea capitis and other dermatophyte infections caused by Trichophyton and Epidermophyton species ii) Antifungal agent that has been in various candida infections including vaginal candidiasisApply sparingly and rub gently onto affected area 1-2 times daily continuing for 14 days after lesions have healed
Miconazole Nitrate 2% PowderD01AC02221F2001XXASkin infections caused by dermatophytes or CandidaDust powder over infected area 1 - 2 times daily
Midazolam 5 mg/5 ml InjectionN05CD08110P3001XXAPre-operative sedation, induction of general anaesthesia, premedication and sedation in ICU and sedation for minor proceduresUsual sedative range 2.5 - 7.5 mg (about 70 mcg/kg by IV injection over 30 seconds). Premedication by IM injection 70 - 100 mcg/kg 30 -60 minutes before surgery; ELDERLY: 1 - 1.5 mg/kg. Induction: Induction by slow IV infusion 200 - 300 mcg/kg (ELDERLY 100 - 200 mcg/kg. CHILD over 7 years 150 - 200 mcg/kg); Maximum: 0.35mg/kg. Sedation in ICU 0.03 - 0.2 mg/kg/hour
Midazolam 5 mg/ml InjectionN05CD08110P3002XXAPre-operative sedation, induction of general anaesthesia, premedication and sedation in ICU and sedation for minor proceduresUsual sedative range 2.5 - 7.5 mg (about 70 mcg/kg by IV injection over 30 seconds). Premedication by IM injection 70 - 100 mcg/kg 30 -60 minutes before surgery; ELDERLY: 1 - 1.5 mg/kg. Induction: Induction by slow IV infusion 200 - 300 mcg/kg (ELDERLY 100 - 200 mcg/kg. CHILD over 7 years 150 - 200 mcg/kg); Maximum: 0.35mg/kg. Sedation in ICU 0.03 - 0.2 mg/kg/hour
Midazolam 7.5 mg TabletN05CD08253T1001XXA/KKPre and post-operative sedationADULT: Usually 7.5 - 15 mg at bedtime; or for premedication, 30 - 60 minutes before the procedure. For ELDERLY, debilitated or impaired liver/kidney function: 7.5 mg
Minocycline 100 mg CapsuleJ01AA08110C1002XXA*As second-line treatment for leprosy only100 mg daily 6 - 18 months
Minocycline 50 mg CapsuleJ01AA08110C1001XXA*As second-line treatment for leprosy only100 mg daily 6 - 18 months
Minoxidil 5 mg TabletC02DC01000T1001XXA*Severe hypertensionADULTS and CHILD above 12 years old: Initially 5 mg daily in single or divided doses (elderly 2.5 mg). May increase by 5 - 10 mg daily at intervals of 3 or more days until optimum control is achieved. Maximum 50 mg daily
Mirtazapine 15 mg Orodispersible TabletN06AX11000T4001XXA*Major depressionInitially 15 mg daily at bedtime increased according to response up to 45 mg daily as a single dose at bedtime or in 2 divided doses. CHILD and ADOLESCENT under 18 years not recommended
Mirtazapine 30 mg Orodispersible TabletN06AX11000T4002XXA*Major depressionInitially 15 mg daily at bedtime increased according to response up to 45 mg daily as a single dose at bedtime or in 2 divided doses. CHILD and ADOLESCENT under 18 years not recommended
Mitomycin C 0.002% Eye DropsS01AX00000D2003XXAPterygium, conjunctival tumour, glaucoma surgery1 - 2 drops several times a day
Mitomycin C 0.02% Eye DropsS01AX00000D2001XXAPterygium, conjunctival tumour, glaucoma surgery1 - 2 drops several times a day
Mitomycin C 0.04% Eye DropsS01AX00000D2002XXAPterygium, conjunctival tumour, glaucoma surgery1 - 2 drops several times a day
Mitomycin-C 10 mg InjectionL01DC03000P4001XXA*i) Gastrointestinal, lung, breast, cervical cancers ii) Bladder tumours iii) Opthalmological conditions: conjunctival squamous neoplasia, squamous cell carcinoma of conjunctiva, trabeculectomy chronic lymphocytic leukaemia, chronic myelogenous leukaemia. Gastric, colorectal, lung canceri) 10 - 20 mg/m2 body surface area (BSA) given as a single dose through a running IV infusion repeated every 6 - 8 weeks. The whole schedule may be repeated depending on the bone marrow ii) 10 - 40 mg daily or every other day (intravesical) iii) 0.4 mg topically as a single application for opthalmological conditions, duration: 1 to 3 minutes
Mitoxantrone 20 mg/10ml InjectionL01DB07110P3001XXA*Acute leukaemia, elderly patients with acute myeloid leukaemia (AML), relapsed/resistant acute leukaemia, non-Hodgkin's lymphoma (NHL)10 - 12 mg/m2 IV daily for 3 days, in combination with other cytotoxic agents. Refer to protocol. CHILD: 5 - 10 mg/m2 daily for 3 - 5 days according to protocol. Treatment of acute leukaemia, ADULT: 8 - 12 mg/m2/day once daily for 4 - 5 days. CHILD more than 2 years: same as adult dose. CHILD 2 years: 0.4 mg/kg/day once daily for 3 - 5 days
Mixed Gas-Gangrene Antitoxin 25,000 units/5 ml InjectionJ06AA05000P3001XXBMixed gas-gangreneProphylactic: 25,000 units IM or IV. Therapeutic: Not less than 75,000 units IV
Moclobemide 150 mg TabletN06AG02000T1001XXA*Treatment of depressive syndromeInitially 300 mg daily in divided doses. Gradually to increase up to 600 mg daily in divided doses depending on response. Usual range 150 - 600 mg daily. Not recommended in children
Modified Fluid Gelatin 4% InjectionB05AA06905P9901XXBFor primary volume replacement in hypovolaemia, peri-operative stabilization of the circulation, haemodilution, extracorporeal circulation (haemodialysis and heart-lung machine)ADULT 500 - 1500 ml given as IV infusion
Modified Polypeptides (Polygeline) 3.5% InjectionB05AA10905P9901XXBFor primary volume replacement in hypovolaemia, peri-operative stabilization of the circulation, haemodilution, extracorporeal circulation (haemodialysis and heart-lung machine)Administered by intravenous infusion only. Total dosage and rate of infusion depend upon the amount of blood loss and hemodynamic parameters. The usual dose is 500 to 1000 milliliters (mL), with total dosage not to exceed 2500 mL daily
Molgramostim 300 mcg InjectionL03AA03000P4002XXA*i) As secondary prophylaxis and therapeutic use against chemotherapy induced leucopenia according to clinician's discretion ii) Haemopoietic stem cell transplantation (HSCT)SC or IV 250 mcg/m2/day. Initiation: 24 to 72 hours after chemotherapy. Duration: Until a clinically adequate neutrophil recovery is achieved
Mometasone Furoate 0.1% CreamD07AC13139G1001XXA*Steroid responsive dermatosis and vitiligo. Used where a potent steroid is required for short duration not more than 6 weeksApply thin layer to the affected skin areas once daily until the lesion heals or for a duration of 3 weeks whichever is sooner.Massage gently and thoroughly until the medication disappears.
Mometasone Furoate 50 mcg Aqueous Nasal SprayR01AD09139A4101XXA*Allergic rhinitisADULT and CHILD over 12 years: 100 mcg/day (2 sprays) to each nostril once daily. Maximum 200 mcg (4 sprays) once daily. Reduce to 50 mcg (1 spray) once daily when control achieved. CHILD 6 - 12 years old: 50 mcg (1 spray) to each nostril once daily
Monobasic Sodium Phosphate 48%, Dibasic Sodium Phosphate 18%A06AG01162L5001XXABowel cleansing prior to colonoscopy, radiological examination or bowel surgery45 ml diluted with half a glass (120 ml) of water, followed by one full glass (240 ml) of water to be taken depending on the time of the procedure. For morning procedure, 45 ml dilute with half glass of water should be taken at 7 am and the second 45 ml at 7 pm on the day before the procedure. For afternoon procedure, the first dose should be taken at 7 pm on the day before and the second dose at 7 am on the day of the procedure. Solid food must not be taken during the preparation period; clear fluids or water can be taken liberally. Not recommended for use in children
Montelukast Sodium 10 mg TabletR03DC03520T1001XXA/KKChronic treatment of asthma and relief of symptoms of seasonal allergic rhinitis for children more than 15 years and adultsCHILD more than 15 years and ADULT: 10 mg daily at bedtime
Montelukast Sodium 4 mg Oral GranulesR03DC03520F1001XXA*Asthmatics, not controlled on high dose inhaled corticosteroids more than 1600 mcg/day and with co-morbid allergic disorders. Chronic treatment of asthma12 months - 5 years: 1 packet of 4mg oral granules daily at bedtime
Montelukast Sodium 5 mg TabletR03DC03520T2001XXA*Asthmatics, not controlled on high dose inhaled corticosteroids more than 1600 mcg/day and with co-morbid allergic disorders. Chronic treatment of asthmaCHILD 6 - 14 years: One 5 mg chewable tablet daily at bedtime
Morphine HCl 10 mg/5 ml SolutionN02AA01110L9901XXBFor use in management of moderate to severe pain especially that associated with neoplastic disease5 - 20 mg or more regularly every 4 hours in terminal pain
Morphine Sulphate 10 mg Controlled Release TabletN02AA01183T5001XXAProlonged relief of severe pain associated with neoplastic disease; assists in procuring sleep where sleeplessness is due to pain or shock10 - 60 mg 12 hourly intervals, depend upon the severity of the pain. Children (more than 1 year of age) with severe cancer pain: 0.2 - 0.8mg/kg 12 hourly.
Morphine Sulphate 10 mg Immediate Release TabletN02AA01183T6002XXA*Relief of moderate to severe pain (cancer patient)5-10 mg every four hours. The dose may be increased according to needs
Morphine Sulphate 10 mg SuppositoryN02AA01183S2001XXA*Relief of severe chronic pain (cancer patient)15 - 30 mg regularly every 4 hours
Morphine Sulphate 10 mg/ml InjectionN02AA01183P3001XXBFor moderate to severe pain especially that associated with neoplastic diseaseADULT: 10 - 20 mg/kg or more SC or IM every 4 hours in terminal pain. CHILD: Up to 1 month: 0.15 mg/kg body weight; 1 - 12 months: 0.2 mg/kg body weight; 1 - 5 years: 2.5 - 5 mg ; 6 - 12 years: 5 - 10 mg
Morphine Sulphate 20 mg SuppositoryN02AA01183S2002XXA*Relief of severe chronic pain (cancer patient)15 - 30 mg regularly every 4 hours
Morphine Sulphate 30 mg Controlled Release TabletN02AA01183T5002XXAProlonged relief of severe pain associated with neoplastic disease; assists in procuring sleep where sleeplessness is due to pain or shock10 - 60 mg 12 hourly intervals, depend upon the severity of the pain
Morphine Sulphate 30 mg SuppositoryN02AA01183S2003XXA*Relief of severe chronic pain (cancer patient)15 - 30 mg regularly every 4 hours
Morphine Sulphate 5 mg Immediate Release TabletN02AA01183T6001XXA*Relief of moderate to severe pain (cancer patient)5-10 mg every four hours. The dose may be increased according to needs
Morphine Sulphate 60 mg Controlled Release TabletN02AA01183T5003XXAProlonged relief of severe pain associated with neoplastic disease; assists in procuring sleep where sleeplessness is due to pain or shock10 - 60 mg 12 hourly intervals, depend upon the severity of the pain. Children (more than 1 year of age) with severe cancer pain: 0.2 - 0.8mg/kg 12 hourly.
Moxifloxacin 0.5% Ophthalmic SolutionS01AX22110D2001XXA*Treatment of conjunctivitis caused by susceptible organismCHILD more than 1 year and ADULT: 1 drop to affected eye(s) 3 times daily for 7 days
Moxifloxacin 400 mg InjectionJ01MA14110P3001XXA*Second line therapy for Severe Community Acquired Pneumonia (CAP) patients with co-morbidity or with recent antibiotic therapy, suspected infections of resistant pathogens including Streptococcus pneumoniae, Haemophilus influenzae & Mycoplasma pneumoniae.IV or Oral: 400 mg once daily. The recommended total treatment duration for sequential administration (intravenous followed by oral therapy) is 7 to 14 days
Moxifloxacin 400mg TabletJ01MA14110T1001XXA*Second line therapy for Severe Community Acquired Pneumonia (CAP) patients with co-morbidity or with recent antibiotic therapy, suspected infections of resistant pathogens including Streptococcus pneumoniae, Haemophilus influenzae & Mycoplasma pneumoniae.IV or Oral: 400 mg once daily. The recommended total treatment duration for sequential administration (intravenous followed by oral therapy) is 7 to 14 days
Multivitamin DropsA11BA00901D5001XXBFor prevention and treatment of vitamin deficienciesINFANT less than 1 year: 1 ml daily
Multivitamin InjectionA11BA00901P3001XXBFor prevention and treatment of vitamin deficienciesInitially 2 - 4 pairs IV 4 - 8 hourly, reducing to 1 pair IV daily. For less serious cases, 1 pair IV 1 - 2 times daily or based on individual requirements
Multivitamin SyrupA11BA00901L9001XXC+For prevention and treatment of vitamin deficienciesCHILD 5 ml daily or based on manufacturer
Multivitamin TabletA11BA00901T1001XXBFor prevention and treatment of vitamin deficiencies1 - 2 tablets daily or based on individual requirements
Mupirocin 2% CreamD06AX09000G1001XXASkin infection by Staphylococcus aureus (including MRSA), Staphylococcus epidermidis and beta-haemolytic streptococcusAdults and child over 1 year, apply up to 3 times daily for up to 10 days
Mupirocin 2% OintmentD06AX09000G5001XXAFor MRSA infections onlyADULT and CHILD: Apply up to three times daily for up to 10 days
Mycophenolate Mofetil 250 mg CapsuleL04AA06236C1001XXA*i) Prophylaxis of acute organ rejection in patients receiving allogenic renal, cardiac and hepatic transplant ii) Used with steroids for induction and maintenance of severe lupus nephritis resistant or intolerant to cyclophosphamide therapyi) Renal transplant rejection: ADULT: 1 g twice daily. CHILD (3 months and older): 600 mg/m(2)/dose, twice daily; maximum daily dose, 2 g/10 mL. Cardiac transplant rejection: 1.5 g twice daily. Hepatic transplant rejection: 1.5 g twice daily ii) Induction phase: 2 - 3 g/day for up to 6 months. Maintenance phase: dose gradually tapers to 1 g/day
Mycophenolate Mofetil 500 mg tabletL04AA06236T1002XXA*i) Prophylaxis of acute organ rejection in patients receiving allogenic renal, cardiac and hepatic transplant ii) Used with steroids for induction and maintenance of severe lupus nephritis resistant or intolerant to cyclophosphamide therapyi) Renal transplant rejection: ADULT: 1 g twice daily. CHILD (3 months and older): 600 mg/m(2)/dose, twice daily; maximum daily dose, 2 g/10 mL. Cardiac transplant rejection: 1.5 g twice daily. Hepatic transplant rejection: 1.5 g twice daily ii) Induction phase: 2 - 3 g/day for up to 6 months. Maintenance phase: dose gradually tapers to 1 g/day
Mycophenolate Sodium 180mg TabletL04AA06520T1001XXA*Prophylaxis of acute transplant rejection in adult patients receiving allogenic renal transplant in combination with ciclosporin and corticosteroids720 mg twice daily
Mycophenolate Sodium 360mg TabletL04AA06520T1002XXA*Prophylaxis of acute transplant rejection in adult patients receiving allogenic renal transplant in combination with ciclosporin and corticosteroids720 mg twice daily
Nalbuphine HCl 10 mg/ml InjectionN02AF02110P3001XXBPerioperative analgesia, for relief of moderate to severe pain10 - 20 mg SC, IM or IV every 3 - 6 hours
Naloxone HCl 0.02 mg/ml InjectionV03AB15110P3001XXBFor the complete/partial reversal of narcotic depression including respiratory depression induced by opioids such as natural and synthetic narcotics. Diagnosis of suspected acute opioids overdosage0.005 - 0.01 mg/kg body weight repeated at intervals of 2 - 3 minutes according to the patient's needs by IM, IV or SC
Naloxone HCl 0.4 mg/ml InjectionV03AB15110P3002XXBFor the complete/partial reversal of narcotic depression including respiratory depression induced by opioids such as natural and synthetic narcotics. Diagnosis of suspected acute opioids overdosageInitially 0.4 - 2 mg IV repeated at intervals of 2 - 3 minutes according to patient's needs
Naltrexone HCl 50 mg TabletN07BB04110T1001XXAAdjunct in relapse prevention treatment in detoxified formerly opioid-dependant patientsInitial 25 mg may be increased to 50 mg. Maintenance: 350 mg weekly; administered as 50 mg daily. Dosing interval may be lengthened to improve compliance; 100 mg on alternate days or 150 mg every third day
Nandrolone Decanoate 25 mg/ml InjectionA14AB01135P3001XXAAnabolic therapyADULT: 25 - 50 mg every 3 weeks by IM. CHILD over 2 years: 25 - 50 mg every 3 to 4 weeks
Naproxen 250 mg TabletM01AE02000T1001XXA/KKi) Rheumatic arthritis, osteoarthritis and ankylosing spondylitis ii) Acute gout iii) Muscular skeletal disorder, dysmenorrhoeai) 0.5 - 1 g daily in 2 divided doses ii) 750 mg initially then 250 mg 8 hourly iii) 500 mg initially then 250 mg every 6 - 8 hour as required
Naproxen Sodium 275 mg TabletM01AE02520T1001XXAi) Rheumatic arthritis, osteoarthritis and alkylosing spondylitis ii) Acute gout iii) Muscular skeletal disorder and dysmenorrhoea550 mg- 1100 mg in two divided doses
Neomycin 0.5% CreamD06AX04256G1001XXBInfections of the skin due to susceptible organismsApply sparingly to affected area up to 3 times daily (For short term use, 1 - 2 weeks)
Neomycin 0.5% in Betamethasone 17-Valerate 0.01% CreamD07CC01947G1001XXBTreatment of the following conditions where bacterial infection is present or likely to occur: eczemas, prurigo nodularis, psoriasis (excluding widespread plaque psoriasis), neurodermatoses, anal and genital intertrigoApply sparingly to affected area 2 - 3 times daily. (May cause sensitisation to neomycin. Use with caution)
Neomycin 0.5% in Betamethasone 17-Valerate 0.01% OintmentD07CC01947G5001XXBTreatment of the following conditions where bacterial infection is present or likely to occur: eczemas, prurigo nodularis, psoriasis (excluding widespread plaque psoriasis), neurodermatoses, anal and genital intertrigoApply sparingly to affected area 2 to 3 times daily. (May cause sensitisation to Neomycin. Use with caution)
Neomycin 0.5% in Betamethasone 17-Valerate 0.1% CreamD07CC01947G1002XXATreatment of the following conditions where bacterial infection is present or likely to occur: eczemas, prurigo nodularis, psoriasis (excluding widespread plaque psoriasis), neurodermatoses, anal and genital intertrigoApply sparingly to affected area 2 - 3 times daily (May cause sensitisation to neomycin. Use with caution)
Neomycin 0.5% in Betamethasone 17-Valerate 0.1% OintmentD07CC01947G5002XXATreatment of the following conditions where bacterial infection is present or likely to occur: eczemas, prurigo nodularis, psoriasis (excluding widespread plaque psoriasis), neurodermatoses, anal and genital intertrigoApply sparingly to affected area 2 to 3 times daily. (May cause sensitisation to neomycin. Use with caution)
Neomycin 0.5% OintmentD06AX04256G5001XXBInfections of the skin due to susceptible organismsApply sparingly to affected area up to 3 times daily (For short term use, 1- 2 weeks)
Neomycin with Polymyxin B Sulphate and Gramicidin Eye DropsS01AA30990D2001XXAEye infections that require a broad spectrum antibiotic1 - 2 drops in the affected eye 2 - 4 times daily. In severe infections : 1 - 2 drops every 15 - 30 minutes
Neostigmine Methylsulphate 2.5 mg/ml InjectionN07AA01183P3002XXBi) Myasthenia gravis ii) Reversal of non-depolarising neuromuscular blockadei) ADULT: 1 - 2.5 mg at suitable intervals by SC, IM or IV. Usual total daily dose 5 - 20 mg. CHILD: 200 - 500 mcg at suitable intervals throughout the day. NEONATE: 50 - 250 mcg every 4 hours ii) By IV injection over 1 minute, 50 - 70 mcg/kg (maximum 5 mg) after or with atropine sulphate 0.6 - 1.2 mg
Netilmicin Sulphate 100 mg/2 ml InjectionJ01GB07183P3002XXASystemic infectionsADULT: 4 - 6.5 mg/kg/day IM or IV in 2 - 3 equally divided doses for 7 - 14 days. Maximum: 7.5 mg/kg/day. CHILD: 5 - 7.5 mg/kg/day 8 - 12 hourly depending on gestation and age. Maximum: 7.5 mg/kg/day
Netilmicin Sulphate 150 mg/2 ml InjectionJ01GB07183P3003XXASystemic infectionsADULT: 4 - 6.5 mg/kg/day IM or IV in 2 - 3 equally divided doses for 7 - 14 days. Maximum: 7.5 mg/kg/day. CHILD: 5 - 7.5 mg/kg/day 8 - 12 hourly depending on gestation and age. Maximum: 7.5 mg/kg/day
Netilmicin Sulphate 50 mg/2 ml InjectionJ01GB07183P3001XXASystemic infectionsADULT: 4 - 6.5 mg/kg/day IM or IV in 2 - 3 equally divided doses for 7 - 14 days. Maximum: 7.5 mg/kg/day. CHILD: 5 - 7.5 mg/kg/day 8 - 12 hourly depending on gestation and age. Maximum: 7.5 mg/kg/day
Nevirapine 200 mg TabletJ05AG01000T1001XXA/KKTreatment of HIV-1 infection in combination with other antiretroviral agentsCombined with other antiretrovirals: 200 mg once daily for the 1st 14 days; up to 200 mg twice daily if rash does not develop. Re-introduce at a lower dose for the 1st 14 days if treatment is interrupted for >7 days,necessitate reintroduction at a lower dose for the first 14 days.
Nicotine 10 mg/ 16 hour Transdermal PatchN07BA01000M7005XXA/KKFor the treatment of tobacco dependence by relieving nicotine withdrawal symptoms, thereby facilitating smoking cessation in smokers motivated to quit.Adult over 18 years old: 15 mg patch on waking (usually in the morning) and remove 16 hours later (usually at bedtime) for 8 weeks, then 10 mg patch daily for 2 weeks followed by one 5 mg patch daily for another 2 weeks. Apply to dry non-hairy skin site. Application limited to 16 hours in a 24-hr period in each case. Review at 3 months.
Nicotine 15 mg/ 16 hour Transdermal PatchN07BA01000M7006XXA/KKFor the treatment of tobacco dependence by relieving nicotine withdrawal symptoms, thereby facilitating smoking cessation in smokers motivated to quit.Adult over 18 years old: 15 mg patch on waking (usually in the morning) and remove 16 hours later (usually at bedtime) for 8 weeks, then 10 mg patch daily for 2 weeks followed by one 5 mg patch daily for another 2 weeks. Apply to dry non-hairy skin site. Application limited to 16 hours in a 24-hr period in each case. Review at 3 months.
Nicotine 2 mg GumN07BA01000M9901XXA/KKFor the treatment of tobacco dependence by relieving nicotine withdrawal symptoms, thereby facilitating smoking cessation in smokers motivated to quit.Smokes ≤ 20 sticks/day, chew 2mg gum. Smokes ≥ 20 sticks/day,chew 4 mg gum. (MAX 24 pieces /day for up to 12 week.)
Nicotine 4 mg GumN07BA01000M9902XXA/KKFor the treatment of tobacco dependence by relieving nicotine withdrawal symptoms, thereby facilitating smoking cessation in smokers motivated to quit.Smokes ≤ 20 sticks/day, chew 2mg gum. Smokes ≥ 20 sticks/day,chew 4 mg gum. (MAX 24 pieces /day for up to 12 week.)
Nicotine 5 mg/ 16 hour Transdermal PatchN07BA01000M7004XXA/KKFor the treatment of tobacco dependence by relieving nicotine withdrawal symptoms, thereby facilitating smoking cessation in smokers motivated to quit.Adult over 18 years old: 15 mg patch on waking (usually in the morning) and remove 16 hours later (usually at bedtime) for 8 weeks, then 10 mg patch daily for 2 weeks followed by one 5 mg patch daily for another 2 weeks. Apply to dry non-hairy skin site. Application limited to 16 hours in a 24-hr period in each case. Review at 3 months.
Nicotinic Acid 50 mg TabletA11HA01000T1001XXBFor prophylaxis and treatment of Vitamin B3 deficiencyProphylactic: 15 - 30 mg daily. Therapeutic: 50 - 250 mg daily. Maximum single dose: 200 mg. Maximum dose in 24 hours: 800 mg
Nicotinic Acid 500 mg TabletC10AD02000T1001XXBHyperlipidaemia100 - 200 mg 3 times daily, gradually increased over 2 - 4 weeks to 1 - 2 g 3 times daily with or after meals. CHILD: 100 - 250 mg/day in 3 divided doses with meals, increase 100 mg/day weekly or 250 mg/day every 2 - 3 weeks as tolerated. Maximum: 10 mg/kg/day
Nifedipine 10 mg CapsuleC08CA05000C1001XXBHypertension10 - 30 mg 3 times daily. Maximum: 120 - 180 mg per day
Nifedipine 10 mg TabletC08CA05000T1001XXBHypertensionInitial dose of 10 mg twice daily. Usual range 10 - 30 mg 3 times daily. Maximum: 120 - 180 mg per day. Elderly: Dose reduction may be necessary.
Nilotinib 150mg capsuleL01XE08110T1001XXA*For the treatment of adult patients with newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia in the chronic phase (CP).300mg twice daily. Dose adjustments or modifications:For neutropenia & thrombocytopenia
Nilotinib 200 mg CapsuleL01XE08110C1001XXA*Treatment of chronic phase and accelerated phase Philadelphia chromosome positive chronic myelogenous leukaemia (CML) in adults who: i) Failed imatinib ie no cytogenic response and no haematological response by 12 months ii) Have molecular resistance to Imatinib as shown by molecular mutation studies iii) Are intolerant to Imatinib400 mg twice daily, 12 hours apart. No food should be taken two hours before and 1 hour after taking the dose
Nimodipine 10 mg/50 ml Infusion SolutionC08CA06000P9901XXA*Prophylaxis & treatment of ischaemic neurological deficits caused by cerebral vasospasm following subarachnoid haemorrhage of aneurysmal originIV infusion of 1 mg/hour for a period of 2 hours (about 15 mcg/kg/hour). IV therapy should be started no later than 4 days after haemorrhage & continue for up to 10 - 14 days
Nimodipine 30 mg TabletC08CA06000T1001XXA*Prophylaxis & treatment of ischaemic neurological deficits caused by cerebral vasospasm following subarachnoid haemorrhage of aneurysmal origin360 mg daily in divided doses for 7 days
Nitrazepam 5 mg TabletN05CD02000T1001XXBEpilepsy (infantile spasms)5 - 10 mg at bedtime. ELDERLY or debilitated 2.5 - 5 mg. CHILD not recommended. Increasing slowly according to response
Nitrofurantoin 100 mg TabletJ01XE01000T1002XXBUncomplicated lower urinary tract infectionsAcute uncomplicated urinary tract infections Adult: 50-100 mg 4 times daily for 7 days. Dual-release preparation: 100 mg bid. Child: >3 mth and older children: 3 mg/kg daily in 4 divided doses. Prophylaxis of uncomplicated urinary tract infections Adult: 50-100 mg at bedtime. Child: >3 mth and older children: 1 mg/kg once daily.
Nonacog alfa 1000 IU injectionB02BD09000P4003XXA*Treatment and prophylaxis of bleeding in patients with haemophilia B (congenital factor IX deficiency)Number of factor IX units required = body weight (kg) x desired factor IX increase (% or units/dL) x reciprocal of observed recovery (units/kg per units/dL). Average dose for secondary prophylaxis for previously treated adult patients (PTP) was 40 units/kg (range 13 to 78 units/kg) at intervals of 3 to 4 days
Nonacog alfa 2000 IU injectionB02BD09000P4004XXA*Treatment and prophylaxis of bleeding in patients with haemophilia B (congenital factor IX deficiency)Number of factor IX units required = body weight (kg) x desired factor IX increase (% or units/dL) x reciprocal of observed recovery (units/kg per units/dL). Average dose for secondary prophylaxis for previously treated adult patients (PTP) was 40 units/kg (range 13 to 78 units/kg) at intervals of 3 to 4 days
Nonacog alfa 250 IU injectionB02BD09000P4001XXA*Treatment and prophylaxis of bleeding in patients with haemophilia B (congenital factor IX deficiency)Number of factor IX units required = body weight (kg) x desired factor IX increase (% or units/dL) x reciprocal of observed recovery (units/kg per units/dL). Average dose for secondary prophylaxis for previously treated adult patients (PTP) was 40 units/kg (range 13 to 78 units/kg) at intervals of 3 to 4 days
Nonacog alfa 500 IU injectionB02BD09000P4002XXA*Treatment and prophylaxis of bleeding in patients with haemophilia B (congenital factor IX deficiency)Number of factor IX units required = body weight (kg) x desired factor IX increase (% or units/dL) x reciprocal of observed recovery (units/kg per units/dL). Average dose for secondary prophylaxis for previously treated adult patients (PTP) was 40 units/kg (range 13 to 78 units/kg) at intervals of 3 to 4 days
Noradrenaline Acid Tartrate (Norepinephrine Bitartrate) 1 mg/ml InjectionC01CA03123P3001XXASeptic shock and shock where peripheral vascular resistance is lowInfuse and titrate to desired pressure response. Range: 0.05 - 0.5 mcg/kg/minute
Norethisterone 0.35 mg TabletG03AC01000T1001XXC+Contraception1 tablet daily starting on the first day of the menstrual bleeding
Norethisterone Enanthate 200 mg/ml InjectionG03AC01257P3001XXBContraceptionBy deep IM injection only. First injection is within first 5 days of the cycle. The next 3 injections are given at 8 weeks interval after which the injection interval should be extended to 12 weeks
Norfloxacin 0.3% Eye DropsS01AX12000D2001XXA*Superficial infections of the eye (Pseudomonas aeruginosa and MRSA) and its adnexaeADULT and CHILD more than 1 year : 1-2 drops 4 times daily. First day : 1 - 2 drops two hourly during waking hours (depending on severity)
Nystatin 100,000 units/g CreamD01AA01000G1001XXCPrevention and treatment of cutaneous infections caused by Candida albicansApply liberally to affected area twice daily or as required. After lesion has disappeared continue treatment for 10 days to prevent relapses. Nail infection: Cut nails as short as possible. Apply cream once daily until growth of new nail has set in
Nystatin 100,000 units/g OintmentD01AA01000G5001XXCPrevention and treatment of cutaneous or mucocutaneous infections caused by Candida albicansApply liberally to affected area twice daily or as required. After lesion has disappeared continue treatment for 10 days to prevent relapses. Nail infection: Cut nails as short as possible. Apply cream once daily until growth of new nail has set in
Nystatin 100,000 units/ml SuspensionA07AA02000L8001XXBPrevention and treatment of candidiasis of the skin and mucous membranes, protection against candidas overgrowth during antimicrobial /corticosteroid therapy and as selective decontamination regimensNEWBORN: 50,000-100,000 units daily. CHILD up to 5 years: 100,000 -500,000 units 6 hourly. CHILD up to 6-12 years and ADULT: 500,000-1,000,000 units 3 to 4 times daily
Nystatin 500,000 units TabletA07AA02000T1001XXBPrevention and treatment of candidiasis of the skin and mucous membranes, protection against candidas overgrowth during antimicrobial /corticosteroid therapy and as selective decontamination regimensADULT: 500,000 -1,000,000 units 6 hourly, according to severity of infections. CHILD: 100,000-500,000 units 6 hourly
Octreotide 0.05 mg/ml InjectionH01CB02122P3002XXAi) Acromegaly ii) Treatment of patients with symptoms associated with gastro-entero-pancreatic endocrine tumours iii) Carcinoid tumours with features of the carcinoid syndrome, VIPomas, glucagonomas, gastrinomas/Zollinger-Ellison syndrome, GRFomas, insulinomas iv) Prevention of complications following pancreatic surgery v) Emergency management of bleeding gastro-eosophageal varices in patients with cirrhosisi, ii and iii) Initially 0.005 - 0.1 mg SC 1 - 2 times daily, increase gradually up to 0.1 - 0.2 mg 3 times daily iv) 0.1 mg 3 times daily for 7 consecutive days, starting on the day of operation, at least 1 hour before laparotomy v) 25 mcg/hour for 5 days by continous IV infusion
Octreotide 0.1 mg/ml InjectionH01CB02122P3001XXAi) Acromegaly ii) Treatment of patients with symptoms associated with gastro-entero-pancreatic endocrine tumours iii) Carcinoid tumours with features of the carcinoid syndrome, VIPomas, glucagonomas, gastrinomas/Zollinger-Ellison syndrome, GRFomas, insulinomas iv) Prevention of complications following pancreatic surgery v) Emergency management of bleeding gastro-eosophageal varices in patients with cirrhosisi, ii and iii) Initially 0.005 - 0.1 mg SC 1 - 2 times daily, increase gradually up to 0.1 - 0.2 mg 3 times daily iv) 0.1 mg 3 times daily for 7 consecutive days, starting on the day of operation, at least 1 hour before laparotomy v) 25 mcg/hour for 5 days by continous IV infusion
Octreotide Acetate 20 mg InjectionH01CB02122P2001XXA*i) Adjunctive treatment for active acromegaly (second/third line therapy in whom surgery or radiotherapy is inappropriate or ineffective- based on level of growth hormone and high IGF-1 and residual pituitary tumor). ii) Treatment of symptoms associated with functional gastro-entero-pancreatic endocrine tumours. iii) Carcinoid tumours with features of the carcinoid syndrome, VIPomas, Glucagonomas, Gastrinomas/Zollinger-Ellison syndrome, Insulinomas, for pre-operative control of hypoglycemia and for maintenance therapy, GRFomas.10 - 30 mg every 4 weeks as deep intragluteal injection
Octreotide Acetate 30 mg InjectionH01CB02122P2002XXA*i) Adjunctive treatment for active acromegaly (second/third line therapy in whom surgery or radiotherapy is inappropriate or ineffective- based on level of growth hormone and high IGF-1 and residual pituitary tumor). ii) Treatment of symptoms associated with functional gastro-entero-pancreatic endocrine tumours. iii) Carcinoid tumours with features of the carcinoid syndrome, VIPomas, Glucagonomas, Gastrinomas/Zollinger-Ellison syndrome, Insulinomas, for pre-operative control of hypoglycemia and for maintenance therapy, GRFomas.10 - 30 mg every 4 weeks as deep intragluteal injection
Ofloxacin 0.3% Otic SolutionS02AA00000D1001XXAAcute otitis media with tympanostomy tubes, chronic suppurative otitis media with perforated tympanic membranes and otitis externaCHILD: 1 - 12 years: 5 drops twice daily for 10 days. ADULT and CHILD over 12 years: 6 - 10 drops twice daily and remain in the ear about 10 minutes
Ofloxacin 100 mg TabletJ01MA01000T1001XXAi) As second-line treatment of leprosy ii) As second-line treatment for tuberculosis and multidrug resistant tuberculosis (MDR-TB) iii) Sequential therapy for UTI and pyelonephritisi) 400 mg/day ii) 400 mg twice daily iii) 200 mg twice daily
Ofloxacin 200 mg InjectionJ01MA01000P4001XXASequential therapy for UTI and pyelonephritis200 mg IV twice daily for 3 - 5 days followed with 200 mg tablet twice daily for 3 - 5 days as maintenance dose (if necessary)
Olanzapine 10 mg Disintegrating TabletN05AH03000T4002XXA*i) Acute and maintenance treatment of schizophrenia and other psychoses where positive and or negative symptoms are prominent ii) Short-term use for acute mania episodes associated with Bipolar 1 disorderi) 5 - 10 mg once daily, increase to 10 mg once daily within 5 - 7 days, adjust by 5 - 10 mg/day at 1 week intervals, maximum 20 mg/day ii) 10 - 15 mg once daily, increase by 5 mg/day at intervals of not less than 24 hours. Maintenance 5 - 20 mg/day; maximum 20 mg/day
Olanzapine 10 mg TabletN05AH03000T1002XXA*i) Acute and maintenance treatment of schizophrenia and other psychoses where positive and or negative symptoms are prominent ii) Short-term use for acute mania episodes associated with Bipolar 1 disorderi) 5 - 10 mg once daily, increase to 10 mg once daily within 5 - 7 days, adjust by 5 - 10 mg/day at 1 week intervals, maximum 20 mg/day ii) 10 - 15 mg once daily, increase by 5 mg/day at intervals of not less than 24 hours. Maintenance 5 - 20 mg/day; maximum 20 mg/day
Olanzapine 5 mg TabletN05AH03000T1001XXA*i) Acute and maintenance treatment of schizophrenia and other psychoses where positive and or negative symptoms are prominent ii) Short-term use for acute mania episodes associated with Bipolar 1 disorderi) 5 - 10 mg once daily, increase to 10 mg once daily within 5 - 7 days, adjust by 5 - 10 mg/day at 1 week intervals, maximum 20 mg/day ii) 10 - 15 mg once daily, increase by 5 mg/day at intervals of not less than 24 hours. Maintenance 5 - 20 mg/day; maximum 20 mg/day
Olanzapine 5mg Disintegrating TabletN05AH03000T4001XXA*i) Acute and maintenance treatment of schizophrenia and other psychoses where positive and or negative symptoms are prominent ii) Short-term use for acute mania episodes associated with Bipolar 1 disorderi) 5 - 10 mg once daily, increase to 10 mg once daily within 5 - 7 days, adjust by 5 - 10 mg/day at 1 week intervals, maximum 20 mg/day ii) 10 - 15 mg once daily, increase by 5 mg/day at intervals of not less than 24 hours. Maintenance 5 - 20 mg/day; maximum 20 mg/day
Olive Oil Ear DropsS02DC00000D1001XXCImpacted wax softener3 - 4 drops 3 - 4 or as directed
Olopatadine hydrochloride ophthalmic solution 0.2%S01GX09110D2002XXA*Temporary prevention of ocular itching due to allergic conjunctivitisOne drop in each affected eye once a day
Omalizumab 150 mg (powder and solvent for solution)R03DX05000P3001XXA*i) For adults and adolescents (≥12 years), for severe persistent allergic asthma whose symptoms are inadequately controlled with inhaled corticosetroids ii) For Children (6 to <12 years of age): As add-on therapy to improve asthma control with severe persistent allergic asthma who have positive skin test or in vitro reactivity to a perennial aero allergen and frequent daytime symptoms or night-time awakenings and who have had multiple documented severe asthma exacerbations despite daily high-dose inhaled corticosteroids, plus a long-acting inhaled beta 2 agonisti) Adult & adolescent ≥12 yr, 150-375 mg SC every 2-4 wk, according to body wt & baseline serum total IgE level.. For subcutaneous administration only. Do not administer by the intravenous or intramuscular route. ii) Appropriate dose and dosing frequency of omalizumab is determined by baseline IgE (IU/ml), measured before the start of treatment, and body weight (kg). Prior to initial dosing, patients should have their IgE level determined for their dose assignment. Based on these measurements 150-375mg in 1 -3 injections may be needed for each administration. Patients whose baseline IgE levels or body weight in kilograms are outside the limits of the dosing table should not be given omalizumab. For subcutaneous administration only.
Omeprazole 10 mg CapsuleA02BC01000C1001XXAOnly for : i)Reflux oesophagitis ii)For eradication of Helicobacter pylori infection iii)Benign peptic ulcer not responding to conventional therapy iv)Zollinger-Ellison Syndromei)20 - 80 mg 1 - 2 times daily up to 8 - 12 weeks ii)20 mg twice daily in combination with any of the 2 antibiotics (clarithromycin 500 mg twice daily, amoxicillin 1 g twice daily or metronidazole 400 mg twice daily)for 1 - 2 weeks iii) 20 mg once daily for 4 - 6 weeks iv) ADULT: 20 - 120 mg once daily adjusted according to the patient's response. CHILD 0.4 - 0.8 mg/kg/day
Omeprazole 20 mg CapsuleA02BC01000C1002XXAOnly for : i)Reflux oesophagitis ii)For eradication of Helicobacter pylori infection iii)Benign peptic ulcer not responding to conventional therapy iv)Zollinger-Ellison Syndromei)20 - 80 mg 1 - 2 times daily up to 8 - 12 weeks ii)20 mg twice daily in combination with any of the 2 antibiotics (clarithromycin 500 mg twice daily, amoxicillin 1 g twice daily or metronidazole 400 mg twice daily)for 1 - 2 weeks iii) 20 mg once daily for 4 - 6 weeks iv) ADULT: 20 - 120 mg once daily adjusted according to the patient's response. CHILD 0.4 - 0.8 mg/kg/day
Omeprazole 40 mg InjectionA02BC01000P4001XXA*i) Reflux oesophagitis, eradication of H. Pylori infection, benign peptic ulcer not responding to conventional therapy, Zollinger-Ellison Syndrome ii) Endoscopically confirmed peptic ulceri) 40 mg IV once daily when oral therapy is inappropriate ii) 40- 160 mg by IV in single or divided doses
Ondansetron 2 mg/ml InjectionA04AA01110P3001XXAi)Prevention of nausea and vomiting induced by chemotherapy and radiotherapy ii)Postoperative nausea and vomitingi)8 mg given by IV infusion over 15 minutes or by IM immediately before treatment followed by 8 mg orally every 12 hours for up to 5 days. CHILD 5 mg/m2 body surface IV over 15 minutes immediately before chemotherapy followed by 4 mg orally every 12 hours for up to 5 days ii)Prevention : 4 mg given by IV at induction of anaesthesia. CHILD over 2 years, 100 mcg/kg (max 4mg) by slow IV before, during or after induction of anaesthesia. Treatment of postoperative: 4 mg by IM or slow. CHILD over 2 years 100 mcg/kg (maximum 4mg) by slow IV
Ondansetron 4 mg TabletA04AA01110T1001XXAi)Prevention of nausea and vomiting induced by chemotherapy and radiotherapy ii) Postoperative nausea and vomitingi)8 mg 1 - 2 hours before treatment then 8 mg every 12 hours for up to 5 days. CHILD, treatment by infusion followed by 4 mg by mouth every 12 hours for up to 5 days ii)Prevention of postoperative nausea and vomiting, 16 mg 1 hour before anaesthesia or 8 mg 1 hour before anaesthesia followed by 8 mg at intervals of 8 hours for a further 2 doses
Ondansetron 8 mg TabletA04AA01110T1002XXAi)Prevention of nausea and vomiting induced by chemotherapy and radiotherapy ii) Postoperative nausea and vomitingi)8 mg 1 - 2 hours before treatment then 8 mg every 12 hours for up to 5 days. CHILD, treatment by infusion followed by 4 mg by mouth every 12 hours for up to 5 days ii)Prevention of postoperative nausea and vomiting, 16 mg 1 hour before anaesthesia or 8 mg 1 hour before anaesthesia followed by 8 mg at intervals of 8 hours for a further 2 doses
Ondansetron 8 mg/4ml InjectionA04AA01110P3002XXAi)Prevention of nausea and vomiting induced by chemotherapy and radiotherapy ii)Postoperative nausea and vomitingi)8 mg given by IV infusion over 15 minutes or by IM immediately before treatment followed by 8 mg orally every 12 hours for up to 5 days. CHILD 5 mg/m2 body surface IV over 15 minutes immediately before chemotherapy followed by 4 mg orally every 12 hours for up to 5 days ii)Prevention : 4 mg given by IV at induction of anaesthesia. CHILD over 2 years, 100 mcg/kg (max 4mg) by slow IV before, during or after induction of anaesthesia. Treatment of postoperative: 4 mg by IM or slow. CHILD over 2 years 100 mcg/kg (maximum 4mg) by slow IV
Oral Rehydration SaltA07CA00905F2101XXCReplacement of fluid and electrolytes loss in diarrhoeaADULT: 200 - 400 ml ( 1 - 2 sachets ) for every loose motion. CHILD: 200 ml (1 sachet) for every loose motion. In severe dehydration 100 ml/kg for 3 - 4 hours. INFANT: 1 - 1.5 times their usual feed volume (50 ml per stool for small infant)
Orphenadrine 100 mg TabletM03BC01110T1001XXAPainful muscle spasmInitially 150 mg daily in divided doses. Maximum: 400 mg daily
Ortho-phthalaldehyde 0.55% SolutionV07AV00000L9909XXAHigh level disinfectant for sensitive endoscopes or semi-critical reusable medical devicesManual reprocessing, at least 12 minute immersion time at room temperature (20 degree celcius) is required. Automatic endoscope reprocessor, at least 5 minute immersion time at a minimum of 25 degree celcius is required
Oxaliplatin 50 mg InjectionL01XA03000P4001XXA*Only for patients with colorectal cancer who: i) have relapsed within 6 months after the end of adjuvant chemotherapy with 5-fluorouracil-based regime ii) have progressive disease despite 5-fluorouracil chemotherapy for advanced disease iii) good performance status (WHO of 2 or less). The treatment must be given in a tertiary oncology centre or have clearance in writing by an oncologist85 mg/m2 IV repeated every 2 weeks
Oxybutynin Chloride 5 mg TabletG04BD04110T1001XXA*For the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (ie urgency, frequency, urinary leakage, urge incontinence, dysuria)ADULT: Initially 5 mg 2 - 3 times daily increased if necessary to maximum 5 mg 4 times daily. ELDERLY: Initially 2.5 - 3 mg twice daily, increased to 5 mg twice daily according to response and tolerance. CHILD over 5 years, neurogenic bladder instability: 2.5 - 3 mg twice daily increased to 5 mg twice daily to maximum 3 times daily
Oxycodone HCl 10 mg Immediate Release CapsulesN02AA05110C1002XXA*i)As a second line drug in the management of opioid responsive, moderate to severe chronic cancer pain ii)As a step-down analgesic drug in post-operative procedures (Initiated by palliative medicine physicians, oncologists, anaesthesiologists, haematologists and pain specialists only)Initially 5 mg every 4 to 6 hours, increased if necessary according to severity of pain, usual max. 400 mg daily, but some patients may require higher doses
Oxycodone HCl 10 mg Prolonged Release TabletN02AA05110T5001XXA*Management of moderate to severe chronic cancer pain non-responsive to morphine (in accordance with WHO step-wise ladder of chronic pain management) [Initiated by Chronic Pain Specialist only]ADULT, ELDERLY and CHILDREN more than 18 years, opioid-naive patients: 10 mg 12 hourly. Renal or hepatic impairment: 5 mg 12 hourly. Titrate dose carefully, as frequently as once a day if necessary, to achieve pain relief
Oxycodone HCl 20 mg Immediate Release CapsulesN02AA05110C1003XXA*i)As a second line drug in the management of opioid responsive, moderate to severe chronic cancer pain ii)As a step-down analgesic drug in post-operative procedures (Initiated by palliative medicine physicians, oncologists, anaesthesiologists, haematologists and pain specialists only)Initially 5 mg every 4 to 6 hours, increased if necessary according to severity of pain, usual max. 400 mg daily, but some patients may require higher doses
Oxycodone HCl 20 mg Prolonged Release TabletN02AA05110T5002XXA*Management of moderate to severe chronic cancer pain non-responsive to morphine (in accordance with WHO step-wise ladder of chronic pain management) [Initiated by Chronic Pain Specialist only]ADULT, ELDERLY and CHILDREN more than 18 years, opioid-naïve patients: 10 mg 12 hourly. Renal or hepatic impairment: 5 mg 12 hourly. Titrate dose carefully, as frequently as once a day if necessary, to achieve pain relief
Oxycodone HCl 40 mg Prolonged Release TabletN02AA05110T5003XXA*Management of moderate to severe chronic cancer pain non-responsive to morphine (Initiated by palliative medicine physicians, oncologists, anaesthesiologists, haematologists and pain specialists only)Initially, 10 mg every 12 hours, increased if necessary according to severity of pain, usual max. 200 mg every 12 hours, but some patients may require higher doses
Oxycodone HCl 5 mg Immediate Release CapsulesN02AA05110C1001XXA*i)As a second line drug in the management of opioid responsive, moderate to severe chronic cancer pain ii)As a step-down analgesic drug in post-operative procedures (Initiated by palliative medicine physicians, oncologists, anaesthesiologists, haematologists and pain specialists only)Initially 5 mg every 4 to 6 hours, increased if necessary according to severity of pain, usual max. 400 mg daily, but some patients may require higher doses
Oxycodone Hydrochloride 10 mg/ml InjectionN02AA05110P3001XXA*For the treatment of moderate to severe pain in patients with cancer and post-operative pain. For the treatment of severe pain requiring the use of a strong opioid.Adults over 18 years: The following starting doses are recommended. A gradual increase in dose may be required if analgesia is inadequate or if pain severity increases. IV Bolus: Dilute to 1 mg/ml in 0.9% saline, 5% dextrose or water for injections. Administer a bolus dose of 1 to 10 mg slowly over 1-2 minutes. Doses should not be administered more frequently than every 4 hours. IV Infusion: Dilute to 1 mg/ml in 0.9% saline, 5% dextrose or water for injections. A starting dose of 2 mg/hour is recommended. IV PCA: Dilute to 1 mg/ml in 0.9% saline, 5% dextrose or water for injections. Bolus doses of 0.03 mg/kg should be administered with a minimum lock-out time of 5 minutes. SC Bolus: Use as 10 mg/ml concentration. A starting dose of 5 mg is recommended, repeated at 4-hourly intervals as required. SC Infusion: Dilute in 0.9% saline, 5% dextrose or water for injections if required. A starting dose of 7.5 mg/day is recommended in opioid naïve patients, titrating gradually according to symptom control. Cancer patients transferring from oral oxycodone may require much higher doses (see below). Transferring patients between oral and parenteral oxycodone: The dose should be based on the following ratio: 2 mg of oral oxycodone is equivalent to 1 mg of parenteral oxycodone. It must be emphasised that this is a guide to the dose required.Inter-patient variability requires that each patient is carefully titrated to the appropriate dose.
Oxycodone Hydrochloride 10mg and Naloxone Hydrochloride Dihydrate 5mg TabletN02AA55900T1002XXA*The management of moderate to severe chronic pain unresponsive to non-narcotic analgesics. The opioid antagonist naloxone in the fixed combination is added to counteract and/or prevent opioid-induced constipatio. For pain specialist onlyAdults and paediatric patients from 18 years of age: The usual starting dose for opioid-naïve patients or patients presenting with moderate to severe chronic pain uncontrolled by weaker opioids is one tablet 10mg/5mg at 12 hourly intervals, or one tablet 5mg/2.5mg 12-hourly for patients with mild hepatic impairment and patients with renal impairment. The dose should then be cautiously titrated, as frequently as every 1-2 days if necessary, to achieve pain relief.
Oxycodone Hydrochloride 20mg and Naloxone Hydrochloride Dihydrate 10mg TabletN02AA55900T1003XXA*The management of moderate to severe chronic pain unresponsive to non-narcotic analgesics. The opioid antagonist naloxone in the fixed combination is added to counteract and/or prevent opioid-induced constipatio. For pain specialist onlyAdults and paediatric patients from 18 years of age: The usual starting dose for opioid-naïve patients or patients presenting with moderate to severe chronic pain uncontrolled by weaker opioids is one tablet 10mg/5mg at 12 hourly intervals, or one tablet 5mg/2.5mg 12-hourly for patients with mild hepatic impairment and patients with renal impairment. The dose should then be cautiously titrated, as frequently as every 1-2 days if necessary, to achieve pain relief.
Oxycodone Hydrochloride 40mg and Naloxone Hydrochloride Dihydrate 20mg TabletN02AA55900T1004XXA*The management of moderate to severe chronic pain unresponsive to non-narcotic analgesics. The opioid antagonist naloxone in the fixed combination is added to counteract and/or prevent opioid-induced constipation. For pain specialist onlyAdults and paediatric patients from 18 years of age: The usual starting dose for opioid-naïve patients or patients presenting with moderate to severe chronic pain uncontrolled by weaker opioids is one tablet 10mg/5mg at 12 hourly intervals, or one tablet 5mg/2.5mg 12-hourly for patients with mild hepatic impairment and patients with renal impairment. The dose should then be cautiously titrated, as frequently as every 1-2 days if necessary, to achieve pain relief.
Oxycodone Hydrochloride 5 mg and Naloxone Hydrochloride Dihydrate 2.5mg TabletN02AA55900T1001XXA*The management of moderate to severe chronic pain unresponsive to non-narcotic analgesics. The opioid antagonist naloxone in the fixed combination is added to counteract and/or prevent opioid-induced constipation. For pain specialist onlyAdults and paediatric patients from 18 years of age: The usual starting dose for opioid-naïve patients or patients presenting with moderate to severe chronic pain uncontrolled by weaker opioids is one tablet 10mg/5mg at 12 hourly intervals, or one tablet 5mg/2.5mg 12-hourly for patients with mild hepatic impairment and patients with renal impairment. The dose should then be cautiously titrated, as frequently as every 1-2 days if necessary, to achieve pain relief.
Oxymetazoline HCI 0.01% Nasal DropsR01AA05110D6003XXA*Acute cold, paranasal sinusitis, syringitis, otitis media.Newborn (up to 4 weeks): 1 drop. Infant (1 - 12 month): 1 - 2 drop. Doses to be given twice or three times daily
Oxymetazoline HCl 0.025% (Paediatric) Nasal DropsR01AA05110D6001XXA/KKAcute colds, paranasal sinusitis and otitis media1 - 2 drops twice daily in each nostril for child more than 1 year
Oxymetazoline HCl 0.025% (Paediatric) Nasal SprayR01AA05110A4101XXAAcute colds, paranasal sinusitis and otitis media2 - 3 sprays into each nostril twice daily for child more than 1 year
Oxymetazoline HCl 0.05% (Adult) Nasal DropsR01AA05110D6002XXA/KKAcute colds, paranasal sinusitis and otitis media1 - 2 drops twice daily in each nostril
Oxymetazoline HCl 0.05% (Adult) Nasal SprayR01AA05110A4102XXAAcute colds, paranasal sinusitis and otitis media2 - 3 sprays into each nostril twice daily, maximum 6 sprays per nostril/day
Oxymetholone 50 mg TabletA14AA05000T1001XXAAnaemias caused by the administration of myelotoxic drugs, treatment of AIDS-wasting syndromeADULT and CHILD: 1 - 5 mg/kg daily in one daily dose. Usual effective dose 1 - 2 mg/kg/day, given for a minimum trial of 3 - 6 months because response may be delayed
Oxytetracycline with Polymyxin B Sulphate Eye OintmentS01AA30947G5101XXBConjunctivitis, dacryocystitis, blepharoconjunctivitis, keratitis, trachoma, blepharitis, pre-op prophylaxis against infectionApply into the conjunctival sac 4 times daily
Oxytocin 10 units/ml InjectionH01BB02000P3001XXBInduction of labourIV: 0.5 - 1 milliunits/minute; gradually increase dose in increments of 1 - 2 milliunits/minute until desired contraction pattern is established; dose may be decreased after desired frequency of contractions is reached and labor has progressed to 5 - 6 cm dilation
Oxytocin 5 units & Ergometrine Maleate 0.5 mg/ml InjectionG02AC01900P3001XXC+i) Prevention and treatment of post partum haemorrhage ii) Management of third stage of labouri) 1 ml IM, may be repeated after 2 hours. Should not exceed 3 ml within 24 hours ii) For routine management of third stage of labour, 1 ml IM following delivery of the anterior shoulder or immediately after delivery of the child
Paclitaxel 100 mg/16.6 ml InjectionL01CD01000P3002XXA*i) Treatment of recurrent breast cancer, after failure of anthracycline-based chemotherapy ii) Primary adjuvant therapy in advanced ovarian cancer in combination with cisplatin iii) Treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in chemonaive patients in combination with platinum compoundsi) 175 mg/m2 IV over 3 hours every 3 weeks ii) 175 mg/m2 IV over 3 hour followed by cisplatin 75 mg/m2 in every 3 weeks or 135 mg/m2 IV over 24 hours followed by cisplatin 75 mg/m2 every 3 weeks iii) 135 mg/m2 IV over 24 hours followed by cisplatin 75 mg/m2 every 3 weeks
Paclitaxel 30 mg/5 ml InjectionL01CD01000P3001XXA*i) Treatment of recurrent breast cancer, after failure of anthracycline-based chemotherapy ii) Primary adjuvant therapy in advanced ovarian cancer in combination with cisplatin iii) Treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in chemonaive patients in combination with platinum compoundsi) 175 mg/m2 IV over 3 hours every 3 weeks ii) 175 mg/m2 IV over 3 hour followed by cisplatin 75 mg/m2 in every 3 weeks or 135 mg/m2 IV over 24 hours followed by cisplatin 75 mg/m2 every 3 weeks iii) 135 mg/m2 IV over 24 hours followed by cisplatin 75 mg/m2 every 3 weeks
Paliperidone 100 mg Prolonged Release InjectionN05AX13000P2004XXA*Second or third line treatment of acute and maintenance treatment of schizophrenia in adultsInitiation: Deltoid IM 150 mg eq on Day1, followed by deltoid IM 100 mg eq on one week later. Maintenance: Monthly dose of 75 mg eq ( this can be increased or decreased based on individual patient?s tolerability and/or efficacy). These monthly maintenace dose can be administered in either the deltoid or gluteal muscle
Paliperidone 150 mg Prolonged Release InjectionN05AX13000P2005XXA*Second or third line treatment of acute and maintenance treatment of schizophrenia in adultsInitiation: Deltoid IM 150 mg eq on Day1, followed by deltoid IM 100 mg eq on one week later. Maintenance: Monthly dose of 75 mg eq ( this can be increased or decreased based on individual patient?s tolerability and/or efficacy). These monthly maintenace dose can be administered in either the deltoid or gluteal muscle
Paliperidone 3 mg Extended Released TabletN05AX13000T5001XXA*Second or third line treatment of schizophreniaADULT 6 mg once daily in the morning, adjusted if necessary; usual range 3 -12 mg daily. Renal impairment (creatinine clearance between 10-50 mL/min) 3 mg once daily. Avoid if creatinine clearance less than 10mL/min
Paliperidone 50 mg Prolonged Release InjectionN05AX13000P2002XXA*Second or third line treatment of acute and maintenance treatment of schizophrenia in adultsInitiation: Deltoid IM 150 mg eq on Day1, followed by deltoid IM 100 mg eq on one week later. Maintenance: Monthly dose of 75 mg eq ( this can be increased or decreased based on individual patient?s tolerability and/or efficacy). These monthly maintenace dose can be administered in either the deltoid or gluteal muscle
Paliperidone 6 mg Extended Released TabletN05AX13000T5002XXA*Second or third line treatment of schizophreniaADULT 6 mg once daily in the morning, adjusted if necessary; usual range 3 -12 mg daily. Renal impairment (creatinine clearance between 10-50 mL/min) 3 mg once daily. Avoid if creatinine clearance less than 10mL/min
Paliperidone 75 mg Prolonged Release InjectionN05AX13000P2003XXA*Second or third line treatment of acute and maintenance treatment of schizophrenia in adultsInitiation: Deltoid IM 150 mg eq on Day1, followed by deltoid IM 100 mg eq on one week later. Maintenance: Monthly dose of 75 mg eq ( this can be increased or decreased based on individual patient?s tolerability and/or efficacy). These monthly maintenace dose can be administered in either the deltoid or gluteal muscle
Paliperidone 9 mg Extended Released TabletN05AX13000T5004XXA*Second or third line treatment of schizophreniaADULT 6 mg once daily in the morning, adjusted if necessary; usual range 3 -12 mg daily. Renal impairment (creatinine clearance between 10-50 mL/min) 3 mg once daily. Avoid if creatinine clearance less than 10mL/min
Palivizumab 100mg InjectionJ06BB16000P3001XXA*For the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in paediatric patients at high risk of RSV disease15 mg/kg IM once a month during season of RSV risk
Pamidronate Disodium 30 mg InjectionM05BA03520P3001XXA*Hypercalcaemia of malignancy (tumour -induced hypercalcaemia)Dose depends on the initial serum calcium levels. Doses range from a single infusion of 30 - 90 mg
Pamidronate Disodium 90 mg InjectionM05BA03520P3002XXA*Hypercalcaemia of malignancy (tumour -induced hypercalcaemia)Dose depends on the initial serum calcium levels. Doses range from a single infusion of 30 - 90 mg
Pancreatin 150 mg CapsuleA09AA02000C1001XXA/KKTreatment of pancreatic exocrine insufficiency due to conditions such as cystic fibrosis, chronic pancreatitis and non-pancreatic diseasesInitially 1 - 2 capsules with each meal. May increase to 5 - 15 capsules daily
Pancuronium Bromide 2 mg / ml lnjectionM03AC01320P3001XXBMuscle relaxant as an adjunct to general anaesthesiaADULT: Initially 50 - 100 mcg/kg IV, then 10 - 20 mcg/kg as required. CHILD > 2 YEARS: Initially 60 - 100 mcg/kg then 10 - 20 mcg/kg. Intensive care, by IV, 60 mcg/kg every 60 - 90 minutes
Pantoprazole 40 mg InjectionA02BC02000P3001XXA*Bleeding peptic ulcer and acute stress ulceration40 mg twice daily until oral administration can be resumed. CHILD not recommended
Pantoprazole 40 mg TabletA02BC02000T1001XXA*i) Helicobacter pylori eradication ii) Peptic ulcer disease iii) Erosive and non-erosive reflux oesophagitis (GERD and NERD) iv) Zollinger-Ellison Syndrome v) Prevention of NSAID induced gastropathyi) 40 mg twice daily in combination with any of the 2 antibiotics (Clarithromycin 500 mg twice daily, Amoxicillin 1 g twice daily or Metronidazole 400 mg twice daily) for 1-2 weeks ii) 40 mg daily for 2 - 4 weeks iii) 20 - 40 mg daily on morning for 4 weeks iv) Initially 80 mg daily, dose can be titrated up or down as needed. v) 20 mg daily. CHILD not recommended
Papaverine HCl 120 mg/10ml InjectionA03AD01110P3002XXARelief of cerebral and peripheral ischaemia associated with arterial spasm and myocardial ischaemia complicated by arrhythmiasADULT: 30 - 120 mg may be repeated every 3 hours as necessary. CHILD: 6 mg/kg daily in 4 divided doses
Paracetamol 120 mg/5 ml SyrupN02BE01000L9001XXC+Mild to moderate pain and pyrexiaCHILD: up to 1 year: 60 - 120 mg. 1 - 5 years: 120 - 240 mg. 6 - 12 years: 240 - 480 mg per dose. Repeat every 4 - 6 hours when necessary. Maximum of 4 doses in 24 hours
Paracetamol 125 mg SuppositoryN02BE01000S2002XXC+Symptomatic relief of fever and post operative pain for paediatric casesCHILD 1 - 5 years: 125 - 250 mg; 6 - 12 years: 250 - 500 mg; 3 - 11 months: 80 mg inserted every 4 - 6 hours if necessary, maximum 4 doses in 24 hours. INFANTS under 3 months should not be given Paracetamol unless advised by doctor; a dose of 10 mg/kg (5 mg/kg if jaundiced) is suitable
Paracetamol 250 mg SuppositoryN02BE01000S2001XXBSymptomatic relief of fever and post operative pain for paediatric casesCHILD 1 - 5 years : 125 - 250 mg; 6 - 12 years : 250 - 500 mg; 3 - 11 months : 80 mg inserted every 4 - 6 hours if necessary, maximum 4 doses in 24 hours. INFANTS under 3 months should not be given Paracetamol unless advised by doctor; a dose of 10 mg/kg (5 mg/kg if jaundiced) is suitable
Paracetamol 500 mg TabletN02BE01000T1001XXC+Mild to moderate pain and pyrexiaADULT: 500 - 1000 mg every 4 - 6 hours, maximum of 4 g daily
Paradichlorobenzene, Turpentine Oil and Chlorbutol Ear DropsS02DA30900D1001XXBOcclusion or partial occlusion of the external auditory meatus by soft wax or wax plugInstill 5 drops into the ears
Paraffin Mole Alba (White Soft Paraffin)D02AC00000G5001XXCXerosis and ichthyosisApply to the affected area
Paraffin Mole FlavaD02AC00000G5002XXCXerosis and ichthyosisApply to the affected area
Paraldehyde InjectionN05CC05000P3001XXCStatus epilepticusThe usual intramuscular dose of paraldehyde for status epilepticus is 0.15 to 0.3 milliliter/kilogram, a moderate additional dose (0.05 milliliter/kilogram) may be necessary. The dose may be repeated in 2 to 6 hours and no more than 5 milliliters should be administered in one site
Parecoxib Sodium 40mg InjectionM01AH04520P3001XXA*Management of post operative pain in the immediate post operative setting only40 mg followed by 20 or 40 mg every 6 to 12 hours, as required. Use limited to two days only with a maximum dose of 80 mg/day. Reduce the initial dose by 50% in elderly less than 50 kg
Pazopanib Hydrochloride 200 mg TabletL01XE11110T1001XXA*For treatment of advanced and/or metastatic renal cell carcinoma (RCC)Recommended dose is 800 mg ORALLY once daily. Should be taken without food (at least one hour before or two hours after meal). The dose should not exceed 800 mg.
Pazopanib Hydrochloride 400 mg TabletL01XE11110T1002XXA*For treatment of advanced and/or metastatic renal cell carcinoma (RCC)Recommended dose is 800 mg ORALLY once daily. Should be taken without food (at least one hour before or two hours after meal). The dose should not exceed 800 mg.
Pefloxacin 400 mg InjectionJ01MA03196P3001XXAInfections due to gram-positive and gram-negative pathogensAdministered as a slow (one hour) intravenous perfusion, after diluting the contents of the 400 mg in 250 ml 5% glucose (two perfusions daily, morning and evening)
Pefloxacin 400 mg TabletJ01MA03000T1001XXAi) Infections due to gram-positive and gram-negative pathogens ii) Uncomplicated UTI, chancroid gonococcal urethritisADULT i) 800 mg/day in 2 divided doses ii) 800 mg stat
Pegfilgrastim Pre-filled Syringe 6 mg/0.6 ml (10 mg/ml)L03AA13000P5001XXA*Reduction in the duration of neutropenia, the incidence of febrile neutropenia and the incidence of infection as manifested by febrile neutropenia in patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes)Adults (≥18 years): One 6 mg dose (a single pre-filled syringe) of pegfilgrastim for each chemotherapy cycle, administered as a subcutaneous injection approximately 24 hours following cytotoxic chemotherapy. Renal impairment: Pharmacokinetics of pegfilgrastim is not expected to be affected by renal impairment. Hepatic impairment: Pharmacokinetics of pegfilgrastim is not expected to be affected by hepatic impairment. Paediatric population: Insufficient data to recommend the use of pegfilgrastim in children and adolescents under 18 years of age.
Peginterferon Alfa-2b 80 mcg InjectionL03AB10000P5002XXA*Treatment of: i) Chronic Hepatitis C ii) Chronic Hepatitis Bi) Combination therapy with Ribavirin: ADULT: SC 1.5 mcg/kg/week CHILD and ADOLESCENT (3-17 yr): SC 60 mcg/m2/week for 24-48 weeks Monotherapy: ADULT: SC 1 mcg/kg/week for 24 weeks to 1 year ii) SC 1.0 - 1.5 mcg/kg once weekly for 52 weeks
Peginterferon Alpha-2a 135 mcg Prefilled SyringeL03AB11000P5002XXA*i) Chronic hepatitis C usually in combination with ribavirin (Important to establish hepatitis C virus (HCV) genotype and viral load where combination treatment is advocated) ii) For the treatment of both HbeAg-positive and HbeAg-negative chronic hepatitis B with compensated liver disease and evidence of viral replication who are not responding or tolerating oral antiviral therapy (Initiated by Hepatologist and Gasteroenterologist only)i) 180 mcg weekly SC with ribavirin 800 mg daily for 24 weeks in patients in genotype 2 and 3 and 180 mcg weekly SC with ribavirin (1000 - 1200 mg) for 48 weeks for those with genotype 1 and 4. 135 mg dose may be used for patients who cannot tolerate the 180 mcg dose ii) 180 mcg weekly SC for 48 weeks
Peginterferon Alpha-2a 180 mcg Prefilled SyringeL03AB11000P5001XXA*i) Chronic hepatitis C usually in combination with ribavirin (Important to establish hepatitis C virus (HCV) genotype and viral load where combination treatment is advocated) ii) For the treatment of both HbeAg-positive and HbeAg-negative chronic hepatitis B with compensated liver disease and evidence of viral replication who are not responding or tolerating oral antiviral therapy (Initiated by Hepatologist and Gasteroenterologist only)i) 180 mcg weekly with ribavirin 800 mg daily for 24 weeks in patients in genotype 2 and 3 and 180 mcg weekly with ribavirin (1000 - 1200 mg) for 48 weeks for those with genotype 1 and 4. 135 mg dose may be used for patients who cannot tolerate the 180 mcg dose ii) 180 mcg subcutaneously once a week for 48 weeks
Pegylated Interferon Alpha-2b 100 mcg InjectionL03AB10000P5003XXA*Treatment of: i) Chronic Hepatitis C ii) Chronic Hepatitis Bi) Combination therapy with Ribavirin: ADULT: SC 1.5 mcg/kg/week CHILD and ADOLESCENT (3-17 yr): SC 60 mcg/m2/week for 24-48 weeks Monotherapy: ADULT: SC 1 mcg/kg/week for 24 weeks to 1 year ii) SC 1.0 - 1.5 mcg/kg once weekly for 24-52 weeks
Pegylated Interferon Alpha-2b 120 mcg InjectionL03AB10000P5004XXA*Treatment of: i) Chronic Hepatitis C ii) Chronic Hepatitis Bi) Combination therapy with Ribavirin: ADULT: SC 1.5 mcg/kg/week CHILD and ADOLESCENT (3-17 yr): SC 60 mcg/m2/week for 24-48 weeks Monotherapy: ADULT: SC 1 mcg/kg/week for 24 weeks to 1 year ii) SC 1.0 - 1.5 mcg/kg once weekly for 24-52 weeks
Pegylated Interferon Alpha-2b 150 mcg InjectionL03AB10000P5005XXA*Treatment of: i) Chronic Hepatitis C ii) Chronic Hepatitis Bi) Combination therapy with Ribavirin: ADULT: SC 1.5 mcg/kg/week CHILD and ADOLESCENT (3-17 yr): SC 60 mcg/m2/week for 24-48 weeks Monotherapy: ADULT: SC 1 mcg/kg/week for 24 weeks to 1 year ii) SC 1.0 - 1.5 mcg/kg once weekly for 24-52 weeks
Pegylated Interferon Alpha-2b 50 mcg InjectionL03AB10000P5001XXA*Treatment of: i) Chronic Hepatitis C ii) Chronic Hepatitis Bi) Monotherapy: Peg-Intron RediPen pre-filled pen monotherapy is administered SC at a dose of 0.5 or 1 mcg/kg once weekly for at least 6 months. Combination Therapy: Peg-Intron RediPen pre-filled pen 1.5 mcg/kg/week SC in combination with ribavirin capsules. ii) 1-1.5 mcg/kg once weekly for at least 24 weeks and up to 52 weeks.
Pegylated Liposomal Doxorubicin HCl 20 mg/vialL01DB01110P3003XXA*i) For patients with platinum-resistant ovarian cancer where the disease relapses within 6 months after completion of the initial platinum-based chemotherapy ii) For patients with platinum-sensitive ovarian cancer where the disease responds to first-line platinum-based therapy but relapses 12 months or more after completion of the initial platinum based chemotherapy. As third line therapy for very selected patients. (Gyne Oncology Specialist only)50 mg/m2 IV every 4 weeks for as long as the disease does not progress & patient continues to tolerate treatment.For doses <90 mg: dilute in 250 ml Dextrose 5 % in Water. For doses >90 mg: dilute in 500 ml Dextrose 5 % in Water. To minimize the risk of infusion reactions, the initial dose is administered at a rate no greater than 1 mg/minute. Renal impairment: No dose adjustment required in patients with creatinine clearance 30-156 ml/min, no pharmacokinetic data are available in patients with creatinine clearance of less than 30 ml/min. Hepatic impairment: At initiation of therapy: Bilirubin 1.2 - 3.0 mg/dl, the first dose is reduced by 25 %, Bilirubin > 3.0 mg/dl, the first dose is reduced by 50 %.
Pemetrexed Disodium 100 mg InjectionL01BA04016P3002XXA*In combination with Cisplatin for the 2nd line treatment of patients with locally advanced or metastatic non small cell lung cancer (NSCLC) other than predominantly squamous cell histologyInitial therapy 500 mg/m(2) IV over 10 minutes on day 1, followed 30 minutes later by cisplatin 75 mg/m(2) infused IV over 2 hours; repeat cycle every 21-days. Prior chemotherapy : 500 mg/m(2) IV, as a single-agent, over 10 minutes on day 1 of each 21-day cycle
Pemetrexed Disodium 500 mg InjectionL01BA04016P3001XXA*In combination with Cisplatin for the 2nd line treatment of patients with locally advanced or metastatic non small cell lung cancer (NSCLC) other than predominantly squamous cell histologyInitial therapy 500 mg/m(2) IV over 10 minutes on day 1, followed 30 minutes later by cisplatin 75 mg/m(2) infused IV over 2 hours; repeat cycle every 21-days. Prior chemotherapy : 500 mg/m(2) IV, as a single-agent, over 10 minutes on day 1 of each 21-day cycle
Pentamidine Isethionate 300 mg InjectionP01CX01198P3001XXA*Only for the treatment of pneumonia due to Pneumocytosis carinii4 mg/kg once daily by slow IV infusion for at least 14 days
Pentoxifylline 400 mg TabletC04AD03000T1001XXA/KKPeripheral vascular disease400 mg 2 - 3 times daily
Peracetic Acid and Hydrogen PeroxideV07AV00000L9906XXAHigh level disinfectant or sterilant for heat labile endoscopesImmersion time based on manufacturer recommendation
Perindopril 4 mg and Indapamide 1.25 mg TabletC09BA04900T1001XXA/KKEssential hypertension, for patients whose blood pressure is insufficiently controlled by perindopril alone.One tablet daily, preferably taken in the morning and before a meal.
Perindopril 4 mg TabletC09AA04000T1001XXBi) Hypertension ii) Congestive heart failure iii) Stable coronary artery diseasei) 4 mg as single dose, may be increased to a single 8 mg dose. ELDERLY: Start treatment with 2 mg dose. In renal insufficiency, dose should be adapted according to creatinine clearance ii) Single starting oral dose of 2 mg should be increased to a single 4 mg once BP acceptability has been demonstrated iii) 4 mg once daily for 2 weeks, may be increased to 8 mg once daily. ELDERLY: 2 mg once daily for 1 week, then 4 mg once daily for the following week, may be increased up to 8 mg once daily
Perindopril 8 mg TabletC09AA04000T1002XXBi) Hypertension ii) Congestive heart failure iii) Stable coronary artery diseasei) 4 mg as single dose, may be increased to a single 8 mg dose. ELDERLY: Start treatment with 2 mg dose. In renal insufficiency, dose should be adapted according to creatinine clearance ii) Single starting oral dose of 2 mg should be increased to a single 4 mg once BP acceptability has been demonstrated iii) 4 mg once daily for 2 weeks, may be increased to 8 mg once daily. ELDERLY: 2 mg once daily for 1 week, then 4 mg once daily for the following week, may be increased up to 8 mg once daily
Peritoneal Dialysis Solution (1.5% Dextrose 5 Litres)B05DB00908H2001XXBFor chronic renal disease requiring dialysis and for acute renal failureDose depending on clinical cases
Peritoneal Dialysis Solution (4.25% Dextrose, 2 Litres)B05DB00908H2002XXBFor chronic renal disease requiring dialysis and for acute renal failureDose depending on clinical cases
Peritoneal Dialysis with 7.5% Icodextrin SolutionB05DB00908H2003XXA*As a once replacement for a single glucose exchange as part of a continuous ambulatory peritoneal dialysis (CAPD) or automated peritoneal dialysis (APD) regimen for the treatment of chronic renal failure, particularly for patients who have lost ultra filtration on glucose solutionsAdministered as a single daily exchange for the long dwell in continuous ambulatory peritoneal dialysis or automated peritoneal dialysis. The recommended dwell time is 8 to 16 hours
Permethrin 5% w/v LotionP03AC04000L6001XXA*Treatment of scabiesApply thoroughly to all body parts. Leave on for 8 - 14 hours. Not recommended for children less than 2 years old
Perphenazine 4 mg TabletN05AB03000T1001XXBSchizophrenia and other psychosesADULT: Initially 4 mg 3 times daily adjusted according to response, maximum 24 mg daily. ELDERLY: 1/4 to 1/2 adult dose. CHILD not recommended
Pethidine HCl 100 mg/2 ml InjectionN02AB02110P3002XXBFor relief of moderate to severe pain (medical and surgical), pre-anaesthetic medication and obstetrical analgesiaADULT: 0.5 - 2 mg/kg SC or IM every 3 - 4 hours if necessary. CHILD: by IM 0.5 - 2 mg/kg. Up to 1 year : 1- 2 mg/kg weight IM, 1 - 5 years : 12.5 - 25 mg IM, 6 - 12 years: 25 - 50 mg IM
Pethidine HCl 50 mg/ml InjectionN02AB02110P3001XXBFor relief of moderate to severe pain (medical and surgical), pre-anaesthetic medication and obstetrical analgesiaADULT: 0.5 - 2 mg/kg SC or IM every 3 - 4 hours if necessary. CHILD: by IM 0.5 - 2 mg/kg. Up to 1 year : 1- 2 mg/kg weight IM, 1 - 5 years : 12.5 - 25 mg IM, 6 - 12 years: 25 - 50 mg IM
Phenobarbitone 30 mg TabletN03AA02000T1002XXBEpilepsyADULT: 60 - 180 mg daily on. CHILD: Up to 8 mg/kg daily
Phenobarbitone Sodium 200 mg/ml InjectionN03AA02520P3001XXBStatus EpilepticusADULT: 10 mg/kg IV at a rate of not faster than 100 mg/minute. Initial maximum dose does not exceeding 1 gm. Daily maintenance of 1 - 4 mg/kg/day. CHILD: 10 - 20 mg/kg/dose loading dose, followed by repeated doses at 10 mg/kg/dose (strictly in ICU setting). Maintenance 5 - 8 mg/kg/day
Phenol 80% w/w LiquidD08AE03000L5001XXCAs disinfectantUse in various dilutions
Phenoxybenzamine HCl 100 mg/2 ml InjectionC04AX02110P3001XXA*Hypertensive episodes associated with phaeochromocytoma1 mg/kg daily over at least 2 hours into large vein. Do not repeat within 24 hours.
Phenoxymethyl Penicillin 125 mg TabletJ01CE02500T1001XXCi) Treatment or prophylaxis of infections caused by susceptible organisms ii) Prophylactic, rheumatic feveri) ADULT: 500 - 750 mg 6 hourly.CHILD; up to 1 year: 62.5 mg, 1 - 5 years: 125 mg, 6 - 12 years: 250 mg 6 hourly ii) ADULT: 125 - 250 mg twice daily. CHILD: 25 - 50 mg/kg in divided doses every 6 - 8 hours. Maximum: 3 g/day
Phenoxymethyl Penicillin 125 mg/5 ml SyrupJ01CE02500F2101XXCTreatment or prophylaxis of infections caused by susceptible organismsCHILD: Up to 1 year: 62.5 mg 6 hourly; 1 - 5 years: 125 mg 6 hourly; 6 - 12 years: 250 mg 6 hourly
Phenoxymethyl Penicillin 250 mg TabletJ01CE02500T1002XXCi) Treatment or prophylaxis of infections caused by susceptible organisms ii) Prophylactic, rheumatic feveri) ADULT: 500 - 750 mg 6 hourly.CHILD; up to 1 year: 62.5 mg, 1 - 5 years: 125 mg, 6 - 12 years: 250 mg 6 hourly ii) ADULT: 125 - 250 mg twice daily. CHILD: 25 - 50 mg/kg in divided doses every 6 - 8 hours. Maximum: 3 g/day
Phenylephrine HCI 2.5% Eye DropsS01FB01110D2001XXBFor pupillary dilation in uveitis, for refraction without cyclopegic. For fundoscopy and other diagnostic proceduresMydriasis and vasoconstriction: 1 drop of 2.5% or 10% solution, repeated in one hour if necessary. Chronic mydriasis: 1 drop of a 2.5% or 10% solution 2 - 3 times a day. Uveitis with posterior synechiae (treatment) or synechiae, posterior (prophylaxis): 1 drop of a 2.5% or 10% solution, repeated in one hour if necessary, not to exceed three times a day. Treatment may be continued the following day, if necessary
Phenylephrine HCl 10% Eye DropsS01FB01110D2002XXBFor pupillary dilation in uveitis, for refraction without cyclopegic. For fundoscopy and other diagnostic proceduresMydriasis and vasoconstriction: 1 drop of 2.5% or 10% solution, repeated in one hour if necessary. Chronic mydriasis: 1 drop of a 2.5% or 10% solution 2 - 3 times a day. Uveitis with posterior synechiae (treatment) or synechiae, posterior (prophylaxis): 1 drop of a 2.5% or 10% solution, repeated in one hour if necessary, not to exceed three times a day. Treatment may be continued the following day, if necessary
Phenytoin Sodium 100 mg CapsuleN03AB02520C1002XXBEpilepsyADULT and CHILD more than 6 years: 300-400 mg/day in 3 - 4 divided doses before meals. Maximum: 600 mg/day. CHILD: Initially 5 mg/kg/day in 2 - 3 divided doses. Maintenance: 4 - 8 mg/kg/day. Maximum: 300 mg/day
Phenytoin Sodium 125 mg/5ml SuspensionN03AB02520L8001XXBEpilepsyADULT: Patients with no previous treatment may be started on 1 teaspoonful or 5 mL (125 milligrams) 3 times daily. It is then individualized to the patient. An increase to 5 teaspoonfuls (625 milligrams) may be made if necessary. CHILD: Initially 5 mg/kg/day in 2 - 3 divided doses. Maintenance: 4 - 8 mg/kg/day. Maximum: 300 mg/day. Children over 6 years and adolescents may require the minimum adult dose (300mg/day).
Phenytoin Sodium 30 mg CapsuleN03AB02520C1001XXBEpilepsyADULT and CHILD more than 6 years: 300-400 mg/day in 3 - 4 divided doses before meals. Maximum: 600 mg/day. CHILD: Initially 5 mg/kg/day in 2 - 3 divided doses. Maintenance: 4 - 8 mg/kg/day. Maximum: 300 mg/day
Phenytoin Sodium 50mg/ml lnjectionN03AB02520P3001XXBStatus epilepticusi) Status epilepticus: ADULT 10 - 15 mg/kg by slow IV. Maximum 50 mg/minute. Maintenance: 100 mg orally/IV every 6 - 8 hours. CHILD 15 - 20 mg/kg by slow IV. Maximum: 1 - 3 mg/kg/minute ii) Neurosurgery 100 - 200 mg IM approximately at 4 hourly interval
Phosphate Solution containing Sodium Acid Phosphate 1.936 g /15 mlB05XA09902L5001XXAFor supplemental ionic phosphorus for correction of hypophosphataemiaAccording to the needs of the patient
Phyllanthus Niruri Extract 250 mg CapsuleHA05BA5999C1001XXA/KKLiver tonic2 capsules to be taken orally, 3 times a day, before or after meals
Pilocarpine 1% Eye DropsS01EB01110D2001XXBMiotics in chronic open-angle glaucoma1 drop 1 - 4 times a day
Pilocarpine 2% Eye DropsS01EB01110D2002XXBMiotics in chronic open-angle glaucoma1 drop 1 - 4 times a day
Pilocarpine 4% Eye DropsS01EB01110D2003XXBMiotics in chronic open-angle glaucoma1 drop 1 - 4 times a day
Piperacillin 4 g & Tazobactam 500 mg InjectionJ01CR05961P3001XXA*Febrile neutropenia, lower respiratory tract infection and severe sepsisAdult and children more than 12 years: 4.5g 6 hourly, for neutropenia adult and children more than 50kg: 4.5g 6 hourly. Children less than 50kg: 90mg/kg 6 hourly
Piperacillin Sodium 4 g InjectionJ01CA12520P4002XXAInfections due to Pseudomonas aeruginosaADULT: 100 - 150 mg/kg IM/IV in divided doses. Increase to 200 - 300 mg/kg in severe infections & at least 16 g in life-threatening infections. Single dose over 2 g: IV route only. Maximum: 24 g/day. CHILD: 50-75 mg/kg/dose every 6 - 8 hourly
Piracetam 1 g InjectionN06BX03000P3001XXA*Treatment of cerebral functional impairment30 - 160 mg/kg/day orally or parenterally 2 times daily or 3 to 4 times daily. Maximum: 24 g/day
Piracetam 1.2 g TabletN06BX03000T1001XXA*Mild cognitive impairment, post concussional head syndrome, head injury disorder, chronic vertigo and myoclonusInitially 7.2 g daily in 2 - 3 divided doses, increased according to response by 4.8 g daily every 3 - 4 days to maximum of 20 g daily. CHILD under 16 years not recommended
Piracetam 20% SolutionN06BX03000L5001XXA*Children with learning disability, progressive myoclonic epilepsy and hypoxia30 - 160 mg/kg/day orally. To be given 2 times daily or 3 - 4 times daily. Maximum 24 g/day
Piribedil 50 mg TabletN04BC08000T5001XXA*Parkinson diseaseAs monotherapy: 150 - 250 mg as 3 - 5 divided doses daily. As combination with L-dopa therapy: 50 - 150 mg daily (50 mg per 250 mg of L-dopa)
Piroxicam 10 mg CapsuleM01AC01000C1001XXA/KKi) Rheumatoid arthritis, osteoarthritis, ankylosing spondylitis ii) Acute musculoskeletal disorders iii) Acute gouti) 20 mg daily, maintenance 10 - 30 mg daily, in single or divided doses ii) 40 mg daily in single or divided doses for 2 days, then 20 mg daily for 7 - 14 days iii) 40 mg initially, then 40 mg daily in single or divided doses for 4 - 6 days
Pizotifen 0.5 mg TabletN02CX01253T1001XXBProphylactic treatment of vascular headacheStarting with 0.5mg daily, the dosage should be progressively increased. The average maintenance dosage is 1.5mg daily in divided doses or as a single dose at night. Max dose: 4.5 mg/day and 3 mg/dose. Child: >2 yr: Up to 1.5 mg daily in divided doses. Max dose: 1 mg/dose.
Pneumococcal Vaccine (Polyvalent)J07AL01000P3001XXAPrevention of pneumococcal infections in high risk subjects from the age of 2 years including patient with a history of splenectomy or scheduled splenectomyPrimary injection: 1 single injection (0.5 ml) only. Booster: Must not be given within 5 years except in very high risk patient who received the vaccine while under immunosuppressive treatment
Podophyllum 10 - 20% PaintD06BB04000L7001XXBExternal anogenital wartsApply 2 - 3 drops carefully to lesion after protecting surrounding area with vaseline. Wash off after 6 hours or if feel burning sensation and repeat 2 - 3 times weekly or once weekly
Policresulen 360 mg/g ConcentrateG01AX03900L9901XXALocal treatment of cervical and vaginal inflammation and tissue damage eg. discharge due to bacterial, trichomonal and fungal infections, protrusions of endocervical mucosa (erosion), haemostasis following biopsy or excision of uterine polypsFor cauterization, undiluted once or twice weekly whilst for vaginal douches, to be diluted 1 part concentrate to 5 parts of water
Poliomyelitis Oral Live Vaccine (10 Doses)J07BF02000D5001XXC+Immunisation against poliomyelitisTwo drops (0.1 ml). Primary immunization: 1 oral dose at 3,4 & 5 month of age. Booster doses at 1-4 years & 7 years.
Polycitra SyrupA12BA02955L9001XXCFor treatment of calcium and uric acid stonesThe usual dose of potassium citrate is 30 - 60 mEq/day orally in 3 or 4 doses with meals or within 30 minutes after meals. ADULT: 15 ml 3 times daily well diluted with water. CHILD 5-15 ml 3 times daily, after meals and at bedtime.
Polyethylene Glycol /Macrogol 4000 PowderA06AD15000F2101XXABowel cleansing prior to colonoscopy, radiological examination or colonic surgery. Suitable for patients with heart failure or renal failure1 sachet dissolved in 1 L of water. 2-3 L of oral solution are required. When morning surgery is planned, the oral solution is given in the late afternoon the day prior. If surgery is scheduled in afternoon, the oral solution should be given on the same day for ingestion to be completed three hours before surgery
Polymyxin B Sulphate 10,000 U, Neomycin Sulphate 5 mg and Hydrocortisone 10 mg Ear DropsS02CA03991D1001XXBTreatment of bacterial infection and inflammation of the external auditory meatus3 drops 3 - 4 times daily. External auditory meatus and canal to be thoroughly cleansed and dried before each application but soap should not be used as the antibiotics may be inactivated by it
Potassium Chloride 0.15% w/v & Sodium Chloride 0.9% w/v InjectionA06AD10921L9902XXBPrevention and treatment of potassium, sodium and chloride depletionDosage depends on the age, weight, clinical and biological (acid-base balance) conditions of the patient and concomitant therapy. Maximum recommended dose of potassium is 2 to 3 mmol/kg/24hr
Potassium Chloride 1 g/10 ml InjectionB05XA01100P3001XXBFor the correction of severe hypokalaemia and when sufficient potassium cannot be taken by mouthBy slow IV infusion depending on the deficit or the daily maintenance requirements. 1 g diluted in 500 ml normal saline or glucose and given slowly over 2 - 3 hours
Potassium Chloride 1 g/15 ml MixtureA12BA01100L2101XXCPotassium depletion1 g once or twice daily until serum potassium is restored
Potassium Chloride 600 mg SR TabletA12BA01100T5001XXBFor the treatment and specific prevention of hypokalaemiaADULT: 2 - 3 tablets daily. Severe deficiency: 9 - 12 tablets daily or according to the needs of the patient
Potassium Citrate 3 g/10 ml and Citric Acid MixtureA12BA02955L2101XXCFor systemic or urine alkalinizationADULT: 15-30 ml well diluted with water. CHILD up to 1 year: 2.5 ml 3 times daily; 1 - 5 years: 5 ml 3 times daily; 6 - 12 years: 10 ml 3 times daily. To be taken well diluted with water, after meals and at bedtime.
Potassium Dihydrogen Phosphate InjectionB05XA06170P3001XXAFor treatment of hypophosphataemiaUp to 10mmol phosphate administered over 12 hours
Potassium Iodide MixtureH03CA00200L2101XXBPre-operative management of hyperthyroidism and thyrotoxicosisADULT and CHILD: 50 - 250 mg 3 times daily
Potassium Permanganate 1:10,000 SolutionD08AX06362L9901XXC+Cleansing and deodorising suppurative eczematous reactions and woundsAs soaks or wet dressing 1 - 3 times daily or as required
Potassium Permanganate 1:20,000 SolutionD08AX06362L9902XXCCleansing and deodorising suppurative eczematous reactions and woundsAs a bath once to twice daily or as required
Povidone Iodine 10% (equivalent to 1% iodine) SolutionD08AG02000L9902XXBSkin operation prior to surgery, in cleansing open wounds, as an antiseptic for operative wounds infectionsTo be applied undiluted in pre-operative skin disinfection and general antisepsis.
Povidone Iodine 7.5% (equivalent to 0.75% iodine) ScrubD08AG02000L9901XXBAs preoperative scrub for hands and skinSpread 5 ml over both hands and rub thoroughly for about 5 minutes. Rinse thoroughly. Repeat if desired. Pre-operative use on patient: Apply scrub and rub thoroughly for about 5 minutes. Rinse off using a sterile gauze saturated with water
Pralidoxime 25 mg/ml InjectionV03AB04000P3002XXBAntidote in the treatment of organophosphorus insecticide poisoning and in the control of overdosage by anticholinergic drugs used in the treatment of myasthenia gravisAdult: Used in combination with atropine. Admin atropine via IM/IV inj and repeat as needed until patient shows signs of atropine toxicity. Maintain atropinisation for at least 48 hr. As soon as the effects of atropine are observed, 1-2 g of pralidoxime (chloride, iodide or mesilate) may be given via IM/IV inj. Repeat dose after 1 hr, then every 8-12 hr, if necessary. In severe poisoning, continuous infusion of 200-500 mg/hr may be given, titrated according to response. Alternatively, pralidoxime chloride may be given at an initial dose of 30 mg/kg via IV infusion over 20 minutes or IV inj over 5 minutes, followed by IV infusion at 8 mg/kg/hr. Max: 12 g/24 hr. Child: As mesilate: 20-60 mg/kg. Renal impairment: Dose adjustment may be required.
Pramipexole Dihydrochloride 0.125 mg TabletN04BC05110T1001XXA*Treatment for signs and symptoms of advanced idiopathic Parkinson's disease. It may be used as monotherapy or in combination with levodopaDose escalation: 0.125 mg 3 times daily on week 1 then 0.25 mg 3 times daily week 2 then 0.5 mg 3 times daily on week 3. Increase by 0.75 mg at weekly intervals if needed up to maximum of 4.5 mg/day. Patient on levodopa: Reduce dose. Renal impairment: In patient with creatinine clearance < 20ml/min, the daily dose of pramipexole should be started at 0.125 mg daily instead of 0.25mg and the maximum dose should not > 1.5 mg daily
Pramipexole Dihydrochloride 1 mg TabletN04BC05110T1002XXA*Treatment for signs and symptoms of advanced idiopathic Parkinson's disease. It may be used as monotherapy or in combination with levodopaDose escalation: 0.125 mg 3 times daily on week 1 then 0.25 mg 3 times daily week 2 then 0.5 mg 3 times daily on week 3. Increase by 0.75 mg at weekly intervals if needed up to maximum of 4.5 mg/day. Patient on levodopa: Reduced dose. Renal impairment: In patient with creatinine clearance < 20ml/min, the daily dose of pramipexole should be started at 0.125 mg daily instead of 0.25mg and the maximum dose should not > 1.5 mg daily
Pramipexole Dihydrochloride Extended Release 0.375mg TabletN04BC05110T5001XXATreatment for signs and symptoms of advanced idiopathic Parkinson's disease. It may be used as monotherapy or in combination with levodopaDose escalation: 0.375 mg/day on week 1, 0.75 mg/day on week 2, 1.5 mg/day on week 3. Increase by 0.75 mg at weekly intervals if needed up to a max of 4.5 mg/day. Patient on l-dopa: reduce dose. Renal Impairment: CrCl 30-50 mL/min Initially 0.375 mg every other day. May be increased by 0.375 mg at weekly intervals to max 2.25 mg/day
Pramipexole Dihydrochloride Extended Release 1.5mg TabletN04BC05110T5003XXATreatment for signs and symptoms of advanced idiopathic Parkinson's disease. It may be used as monotherapy or in combination with levodopaDose escalation: 0.375 mg/day on week 1, 0.75 mg/day on week 2, 1.5 mg/day on week 3. Increase by 0.75 mg at weekly intervals if needed up to a max of 4.5 mg/day. Patient on l-dopa: reduce dose. Renal Impairment: CrCl 30-50 mL/min Initially 0.375 mg every other day. May be increased by 0.375 mg at weekly intervals to max 2.25 mg/day
Prasugrel HCl 10 mg TabletB01AC22110T1002XXA*Co-administered with aspirin, is indicated to reduce the rate of thrombotic cardiovascular (CV) events (including stent thrombosis) in patients with acute coronary syndromes who are to be managed with percutaneous coronary intervention (PCI) as follows: STEMI with or without diabetes, UA and NSTEMI with diabetes, age <75yrs old, weight >60kg, without history of TIA stroke and clinically suspected clopidogrel resistance subset. (Only to be used in Cardiology Centre as third line treatment/ adjunctive therapy).Initiate treatment with a single 60mg oral loading dose. Continue at 10mg/5mg once daily with or without food. Patients should also take aspirin (75 mg - 325 mg) daily.
Pravastatin Sodium 20 mg TabletC10AA03520T1001XXA/KKHypercholesterolaemia and coronary heart disease intolerant or not responsive to other forms of therapy. In health clinics, Pravastatin is restricted to HIV patients on HAART.10 - 20 mg once daily. Maximum: 40 mg daily
Prazosin HCl 1 mg TabletC02CA01110T1001XXBHypertensionInitially 0.5 mg 2 - 3 times daily, the initial dose on retiring to bed at night; increased to 1 mg 2 - 3 times daily after 3 - 7 days: further increased if necessary to maximum 20 mg daily
Prazosin HCl 2 mg TabletC02CA01110T1002XXBHypertensionInitially 0.5 mg 2 - 3 times daily, the initial dose on retiring to bed at night; increased to 1 mg 2 - 3 times daily after 3 - 7 days: further increased if necessary to maximum 20 mg daily
Prazosin HCl 5 mg TabletC02CA01110T1003XXBHypertensionInitially 0.5 mg 2 - 3 times daily, the initial dose on retiring to bed at night; increased to 1 mg 2 - 3 times daily after 3 - 7 days: further increased if necessary to maximum 20 mg daily
Pre/Post Natal Vitamin & Mineral CapsuleA11AA03903C1001XXC+Vitamin and mineral supplement for use during pregnancy and lactation1 capsule daily or based on individual requirements
Pre/Post Natal Vitamin & Mineral TabletA11AA03903T1001XXC+Vitamin and mineral supplement for use during pregnancy and lactation1 tablet daily or based on individual requirements
Prednisolone 3 mg/5 ml SyrupH02AB06000L9001XXBi) Replacement therapy for primary and secondary adrenocortical insufficiency ii) Adrenogenital syndrome iii) Other therapyi) 5 - 25 mg daily in divided doses ii) 10 - 20 mg/m2 body surface daily in divided doses iii) ADULT: 5 - 60 mg daily. CHILD: 0.5 - 2 mg/kg/day in divided doses every 6 - 8 hours or as a single daily
Prednisolone 5 mg TabletH02AB06000T1001XXBi) Replacement therapy for primary and secondary adrenocortical insufficiency ii) Adrenogenital syndrome iii) Other therapyi) 5 - 25 mg daily in divided doses ii) 10 - 20 mg/m2 body surface daily in divided doses iii) ADULT: 5 - 60 mg daily. CHILD: 0.5 - 2 mg/kg/day in divided doses every 6 - 8 hours or as a single daily
Pregabalin 150 mg CapsulesN03AX16000C1002XXA*i) Second line treatment of neuropathic pain in patients who do not response to first line drugs ii) Fibromyalgiai) Initially, 75 mg twice daily. May be increased to 150 mg twice daily after 3-7 days. Max: 600 mg/day after an additional 7-day interval ii) Initially, 75 mg twice daily. May be increased to 150 mg twice daily within 1 week or 225 mg twice daily. Max: 450 mg/day
Pregabalin 75 mg CapsuleN03AX16000C1001XXA*i) Second line treatment of neuropathic pain in patients who do not response to first line drugs ii) Fibromyalgiai) Initially, 75 mg twice daily. May be increased to 150 mg twice daily after 3-7 days. Max: 600 mg/day after an additional 7-day interval ii) Initially, 75 mg twice daily. May be increased to 150 mg twice daily within 1 week or 225 mg twice daily. Max: 450 mg/day
Primaquine 7.5 mg base TabletP01BA03162T1001XXBi) Treatment of malaria ii) Prophylaxis together with a schizonticide such as chloroquinei) 15 mg daily for 14 days, increased to higher doses or longer course if resistance in P.vivax occurs. ii) ADULT: 30 mg once weekly. CHILD: 0.5 mg once weekly Child: 250 mcg/kg daily for 14 days. Should be taken with food. Take with meals to avoid GI discomfort.
Primidone 250 mg TabletN03AA03000T1001XXBEpilepsyADULT: Initially 1 tablet daily in the evening, increasing by 1 tablet every 4 - 7 days to 3 - 4 tablets daily. Maximum dosage: 1.5 g daily in divided doses. CHILD: 6 - 8 years: Up to 1/2 adult dose
Probenecid 500 mg TabletM04AB01000T1001XXAHyperuricemia associated with gout and gouty arthritis (for cases allergic to allopurinol or serum uric acid not controlled by allopurinol alone)500 mg to 1000 mg twice daily
Procaine Benzylpenicillin Aqueous 3 mega units (3 g) InjectionJ01CE09702P4001XXBTreatment of infections due to Penicillin G-sensitive organismsADULT: 300,000 - 900,000 units (300 - 900 mg) IM daily. CHILD: Up to 1 year: 150 mg IM daily. 1 - 5 years: 300 mg IM daily. 6 - 12 years: 600 mg IM daily
Procaine Penicillin Fortified 4 MU InjectionJ01CE09702P4002XXBTreatment of infections due to Penicillin G-sensitive organismsADULT: 300,000 - 900,000 units (300 - 900 mg) IM daily. CHILD: Up to 1 year: 150 mg IM daily. 1 - 5 years: 300 mg IM daily. 6 - 12 years: 600 mg IM daily
Procarbazine HCl 50 mg CapsuleL01XB01110C1001XXALymphomasAdult: Monotherapy: Initially, 50 mg/day, increased by 50 mg daily to 250-300 mg daily in divided doses. Continue doses until max response is achieved or appearance of signs of toxicity. Maintenance: 50-150 mg/day or 1-2 mg/kg daily until a cumulative dose of at least 6 g. Combination Therapy: 100 mg/m2 on days 1-14 of each 4- or 6-wk cycle. Child: Initially, 50 mg/m2 daily, up to 100 mg/m2 adjust according to response.
Prochlorperazine Maleate 5mg TabletN05AB04253T1002XXBi) Severe nausea and vomiting ii) Vertigo/labyrinthine disordersNausea and vomiting Adult: As maleate or mesilate: 20 mg, further doses are given if needed. Recommended buccal dose: As maleate: 3-6 mg bid. Vertigo Adult: As maleate or mesilate: 15-30 mg daily, given in divided doses. May reduce gradually to 5-10 mg daily. Recommended buccal dose: 3-6 mg bid. May be taken with or without food.
Prochlorperazine Mesylate 12.5 mg/ml InjectionN05AB04253P3001XXBi) Severe nausea and vomiting ii) Vertigo/labyrinthine disordersDeep IM injection, 12.5 mg repeated if necessary after 6 hours and then followed by an oral dose. Not recommended in children
Procyclidine HCl 5 mg/ ml InjectionN04AA04110P3001XXBi) All forms of Parkinson's disease (idiopathic paralysis agitants), post-encephalitis and arteriosclerosis ii) To control troublesome extrapyramidal symptoms induced by neuroleptic drugs including pseudo-parkinsonism, acute dystonic reactions and akathisiai) Initial dose 2.5mg TDS, increasing by 2.5-5mg/day at intervals of 2 or 3 days until the optimum clinical response is achieved. Usual maintenance dose: 15-30mg/day. Max: 60mg/day ii) Initial dose 2.5mg TDS, increasing by 2.5mg daily until symptoms are relieved. Usual maintenance dose: 10-30mg/day. IV Emergency: 5-10 mg. IM Emergency: 5-10 mg as a single dose, may repeat after 20 mins if needed. Max: 20 mg/day.
Progesterone 100 mg capsuleG03DA04000C1001XXA*Supplementation of the luteal phase200-300mg daily orally. For supplementation of the luteal phase during in IVF, 400-600mg per day in 2-3 divided doses to be insert vaginally.
Progesterone 8% Vaginal GelG03DA04000G3001XXA*Treatment of infertility due to inadequate luteal phase90 mg intravaginally daily from day of egg retrieval till pregnancy established
Prolase TabletM09AB00000T1001XXBOedema and inflammation in conjunction with other physical or chemotherapeutic measures2 tablet 4 times daily
Promethazine HCl 25 mg/ml InjectionR06AD02110P3001XXBAllergic conditionsBy deep IM: ADULT: 25 - 50 mg, maximum 100 mg. CHILD: 5 - 10 years : 6.25 - 12.5 mg. By slow IV: 25 - 50 mg in a solution of 2.5 mg/ml in water for injection. Maximum 100 mg
Promethazine HCl 5 mg/5 ml SyrupR06AD02110L9001XXBAllergic conditionsCHILD 2 - 5 years: 5 - 15 mg daily, 5 - 10 years : 10 - 25 mg daily
Proparacaine HCI 0.5% Ophthalmic DropsS01HA04110D2001XXBTopical anaesthesia in ophthalmic proceduresDeep anaesthesia:1 or 2 drops in the (eyes) every 5 to 10 minutes for 3 to 5 doses. For minor surgical procedures: instill 1 to 2 drops every 5 to 10 minutes for 1 to 3 doses. Tonometry and/or tonography procedure: 1 to 2 drops in each eye before procedure.
Propiverine HCl 15 mg TabletG04BD06110T1001XXA*Treatment of urinary incontinence, urgency and frequency in neurogenic detrusor overactivity (detrusor hyperreflexia) and in idiopathic detrusor overactivity (overactive bladder)ADULT: 15 mg twice daily to 3 times daily, increase to 4 times daily if required. Max dose: 60 mg daily. CHILD more than 5 years: 0.2 to 0.4 mg/kg per day in 2 divided doses
Propofol 10mg/ml (1%) InjectionN01AX10000P9901XXA*Induction & maintenance of general anaesthesia. Sedation of ventilated ICU patientsAdult: Induction: 20- 40 mg by injection or infusion every 10 sec. Usual dose: 1.5-2.5 mg/kg. Maintenance: 4-12 mg/kg/hr or intermittent bolus inj of 20-50 mg. Child: >8 yr: Induction dose of 2.5 mg/kg. Maintenance dose: 9-15 mg/kg/hr by IV infusion or intermittent bolus inj. Elderly: Including neurosurgical and debilitated patients: Infuse at a rate of 20 mg every 10 sec. Maintenance: 3-6 mg/kg/hr. Usual dose needed: 1-1.5 mg/kg. Duration of use : Can be administered for a maximum period of 7 days. Sedation: 0.3 - 4 mg/kg/hour up to 3 days
Propofol 20mg/ml (2%) emulsion for injection of infusionN01AX10000P9902XXA*Induction & maintenance of general anaesthesia. Sedation of ventilated ICU patientsAdult: IV Induction and maintenance of general anesth Induction: 40 mg every 10 sec. Maintenance: 4-12 mg/kg/hr or intermittent boluses of 20-50 mg. Sedation In diagnostic and surgical procedures: Initial: 6-9 mg/kg/hr by infusion. Maintenance: 1.5-4.5 mg/kg/hr. For ventilated patients: 0.3-4 mg/kg/hr. Monitor lipid concentrations if duration of sedation >3 days.
Propranolol HCl 1 mg/ml InjectionC07AA05110P3001XXAArrhythmias and thyrotoxicosis crisisSlow IV injection in a dose of 1 mg over 1 minute, repeated if necessary every 2 minutes until a maximum of 10 mg has been given in conscious patients and 5 mg in patients under anaesthesia. CHILD: 25 - 50 mcg/kg slow IV with appropriate monitoring
Propranolol HCl 10 mg TabletC07AA05110T1001XXBDysrythmias, tachycardia, hypertrophic obstructive cardiomyopathy (For cardiologist only)10 - 40 mg 3 - 4 times daily
Propranolol HCl 40 mg TabletC07AA05110T1002XXBi) Hypertension ii) Angina iii) Myocardial infarct iv) Cardiac arrhythmia v) Portal hypertension vi) Migraine vii) Thyrotoxicosisi) Initially 80 mg twice daily increased as required to a usual range of 160 - 320 mg daily. CHILD: Initial doses of 1 mg/kg in divided doses, can be increased to 2 - 4 mg/kg/day in divided doses ii) Initial dose of 40 mg 2 - 3 times daily. Maintenance 120 - 240 mg daily iii) 40mg 4 times daily for 2 - 3 days then 80 mg twice daily, beginning 5 - 21 days after infarction iv) 10 - 40 mg 3 - 4 times daily v) Initially 40 mg twice daily. The dose may be increased as required up to 160 mg twice daily vi) Initial prophylaxis dose: 40 mg 2 - 3 times daily. The dose may be increased at weekly intervals up to 160 mg daily vii) Adjunct: 10 - 40 mg 3 - 4 times daily. CHILD: Arrythmias, thyrotoxicosis: 0.25 - 0.5 mg/kg 3 - 4 times daily as required
Propylthiouracil 50 mg TabletH03BA02000T1001XXBHyperthyroidismADULT Initially 300-450mg in 8 hourly intervals (can be given up to 600-900mg/daily) until symptoms are controlled in 1-2 months. Maintenance 50-150mg daily for at least 12-18 months. CHILDREN 6-10 years: 50-150mg. CHILDREN > 10 years: 150-300mg daily. All doses are to be given in 3 divided doses daily. Taken with food.
Protamine Sulphate 10 mg/ml InjectionV03AB14183P3001XXBHeparin overdose and following cardiac or arterial surgery or dialysis procedures when required to neutralize the effects of heparin administered during extracorporeal circulation5 ml slow IV injected over 10 minutes. If administered within 15 minutes of heparin dose, 1 mg will neutralise approximately 100 units of heparin. If longer time has elapsed, less protamine is required. Not more than 50 mg should be injected at any one time. The dose is dependent on the amount and type of heparin to be neutralised, its route of administration and the time elapsed since it was last given and blood coagulation studies.
Protein Free Haemodialysate 10% JellyD03AX00000G4001XXATrophic lesions in patients with arterial occlusive disease and with chronic venous insufficiency, burn injuries, impaired wound healing, decubitus ulcers and skin ulcer caused by irradiationApply 3 - 5 times daily
Protein Free Haemodialysate 20% Eye GelS01XA20000G3001XXAEyes disorders e.g. burns, scalds, ulcers, prevention and treatment of radiation dermatitis, traumatic and ischaemic woundInstill 1 drop 3 - 4 times daily
Protein Free Haemodialysate 5% OintmentD03AX00000G5001XXATrophic lesions in patients with arterial occlusive disease and with chronic venous insufficiency, burn injuries, impaired wound healing, decubitus ulcers and skin ulcer caused by irradiationApply 3 - 5 times daily
Protein Free Haemodialysate Dental Adhesive PasteD03AX00000G6001XXAPainful and inflammatory affliction on the oral mucosa, gums and lips, teething pain, denture pressure sores, oral and maxillofacial surgery and dressing after scalingApply to lesions 3 - 5 times daily
Pyrantel Pamoate 125 mg TabletP02CC01127T1001XXCIntestinal nematodesADULT and CHILD : 2 years and older - single dose 10mg/kg body weight once. Maximum 1 g
Pyrantel Pamoate 250 mg TabletP02CC01127T1002XXCIntestinal nematodesADULT and CHILD : 2 years and older - single dose 10mg/kg body weight once. Maximum 1 g
Pyrazinamide 500 mg TabletJ04AK01000T1001XXBTuberculosisAdult: 20-40mg/kg daily (max 1500mg) or 50mg/kg biweekly (max 2000mg). Children: 20-30mg/kg daily or 30-40mg/kg thrice weekly.
Pyridostigmine Bromide 60 mg TabletN07AA02320T1001XXBMyasthenia gravisADULT: 30 - 120 mg at suitable intervals throughout the day, total daily dose 0.3 - 1.2 g. CHILD up to 6 years initially 30 mg, 6 - 12 years initially 60 mg, usual total daily dose 30 - 360 mg
Pyridoxine HCl 10 mg TabletA11HA02110T1001XXC+i)Pyridoxine-dependent convulsions in infant ii)Sideroblastic anaemia iii)B6-deficient anaemia in adult iv) Prophylaxis to peripheral neuritis in isoniazid therapy v) Nausea and vomiting of pregnancy and irradiation sicknessi) INFANT 4 mg/kg daily for short periods ii) 100 - 400 mg daily in divided doses iii) ADULT 20 - 50 mg up to 3 times daily iv) Prophylaxis 10 mg daily, therapeutic 50 mg 3 times daily v) 20 - 100 mg daily
Pyridoxine HCl 50 mg/2 ml InjectionA11HA02110P3001XXBi) Pyridoxine-dependent convulsions in infancy ii) Sideroblastic anaemia iii) B6-deficient anaemia in adult iv) Prophylaxis to peripheral neuritis in isoniazid therapy v) Nausea and vomiting of pregnancy and irradiation sicknessi) INFANT 4 mg/kg daily for short periods ii) 100 - 400 mg daily in divided doses iii) ADULT 20 - 50 mg up to 3 times daily iv) Prophylaxis 10 mg daily, therapeutic 50 mg 3 times daily v) 20 - 100 mg daily
Quetiapine Fumarate 100 mg Immediate Release TabletN05AH04138T1002XXA*i) Schizophrenia ii) Short term treatment of acute manic episodes associated with bipolar I disorder, either monotherapy or adjunct to lithium or divalproex iii) Treatment of depressive episodes associated with bipolar disorderi) Initial titration schedule over 4 days: 25 mg twice daily on Day 1, increase in steps of 25 - 50 mg 2 to 3 times daily on Days 2 and 3 to reach target dose of 300 - 400 mg daily by Day 4, given in 2 - 3 divided doses. Institute further dose adjustments, if indicated, at intervals of 2 days or more, in steps of 25 - 50 mg twice daily ii) 100 mg (Day 1), 200 mg (Day 2), 300 mg (Day 3) & 400 mg (Day 4). Further dosage adjustments up to 800 mg/day by Day 6 should be in increments of not more than 200 mg/day. Adjust dose within the range of 200 - 800 mg/day depending on clinical response and tolerability of the patient. Usual effective dose range: 400 - 800 mg/day iii) 50 mg ORALLY once a day on Day 1, then 100 mg once daily on Day 2, then 200 mg once daily on Day 3, then 300 mg once daily on Day 4 (all doses given at bedtime); patients requiring higher doses should receive 400 mg on Day 5, increased to 600 mg on Day 8 (week 1)
Quetiapine Fumarate 200 mg Extended Release TabletN05AH04138T5002XXA*i)Schizophrenia ii) Moderate to severe manic episodes in bipolar disorder iii) Major depressive episodes in bipolar disorderi) & ii) 300 mg once daily on Day 1 then 600 mg on Day 2. Maintenance dose: 400 to 800 mg once daily. Maximum dose: 800 mg daily iii) 50 mg on Day 1, 100 mg on Day 2, 200 mg on Day 3 and 300 mg on Day 4. Recommended daily dose is 300 mg. May be titrated up to 600 mg daily. In elderly or hepatic impairment:Start with 50mg/ day, may be increased in increments of 50mg /day to an effective dose.
Quetiapine Fumarate 200 mg Immediate Release TabletN05AH04138T1004XXA*i) Schizophrenia ii) Short term treatment of acute manic episodes associated with bipolar I disorder, either monotherapy or adjunct to lithium or divalproex iii) Treatment of depressive episodes associated with bipolar disorderi) Initial titration schedule over 4 days: 25 mg twice daily on Day 1, increase in steps of 25 - 50 mg 2 to 3 times daily on Days 2 and 3 to reach target dose of 300 - 400 mg daily by Day 4, given in 2 - 3 divided doses. Institute further dose adjustments, if indicated, at intervals of 2 days or more, in steps of 25 - 50 mg twice daily ii) 100 mg (Day 1), 200 mg (Day 2), 300 mg (Day 3) & 400 mg (Day 4). Further dosage adjustments up to 800 mg/day by Day 6 should be in increments of not more than 200 mg/day. Adjust dose within the range of 200 - 800 mg/day depending on clinical response and tolerability of the patient. Usual effective dose range: 400 - 800 mg/day iii) 50 mg ORALLY once a day on Day 1, then 100 mg once daily on Day 2, then 200 mg once daily on Day 3, then 300 mg once daily on Day 4 (all doses given at bedtime); patients requiring higher doses should receive 400 mg on Day 5, increased to 600 mg on Day 8 (week 1)
Quetiapine Fumarate 300 mg Extended Release TabletN05AH04138T5003XXA*i) Schizophrenia ii) Moderate to severe manic episodes in bipolar disorder iii) Major depressive episodes in bipolar disorderi) & ii) 300 mg once daily on Day 1 and 600 mg on Day 2. Maintenance dose: 400 ? 800 mg once daily. Maximum dose: 800 mg daily iii) 50 mg on Day 1, 100 mg on Day 2, 200 mg on Day 3 and 300 mg on Day 4. Recommended daily dose is 300 mg. May be titrated up to 600 mg daily
Quetiapine Fumarate 400 mg Extended Release TabletN05AH04138T5004XXA*i) Schizophrenia ii) Moderate to severe manic episodes in bipolar disorder iii) Major depressive episodes in bipolar disorderi) & ii) 300 mg once daily on Day 1 and 600 mg on Day 2. Maintenance dose: 400 ? 800 mg once daily. Maximum dose: 800 mg daily iii) 50 mg on Day 1, 100 mg on Day 2, 200 mg on Day 3 and 300 mg on Day 4. Recommended daily dose is 300 mg. May be titrated up to 600 mg daily
Quetiapine Fumarate 50 mg Extended Release TabletN05AH04138T5001XXA*i)Schizophrenia ii)Moderate to severe manic episodes in bipolar disorder iii)Major depressive episodes in bipolar disorderi) & ii) 300 mg once daily on Day 1 then 600 mg on Day 2. Maintenance dose: 400 to 800 mg once daily. Maximum dose: 800 mg daily. iii)50 mg on Day 1, 100 mg on Day 2, 200 mg on Day 3 and 300 mg on Day 4. Recommended daily dose is 300 mg. May be titrated up to 600 mg daily. In elderly or hepatic impairment: Start with 50mg/ day, may be increased in increments of 50mg /day to an effective dose.
Quinine Dihydrochloride 600 mg/2 ml InjectionP01BC01110P3001XXBSevere and complicated malariaBy slow intravenous infusion (over 4 hours). ADULT : 20 mg/kg followed by 10 mg/kg every 8 hours. CHILD : 20 mg/kg followed by 10 mg/kg every 12 hours, initial dose should be half in patients who have received quinine, quinidine or mefloquine during the previous 12 or 24 hours
Quinine Sulphate 300 mg TabletP01BC01183T1001XXBSevere and complicated malaria300 - 600 mg daily. Treatment : 1.2 - 2 g daily in divided doses. CHILDS less than 1 year : 100 - 200 mg daily, 1 - 3 years : 200 - 300 mg daily, 4 - 6 years: up to 500 mg daily, more than 7 years : up to 1 g daily. All above doses are given for 7 days in 2 - 3 divided doses
Rabeprazole Sodium 20 mg TabletA02BC04520T1001XXA*i) Treatment and maintenance of erosive or ulcerative gastroesophageal reflux disease (GERD) ii) Duodenal ulcersi) 10-20 mg daily for 4-8 weeks, maintenance 10-20 mg daily ii) 20 mg daily at morning for up to 4-8 weeks
Rabies Human Diploid Cell Vaccine (Lyophilised) InjectionJ07BG01000P4001XXBPre-exposure and post-exposure vaccination against rabiesProphylaxis: 3 dose (1 ml each) schedule on D0, D7 and D28. Booster dose after every 2 - 3 years. Post exposure prophylaxis: use after attack of a potential rabid animal: 1 dose on D0, D3, D7, D14 and D28. In previously vaccinated individuals 2 doses on D0 and D3
Raloxifene HCl 60 mg TabletG03XC01110T1001XXA*Prevention and treatment of post menopausal osteoporosis1 tablet daily
Raltegravir 400 mg tabletJ05AX08500T1001XXA*Raltgeravir combination with other antiretroviral agents is indicated for the treatment of HIV-1 infection in patients who are contraindicated to boosted Protease Inhibitor or who are intolerant to boosted Protease Inhibitor.400mg administered orally, twice daily with or without food, to be given combination with other antiretroviral agent.
Ramipril 2.5 mg TabletC09AA05000T1001XXAi) Hypertension and congestive heart failure ii) Post-myocardial infarction iii) Reducing risk of myocardial infarction, stroke or cardiovascular death in diabetics or patients with increased cardiovascular risksi) Hypertension: Initially 2.5 mg once daily, increased at intervals of 1 - 2 weeks to maximum 10 mg once daily; Congestive heart failure:Initially 1.25 mg once daily. Max: 10 mg/day ii) Initially 2.5 mg twice daily for 2 days then increased to maximum 5 mg twice daily iii) Initially 1.25 - 2.5 mg once daily, increased to 5 mg once daily after 1 week, maximum dose: 10 mg once daily after 3 weeks
Ramipril 5 mg TabletC09AA05000T1002XXAi) Hypertension and congestive heart failure ii) Post-myocardial infarction iii) Reducing risk of myocardial infarction, stroke or cardiovascular death in diabetics or patients with increased cardiovascular risksi) Hypertension: Initially 2.5 mg once daily, increased at intervals of 1 - 2 weeks to maximum 10 mg once daily; Congestive heart failure:Initially 1.25 mg once daily. Max: 10 mg/day ii) Initially 2.5 mg twice daily for 2 days then increased to maximum 5 mg twice daily iii) Initially 1.25 - 2.5 mg once daily, increased to 5 mg once daily after 1 week, maximum dose: 10 mg once daily after 3 weeks
Ranibizumab 10 mg/ ml InjectionS01LA04000P3001XXA*Treatment of Neovascular (wet) Age-Related Macular Degeneration (ARMD)0.5 mg (0.05ml) as a single intravitreal Injection.Interval between 2 doses should not be shorter than 1 month, then monitor for visual acuity monthly. Treatment is given monthly & continued until max visual acuity is achieved, confirmed by stable visual acuity for 3 consecutive monthly assessments.
Ranitidine 150 mg TabletA02BA02110T1001XXBi) Benign gastric and duodenal ulcer ii) Reflux oesophagitis iii) Non-ulcer dyspepsia iv) Zollinger-Ellison Syndromei) 150 mg twice daily (at morning and night) or 300 mg on night for 4-8 weeks. Maintenance: 150-300 mg on night ii) 150 mg twice daily or 300 mg on night for 8-12 weeks iii) 150 mg daily or twice daily iv) 150 mg and may be increased as necessary to 6 g/day
Ranitidine 150 mg/10 ml SyrupA02BA02110L9001XXBPeptic ulcer diseaseCHILD 2-4 mg/kg 2 times daily. Maximum 300 mg daily
Ranitidine 25 mg/ml InjectionA02BA02110P3001XXBi) Benign gastric/ duodenal ulceration, reflux oesophagitis, Zollinger Ellison Syndrome ii) Stress ulcer prophylaxis in post-operative and high risk patientsi) ADULT: Slow IV injection of 50 mg diluted to 20 ml and given over at least 2 minutes. May be repeated every 6-8 hours or IV infusion at rate of 25 mg/hour for 2 hours, may be repeated at 6-8 hours intervals or IM. CHILD: 1 mg/kg/dose 6-8 hourly. ii) Initial slow IV injection of 50 mg, then continuous infusion of 125-250 mcg/kg/hour
Ranitidine 300 mg TabletA02BA02110T1002XXBi) Benign gastric and duodenal ulcer ii) Reflux oesophagitis iii) Non-ulcer dyspepsia iv) Zollinger-Ellison Syndromei) 150 mg twice daily (at morning and night) or 300 mg on night for 4-8 weeks. Maintenance: 150-300 mg on night ii) 150 mg twice daily or 300 mg on night for 8-12 weeks iii) 150 mg daily or twice daily iv) 150 mg and may be increased as necessary to 6 g/day
Recombinant Human Erythropoietin 4000 IU Injection (Prefilled Syringe)B03XA01000P5002XXAi) Treatment of anaemia associated with chronic renal failure. Dialysis patients who are haemoglobin less than 8 g or exhibiting symptoms of anaemia although haemoglobin more than 8 g and pre-transplant cases ii) Anaemia in cancer (non-myeloid malignancies) with concomitant chemotherapyi) ADULT by IV injection over 1-5 minutes, initially 50 units/kg 3 times weekly adjusted according to response in step of 25 units/kg 3 times weekly at interval of at least 4 weeks. CHILD initially as for adult. Maintenance, bodyweight under 10 kg usually 75-150 units/kg 3 times weekly, bodyweight 10-30 kg usually 60-150 units/kg 3 times weekly, bodyweight over 30 kg usually 30-100 units/kg 3 times weekly ii) ADULT by SC injection (max. 1 ml per injection site), initially 150 units/kg 3 times weekly, increased if appropriate rise in haemoglobin not achieved after 4 weeks to 300 units/kg 3 times weekly. Discontinue if inadequate response after 4 weeks at higher dose
Remifentanil 5 mg InjectionN01AH06110P4001XXA*i) As an analgesic agent for use during induction and/or maintenance of general anaesthesia during surgical procedures including cardiac surgery. ii)Continuation of analgesia into the immediate post-operative period under close supervision, during transition to longer acting analgesia. iii)Provision of analgesia and sedation in mechanically ventilated intensive care patients.For IV use only. ADULT: Induction:Bolus infusion: 1µg/kg over 30-60 seconds; Continuous infusion: 0.5-1µg/kg/min; Maintenance: Continuous infusion: 0.025 to 2 µg/kg/min. CHILD (1-12 years of age): Induction: Insufficient data; Neonates: IV infusion 0.4-1.0 mcg/kg/minute depending on the anaesthetic method and adjust according to patient response, supplemental IV inj of 1 mcg/kg dose may be given. 1-12 yr: initially 0.1-1 mcg/kg by IV inj over at least 30 seconds (excluded if not needed), followed by IV infusion 0.05-1.3 mcg/kg/minute depending on the anaesthetic method and adjust according to patient response, supplemental IV bolus inj may be admin during infusion. 12-18 yr: 0.1-1 mcg/kg IV inj over at least 30 seconds (excluded if not needed), followed by IV infusion of 0.05-2 mcg/kg/minute depending on anaesthetic method and adjust according to patient response, supplemental IV bolus inj may be admin during infusion.
Repaglinide 2 mg TabletA10BX02000T1001XXA*Type 2 diabetes mellitus (as monotherapy or in combination with metformin when metformin alone is inadequate)OHA naïve patient: Start dose with 0.5mg per meal Patients transferred from another oral hypoglycaemic agent: Start dose with 0.5-1mg per meal In combination with metformin: Start dose as 0.5mg per meal Titrate every 1-2weeks according to blood glucose response. Max single dose: 4mg before each main meal. Max total daily dose: 16mg. Doses to be taken within 30 minutes of meals, 2-4 meals a day
Ribavirin 200 mg CapsuleJ05AB04000C1001XXA*For the treatment of chronic hepatitis C (in combination with interferon alfa-2a/2b)ADULT (more than 18 years old): 50mg/kg/day Recommended: Body weight: ≤ 75kg should receive 1000mg daily as two 200mg capsules in the morning and three 200mg capsules in the evening Body weight: >75kg should receive 1200mg as three 200mg capsules in the morning and three 200mg capsules in the evening Genotype 1,4: 48 weeks Genotype: 24 weeks duration should be individualized in accordance with the baseline characteristics of the disease.
Riboflavine 3 mg TabletA11HA04000T1001XXCFor prevention and treatment of riboflavine deficiencyCHILD: 2.5-10 mg/day in divided doses. ADULT: 5-30 mg/day in divided doses
Rifampicin 100 mg/5 ml SyrupJ04AB02000L9001XXATuberculosis and leprosyCHILD: 20 mg/kg body weight daily in 1 - 2 doses. Up to 1 year: 10 mg/kg body weight in a single daily dose
Rifampicin 150 mg CapsuleJ04AB02000C1001XXBi) Tuberculosis ii) Leprosy iii) Prophylaxis for meningococcal meningitisi) ADULT: 450 - 600 mg as a single morning dose. CHILD: 10 - 20 mg/kg body weight daily in 1 - 2 doses. Directly observed therapy (DOT): 10 mg/kg twice weekly or 3 times/week. Maximum: 600 mg ii) 600 mg/day iii) 600 mg twice daily for 2 days
Rifampicin 150 mg, Isoniazid 75 mg & Pyrazinamide 400 mg TabletJ04AM05000T1001XXBInitial phase (2 months) of tuberculosis treatmentPatient more than or 71 kg: 5 tab/day, 55 -70 kg: 4 tab/day, 38-54 kg: 3 tab/day, 30-37 kg: 2 tab/day. To be taken as a single dose
Rifampicin 150 mg, Isoniazid 75 mg, Pyrazinamide 400 mg & Ethambutol HCl 275 mg TabletJ04AM06000T1001XXBTreatment of both pulmonary and extrapulmonary tuberculosis, in the intensive treatment phaseADULT: 30 - 37 kg: 2 tablets daily, 38 - 54 kg: 3 tablets daily, 55 - 70 kg: 4 tablets daily, more than 70 kg: 5 tablets daily
Rifampicin 150mg + Isoniazid 75mg tabletJ04AM02000T1001XXBFor pulmonary tuberculosis in which organisms are susceptible in continuation phase treatment for 4 months30-37kg: 2 tablets once daily, 38-54kg: 3 tablets once daily, 55-70kg: 4 tablets once daily, Above 70kg: 5 tabs once daily
Rifampicin 300 mg CapsuleJ04AB02000C1002XXBi) Tuberculosis ii) Leprosy iii) Prophylaxis for meningococcal meningitisi) Tuberculosis ADULT: Daily doses: 10mg/kg/day Body weight doses: 10-15/kg/day CHILD: 10 - 20 mg/kg body weight daily in 1 - 2 doses. Maximum daily dose : 600mg Directly observed therapy (DOT): 10 mg/kg twice weekly or 3 times/week. Maximum: 600 mg ii) Leprosy: ADULT: 600 mg/day CHILDREN: 10mg/kg iii) Prophylaxis for meningococcal meningitis: ADULT: 600 mg twice daily for 2 days CHILDREN: 10mg/kg twice daily for 2 days INFANT: 5mg/kg twice daily for 2 days"
Rifampicin, Dapsone & ClofazimineJ04AM02961T9901XXBFor the treatment of leprosy and tuberculosisRifampicin: 600 mg once monthly, Dapsone: 100 mg daily, Clofazimine: 300 mg once monthly and 50 mg daily (or 100 mg on alternate days)
Ringers Solution (contained sodium chloride, potassium chloride and calcium chloride)B05XA30905P6001XXBAs a source of electrolytes and water for hydration/replenishing of chlorideAccording to the needs of the patient
Risperidone 1 mg TabletN05AX08000T1001XXBPsychoses and schizophreniaADULT : 2 mg in 1 - 2 divided doses on first day then 4 mg in 1 - 2 divided doses on 2nd day then 6 mg in 1 - 2 divided doses on 3rd day (slower titration appropriate in some patients); usual range 4 - 8 mg daily; dose above 10 mg daily only if benefit outweigh risk (maximum 16 mg daily). Elderly (or in hepatic or renal impairment): initially 0.5 mg twice daily increased in steps of 0.5 mg twice daily to 1 - 2 mg twice daily. Not recommended in children under 15 years
Risperidone 1 mg/ml Oral SolutionN05AX08000L5001XXAPsychoses and schizophreniaADULT: 2 mg in 1 - 2 divided doses on 1st day then 4 mg in 1 - 2 divided doses on 2nd day then 6 mg in 1 - 2 divided doses on 3rd day (slower titration appropriate in some patients); usual range 4 - 8 mg daily; dose above 10 mg daily only if benefit outweighs risk (maximum 16 mg daily). Elderly (or in hepatic or renal impairment): initially 0.5 mg twice daily increased in steps of 0.5 mg twice daily to 1-2 mg twice daily. Not recommended in children under 15 years
Risperidone 2 mg TabletN05AX08000T1002XXBPsychoses and schizophreniaADULT : 2 mg in 1 - 2 divided doses on first day then 4 mg in 1 - 2 divided doses on 2nd day then 6 mg in 1 - 2 divided doses on 3rd day (slower titration appropriate in some patients); usual range 4 - 8 mg daily; dose above 10 mg daily only if benefit outweigh risk (maximum 16 mg daily). Elderly (or in hepatic or renal impairment): initially 0.5 mg twice daily increased in steps of 0.5 mg twice daily to 1 - 2 mg twice daily. Not recommended in children under 15 years
Risperidone 25 mg Injection (Long Acting)N05AX08000P3001XXA*Treatment of acute and chronic schizophrenic psychosis and other psychotic conditions, in which positive and negative symptoms are prominent. It also alleviates affective symptoms associated with schizophrenia25 mg IM every 2 weeks. Dose increments (if required) to 37.5 mg or 50 mg can be considered after a minimum of 4 weeks on each dosage
Risperidone 37.5 mg Injection (Long Acting)N05AX08000P3002XXA*Treatment of acute and chronic schizophrenic psychosis and other psychotic conditions, in which positive and negative symptoms are prominent. It also alleviates affective symptoms associated with schizophrenia25 mg IM every 2 weeks. Dose increments (if required) to 37.5 mg or 50 mg can be considered after a minimum of 4 weeks on each dosage
Risperidone 50 mg Injection (Long Acting)N05AX08000P3003XXA*Treatment of acute and chronic schizophrenic psychosis and other psychotic conditions, in which positive and negative symptoms are prominent. It also alleviates affective symptoms associated with schizophrenia25 mg IM every 2 weeks. Dose increments (if required) to 37.5 mg or 50 mg can be considered after a minimum of 4 weeks on each dosage
Ritodrine HCl 50 mg/5 ml InjectionG02CA01110P3001XXAPrevention of preterm labourIV 0.05 mg/min to be gradually increased by 0.05 mg/min every 10-15 minutes. IM injection: 10 mg 4-6 hourly. Continue treatment for 12-48 hours after ceased contraction
Ritonavir 100 mg CapsuleJ05AE03000C1001XXA*Progressive or advanced HIV infection in combination with other antiretroviral agents. Criteria for use: a) Clinical AIDS b) CD4 less than 350 cells or c) Viral load more than 10,000 copies/mlADULT: (Single PI) initially 300 mg twice daily, increase by 100 mg twice daily increments to 600 mg twice daily. (Dual PI) Initially 200mg BD, then increase by 100mg BD & reaching 400mg BD within 2 wk.
Ritonavir 80 mg/ml SolutionJ05AE03000L9901XXA*Progressive or advanced HIV infection in combination with other antiretroviral agents. Criteria for use: a) Clinical AIDS b) CD4 less than 350 cells or c) Viral load more than 10,000 copies/mlADULT: 400 - 600 mg twice daily. CHILD: >1 month, initiate at dise of 25mg/m2 twice daily, titrate dose upward every 2-3 days by 50mg/m2 twice daily (maximum dose 600mg twice daily)
Rituximab 10 mg/ml InjectionL01XC02000P3001XXA*i) Treatment of patients with relapsed or chemo-resistant low grade or follicular B-cell Non-Hodgkin's lymphoma ii) Adjunctive therapy with combination chemoagents for aggressive Non-Hodgkin Lymphoma iii) Severe active rheumatoid arthritis with inadequate response or intolerance to other disease-modifying anti-rheumatic drugs (DMARDs) including one or more tumour necrosis factor (TNF) inhibitor therapies iv) Maintenance in relapsed/ refractory follicular lymphoma after response to induction therapyi) 375 mg/m2 BSA administered as an IV infusion through a dedicated line once weekly for 4 weeks ii) Combination with CHOP (cyclophosphamide, doxorubicin, prednisone and vincristine) as 375 mg/m2 BSA on day 1 of each chemotherapy cycle for 8 cycles after IV administration of the glucocorticoid component of CHOP. iii) 1000 mg IV infusion followed by a second 1000 mg IV infusion two weeks later iv) 375mg/m2 BSA once every 3 months until disease progression or for a maximum period of two years.
Rivaroxaban 10 mg TabletB01AX06000T1001XXA*Prevention of venous thromboembolism in patients undergoing elective hip or knee replacement surgery10 mg once daily. Initial dose should be taken 6 to 10 hour post-surgery provided that haemostasis has been established. Duration of treatment: Major hip surgery 5 weeks. Major knee surgery 2 weeks
Rivaroxaban 15 mg TabletB01AX06000T1002XXA*i)Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as Congestive heart failure (CHF), hypertension, age ≥ 75 yrs, diabetes mellitus, prior stroke or transient ischaemic attack. ii)Treatment of deep vein thrombosis (DVT), and prevention of recurrent DVT and pulmonary embolism (PE) following an acute DVT in adults. iii) Treatment of Pulmonary Embolism (PE), and prevention of recurrent DVT and pulmonary embolism (PE) following an acute PE in adults.i)20mg once daily or 15mg once daily (for patients with moderate renal impairment (creatinine clearance 30-49 ml/min) Dosage: ii) & (iii) 15mg BD for 21 days, followed by 20mg OD.
Rivaroxaban 20 mg TabletB01AX06000T1003XXA*i)Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as Congestive heart failure (CHF), hypertension, age ≥ 75 yrs, diabetes mellitus, prior stroke or transient ischaemic attack. ii)Treatment of deep vein thrombosis (DVT), and prevention of recurrent DVT and pulmonary embolism (PE) following an acute DVT in adults. iii) Treatment of Pulmonary Embolism (PE), and prevention of recurrent DVT and pulmonary embolism (PE) following an acute PE in adults.i)20mg once daily or 15mg once daily (for patients with moderate renal impairment (creatinine clearance 30-49 ml/min) Dosage (ii) & (iii)15mg BD for 21 days, followed by 20mg OD.
Rivastigmine 1.5 mg CapsuleN06DA03123C1001XXA*For psychiatrists and neurologists only. Mild to moderately severe dementia associated with Alzheimer's or Parkinson's diseaseInitial dose 1.5 mg 2 times daily, may increase by 1.5 mg 2 times daily every 2 weeks to maximum of 6 mg 2 times daily. If treatment is interrupted for several days, should be reinitiated at the lowest daily dose
Rivastigmine 2 mg/ml Oral SolutionN06DA03123L9901XXA*For psychiatrists and neurologists only. Mild to moderately severe dementia associated with Alzheimer's or Parkinson's diseaseInitial dose 1.5 mg 2 times daily. May be increased after a minimum of 2 weeks of treatment to 3 mg 2 times daily. Subsequently to 4.5 mg 2 times daily, up to maximum of 6 mg 2 times daily. If treatment is interrupted for several days, should be reinitiated at the lowest daily dose
Rivastigmine 3 mg CapsuleN06DA03123C1002XXA*For psychiatrists and neurologists only. Mild to moderately severe dementia associated with Alzheimer's or Parkinson's diseaseInitial dose 1.5 mg 2 times daily, may increase by 1.5 mg 2 times daily every 2 weeks to maximum of 6 mg 2 times daily. If treatment is interrupted for several days, should be reinitiated at the lowest daily dose
Rivastigmine 4.5 mg CapsuleN06DA03123C1003XXA*For psychiatrists and neurologists only. Mild to moderately severe dementia associated with Alzheimer's or Parkinson's diseaseInitial dose 1.5 mg 2 times daily, may increase by 1.5 mg 2 times daily every 2 weeks to maximum of 6 mg 2 times daily. If treatment is interrupted for several days, should be reinitiated at the lowest daily dose
Rivastigmine 4.6mg/24hr Transdermal PatchN06DA03123M7001XXA*Mild to moderately severe dementia associated with Alzheimer's or Parkinson's diseaseInitial, 4.6 mg/24 hr patch TOPICALLY once daily; after a minimum of 4 weeks and good tolerability, increase the dose to 9.5 mg/24 hr patch once daily
Rivastigmine 6 mg CapsuleN06DA03123C1004XXA*For psychiatrists and neurologists only. Mild to moderately severe dementia associated with Alzheimer's or Parkinson's diseaseInitial dose 1.5 mg 2 times daily, may increase by 1.5 mg 2 times daily every 2 weeks to maximum of 6 mg 2 times daily. If treatment is interrupted for several days, should be reinitiated at the lowest daily dose
Rivastigmine 9.5 mg/24hr Transdermal PatchN06DA03123M7002XXA*Mild to moderately severe dementia associated with Alzheimer's or Parkinson's diseaseInitial, 4.6 mg/24 hr patch TOPICALLY once daily; after a minimum of 4 weeks and good tolerability, increase the dose to 9.5 mg/24 hour patch once daily
Rocuronium Bromide 10 mg/ml InjectionM03AC09320P3001XXA*As an adjunct to general anaesthesia to facilitate endotracheal intubation, to provide skeletal muscle relaxation during surgery and to facilitate mechanical ventilation in adults, children and infants from 3 months of ageAdult: Initially, 600 mcg/kg by inj. Higher doses of 1 mg/kg may be used for intubation during rapid sequence induction of anaesthesia. Maintenance: 150 mcg/kg by inj (may reduce to 75-100 mcg/kg if inhalational anaesthesia is used) or by infusion at a rate of 300-600 mcg/kg/hr. Doses should be based on lean body weight for obese patients weighing >30% above the ideal body weight. Child: Infants and children >1 mth: Initially, 600 mcg/kg by inj. Maintenance: 150 mcg/kg by inj or by infusion at a rate of 300-600 mcg/kg/hr, maintenance doses may be required more frequently than in adult patients. Elderly: Reduced maintenance doses: 75-100 mcg/kg. Renal impairment: Initially, 600 mcg/kg by inj. Maintenance: 75-100 mcg/kg. Hepatic impairment: or biliary tract disease: Initially, 600 mcg/kg by inj. Maintenance: 75-100 mcg/kg.
Ropinirole HCI 2 mg Extended Release TabletN04BC04110T5003XXA*Treatment of idiopathic Parkinson?s disease. It may be used as monotherapy or in combination with levodopaADULT: Initially 2 mg once daily for the 1st week. May be increased by 2 mg at ≥1 week intervals. Max: 24 mg/day. Switching from ropinirole immediate-realease to prolonged-release tablet; dose of ropinirole prolonged release tablet should be based on the total daily dose of ropinirole immediate-release tab the patient was taking. Tablets should be taken at a similar time each day with or without food, must be swallowed whole and must not be chewed, crushed or divided.
Ropinirole HCI 4 mg Extended Release TabletN04BC04110T5004XXA*Treatment of idiopathic Parkinson?s disease. It may be used as monotherapy or in combination with levodopaADULT: Initially 2 mg once daily for the 1st week. May be increased by 2 mg at ≥1 week intervals. Max: 24 mg/day. Switching from ropinirole immediate-realease to prolonged-release tablet; dose of ropinirole prolonged release tablet should be based on the total daily dose of ropinirole immediate-release tab the patient was taking. Tablets should be taken at a similar time each day with or without food, must be swallowed whole and must not be chewed, crushed or divided.
Ropinirole HCl 0.25 mg TabletN04BCO4110T1001XXA*Parkinson disease in younger patients and patients with dyskinesias, especially peak dose dyskinesias0.25 mg 3 times daily gradually increasing till adequate response obtained up to a maximum of 24 mg/day. Most patients need 3-9 mg/day
Ropinirole HCl 1 mg TabletN04BCO4110T1002XXA*Parkinson disease in younger patients and patients with dyskinesias, especially peak dose dyskinesias0.25 mg 3 times daily gradually increasing till adequate response obtained up to a maximum of 24 mg/day. Most patients need 3-9 mg/day
Ropivacaine HCl 2 mg/ml InjectionN01BB09110P3001XXA*i) Surgical anaesthaesia including obstetrics ii) Acute pain managementDose adjusted according to patient physical status and nature of procedure. i) Lumbar epidural: 15-25 ml of 7.5 mg/ml solution; Caesarean section, 15-20 ml of 7.5 mg/ml solution in incremental doses ( max . total dose 150 mg). ii) lumbar epidural: 10-20 ml of 2mg/ml solution followed by 10-15 ml of 2 mg/ml solution at interval at of least 30 minutes. Labour pain 6-10 ml/hour of 2mg/ml solution
Ropivacaine HCl 7.5 mg/ml InjectionN01BB09110P3002XXA*i) Surgical anaesthaesia including obstetrics ii) Acute pain managementDose adjusted according to patient physical status and nature of procedure. i) Lumbar epidural: 15-25 ml of 7.5 mg/ml solution; Caesarean section, 15-20 ml of 7.5 mg/ml solution in incremental doses ( max . total dose 150 mg). ii) lumbar epidural: 10-20 ml of 2mg/ml solution followed by 10-15 ml of 2 mg/ml solution at interval at of least 30 minutes. Labour pain 6-10 ml/hour of 2mg/ml solution
Rosiglitazone 4 mg TabletA10BG02000T1002XXA*Type 2 diabetes with insulin resistant features. Prescribed to new patients only if inadequate glycaemic control with all other combination of oral antidiabetic medications (such as sulphonylureas, metformin, acarbose or DPPIV inhibitors) and is the only suitable alternative. Use of rosiglitazone in combination with insulin (for new patients) is not recommended. Combined use with insulin should be limited to existing cases with stable glycaemic control and requires close monitoring in view of increased risk of fluid retention, weight gain and hypoglycaemia. In cases of existing use in patients with optimal glycaemic control, rosiglitazone should be continued with close monitoring of cardiovascular, osteoporosis and fracture risk.4 mg once daily or in 2 divided doses, may be increased to 8 mg/day in 1-2 divided doses after 12 week
Rosuvastatin 10 mg TabletC10AA07390T1002XXA*Dyslipidaemia not responsive to atorvastatin 40 mg or equivalent doses of other statinsInitially 5-10 mg once daily increased if necessary at intervals of at least 4 weeks to 20 mg once daily, increased after further 4 weeks to 40 mg daily ONLY in severe hypercholesterolemia with high cardiovascular risk. Patient of Asian origin, patients on concomitant ciclosporin/fibrate and patients with risk factors for myopathy/rhabdomyolysis (including personal/family history of muscular disorders/toxicity), the maximum dose should be 20 mg daily
Rosuvastatin 20 mg TabletC10AA07390T1003XXA*Dyslipidaemia not responsive to atorvastatin 40 mg or equivalent doses of other statinsInitially 5-10 mg once daily increased if necessary at intervals of at least 4 weeks to 20 mg once daily, increased after further 4 weeks to 40 mg daily ONLY in severe hypercholesterolemia with high cardiovascular risk. Patient of Asian origin, patients on concomitant ciclosporin/fibrate and patients with risk factors for myopathy/rhabdomyolysis (including personal/family history of muscular disorders/toxicity), the maximum dose should be 20 mg daily
Rotigotine 2 mg per 24 hour Transdermal PatchN04BC09000M7001XXA*For stage IV Parkinson Disease with peak dyskinesiaA single daily dose should be initiated at 4mg/24 h and then increased in weekly increments of 2mg/24 h to an effective dose up to a maximal dose of 16mg/24 hr.
Rotigotine 4 mg per 24 hour Transdermal PatchN04BC09000M7002XXA*For stage IV Parkinson Disease with peak dyskinesiaA single daily dose should be initiated at 4mg/24 h and then increased in weekly increments of 2mg/24 h to an effective dose up to a maximal dose of 16mg/24 hr.
Rotigotine 6 mg per 24 hour Transdermal PatchN04BC09000M7003XXA*For stage IV Parkinson Disease with peak dyskinesiaA single daily dose should be initiated at 4mg/24 h and then increased in weekly increments of 2mg/24 h to an effective dose up to a maximal dose of 16mg/24 hr.
Rotigotine 8 mg per 24 hour Transdermal PatchN04BC09000M7004XXA*For stage IV Parkinson Disease with peak dyskinesiaA single daily dose should be initiated at 4mg/24 h and then increased in weekly increments of 2mg/24 h to an effective dose up to a maximal dose of 16mg/24 hr.
Rubella Virus Vaccine Injection (Single injection)J07BJ01000P3001XXCImmunization against rubella (German measles)0.5 ml SC as a a single dose
Salbutamol 0.5 % Inhalation SolutionR03AC02183A3001XXBAsthma and other conditions associated with reversible airways obstruction2 ml may be inhaled up to 4 times daily over a period of 3 minutes per inhalation (0.5 ml diluted in 2.5 ml of normal saline by inhalation over 5 to 15 minutes)
Salbutamol 0.5 mg/ml InjectionR03CC02183P3001XXAAsthma and other conditions associated with reversible airways obstruction500 mcg by SC/IM injection 4 hourly or 250 mcg by slow IV. If required, by IV infusion, initially 5 mcg/min adjusted according to response and heart rate, usually in the range 3 - 20 mcg/min
Salbutamol 100 mcg/dose InhalationR03AC02183A1001XXBAsthma and other conditions associated with reversible airways obstructionADULT : 100 - 200 mcg up to 3 - 4 times daily. CHILD : 100 mcg increased to 200 mcg if necessary
Salbutamol 2 mg TabletR03CC02183T1001XXBAsthma and other conditions associated with reversible airways obstructionCHILD 2 - 6 years : 1 - 2 mg 3 - 4 times daily, 6 - 12 years : 2 mg 3 - 4 times daily. CHILD over 12 years and ADULT : 2 - 4 mg 3 - 4 times daily
Salbutamol 2 mg/5 ml SyrupR03CC02183L9001XXBAsthma and other conditions associated with reversible airways obstructionCHILD 2 - 6 years : 1 - 2 mg 3 - 4 times daily, 6 - 12 years : 2 mg 3 -4 times daily
Salbutamol 200mcg/dose InhalerR03AC02183A2001XXBAsthma and other conditions associated with reversible airways obstructionCHILD : 100 - 200 mcg. Maintenance : 100 - 200 mcg 2 - 4 times daily. ADULT : 100 - 400 mcg. Maitenance : 100 - 400 mcg 2 - 4 times daily
Salbutamol 5 mg/5 ml InjectionR03CC02183P3002XXA*Prevention of uncomplicated premature labour onlyInfusions containing 5 mg in 500ml (10 mcg/ml) at the rate of 10 - 45 mcg/min increased at intervals of 10 minutes until evidence of patient response as shown by reduction of strength, frequency or duration of contractions; maintain rate for 1 hour after contractions have stopped, then gradually reduce by 50% every 6 hours
Salicylazosulphapyridine (Sulfasalazine) 500 mg TabletA07EC01000T1001XXA/KKi) Treatment of inflammatory bowel disease of ulcerative colitis and Crohn's disease ii) Rheumatoid arthritisi) ADULT, acute attack 1-2 g 4 times daily until remission occurs (if necessary corticosteroids may also be given), reducing to a maintenance dose of 500 mg 4 times daily, CHILD over 2 years, acute attack 40-60 mg/kg daily, maintenance dose 20-30 mg/kg daily ii) ADULT, initially; 0.5-1 g/day, increase weekly to maintenance dose of 2 g/day in 2 divided doses, maximun 3 g/day. CHILD over 6 years, juvenile rheumatoid arthritis: 30-50 mg/kg/day in 2 divided doses up to a maximum of 2 g/day
Salicylic Acid 1 - 2% in Hydrocortisone 1% OintmentD07XA01952G5001XXBSeborrhoeic capitisApply sparingly to affected areas 1-2 times daily
Salicylic Acid 2 - 10% CreamD01AE12000G1001XXCSeborrhoeic dermatitis, scalp psoriasis and hyperkeratotic skin conditionsApply sparingly to the affected area 2-3 times daily
Salicylic Acid 2 - 10% OintmentD01AE12000G5001XXCSeborrhoeic dermatitis, scalp, psoriasis and hyperkeratotic skin disordersApply sparingly to the affected area 2-3 times daily
Salicylic Acid 2 % LotionD01AE12000L6001XXBSeborrhoeic dermatitis, scalp, psoriasis and hyperkeratotic skin conditionsApply sparingly to the affected area 2-3 times daily. Wash with cleanser 2 - 3 times per day
Salicylic Acid 20% OintmentD01AE12000G5002XXCPlantar wartsApply daily and protect surrounding skin (eg with soft paraffin or specially designed plaster) ,may need to continue up to 3 months
Salicylic Acid, Starch, Zinc Oxide PasteD01AE12952G6001XXCUse as a protective or baseApply the paste liberally and carefully to the lesions twice daily
Salmeterol 25 mcg and Fluticasone Propionate 125 mcg InhalationR03AK06989A2102XXA*Regular treatment of reversible obstructive airway diseases including asthma.ADULT and CHILD more than 12 years : 1 - 2 puff twice daily. CHILD over 4 years : 1 puff twice daily
Salmeterol 25mcg and Fluticasone Propionate 50mcg InhalationR03AK06989A2104XXA*Regular treatment of reversible obstructive airway diseases including asthma in children, where use of lower dose of a combination (bronchodilator and inhaled corticosteroids) is appropriate.ADULT and CHILD more than 12 years : 2 puff twice daily. CHILD over 4 years : 2 puff twice daily No data on use for children aged under 4 years.
Salmeterol 50 mcg and Fluticasone Propionate 250 mcg InhalationR03AK06989A2101XXA/KKi) Regular treatment of reversible obstructive airways diseases including asthma ii) For the regular treatment of chronic obstructive pulmonary disease (COPD) including chronic bronchitis and emphysemai) ADULT and CHILD more than 12 years : 1 - 2 puff twice daily. CHILD over 4 years : 1 puff twice daily ii) For COPD: Dose is one inhalation 50/250mcg to 50/500mcg twice daily.
Salmeterol 50 mcg and Fluticasone Propionate 500 mcg InhalationR03AK06989A2106XXA*i) Regular treatment of reversible obstructive airways diseases including asthma ii) Chronic obstructive pulmonary disease including chronic bronchitis and emphysemai) ADULT and CHILD more than 12 years : 1 puff twice daily ii) ADULT 1 puff twice daily
Saxagliptin 2.5 mg TabletA10BH03000T1001XXA/KKi) As add on therapy in type 2 diabetes patients inadequately controlled on metformin monotherapy and high risk of hypoglycaemia, especially elderly patients with co-morbidities. ii) As add on therapy in type 2 diabetes patients inadequately controlled with a sulphonylure and intolerant/contraindicated for metformin therapy iii) As add on therapy in type 2 diabetes patients inadequately controlled on metformin and sulphonylurea combination therapy iv) In patients with renal failure where metformin contraindicated Not to be used in patients with HbA1c > 8% on single/combination OAD, as insulin initiation is preferred.Recommended starting dose and maintenance dose in patients with normal renal function and mild renal insufficiency (CrCl more than 50 ml/min) is 5 mg once daily. For patients with moderate to severe renal insufficiency (CrCl less than or equal to 50 ml/min) dose is 2.5 mg once daily
Saxagliptin 2.5mg and Metformin HCl 1000mg Extended-Release TabletA10BD10926T1001XXAIndicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both saxagliptin and metformin is appropriate.The recommended starting dose of in patients who need 5mg of saxagliptin and who are not currently treated with metformin is 5mg saxagliptin/500 mg metformin extended-release once daily with gradual dose escalation to reduce the gastrointestinal side effects due to metformin. In patients treated with metformin, the dose of should provide metformin at the dose already being taken, or the nearest therapeutically appropriate dose. Patients who need 2.5mg saxagliptin in combination with metformin extended-release may be treated with 2.5mg/1000mg. Patients who need 2.5mg saxagliptin who are either metformin naive or who require a dose of metformin higher than 1000mg should use the individual components. Max daily recommended dose is 5mg/2000mg.
Saxagliptin 5 mg TabletA10BH03000T1002XXA/KKi) As add on therapy in type 2 diabetes patients inadequately controlled on metformin monotherapy and high risk of hypoglycaemia, especially elderly patients with co-morbidities. ii) As add on therapy in type 2 diabetes patients inadequately controlled with a sulphonylure and intolerant/contraindicated for metformin therapy iii) As add on therapy in type 2 diabetes patients inadequately controlled on metformin and sulphonylurea combination therapy iv) In patients with renal failure where metformin contraindicated Not to be used in patients with HbA1c > 8% on single/combination OAD, as insulin initiation is preferred.2.5-5mg once daily. Patients with CrCl < 50ml/min, and when coadministered with strong CYP450 3A4/5 inhibitors: 2.5mg OD
Saxagliptin 5mg and Metformin HCl 1000mg Extended-Release TabletA10BD10926T1002XXAIndicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both saxagliptin and metformin is appropriate.The recommended starting dose of in patients who need 5mg of saxagliptin and who are not currently treated with metformin is 5mg saxagliptin/500 mg metformin extended-release once daily with gradual dose escalation to reduce the gastrointestinal side effects due to metformin. In patients treated with metformin, the dose of should provide metformin at the dose already being taken, or the nearest therapeutically appropriate dose. Patients who need 2.5mg saxagliptin in combination with metformin extended-release may be treated with 2.5mg/1000mg. Patients who need 2.5mg saxagliptin who are either metformin naive or who require a dose of metformin higher than 1000mg should use the individual components. Max daily recommended dose is 5mg/2000mg.
Saxagliptin 5mg and Metformin HCl 500 mg Extended-Release TabletA10BD10926T1003XXAIndicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both saxagliptin and metformin is appropriate.The recommended starting dose of in patients who need 5mg of saxagliptin and who are not currently treated with metformin is 5mg saxagliptin/500 mg metformin extended-release once daily with gradual dose escalation to reduce the gastrointestinal side effects due to metformin. In patients treated with metformin, the dose of should provide metformin at the dose already being taken, or the nearest therapeutically appropriate dose. Patients who need 2.5mg saxagliptin in combination with metformin extended-release may be treated with 2.5mg/1000mg. Patients who need 2.5mg saxagliptin who are either metformin naive or who require a dose of metformin higher than 1000mg should use the individual components. Max daily recommended dose is 5mg/2000mg.
Selected Plasma Protein 5 g/100 ml InjectionB05AA02000P3001XXBFor treatment of shock due to burns, crushing injuries, abdominal emergencies and where there is a predominant loss of plasma fluids and red blood cells, emergency treatment of shock due to haemorrhage and in infants and small children in the initial therapy of shock due to dehydration and infectionADULT 12.5-25 g (250-500 ml) by IV. CHILD usual dose 33 ml/kg body weight at rate of 5-10 ml/min
Selegiline HCl 5 mg TabletN04BD01110T1001XXA*Only for treatment of late stage Parkinsonism with on and off phenomenon5 mg twice daily at breakfast and lunch. Maximum 10 mg/day
Selenium Sulphide 2.5% ShampooD11AC03180L5201XXA/KKDandruff, seborrheic dermatitis of scalpDandruff: apply 5-10 mL topically twice weekly for 2 weeks, then 1-4 times per month, as needed, leave on for 2-3 min, then rinse thoroughly. Seborrheic dermatitis of scalp: apply 5-10 mL topically twice weekly for 2 weeks, then 1-4 times per month, as needed, leave on for 2-3 min, then rinse thoroughly
Sertraline HCI 50 mg TabletN06AB06110T1001XXBMajor depression, obsessive-compulsive disorder (OCD), panic disorderDepression, obsessive-compulsive disorder: 50 mg/day, may increase in steps of 50mg at weekly interval, max:200mg/day. Panic disorder: Initially 25 mg/day. After 1 week, increase dose to 50 mg/day. All dose changes should be made at intervals of more than 1 week, max: 200 mg/day
Sevoflurane LiquidN01AB08000L5001XXA*To be used only for i) induction and ii) maintenance of anaesthesiai) Adult: Given via a calibrated vaporiser: Up to 5% v/v with oxygen or a mixture of oxygen and nitrous oxide. Child: Given via a calibrated vaporiser: Up to 7% v/v. ii) Adult: 0.5-3% v/v with or without nitrous oxide. Child: 0.5-3% v/v with or without nitrous oxide.
Sildenafil Citrate 20 mg Film-coated TabletG04BE03136T1004XXA*Treatment of adult patients with pulmonary arterial hypertension classified as WHO functional class II and III, to improve exercise capacity. Efficacy has been shown in primary pulmonary hypertension and pulmonary hypertension associated with connective tissue disease.ADULTS ≥ 18 years: The recommended dose is 20mg three times a day. Tablets should be taken approximately 6 to 8 hours apart with or without food. ELDERLY (≥65 years): Dosage adjustments are not required in elderly patients. Clinical efficacy as measured by 6-minute walk distance could be less in elderly patients. IMPAIRED RENAL FUNCTION: Initial dose adjustments are not required in patients with renal impairment, including severe renal impairment (creatinine clearance <30ml/min). A downward dose adjustment to 20 mg twice daily should be considered after a careful benefit-risk assessment only if therapy is not well-tolerated. IMPAIRED HEPATIC FUNCTION: Initial dose adjustments are not required in patients with hepatic impairment (Child-Pugh class A and B). A downward dose adjustment to 20mg twice daily should be considered after a careful benefit-risk assessment only if therapy is not well-tolerated.
Silver Nitrate 0.5% LotionD08AL01221L6001XXBUse as antisepticApply undiluted to affected area for a limited period
Silver Sulfadiazine 1% CreamD06BA01199G1001XXBPrevention and treatment of infections in severe burns, leg ulcers where infections may prevent healing and for the prophylaxis of infections in skin graftingBurns: Apply 3 mm thick layer twice daily with sterile applicator. Leg ulcer: apply at least 3 times a week
Simvastatin 10 mg TabletC10AA01000T1001XXBHypercholesterolaemia and coronary heart disease intolerant or not responsive to other forms of therapy10 - 20 mg once daily. Maximum: 80 mg daily
Simvastatin 20 mg TabletC10AA01000T1002XXBHypercholesterolaemia and coronary heart disease intolerant or not responsive to other forms of therapy10 - 20 mg once daily. Maximum: 80 mg daily
Simvastatin 40 mg TabletC10AA01000T1003XXBHypercholesterolaemia and coronary heart disease intolerant or not responsive to other forms of therapy10 - 20 mg once daily. Maximum: 80 mg daily
Sitagliptin 100 mg TabletA10BH01000T1003XXA*Management of diabetes in patients with renal failure where metformin/sulphonylurea is contraindicated/untolerated and elderly with multiple co morbidities that always experience hypoglycemia with other antidiabetic. Not to be used in diabetic patient whose HbA1c is more than 9%ADULT over 18 years, 100 mg once daily: 100mg once daily CrCl ≥ 30 to < 50ml/min: 50mg once daily CrCl < 30 ml/min: 25mg once daily
Sitagliptin 25 mg TabletA10BH01000T1001XXA*Management of diabetes in patients with renal failure where metformin/sulphonylurea is contraindicated/untolerated and elderly with multiple co morbidities that always experience hypoglycemia with other antidiabetic. Not to be used in diabetic patient whose HbA1c is more than 9%ADULT over 18 years, 100 mg once daily: 100mg once daily CrCl ≥ 30 to < 50ml/min: 50mg once daily CrCl < 30 ml/min: 25mg once daily
Sitagliptin 50 mg and Metformin HCl 1000 mg TabletA10BD07926T1003XXA*i)Type 2 diabetes patients, especially the elderly, with multiple co-morbidities that always experience hypoglycaemia with other antidiabetics who are inadequately controlled on metformin or sitagliptin alone or already being treated with the combination of sitagliptin and metformin ii)Newly diagnosed type 2 diabetes patients with high baseline HbA1c and multiple co-morbidities who may experience hypoglycaemia with other antidiabetics50 mg/500 mg twice daily. The recommended maximum daily dose is 100 mg sitagliptin plus 2000 mg metformin
Sitagliptin 50 mg and Metformin HCl 500 mg TabletA10BD07926T1001XXA*i)Type 2 diabetes patients, especially the elderly, with multiple co-morbidities that always experience hypoglycaemia with other antidiabetics who are inadequately controlled on metformin or sitagliptin alone or already being treated with the combination of sitagliptin and metformin ii)Newly diagnosed type 2 diabetes patients with high baseline HbA1c and multiple co-morbidities who may experience hypoglycaemia with other antidiabetics50 mg/500 mg twice daily. The recommended maximum daily dose is 100 mg sitagliptin plus 2000 mg metformin
Sitagliptin 50 mg and Metformin HCl 850 mg TabletA10BD07926T1002XXA*i)Type 2 diabetes patients, especially the elderly, with multiple co-morbidities that always experience hypoglycaemia with other antidiabetics who are inadequately controlled on metformin or sitagliptin alone or already being treated with the combination of sitagliptin and metformin ii)Newly diagnosed type 2 diabetes patients with high baseline HbA1c and multiple co-morbidities who may experience hypoglycaemia with other antidiabetics50 mg/500 mg twice daily. The recommended maximum daily dose is 100 mg sitagliptin plus 2000 mg metformin
Sitagliptin 50 mg TabletA10BH01000T1002XXA*Management of diabetes in patients with renal failure where metformin/sulphonylurea is contraindicated/untolerated and elderly with multiple co morbidities that always experience hypoglycemia with other antidiabetic. Not to be used in diabetic patient whose HbA1c is more than 9%ADULT over 18 years, 100 mg once daily: 100mg once daily CrCl ≥ 30 to < 50ml/min: 50mg once daily CrCl < 30 ml/min: 25mg once daily
Sodium Alginate 1000 mg/10 ml & Potassium Bicarbonate 200 mg/10 ml SuspensionA02BX13915L8001XXA*Treatment of symptoms of gastro-oesophageal reflux eg. acid regurgitation, heartburn, indigestion due to the reflux of stomach contents not responding to conventional antacids or as an addition to PPI when PPI alone fails to control the symptomsAdult, elderly & children ≥12 year: 5-10 mL.
Sodium and Meglumine Diatrizoate 58-60% InjectionV08AA01993P3002XXBFor IV pyelographyDepend on the type of procedure and the degree and extent of contrast required
Sodium Bicarbonate 1 g/15 ml MixtureA02AH00131L2102XXBi) Relief of discomfort in mild urinary tract ii) Alkalinisation of urinei) 3 g in every 2 hours until urinary pH exceeds 7 ii) Maintenance of alkaline urine 5-10 g daily
Sodium Bicarbonate 4.2% (0.5 mmol/ml) InjectionB05XA02131P3001XXBFor acceleration of excretion in drug intoxication (where excretion of the drug into the urine is accelerated by elevated urine pH) and for acidosisIV infusion of 2 - 5 mmol/kg body weight over a period of 4 - 8 hours or according to the needs of the patients
Sodium Bicarbonate 5% w/v Ear DropsS02DC00131D1001XXCTo soften the impacted ear wax2-3 drops 3-4 times daily
Sodium Bicarbonate 8.4% (1 mmol/ml) InjectionB05XA02131P3002XXBFor acceleration of excretion in drug intoxication (where excretion of the drug into the urine is accelerated by elevated urine pH) and for acidosisAccording to the needs of the patient. In severe shock due to cardiac arrest: 50 ml by IV
Sodium Bicarbonate Mixture (Paediatric)A02AH00131L2101XXCHeartburn for rapid relief of dyspepsiaCHILD up to 1 year 5 ml; up to 1-5 years 10 ml in 4 to 6 divided doses
Sodium Bicarbonate, Citric Acid, Sodium Citrate and Tartaric Acid - 4 g per sachetB05CB10955M4001XXBFor relieving of discomfort in mild urinary tract infection, symptomatic relief of dysuria to enchance the action to certain antibiotics especially some sulphonamides. In gout as urinary alkalinizers to prevent cystallisation of urates4 - 8 g (1- 2 sachets) dissolved in a glass of cold water 4 times daily as prescribed
Sodium Bicarbonate, Magnesium Carbonate, Tincture Cardamom Compound MixtureA02AH00912L2101XXCHeartburn, for rapid relief of dyspepsiaADULT 10-20 ml 3 times daily
Sodium Biphosphate 16%, Sodium Phosphate 6% Rectal SolutionA06AG01162G2001XXABowel cleansing before colonic surgery, colonoscopy or radiological examination to ensure the bowel is free of solid contents. It is not to be used for treatment of constipationADULT 133 ml (1 bottle) administered rectally. CHILD more than 2 years half the adult dose (66.6ml)
Sodium Biphosphate 16%, Sodium Phosphate 6% SolutionA06AG01162L9901XXABowel cleansing before colonic surgery, colonoscopy or radiological examination to ensure the bowel is free of solid contents. It is not to be used for treatment of constipation45 ml diluted with half a glass (120 mL) of water, followed by one full glass (240 mL) of water. Timing of doses is dependent on the time of the procedure. For morning procedure, first dose should be taken at 7 a.m. and second at 7 p.m. on day before the procedure. For afternoon procedure, first dose should be taken at 7 p.m. on day before and second dose at 7 a.m. on day of the procedure. Solid food should not be taken during the bowel preparation period. However clear fluids or water can be taken liberally. CHILD under 12 years not recommended
Sodium Chloride 0.18% with Dextrose 10% InjectionB05XA03904P6001XXBFor replenishing fluid and energy and for restoring or maintaining the concentration of sodium and chloride ionsAccording to the needs of the patient
Sodium Chloride 0.18% with Dextrose 4.23% InjectionB05XA03904P6004XXBFor replenishing fluid and energy and for restoring or maintaining the concentration of sodium and chloride ionsAccording to the needs of the patient
Sodium Chloride 0.45% InjectionB05XA03100P6001XXBFor replenishing fluid and for restoring / maintaining the concentration of sodium and chloride ions100 - 1000 ml by IV or according to the needs of the patient
Sodium Chloride 0.45% with Dextrose 10% InjectionB05XA03904P6002XXBFor replenishing fluid and energy and for restoring or maintaining the concentration of sodium and chloride ionsAccording to the needs of the patient
Sodium Chloride 0.45% with Dextrose 5% InjectionB05XA03904P6005XXBFor replenishing fluid and energy and for restoring or maintaining the concentration of sodium and chloride ionsAccording to the needs of the patient
Sodium Chloride 0.9% Eye DropsS01XA03000D2001XXCIrrigation of conjunctival sac1 - 2 drops every 3 - 4 hours
Sodium Chloride 0.9% InjectionB05XA03100P6002XXC+For replenishing fluid and for restoring/maintaining the concentration of sodium and chloride ions100 - 1000 ml by IV or according to the needs of the patient
Sodium Chloride 0.9% with Dextrose 5% InjectionB05XA03904P6003XXC+For replenishing fluid and energy and for restoring or maintaining the concentration of sodium and chloride ionsAccording to the needs of the patient
Sodium Chloride 20% InjectionB05XA03100P9902XXBAddition of sodium electrolyte in parenteral nutrition bags especially in paediatrics or neonates with restricted fluid allowanceAccording to the needs of the patient
Sodium Chloride 3% InjectionB05XA03100P9901XXBAcute dilutional hyponatraemiaAccording to the needs of the patient
Sodium Chromate (Chromium-51) SolutionV09GX00143L9901XXA*Labelling of erythrocytes for the investigation of haemotological disordersUsual dose range : 10 - 200 microcuries IV by IV injection
Sodium Citrate 0.3 M SolutionB05CB02136L9901XXBProphylaxis for aspiration pneumonitis (use as an oral solution)Dose depending on clinical cases. Usually, 30 ml given 10- 60 minutes before anaesthesia prior to elective cesarean surgery is an effective antacid
Sodium Citrate 3.8% SolutionB05CB02136H3001XXBSterile solution for irrigation or washout of infected bladderDose depending on clinical cases
Sodium Citrate, Citric Acid Mixture 3 g/10 mlB05CB02136L2101XXBCitrates and citric acid solutions are used to correct the acidosis of certain renal tubular disorders to treat metabolic acidosis for long-term urine alkalinization for prevention and treatment of uric acid and calcium kidney stones and as nonparticulate neutralizing buffersADULT 10 - 20 ml. CHILD up to 1 year 2.5 ml tds; 1-5 year 5 ml tds; 6-12 years 10 ml tds. To be taken well diluted with water
Sodium Cromoglycate 2% Eye DropsS01GX01520D2001XXA/KKPrevention and treatment of allergic conjunctivitis including seasonal and perennial allergic conjunctivitis and vernal keratoconjunctivitis1 or 2 drops 4 times daily
Sodium Dichloroisocyanurate 2.5 g TabletV07AV00000T1001XXCLow and medium level disinfectant50 - 10,000 ppm av chlorine
Sodium Dichloroisocyanurate 5 g TabletV07AV00000T1002XXCLow and medium level disinfectant50 - 10,000 ppm av chlorine
Sodium Fusidate 2% OintmentD06AX01520G5001XXASkin infections caused by staphylococci, streptococci, corynebacterium minutissumun and other sodium fusidate-sensitive organismsApply to affected area 2 - 3 times daily
Sodium glycerophosphate for addition into infusion solution, 20ml vialB05XA14171P3001XXAIndicated in adult patients and infants as a supplement in intravenous nutrition to meet the requirement of phosphate.Adults: The recommended dosage is individual. The recommended daily dosage of phosphate during intravenous nutrition would normally be 10-20mmol. This can be met by using 10-20ml of sodium glycerophosphate to the infusion solution or to the admixture for which compatibility has been proved. Infants: The recommended dosage is individual. The recommended dose for infants and neonates is 1.0-1.5 mmol/kg bodyweight/day.
Sodium Hypochlorite SolutionV07AV00000L9903XXCLow-level disinfectant and antisepticAntiseptic: less than 0.5%. Disinfectant: 5%
Sodium Iodide (Iodide-131) InjectionV09FX03200P3001XXA*Used in the determination of various thyroid functions5 - 50 millicuries
Sodium Iodide (Iodine-131) CapsuleV09FX03200C1001XXA*Determination of various thyroid functions5 - 10 milicuries (5 mCi for whole body scan)
Sodium Iodide (Iodine-131) Capsule (Therapeutic)V10XA01200C1001XXA*i) Thyrotoxicosis ii) Thyroid carcinomai) 2 - 30 millicuries ii) 80 - 300 millicuries
Sodium Iodide (Iodine-131) SolutionV10XA01200L9901XXA*i) Thyrotoxicosis ii) Thyroid carcinomai) 5-25 millicuries ii) 30-150 millicuries
Sodium Nitrite 30 mg/ml InjectionV03AB08220P3001XXBFor cyanide poisoningAdult: 300 mg sodium nitrite IV over 3 minutes followed after 5 minutes with 12.5g sodium thiosulphate IV administered over 10 minutes. CHILD: 4 - 10 mg/kg of sodium nitrite (max: 300 mg) followed by 400 mg/kg of sodium thiosulfate, as a 25 or 50% solution (max: 12.5 g). Methaemoglobin concentration should not exceed 30-40%. If symptoms of cyanide toxicity recur, the doses of nitrite and thiosulfate may be repeated after 30 min at half the initial doses.
Sodium Nitroprusside 10 mg/ml InjectionC02DD01520P3001XXAi) Hypertensive crisis ii) Controlled hypotension during anaesthesia in order to reduce bleeding in surgical proceduresi) By IV infusion, initially 0.5-1.5 mcg/kg/min, then adjusted before increasement of 0.5 mcg/kg/min every 5 mins within range 0.5-8 mcg/kg/min (lower doses in patients already receiving other antihypertensives); stop if marked response not obtained with max dose in 10 minutes. Use only in infusion with 5 % Dextrose IV. ii) By IV infusion, max: 1.5 mcg/kg/min
Sodium Phosphate (Phosphorus-32) InjectionV10XX01162P3001XXA*Polycythemia vera, chronic myeloid and chronic lymphocytic leukaemia and palliative treatment of bone metastasesInitially 5 millicuries, follow if necessary by a dose of not more than 3 or 4 millicurie at intervals of not less than 2 months
Sodium Polystyrene Sulphonate PowderV03AE01520F2101XXATreatment and prevention of hyperkalaemia associated with anuria or severe oliguria, in dialysis patients or those on prolonged peritoneal dialysisADULT : Oral : 15 g 1 - 4 times/day. Rectal : 30 g in 100 ml 2% methylcellulose and 100 ml water as a daily retention enema. Retain for 9 hours followed by non-sodium cleansing enema. CHILD : 1 g/kg in 1 - 4 doses in acute hyperkalemia. Maintenance : 0.5 g/kg/daily
Sodium Tetradecyl Sulphate 1 % InjectionC05BB04183P3001XXA*Sclerotherapy of oesophageal varices, haemorrhoids and varicose veins0.5-2 mL into the submucosal layer at the base of the oesophageal varix or the haemorrhoid; several injections may be given at different sites, max. total injected 10-15 mL of 1% per treatment
Sodium Tetradecyl Sulphate 3 % InjectionC05BB04183P3002XXA*Sclerotherapy of oesophageal varices, haemorrhoids and varicose veins0.5-2 mL into the submucosal layer at the base of the oesophageal varix or the haemorrhoid, several injections may be given at different sites, max. total injected 10-15 mL of 1% per treatment
Sodium Thiosulphate 10-20% SolutionD01AE00181L9901XXCFungicides. For the treatment of pityriasis versicolorApply to all affected parts of the body and face with a brush after a bath once daily or twice daily or 3 times daily
Sodium Thiosulphate 500 mg/ml InjectionV03AB06181P3001XXBFor cyanide poisoningAdult: To be given after 300 mg of sodium nitrite has been admin over 5-20 min: 12.5 g of sodium thiosulfate (50 ml of a 25% solution or 25 ml of a 50% solution) given over 10 min. Methaemoglobin concentration should not exceed 30-40%. If symptoms of cyanide toxicity recur, the doses of nitrite and thiosulfate may be repeated after 30 min at half the initial doses. Child: To be given after 4-10 mg/kg of sodium nitrite (max: 300 mg) has been admin: 400 mg/kg of sodium thiosulfate, as a 25 or 50% solution (max: 12.5 g). Methaemoglobin concentration should not exceed 30-40%. If symptoms of cyanide toxicity recur, the doses of nitrite and thiosulfate may be repeated after 30 min at half the initial doses.
Sodium Valproate 200 mg TabletN03AG01520T1001XXBEpilepsyADULT: Initially 600 mg/day in 2 - 3 divided doses, dose may be increased by 200 mg at 3-day intervals to max 2.5 g/day. Usual maintenance dose: 1-2 g/day (20-30 mg/kg/day). CHILD: More than 20 kg. Initially 400 mg/day with spaced increases until control is achieved (usually 20-30 mg/kg/day), dose may be increased to 35 mg/kg/day. Less than 20 kg 20 mg/kg/day, in severe cases the dose may be increased provided plasma concentration can be monitored
Sodium Valproate 200 mg/5 ml SyrupN03AG01520L9001XXBEpilepsyADULT: Initially 600 mg/day; dose may be increased by 200 mg at 3-day intervals to max 2500 mg/day. Usual maintenance dose: 1000-2000 mg/day (20-30 mg/kg/day). CHILD: More than 20 kg. Initially 400 mg/day with spaced increases until control is achieved (usually 20-30 mg/kg/day), dose may be increased to 35 mg/kg/day. Less than 20 kg, 20 mg/kg/day. Severe cases: 50 mg/kg daily
Sodium Valproate 400 mg InjectionN03AG01520P4001XXBStatus epilepticusADULT and CHILD above 10 years: 10 to 15 mg/kg/day IV, may increase 5 to 10 mg/kg/week to achieve optimal clinical response (Maximum 60 mg/kg/day or less with a therapeutic range of 50 to 100 mcg/mL)
Solifenacin Succinate 5 mg TabletG04BD08000T1001XXA*Symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in patients with overactive bladder syndrome.5mg od. Dose can be increased to 10mg if necessary.
Somatropin 10 mg/1.5 ml (30iu) Injection in Prefilled SyringeH01AC01000P5002XXA*i) Growth failure due to inadequate endogenous growth hormone. ii) Growth failure in girls due to gonadal dysgenesis (Turner syndrome). iii) Growth failure in short children born small gestational age (SGA)i) 0.7-1 mg/m2/day or 0.025-0.035 mg/kg/day SC/IM. ii) 1.4 mg/m2/day or 0.045-0.05 mg/kg/day SC. iii) 0.035 mg/kg/day or 1 mg/m2/day SC
Somatropin 12 mg (36IU) InjectionH01AC01000P3002XXA*i) Growth failure due to inadequate endogenous growth hormone ii) Growth failure in girls due to gonadal dysgenesis (Turner syndrome) iii) Growth failure in short children born small gestational age (SGA)i) 0.7-1 mg/m2/day or 0.025-0.035 mg/kg/day SC/IM ii) 1.4 mg/m2/day or 0.045-0.05 mg/kg/day SC iii) 0.035 mg/kg/day or 1 mg/m2/day SC
Somatropin 5mg (15IU) InjectionH01AC01000P3004XXA*i)Growth failure due to growth hormone insufficiency ii)Growth failure in girls due to gonadal dysgenesis (Turner syndrome), growth retardation in prepubertal children due to chronic renal disease, growth disturbance (current height standard deviation score (SDS)<2.5 and parental adjusted height SDS<-1) in short children born small for gestational age (SGA) with a birth weight and/or length below -2 std deviation (SD), who failed to show catch-up growth (height velocity standard deviation score (HV SDS) <0 during the last year) by 4 years of age or lateri) 0.7-1 mg/m2/day or 0.025-0.035 mg/kg/day SC/IM ii) 1.4 mg/m2/day or 0.045-0.05 mg/kg/day SC iii) 0.035 mg/kg/day or 1 mg/m2/day SC
Somatropin 8 mg (24IU) InjectionH01AC01000P3003XXA*i)Growth failure due to growth hormone insufficiency ii)Growth failure in girls due to gonadal dysgenesis (Turner syndrome) iii)growth retardation in prepubertal children due to chronic renal disease, growth disturbance (current height standard deviation score (SDS)<2.5 and parental adjusted height SDS<-1) in short children born small for gestational age (SGA) with a birth weight and/or length below -2 std deviation (SD), who failed to show catch-up growth (height velocity standard deviation score (HV SDS) <0 during the last year) by 4 years of age or lateri) 0.7-1 mg/m2/day or 0.025-0.035 mg/kg/day SC/IM ii) 1.4 mg/m2/day or 0.045-0.05 mg/kg/day SC iii) 0.035 mg/kg/day or 1 mg/m2/day SC
Sotalol HCl 160 mg TabletC07AA07110T1002XXA*Ventricular tachyarrythmiasSupraventricular and ventricular arrhythmias Adult: Initially, 80 mg/day as single or in 2 divided doses, increased gradually every 2-3 days. Usual dose: 160-320 mg/day in 2 divided doses. Life-threatening ventricular arrhythmias Adult: Initially, 80 mg bid, increased gradually every 3 days to 240-320 mg/day in divided doses if needed. Maintenance: 160-320 mg/day in divided doses. Max: 480-640 mg in divided doses.
Sotalol HCl 80 mg TabletC07AA07110T1001XXA*Ventricular tachyarrythmiasSupraventricular and ventricular arrhythmias Adult: Initially, 80 mg/day as single or in 2 divided doses, increased gradually every 2-3 days. Usual dose: 160-320 mg/day in 2 divided doses. Life-threatening ventricular arrhythmias Adult: Initially, 80 mg bid, increased gradually every 3 days to 240-320 mg/day in divided doses if needed. Maintenance: 160-320 mg/day in divided doses. Max: 480-640 mg in divided doses.
Spironolactone 25 mg TabletC03DA01000T1001XXBOedema and ascites in cirrhosis of the liver, congestive heart failureADULT: 100 - 200 mg daily in divided doses. Increase to 400 mg if required. CHILD: initially 3 mg/kg daily in divided doses
Stavudine 1 mg/ml SolutionJ05AF04000L5001XXA*HIV infection, in combination with other antiretroviralsInfant: 0 - 13 days old: 0.5 mg/kg/dose twice daily. Infant 14 days and older and weighing less than 30 kg: 1 mg/kg twice daily; more than 30 kg and <60kg: 30 mg twice daily
Stavudine 30 mg CapsuleJ05AF04000C1001XXA/KKHIV infection, in combination with other antiretroviralsADULT more than 60 kg: 40 mg twice daily; less than 60 kg: 30 mg twice daily. CHILD <30kg: 1mg/kg twice daly; >30kg refer to adult dosage
Stavudine 30 mg, Lamivudine 150 mg & Nevirapine 200 mg TabletJ05AR07964T1001XXA/KKFixed dose triple therapy for treatment of HIV infection in adults once patients have been stabilized on the maintenance regimen of nevirapine 200 mg twice daily and have demonstrated adequate tolerability to nevirapineSLN 30: 30-60 kg 1 tablet twice daily. SLN 40 ≥60 kg 1 tablet twice daily
Stavudine 40 mg CapsuleJ05AF04000C1002XXA*HIV infection, in combination with other antiretroviralsADULT more than 60 kg: 40 mg twice daily; less than 60 kg: 30 mg twice daily. CHILD <30kg: 1mg/kg twice daly; >30kg refer to adult dosage
Stavudine 40 mg, Lamivudine 150 mg & Nevirapine 200 mg TabletJ05AR07964T1002XXA*Fixed dose triple therapy for treatment of HIV infection in adults once patients have been stabilized on the maintenance regimen of nevirapine 200 mg twice daily and have demonstrated adequate tolerability to nevirapineSLN 30: 30-60 kg 1 tablet twice daily. SLN 40 ≥60 kg 1 tablet twice daily
Streptokinase 1,500,000 IU InjectionB01AD01000P4001XXA*Acute myocardial infarction, acute pulmonary embolismMyocardial infarction: 1,500,000 units over 30 - 60 minutes. Pulmonary embolism: 250,000 units by IV infusion over 30 minutes, then 100,000 units every hour for up to 12-72 hours with monitoring of clotting factors
Streptomycin Sulphate 1 g InjectionJ01GA01183P4001XXBTuberculosisADULT: 15 mg/kg daily; max: 1 g daily. Reduce max daily dose to 500-750 mg in patients >40 yr. As part of an intermittent therapy: 25-30 mg/kg/day 2-3 times/wk; max: 1.5 g/dose. Not >120 g over the course of treatment should be given unless there are no other treatment options. Child: 20-40 mg/kg (max: 1 g) daily or 25-30 mg/kg (max: 1.5 g) 2-3 times wkly.
Strontium Ranelate 2 g GranulesM05BX03000F1001XXA*Treatment of postmenopausal osteoporosis to reduce risk of vertebral and hip fractures when biphosphonates are contraindicated or not tolerated2 g sachet once daily
Succindialdehyde 11% & Dimethoxytetrahydrofuran 3%V07AV00000L9907XXAHigh level disinfection for endoscopes, ultrasonicprobes, anaesthesia equipment etcImmersion time is based on manufacturers recommendation
Sucralfate 1 g TabletA02BX02000T1001XXAi) Benign gastric and duodenal ulceration ii) Stress ulcer prophylaxisi) 2 g twice daily or 1 g 4 times daily for 4-6 weeks or in resistant cases up to 12 weeks (maximum 8 g daily) ii) 1 g 6 times daily (maximum 8 g daily). CHILD not recommended
Sugammadex 100 mg/ml InjectionV03AB35000P3001XXA*Indicated for reversal of neuromuscular blockade induced by rocuronium and vecuronium in selective patient group: obese, elderly, underlying cardiovascular disease. For pediatric population, sugammadex is recommended for routine reversal2 mg/kg sugammadex is recommended, if spontaneous recovery has occurred up to at least the reappearance of second twitch tension of the train-of-four (T2). 4 mg/kg sugammadex is recommended if recovery has reached at least 1- 2 post-tetanic counts (PTC). For immediate reversal following administration of rocuronium a dose of 16 mg/kg sugammadex is recommended
Sulfadoxine 500 mg and Pyrimethamine 25 mg TabletP01BD51981T1001XXBTreatment of Plasmodium falciparum malaria in patients in whom chloroquine resistance is suspected and malaria prophylaxis for travellers to areas where chloroquine-resistant malaria is endemicChloroquine resistant falciparum malaria acute attack Adult: Per tab contains pyrimethamine 25 mg and sulfadoxine 500 mg: 2-3 tabs as a single dose. Do not repeat for at least 7 days. Child: Pyrimethamine 25mg + Sulfadoxine 500mg (Tablet): <2 yr (5-10 kg): ? tab as a single dose; 2-5 yr (>10-20 kg): 1 tab as a single dose; 5-10 yr (< 20-30 kg): 1? tab as a single dose; 10-14 yr (> 30-45 kg): 2 tab as a single dose. Do not repeat for at least 7 days. Renal impairment: Dose reduction may be needed. Severe: contra-indicated. Hepatic impairment: Dose reduction may be needed. Severe: contra-indicated.
Sulphamethoxazole 200 mg & Trimethoprim 40 mg/5ml SuspensionJ01EE01961L8001XXBInfections caused by susceptible pathogensMild to moderate infections: more than 2months: 8 - 12mg Trimethoprim/kg/day divided every 12hours. Serious Infections: 15-20mg Trimethoprim/kg/day divided every 6hours.
Sulphamethoxazole 400 mg & Trimethoprim 80 mg InjectionJ01EE01961P3001XXAi) Severe or complicated infections when oral therapy is not feasible ii) Treatment and prophylaxis of pneumocystis carinii pneumonia (PCP) in immunocompromised patientsi) ADULT: 960 mg twice daily increased to 1.44 g twice daily in severe infections. CHILD: 36 mg/kg daily in 2 divided doses increased to 54 mg/kg/day in severe infections ii) Treatment: ADULT & CHILD over 4 weeks: 120 mg/kg/day PO/IV infusion in 2 - 4 divided doses for 14 days. Prophylaxis: ADULT: 960 mg once daily or 960 mg on alternate days (3 times a week) or 960 mg twice daily on alternate days (3 times a week). CHILD 6 weeks - 5 months: 120 mg twice daily on 3 consecutive days or 7 days per week; 6 months - 5 years: 240 mg; 6 - 12 years: 480 mg
Sulphamethoxazole 400 mg & Trimethoprim 80 mg TabletJ01EE01961T1001XXBi) Severe or complicated infections due to susceptible infection ii) Treatment and prophylaxis of pneumocystis carinii pneumonia (PCP) in immunocompromised patientsi) ADULT: 1 - 3 tablets twice daily ii) Treatment: ADULT & CHILD over 4 weeks: 120 mg/kg/day in 2 - 4 divided doses for 14 days. Prophylaxis: ADULT: 960 mg once daily or 960 mg on alternate days (3 times a week) or 960 mg twice daily on alternate days (3 times a week). CHILD; 6 weeks - 5 months: 120 mg twice daily on 3 consecutive days or 7 days per week; 6 months - 5 years: 240 mg; 6 - 12 years: 480 mg
Sulphur 2% & Salicylic Acid 2% CreamD10AB02951G1001XXCAcne vulgaris and seborrhoeic dermatitisWhen used in scalp disorders, a small amount of cream should be rubbed gently into the roots of the hair. When used in skin disorders, the cream should be applied sparingly to the affected area. Apply once daily or until noticeable improvement, then once or twice a week
Sulpiride 200 mg TabletN05AL01000T1001XXBAcute and chronic schizophrenia, chronic delusional psychoses200-400 mg twice daily; 800 mg daily in predominantly negative symptoms and 2.4 g daily in mainly positive symptoms. Elderly, lower initial dose; increased gradually according to response. Child under 14 years not recommended
Sumatriptan 100 mg TabletN02CC01000T1002XXA/KKTreatment of acute migraine attacks50 mg per attack and not more than 300 mg daily
Sumatriptan 50 mg Fast Disintegrating TabletN02CC01000T5001XXATreatment of acute migraine attacks50 mg per attack and not more than 300 mg daily
Sumatriptan 50 mg TabletN02CC01000T1001XXA/KKTreatment of acute migraine attacks50 mg per attack and not more than 300 mg daily
Sumatriptan 6 mg/0.5 ml InjectionN02CC01000P5001XXATreament of acute migraine attacks and cluster headache6 mg given by SC as soon as possible after onset. Dose may be repeated once after not less than 1 hour if needed. Max. 12 mg in 24 hours. Child not recommended
Sunscreen 5 - 20% w/w CreamD02BA02000G1001XXBPhotodermatitisApply to exposed areas at least 30 minutes prior to solar exposure; reapply after swimming, prolonged perspiration and after 2 hours of continuos sun exposure
Suxamethonium Chloride 50 mg/ml lnjM03AB01100P3001XXBMuscle relaxant as an adjunct to anaesthesiaIntravenous: Muscle relaxant in general anaesthesia Adult: As chloride: single dose of 0.3-1.1 mg/kg injected; supplementary doses of 50-100% of the initial dose may be given at 5-10 min intervals. Max dose (repeated IV injection or continuous infusion): 500 mg/hr Child: As chloride: <1 yr: 2 mg/kg; 1-12 yr: 1 mg/kg. Intramuscular: Muscle relaxant in general anaesthesia Adult: As chloride: 3-4 mg/kg. Max total dose: 150 mg Child: As chloride: <1 yr: Up to 4-5 mg/kg; ≥1 yr: Up to 4 mg/kg. Max dose: 150 mg.
Synthetic ACTH (Tetracosactrin Acetate) 250 mcg/ml InjectionH01AA02000P3001XXADiagnostic test to differentiate primary adrenal from secondary (pituitary) adrenocortical insufficiencyDiagnostic test for investigation of adrenocortical insufficiency Adult: As plain preparation: Measure plasma cortisol concentration immediately before and exactly 30 min after IM/IV inj of 250 mcg. Post-inj rise in plasma cortisol concentration ≥200 nmol/l (70 mcg/l) if normal adrenocortical function. As depot preparation (if inconclusive results with plain preparation): Measure plasma cortisol concentration before and exactly 30 min, 1, 2, 3, 4 and 5 hr after an IM inj of 1 mg tetracosactide acetate depot. Adrenocortical function normal if the post-inj rise in plasma cortisol concentration increases 2-fold in 1st hr, and continues to rise steadily. Expected levels in 1st hr: 600-1,250 nmol/l, increasing slowly up to 1000-1800 nmol/l by 5th hr. Child: IV 250 mcg/1.73 m2 BSA. Intramuscular
Tacrolimus 0.03% OintmentD11AH01000G5002XXA*For short-term and intermittent long-term therapy in the treatment of patients with moderate to severe atopic dermatitis in whom the use of alternative, conventional therapies are deemed inadvisable because of potential risks, or in the treatment of patients who are not adequately responsive to or are intolerant of alternative, conventional therapiesAdult ≥16 years: Apply 0.03% or 0.1% to the affected skin twice daily and rub in gently and completely. Children ≥ 2 years: Apply 0.03% ointment thinly to the affected skin bd and rub in gently and completely. Treatment should be continued for 1 week after clearing of signs & symptoms of atopic dermatitis.
Tacrolimus 0.1% OintmentD11AH01000G5001XXA*For short-term and intermittent long-term therapy in the treatment of patients with moderate to severe atopic dermatitis in whom the use of alternative, conventional therapies are deemed inadvisable because of potential risks, or in the treatment of patients who are not adequately responsive to or are intolerant of alternative, conventional therapiesAdult ≥16 years: Apply 0.03% or 0.1% to the affected skin twice daily and rub in gently and completely. Children ≥ 2 years: Apply 0.03% ointment thinly to the affected skin bd and rub in gently and completely. Treatment should be continued for 1 week after clearing of signs & symptoms of atopic dermatitis.
Tacrolimus 0.5 mg CapsuleL04AD02000C1003XXA*i) Primary immunosuppressant agent for all solid organ transplantation ii) Rescue therapy for rejectioni) 0.2 mg/kg/day in 2 divided doses ii) 0.3 mg/kg/day in 2 divided doses
Tacrolimus 1 mg CapsuleL04AD02000C1001XXA*i) Primary immunosuppressant agent for all solid organ transplantation ii) Rescue therapy for rejectioni) 0.2 mg/kg/day in 2 divided doses ii) 0.3 mg/kg/day in 2 divided doses
Tacrolimus 5 mg CapsuleL04AD02000C1002XXA*i) Primary immunosuppressant agent for all solid organ transplantation ii) Rescue therapy for rejectioni) 0.2 mg/kg/day in 2 divided doses ii) 0.3 mg/kg/day in 2 divided doses
Tacrolimus 5mg/ml InjectionL04AD02000P3001XXA*i) Primary immunosuppressant agent for all solid organ transplantation ii) Rescue therapy for rejectioni) 0.2 mg/kg/day in 2 divided doses ii) 0.3 mg/kg/day in 2 divided doses
Tamoxifen Citrate 20 mg TabletL02BA01136T1001XXABreast cancer20 mg in 1-2 divided doses. Max: 40 mg/day
Tamsulosin HCl 400 mcg Extended Release TabletG04CA02110T5001XXA*Second line treatment of functional symptoms of benign prostatic hyperplasia (BPH) in patients who do not tolerate first line drugs or when first line drugs are inappropriate or contraindicated400 mcg once daily
Tar, Coal Tar and Oleyl Alcohol LiquidD05AA00952L5001XXA/KKDandruff, seborrhoeic dermatitis and atopic dermatitisMassage into wet hair, rinse and repeat. Use once or twice weekly
Technetium-99m Sterile GeneratorV09CA01000P3001XXA*Sodium pertechnetate is used for scintigraphy or nuclear scan particularly of the brain and thyroid to prepare various technetium-99m labelled injections for selective organ imagingTechnetium-99m as pertechnetate is obtained by elution with a sterile solution of Sodium Chloride 0.9%. The dosage depend on type of scan i) Thyroid scintigraphy: 18.5-80 MBq (0.5-2.2 mCi) Scintigraphy performed 20 minutes after intravenous injection ii) Salivary gland scintigraphy: 40 MBq (1.1 mCi) Scintigraphy performed immediately after intravenous injection and at regular intervals up to 15 minutes iii) Meckel?s diverticulum scintigraphy: 400 MBq (10.8 mCi) Scintigraphy performed immediately after intravenous injection and at regular interval up to 30 minutes iv) Brain scintigraphy: 370-800 MBq (10-22 mCi) Rapid sequential images are taken immediately within the first minute after intravenous administration, static images 1 to 4 hours later. Thyroid and coriod plexus should be blocked to avoid non-specific 99mTc uptake v) Cardiac and vascular scintigraphy: 740-925 MBq (20-25 mCi) Red cells are labeled in vivo or in vitro by pretreating with a reducing agent. Dynamic images are taken in the first minute after intravenous administration, followed by regular images over 30 minutes vi) Gastrointestinal bleeding: 740-925 MBq (20-25 mCi) Red cells are labeled in vivo or in vitro by pretreating with a reducing agent. Dynamic images are taken in the first minutes after intravenous administration, followed by regular images at appropriate intervals for up to 24 hours vii) Lacrimal duct scintigraphy: 2-4 MBq each eye (50-100 mCi) Drops are instilled into eye and dynamic images are taken over 2 minutes, followed by static images at appropriate intervals over 20 minutes
Tegafur 100 mg & uracil 224 mg CapsuleL01BC53980C1001XXA*Non small cell lung cancer300-600 mg daily in 2-3 divided doses
Telbivudine 600 mg TabletJ05AF11000T1001XXA*Treatment of chronic hepatitis B in patients with evidence of viral replication and active liver inflammationADULT and CHILD over 16 years: 600 mg once daily. Renal Dose Adjustment: 600mg every 48hours (30-49ml/min), 600 mg every 72hours. (<30ml/min; not requiring dialysis); 600mg every 96 days (ESRD)
Telmisartan 40 mg TabletC09CA07000T1001XXA/KKHypertension in patients who cannot tolerate ACE inhibitors because of cough40mg - 80mg once daily
Telmisartan 80 mg & Hydrochlorothiazide 12.5 mg TabletC09DA07000T1001XXA/KKHypertension in patients who cannot tolerate ACE inhibitors because of cough1 tablet daily
Telmisartan 80 mg and Amlodipine 10 mg TabletC09DB04935T1002XXA/KKTreatment of essential hypertension in adults: i) Replacement therapy:Patients receiving telmisartan and amlodipine from separate tablets may instead receive one tablet containing the same component doses ii) Add on therapy: Patients who blood pressure is not adequately controlled on telmisartan or amlodipine monotherapy iii) Initial therapy: May also be used as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goalsSingle-pill combination should be taken once daily. Initiate with telmisartan 80mg/amlodipine 5mg one tablet per day. The maximum recommendation dose is telmisartan 80mg/amlodipine 10mg one tablet per day.
Telmisartan 80 mg and Amlodipine 5 mg TabletC10BX03935T1008XXA/KKTreatment of essential hypertension in adults: i) Replacement therapy:Patients receiving telmisartan and amlodipine from separate tablets may instead receive one tablet containing the same component doses ii) Add on therapy: Patients who blood pressure is not adequately controlled on telmisartan or amlodipine monotherapy iii) Initial therapy: May also be used as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goalsSingle-pill combination should be taken once daily. Initiate with telmisartan 80mg/amlodipine 5mg one tablet per day. The maximum recommendation dose is telmisartan 80mg/amlodipine 10mg one tablet per day.
Telmisartan 80 mg TabletC09CA07000T1002XXA/KKi)Hypertension in patients who cannot tolerate ACE inhibitors because of cough ii)Reduction of the risk of myocardial infarction, stroke, or death from cardiovascular causes in patients 55 years or older at high risk of developing major cardiovascular events who are unable to take ACE inhibitorsi) 40mg - 80mg once daily ii) 80mg once daily
Temozolomide 100 mg CapsuleL01AX03000C1003XXA*In patients with glioblastoma multiforme who fulfill all the following criteria : i. Total /near total resection ii. ECOG/WHO performance status 0-2 iii. Age less than 60 yearsPhase I : 75mg/m2 daily for 42 days concurrent with radiotherapy. Phase II (Total of 6 cycle): Cycle I - 150mg/ m2 once daily for 5/28 days Cycle 2-6 : 200mg/ m2 once daily for 5/28 days
Temozolomide 20 mg CapsuleL01AX03000C1001XXA*In patients with glioblastoma multiforme who fulfill all the following criteria : i. total /near total resection ii. ECOG/WHO performance status 0-2 iii. Age less than 60 yearsPhase I : 75mg/m2 daily for 42 days concurrent with radiotherapy. Phase II (Total of 6 cycles): Cycle I - 150mg/m2 once daily for 5/28 days (given for 5 days followed by 23 days without treatment) Cycle 2-6 : 200mg/m2 once daily for 5/28 days (given for 5 days followed by 23 days without treatment)
Tenecteplase 10,000 unit (50 mg) InjectionB01AD11000P4001XXA*Acute myocardial reinfarction where streptokinase is contraindicated due to previous streptokinase induced antibodies. [Indicated when antibodies was given more than 5 days and less than 12 months]Less than 60 kg: 30 mg, 60 - 69 kg: 35 mg, 70 - 79 kg: 40 mg; 80 -90 kg: 45 mg, 90 kg or above: 50 mg. Administer single IV bolus over 5-10 seconds
Tenofovir Disoproxil Fumarate 300 mg & Emricitabine 200 mg TabletJ05AR03964T1001XXA/KKTreatment of HIV-1 infection in adults in combination with other antiretroviral agents (such as non-nucleoside reverse transcriptase inhibitors or protease inhibitors).1 tablet once daily.
Tenofovir Disoproxil Fumarate 300 mg TabletJ05AF07138T1001XXA*i)Treatment of HIV-1 infected adults in combination with other antiretroviral agents. ii)Use as first line monotherapy for chronic hepatitis B or as a rescue therapy for patients with drug resistance hepatitis B virus (according to resistant profile or treatment guidelines).300mg once daily. Renal Dose Adjustment: 300mg every 48hours (30-49ml/min); 300mg every 72hours (10-29ml/min); 300mg every 7 days after dialysis (Hemodialysis)
Terazosin HCl 1 mg TabletG04CA03110T1001XXAOnly for treatment of Benign Prostatic Hyperplasia. Not to be used for treatment of hypertensionInitially 1 mg at night, increased in a stepwise fashion to 2 mg, 5 mg or 10 mg once daily
Terazosin HCl 2 mg TabletG04CA03110T1002XXAi) Treatment of Benign Prostatic Hyperplasia. ii)Hypertensioni)Initially 1 mg at night, increased in a stepwise fashion to 2 mg, 5 mg or 10 mg once daily. ii)Initial: 1mg once daily at bedtime, Maintenance: 1-5mg once (morning or evening) or twice daily. Max: 20-40mg/day
Terazosin HCl 5 mg TabletG04CA03110T1003XXAi) Treatment of Benign Prostatic Hyperplasia. ii)Hypertensioni) Initially 1 mg at night, increased in a stepwise fashion to 2 mg, 5 mg or 10 mg once daily. ii) Initial: 1mg once daily at bedtime, Maintenance: 1-5mg once (morning or evening) or twice daily. Max: 20-40mg/day
Terbinafine HCl 250 mg TabletD01BA02110T1001XXA*Fungal infections especially onchomycosis caused by dermatophytes250 mg once daily for 6 weeks for fingernails: 12 weeks for toenails
Terbutaline 0.5mg/dose InhalerR03AC03183A2001XXBBronchial asthma, chronic bronchitis, emphysema and other lung diseases where bronchospasm is a complicating factorADULT and CHILD more than 12 years : 1 inhalation 6 hourly. Severe cases : Single dose may be increased to 3 inhalation. Maximum 12 inhalation/24 hour. CHILD 3-12 year : 1 inhalation 6 hourly. Severe cases : Single dose may be increased to 2 inhalation. Maximum 8 inhalation/24 hour
Terbutaline Sulphate 0.3 mg/ml SyrupR03CC03183L9001XXBAsthma and other conditions associated with reversible airways obstructionCHILD less than 7 years : 75 mcg/kg 3 times daily, 7 - 15 years : 2.5 mg 2 - 3 times daily
Terbutaline Sulphate 0.5 mg/ml InjectionR03CC03183P3001XXBBronchial asthma, chronic bronchitis, emphysema and other lung diseases where broncoconstriction is a complicating factorSC, IM or slow IV : 250-500 mcg up to 4 times daily. CHILD 2 - 15 years 10mcg/kg to a maximum of 300 mcg. Continuous IV infusion, as a solution containing 3 - 5 mcg/ml, 1.5 - 5 mcg/minute for 8 - 10 hours; reduce dose for children
Terbutaline Sulphate 10 mg/ml Nebulizer SolutionR03AC03183A3001XXBAsthma and other conditions associated with reversible airways obstructionADULT : 5 - 10 mg 2 -4 times daily, additional doses may be necessary in severe acute asthma. CHILD up to 3 years : 2 mg, 3 - 6 years : 3 mg, 6 - 8 years : 4 mg, over 8 years : 5 mg 2 - 4 times daily
Terbutaline Sulphate 2.5 mg TabletR03CC03183T1001XXBAsthma and other conditions associated with reversible airways obstructionADULT: Initially 2.5 mg 3 times daily for 1 - 2 week, then up to 5 mg 3 times daily. CHILD less than 7 years: 75 mcg/kg 3 times daily, 7 - 15 years: 2.5 mg 2 - 3 times daily
Terlipressin 1mg/5mg InjectionH01BA04000P4001XXA*Acute oesophageal variceal bleeding2 mg IV bolus over 1 minute. Maintenance: 1 - 2 mg IV bolus 4 - 6 hourly until bleeding is controlled, up to 24 - 36 hours. The maximum daily dosage is 120-150 mcg/kg body weight.
Testosterone 250 mg/ml InjectionG03BA03000P3001XXA*Only for treatment of male infertility, protein deficiency during convalescence after surgery and wasting disorder. In women, supplementary therapy of progressive mammary carcinomaBy IM only. Hypogonadism 250 mg every 2-3 weeks. To maintain an adequate androgenic effect 250 mg every 3-6 weeks. Potency disorders 250 mg every 4 weeks. Male climateric disorders: 250 mg every 3-4 weeks. Repeated 6-8 weeks courses at 2-3 months interval
Tetanus Toxoid InjectionJ07AM01000P3001XXC+Immunization against tetanus infection2 doses of 0.5 mL IM at an interval of 4-8 wk, followed by the 3rd dose 6-12 mth later. Booster: 0.5 mL IM every 10 yr.
Tetracycline HCl 250 mg CapsuleJ01AA07110C1001XXBInfections caused by susceptible pathogens"Adult: 250-500 mg 6 hrly. Max: 4 g/day. Child: ≥12 yr Max: 2 g daily"
Tetracycline HCl 250 mg TabletJ01AA07110T1001XXBInfections caused by susceptible pathogens"Adult: 250-500 mg 6 hrly. Max: 4 g/day. Child: ≥12 yr Max: 2 g daily"
Thalidomide 50 mg CapsuleL04AX02000C1001XXA*First line induction therapy in newly diagnosed multiple myeloma, salvage therapy in relapsed multiple myeloma and maintenance therapy in multiple myeloma (contraindicated for pregnant women; pregnancy test for females in reproductive age group before starting treatment should be done).50 mg to 200 mg daily
Thallous Chloride (Thallium-201) InjectionV09GX01100P3001XXA*Used in myocardial perfusion scintigraphy, acute myocardial infarction and post-surgical assessment of coronary artery bypass graft patency, muscle perfusion scintigraphy, visualisation of brain and thyroid tumours and metastasesAs IV infusion
Theophylline 125 mg TabletR03DA04000T1001XXBReversible airways obstruction, acute severe asthmaADULT: 125 mg 3 - 4 times daily after food, increased to 250 mg if required. CHILD: 1 - 15 years : 5 mg/kg/dose (up to 600 mg/ day) every 3 - 4 times daily
Theophylline 250 mg Long Acting TabletR03DA04000T5001XXBReversible airways obstruction and acute severe asthmaADULT: 250 mg 2 times daily. CHILD under 12 years : Up to 10 mg/kg body weight 2 times daily
Theophylline 80 mg/15 ml SyrupR03DA04000L9001XXBReversible airways obstruction and acute severe asthmaADULT : 125 mg 3 - 4 times daily after food, increased to 250 mg if required. CHILD 1 - 15 years : 5 mg/kg/dose (up to 600 mg/day) every 3 - 4 times per day
Thiamine HCl 100 mg/ml InjectionA11DA01110P3001XXBi) For the prevention or treatment of Vitamin B1 deficiency syndromes including beri-beri and peripheral neuritis associated with pellagra ii) Wernicke-Korsakoff Syndromei) Mild to chronic deficiency: 10-25 mg daily. Severe deficiency: 200- 300 mg daily ii) 500 mg every 8 hours for 2 days, followed by 100 mg 2 times daily until patient can take oral dose
Thiamine Mononitrate 10 mg TabletA11DA01221T1002XXCi) For the prevention or treatment of Vitamin B1 deficiency syndromes including beri-beri and peripheral neuritis associated with pellagra ii) Wernicke-Korsakoff Syndromei) Mild to chronic deficiency: 10-25 mg daily. Severe deficiency: 200- 300 mg daily ii) 500 mg every 8 hours for 2 days, followed by 100 mg 2 times daily until patient can take oral dose
Thiamine Mononitrate 3 mg TabletA11DA01221T1001XXCi) For the prevention or treatment of Vitamin B1 deficiency syndromes including beri-beri and peripheral neuritis associated with pellagra ii) Wernicke-Korsakoff Syndromei) Mild to chronic deficiency: 10-25 mg daily. Severe deficiency: 200 - 300 mg daily ii) 500 mg every 8 hours for 2 days, followed by 100 mg 2 times daily until patient can take oral dose
Thioguanine 40 mg TabletL01BB03000T1001XXAFor acute leukaemia and chronic granulocytic leukaemiaRefer to specific protocols. Usually 100 mg/m2 for 5 - 7 days (acute myeloid leukaemia) or up to 2 weeks (chronic myeloid leukaemia for accelerated/ advanced disease). CHILD: 40 - 60 g/m2 daily according to protocol
Thiopental Sodium 500 mg InjectionN05CA19520P3001XXBi) General anaesthesia, induction ii) Anticonvulsant for cases resistant to conventional anticonvulsants in the ICUi) ADULT : For induction 200 - 400 mg. For repeat injection 3 - 5 mg/kg over 10 - 15 seconds until desired depth of anaesthesia is obtained. Not FDA approved for use in pediatric patients ii) 75 - 125 mg IV single dose; for local-anaesthetic induced convulsion: 125 - 250 mg IV over 10 minutes
Thymol Compound GargleA01AD11985M2001XXCFor sore throat and minor mouth inflammationTo be gargled 3-4 times daily
Thyrotropin alfa 0.9mg/ml InjectionH01AB01000P3002XXA*Thyrogen (thyrotropin alfa) is indicated for use as an adjunctive treatment for radioiodine ablation of thyroid tissue remnants in patients who have undergone a near-total or total thyroidectomy for well-differentiated thyroid cancer and who do not have evidence of distant metastatic thyroid cancer.A two-injection regimen is recommended for thyrotropin administration.The two-injection regimen is thyrotropin 0.9 mg intramuscularly (IM), followed by a second 0.9 mg IM injection 24 hours later. After reconstitution with 1.2 mL Sterile Water for Injection, 1.0 mL solution (0.9 mg thyrotropin alfa) is administered by intramuscular injection to the buttock. For radioiodine imaging or treatment, radioiodine administration should be given 24 hours following the final Thyrogen injection. Diagnostic scanning should be performed 48 hours after radioiodine administration, whereas post-therapy scanning may be delayed additional days to allow background activity to decline.
Tibolone 2.5 mg TabletG03CX01000T1001XXA*Treatment of complaints resulting from the natural or surgical menopause & in cases at high risk for breast carcinomas where general hormone replacement therapy is contraindicated2.5mg daily
Ticagrelor 90 mg TabletB01AC24000T1001XXA*a)Patient who failed clopidogrel readmitted to hospital with recurrent atherothrombotic event while patients are on clopidogrel. b) ACS patients with:i) STEMI - going for invasive (PCI), ii) NSTEMI/UA - intermediate to high risk (based on TIMI score). iii) Other complicated ACS cases treated either medically or invasively via PCI or CABG (risk of Stent thrombosis, 3VD etc.)Initially, 180mg as single dose followed by 90mg bd with maintenance dose of ASA 75-150 mg daily.
Ticlopidine HCl 250 mg TabletB01AC05110T1001XXA/KKi) Prevention of thrombotic stroke for patients who are sensitive /intolerant to Acetysalicylic Acid ii) Maintenance of coronary bypass surgery or angioplasty iii) Maintenance of patency of access in patients on chronic haemodialysis250 mg twice daily taken with food
Timolol Maleate 0.5% Eye DropsS01ED01253D2002XXAElevated intraocular pressure, chronic open angle glaucomaInitially, 1 drop of 0.25% 2 times daily, if clinical response is not adequate, 1 drop of 0.5% 2 times daily
Tinidazole 500 mg TabletP01AB02000T1001XXBi) Amoebiasis ii) Urogenital trichomoniasis and giardiasisi) ADULT : 2 g as a single dose for 2 - 3 days. CHILD 3 years and older : 50 mg/kg daily for 3 days ii) ADULT : 2 g as a single dose (repeated once if necessary). Sexual partners should be treated concomitantly with the same dose. CHILD 6 years and older : single dose of 1 gram
Tinzaparin sodium 10,000 anti-Factor Xa IU/ml Injection in Prefilled syringe/cartridgeB01AB10520P5001XXA*i)Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), not amounting to hemodynamic instability. ii)Prevention of post-operative DVT in patients undergoing general and orthopaedic surgery.i)Treatment of DVT and PE, in conjunction with warfarin: 175 anti-Factor Xa IU/kg SC once daily for at least 6 days. ii)Thromboprophylaxis in patients with:Moderate risk of thrombosis (general surgery):3,500 anti-Factor Xa IU SC 2 hrs before surgery and postoperatively, 3,500 anti-Factor Xa IU once daily for 7-10 days. High risk of thrombosis (eg. total hip replacement):4,500 anti-Factor Xa IU SC or 50 anti-Factor Xa IU/kg body weight SC 2 hrs before surgery and then once daily until the patients has been mobilized.
Tinzaparin sodium 20,000 anti-Factor Xa IU/ml Injection in Prefilled syringe/cartridgeB01AB10520P5002XXA*i)Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), not amounting to hemodynamic instability. ii)Prevention of post-operative DVT in patients undergoing general and orthopaedic surgery.i)Treatment of DVT and PE, in conjunction with warfarin: 175 anti-Factor Xa IU/kg SC once daily for at least 6 days. ii)Thromboprophylaxis in patients with:Moderate risk of thrombosis (general surgery):3,500 anti-Factor Xa IU SC 2 hrs before surgery and postoperatively, 3,500 anti-Factor Xa IU once daily for 7-10 days. High risk of thrombosis (eg. total hip replacement):4,500 anti-Factor Xa IU SC or 50 anti-Factor Xa IU/kg body weight SC 2 hrs before surgery and then once daily until the patients has been mobilized.
Tioconazole 1% CreamD01AC07000G1001XXASkin fungal infections resistant to antifungal drugs such as miconazole and clotrimazoleGently massage into the affected and surrounding area 1-2 times daily
Tioconazole 100 mg Vaginal TabletG01AF08000S1001XXAVulvovaginal candidiasisAdult & Child > 12yr: Insert nightly on retiring for 3-6 or 14 days
Tioconazole 6.5% Vaginal OintmentG01AF08000G5001XXAVulvaginal candidiasisApply 4.6 g intravaginally prior to bedtime as a single dose therapy, therapy may extend to 7 days
Tiotropium 2.5mcg/puff solution for inhalationR03BB04320A3001XXA/KKMaintenance bronchodilator treatment to relieve symptoms of patients with chronic obstructive pulmonary disease (COPD) in which the diagnosis of COPD is confirmed by spirometry.5 mcg (2 puff) once daily, at the same time of the day
Tiotropium Bromide 18 mcg Inhalation CapsulesR03BB04320C9901XXA/KKLong term maintenance treatment of bronchospasm and dypsnoea associated with COPD. Tiotropium has usually been added to standard therapy (e.g. inhaled steroids, theophylline, albuterol rescue)Contents of one capsule is inhaled once daily with the Handihaler inhalation device at the same time of the day.
Tirofiban HCl 0.25 mg/ml InjectionB01AC17110P9901XXA*Unstable angina or non-ST segment elevation myocardial infarction with the following: elevated cardiac markers, refractory chest pain, ST-segment changes and thrombolysis in myocardial infarction (TIMI) risk score 4By IV infusion, 0.4 mcg/kg/min for 30 minutes, then 0.1 mcg/kg/min for at least 48 hours, maximum 108 hours
Tocilizumab 20 mg/ml InjectionL04AC07000P3001XXA*Indicated for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients: i) with inadequate respond or intolerance to conventional disease- modifying antirheumatic drugs (DMARDS) ii) who has failed antitumour necrosis factors (antiTNFs) iii) where TNF is contraindicated (patients with history of pulmonary tuberculosis [PTB]) It also can be used as monotherapy or with combination with methotrexate (MTX) and/ or other DMARDS.Recommended dose for rheumatoid arthritis of tocilizumab for adult patients is 8mg/kg given once every 4 weeks as a single-drip IV infusion over 1 hour. It should be diluted to 100 ml by a healthcare professional with sterile 0.9% w/v sodium chloride solution over 1 hour. For patients whose body weight is more than 100kg, doses exceeding 800mg per infusion are not recommended
Tolterodine Tartrate ER 4 mg CapsuleG04BD07123C2002XXA*Treatment of overactive bladder with symptoms of urinary, frequency or urge incontinence4 mg once daily. May decrease to 2 mg once daily depending on response and tolerability
Topiramate 100 mg TabletN03AX11000T1003XXA*Add-on therapy for intractable partial epilepsyADULT: Initially 25-50mg nightly for 1 week. Subsequently at wkly or bi-wkly intervals, increase dose by 25-50 to 100mg/day in 2 divided doses. CHILD aged 2 and above: Approx 5-9 mg/kg/day in 2 divided doses. Titrate at 25mg (or less, based on a range of 1-3mg/kg/day) nightly for the 1st week. Subsequently at 1 or 2 wkly intervals, with increments of 1-3 mg/kg/day in 2 divided dose.
Topiramate 15 mg Capsule SprinkleN03AX11000C1001XXA*Add-on therapy for intractable partial epilepsyADULT: Initially 25-50mg nightly for 1 week. Subsequently at wkly or bi-wkly intervals, increase dose by 25-50 to 100mg/day in 2 divided doses. CHILD aged 2 and above: Approx 5-9 mg/kg/day in 2 divided doses. Titrate at 25mg (or less, based on a range of 1-3mg/kg/day) nightly for the 1st week. Subsequently at 1 or 2 wkly intervals, with increments of 1-3 mg/kg/day in 2 divided dose.
Topiramate 25 mg Capsule SprinkleN03AX11000C1002XXA*Add-on therapy for intractable partial epilepsyADULT: Initially 25-50mg nightly for 1 week. Subsequently at wkly or bi-wkly intervals, increase dose by 25-50 to 100mg/day in 2 divided doses. CHILD aged 2 and above: Approx 5-9 mg/kg/day in 2 divided doses. Titrate at 25mg (or less, based on a range of 1-3mg/kg/day) nightly for the 1st week. Subsequently at 1 or 2 wkly intervals, with increments of 1-3 mg/kg/day in 2 divided dose.
Topiramate 25 mg TabletN03AX11000T1001XXA*Add-on therapy for intractable partial epilepsyADULT: Initially 25-50mg nightly for 1 week. Subsequently at wkly or bi-wkly intervals, increase dose by 25-50 to 100mg/day in 2 divided doses. CHILD aged 2 and above: Approx 5-9 mg/kg/day in 2 divided doses. Titrate at 25mg (or less, based on a range of 1-3mg/kg/day) nightly for the 1st week. Subsequently at 1 or 2 wkly intervals, with increments of 1-3 mg/kg/day in 2 divided dose.
Topiramate 50 mg TabletN03AX11000T1002XXA*Add-on therapy for intractable partial epilepsyADULT: Initially 25-50mg nightly for 1 week. Subsequently at wkly or bi-wkly intervals, increase dose by 25-50 to 100mg/day in 2 divided doses. CHILD aged 2 and above: Approx 5-9 mg/kg/day in 2 divided doses. Titrate at 25mg (or less, based on a range of 1-3mg/kg/day) nightly for the 1st week. Subsequently at 1 or 2 wkly intervals, with increments of 1-3 mg/kg/day in 2 divided dose.
Trace Elements and Electrolytes (Adult) SolutionB05XA30905P3001XXA*Only to be used to cover daily loss of electrolyte and trace elements for patient on parenteral nutrition10 ml added to 500-1000 ml solution, given by IV infusion
Trace Elements and Electrolytes (Paediatric) SolutionB05XA30905P3002XXA*Only to be used to cover daily loss of electrolyte and trace elements for patient on parenteral nutritionAccording to the needs of the patient. INFANT and CHILD weighing 15 kg or less: Basal requirements of the included trace elements are covered by 1 ml/kg/day to a maximum dose of 15 ml. CHILD weighing 15 kg or more, a daily dose of 15 ml, should meet basic trace element requirements. However, for patients weighing more than 40 kg the adult preparation trace element should be used
Tramadol HCl 100 mg SuppositoryN02AX02110S2001XXAPost-operative pain, chronic cancer pain, analgesia/pain relief for patients with impaired renal function100mg rectally up to qds
Tramadol HCl 100 mg/ml DropsN02AX02110D5001XXAPost-operative pain, chronic cancer pain, analgesia/pain relief for patients with impaired renal function.50 - 100 mg every 4 hours. Max : 400 mg daily. Not recommended in children
Tramadol HCl 50 mg CapsuleN02AX02110C1001XXA/KKModerate to severe acute or chronic pain (eg. Post-operative pain, chronic cancer pain and analgesia/pain relief for patients with impaired renal function)ADULT: 50mg initially, can take another 50mg after 30 - 60 min if pain not relieved. Max 400 mg daily. CHILD: 1mg/kg/dose repeated every 6 hours (Max: 2mg/kg/dose and 100mg/dose)
Tramadol HCl 50 mg/ml InjectionN02AX02110P3001XXAModerate to severe acute or chronic pain (eg. Post-operative pain, chronic cancer pain and analgesia/pain relief for patients with impaired renal function)ADULT: IV/IM/SC 50 - 100mg. (IV inj over 2-3 min or IV infusion). Initially 100 mg then 50 - 100 mg every 4 - 6 hours. . Max: 400 mg daily. CHILD (1 year and above): 1 - 2mg/kg/dose
Tranexamic Acid 100 mg/ml InjectionB02AA02000P3001XXBHaemorrhage associated with excessive fibrinolysisADULT: Slow IV 0.5-1 g (10 - 15 mg/kg) 3 times daily. Continuous infusion at a rate of 25 - 50 mg/kg daily. CHILD: slow IV 10 mg/kg/day 2-3 times daily
Tranexamic Acid 250 mg CapsuleB02AA02000C1001XXBHaemorrhage associated with excessive fibrinolysisADULT: 1-1.5 g (15-25 mg/kg) 2-4 times daily. CHILD: 25 mg/kg/day 2-3 times daily. Menorrhagia (initiated when menstruation has started), 1 g 3 times daily for up to 4 days; maximum 4 g daily
Trastuzumab 440 mg InjectionL01XC03000P4001XXA*Used only in adjuvant setting for patients with HER2 over-expressed breast cancer, that is HER2 3+ by immunohistochemistry and over-expressed by FISH (Fluorescence in situ hybridization) and high risk groupInitial loading dose is 4 mg/kg administered as a 90 minutes IV infusion. Subsequent doses is 2 mg/kg administered as 30 minutes IV infusion weekly for 51 weeks
Travoprost 0.004% & Timolol 0.5% Eye DropsS01ED51990D2003XXA*To decrease intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to other topical anti glaucomas1 drop in the affected eye(s) once daily
Tretinoin 0.01% GelD10AD01000G3001XXAAcne vulgaris, recalcitrant cases of acne (comedonal type)Apply thinly to the affected area once daily or twice daily. Avoid exposure to sunlight. Duration of treatment: 8-12 weeks is required before any noticeable response
Tretinoin 0.05% CreamD10AD01000G1001XXA/KKAcne vulgaris and recalcitrant cases of acne (comedonal type)Apply thinly to the affected area once daily or twice daily. Avoid exposure to sunlight. Duration of treatment: 8 - 12 weeks is required before any noticeable response
Tretinoin 0.1% CreamD10AD01000G1002XXAAcne vulgaris and recalcitrant cases of acne (comedonal type)Apply thinly to the affected area once daily or twice daily. Avoid exposure to sunlight. Duration of treatment: 8 - 12 weeks is required before any noticeable response
Triamcinolone Acetonide 0.1% Oral PasteA01AC01351G3101XXBOral and perioral lesionsApply a thin layer to affected area 2-4 times daily
Triamcinolone Acetonide 10 mg/ml InjectionH02AB08351P3001XXAInflammation of joints, bursae and tendon sheathsSmaller joints: 2.5 - 5 mg and larger joints: 5 - 15 mg. Treatment should be limited to 1 mg/injection site to prevent cutaneous atrophy
Triamcinolone Acetonide 40 mg/ml InjectionH02AB08351P3002XXA/KKAllergies, dermatoses, rheumatoid arthritis and inflammatory opthalmic diseases40-80 mg deep into the gluteal muscle
Trifluoperazine HCI 5 mg TabletN05AB06110T1001XXBPsychotic disorderADULT: Initially 5 mg twice daily, increase by 5 mg after 1 week, then at 3-day intervals. Maximum 40 mg/day. CHILD up to 12 years: Initially up to 5 mg daily in divided doses adjusted to response, age and body weight
Trimetazidine 20 mg TabletC01EB15110T1001XXBProphylactic treatment of episodes of angina pectoris20 mg 3 times daily
Trimetazidine 35 mg MR TabletC01EB15110T5001XXBProphylactic treatment of episodes of angina pectoris35 mg twice daily in the morning and evening with meals
Trimethoprim 100 mg TabletJ01EA01000T1001XXBTreatment of urinary tract infections due to susceptible pathogensADULT: 200 mg daily in 1 or 2 divided doses or 300 mg daily as a single dose. Acute infection: 200 mg twice daily. CHILD: 6-8 mg/kg/day in 2 divided doses. 6 - 12 years: 100 mg twice daily; 6 months - 5 years: 50 mg twice daily. 6 weeks - 5 months: 25mg twice daily
Trimethoprim 300 mg TabletJ01EA01000T1002XXBTreatment of urinary tract infections due to susceptible pathogensADULT: 200 mg daily in 1 or 2 divided doses or 300 mg daily as a single dose. Acute infection: 200 mg twice daily. CHILD: 6 - 12 years: 100 mg twice daily; 6 months - 5 years: 50 mg twice daily. 6 weeks - 5 months: 25mg twice daily
Trioxsalen 5 mg TabletD05BA01000T1001XXAVitiligo5 - 10 mg daily, 2 - 4 hours before exposure to sunlight. To increase pigmentation: 10 mg daily, 2 hours prior to UV irradiation
Triprolidine HCl 1.25 mg and Pseudoephedrine HCl 30 mg per 5 ml SyrupR01BA52110L9001XXBDecongestion of the upper respiratory tract in common cold, hay fever, allergic and vasomotor rhinitis and sinusitis. Doses to be taken twice daily or three times dailyADULT and CHILD more than 12 year : 10 ml. CHILD 6 - 12 years : 5 ml, 2 - 5 years : 2.5 ml
Triprolidine HCl 2.5 mg and Pseudoephedrine HCl 60 mg TabletR01BA52988T1002XXBDecongestion of the upper respiratory tract in common cold, hay fever, allergic and vasomotor rhinitis and aerotitisADULT 2.5 mg every 4 - 6 hours; maximum dose 10 mg/day. CHILD 6 - 12 years : 1.25 mg every 4 - 6 hours; maximum dose 5 mg/day, 2 - 4 years : 0.625 mg every 4 - 6 hours; maximum dose 2.5 mg/day, 4 - 6 years : 0.938 mg every 4 - 6 hours; maximum dose 3.744 mg/day
Triptorelin 3.75 mg InjectionL02AE04000P2001XXAi) Treatment of confirmed central precocious puberty (preterm sexual development) in girls under 9 years, boys under 10 years of age ii) Genital and extragenital endometriosis (stage I to stage IV). Treatment should not be administered for more than 6 months. It is not recommended to start a second treatment course with triptorelin or another GnRH analogue.1 intramuscular injection every 4 weeks. The treatment must be started in the first 5 days of the menstrual cycle. The duration of treatment depends on the initial severity of the endometriosis and the changes observed in the clinical features. In principle, the treatment should be administered for at least 4 months and for at most 6 months. It is not recommended to start a second treatment course with triptorelin or another GnRH analogue.
Tropicamide 1% Eye DropsS01FA06000D2002XXA/KKTopical use to produce cycloplegic refraction for diagnostic purposes1 - 2 drops several times a day
Trospium Chloride 20mg coated tabletG04BD09100C1001XXA*Symptomatic treatment for urge incontinence and/or increased urinary frequency and urgency as may occur in patients with overactive bladder (eg. Idiopathic or neurologic detrusor overactivity) Place in therapy: As first line treatment for overactive bladder in patients with Parkinsonism, Alzheimer?s or other cognitive disease1 tablet twice daily. Tablet should be swallowed whole with a glass of water before meals on empty stomach. Severe renal impairment (CrCl between 10 & 30 mL/min/1.73 m2): 1 tab daily or every 2nd day
Tuberculine PPD InjectionV04CF01000P3001XXBFor routine Mantoux (tuberculin sensitivity) test10 units is injected intradermally
Typhoid Vaccine CapsuleJ07AP01000C1001XXBActive immunization against typhoid fever in adult and child 6 years of age or olderADULT and CHILD 6 years of age or older, 1 capsule on days 1, 3 and 5
Typhoid Vaccine Injection (20 doses)J07AP02000P3001XXBActive immunization against typhoid fever in adult and child more than 2 years0.5 ml single IM injection into the deltoid or vastus lateralis, may reimmunize with 0.5 ml IM every 3 years if needed.
Ulipristal Acetate 30mg TabletG03AD02122T1001XXAEmergency contraception within 4-5 days of unprotected sexual intercourse for sexual assault victim.Dosage is one tablet to be taken orally as soon as possible, but no later than 120 hours (5 days) after unprotected sexual intercourse or contraceptive failure.
Urofollitropin (FSH) 150 IU InjectionG03GA04000P3002XXA*Stimulation of follicular growth in infertile womenTo be individualized. 75 IU-150 IU daily and maybe increased or decreased by up to 75 IU/day at 7 or 14 day intervals if necessary
Urofollitropin (FSH) 75 IU InjectionG03GA04000P3001XXA*Stimulation of follicular growth in infertile womenTo be individualized. 75 IU-150 IU daily and maybe increased or decreased by up to 75 IU/day at 7 or 14 day intervals if necessary
Urokinase 6000 IU InjectionB01AD04000P4001XXATreatment of thromboembolic disease such as mycocardial infarction, peripheral artery occlusion, pulmonary embolism, retinal artery thrombosis and other ophthalmologic useADULT: Acute pulmonary embolism: IV loading dose 4400 iu/kg over 10 mins, maintenance 4400 iu/kg/hour for 12 hours. Peripheral vascular occlusion: infuse 2500 iu/ml into clot at a rate of 4000 iu/min for 2 hours. This may be repeated up to 4 times. Hyphaema: 5000 IU in 2 ml saline solution is injected and withdrawn repeatedly over the iris. If residual clot remains, leave 0.3ml in the anterior chambers for 24-48 hours to facilitate futher dissolution
Ursodeoxycholic Acid 250 mg CapsuleA05AA02000C1001XXACholestatic liver diseases (eg. primary biliary cirrhosis, primary cholangitis etc)10-15 mg/kg daily in 2 to 4 divided doses usually for 3 months to 2 years. If there is no decrease in stone size after 18 months, further treatment seems not to be useful
Ustekinumab 90 mg/ml InjectionL04AC05000P3002XXA*Treatment of moderate to severe plaque psoriasis in adults who failed to, or who have contraindication to, or are intolerant to conventional systemic therapies including ciclosporin, methotrexate and photochemotherapy (PUVA).Body weight less than 100kg: Initial dose of 45 mg SC, followed by 45 mg 4 weeks later, then every 12 weeks thereafter. Body weight more than 100 kg: initial dose 90 mg SC, followed by 90 mg 4 weeks later, & then every 12 weeks thereafter.
Valganciclovir 450 mg TabletJ05AB14110T1001XXA*For the prevention of cytomegalovirus (CMV) disease in CMV-negative patients who have received a solid organ transplant from a CMV-positive donorFor adult patients who have received other than kidney transplant, the recommended dose is 900 mg (two 450 mg tablets) once a day starting within 10 days of transplantation until 100 days post-transplantation. For adult patients who have received a kidney transplant, the recommended dose is 900 mg (two 450 mg tablets) once a day starting within 10 days of transplantation until 200 days post-transplantation.
Valproic Acid and Sodium Valproate (ER) 500mg TabletN03AG01520T5001XXBi) In the treatment of generalized or partial epilepsy, particularly with the following patterns of seizures:absence, myoclonic, tonic-clonic, atonic-mixed as well as, for partial epilepsy:simple or complex seizures, secondary generalized seizures, specific syndrome (West, Lennox-Gastatut). ii) Treatment and prevention of mania associated with bipolar disorders.i) Adults: Dosage should start at 500mg daily increasing by 200mg at three-day intervals until control is achieved. This is generally within the dosage range 1000mg to 2000mg per day. Children: >20KG: 500mg/day (irrespective of weight) with spaced increases until control is achieved. ii) Initial dose of 1000mg/day, to be increase rapidly as possible to achieve lowest therapeutic dose, which produce desired clinical effects. Recommend initial dose is 1000mg & 2000mg daily. Max dose 3000mg daily.
Valsartan 160 mg and Hydrochlorothiazide 25 mg TabletC09DA03935T1002XXA/KKHypertension in patients who cannot tolerate ACE inhibitors because of cough1 tablet once daily
Valsartan 160 mg TabletC09CA03000T1002XXA/KKPatients who cannot tolerate ACE inhibitors because of cough, in i) Hypertension ii) Heart failure iii) Post myocardial infarctioni) 80 or 160 mg once daily. May be increased to 320 mg once daily. ii) 40 mg twice daily. Uptitration to 80 mg and 160 mg twice daily. Max: 320 mg in divided doses. iii) 20 mg twice daily. Uptitration to max of 160 mg twice daily.
Valsartan 80 mg and Hydrochlorothiazide 12.5 mg TabletC09DA03935T1001XXA/KKHypertension in patients who cannot tolerate ACE inhibitors because of cough1 tablet once daily
Valsartan 80 mg TabletC09CA03000T1001XXA/KKPatients who cannot tolerate ACE inhibitors because of cough, in i) Hypertension ii) Heart failure iii) Post myocardial infarctioni) 80 or 160 mg once daily. May be increased to 320 mg once daily. ii) 40 mg twice daily. Uptitration to 80 mg and 160mg twice daily. Max: 320 mg in divided doses. iii) 20 mg twice daily increased over several weeks to 160mg twice daily if tolerated.
Vancomycin HCl 500 mg InjectionJ01XA01110P4001XXA*Only for the treatment of MRSA and CAPD peritonitisSlow IV infusion, ADULT: 500 mg over at least 60 minutes every 6 hours or 1 g over at least 100 minutes every 12 hours. NEONATE up to 1 week, 15 mg/kg initially, then 10 mg/kg every 12 hours. INFANT 1 - 4 weeks, 15 mg/kg initially then 10 mg/kg every 8 hours. CHILD over 1 month, 10 mg/kg every 6 hours
Varenicline Tartrate 0.5 mg TabletN07BA03123T1001XXA/KKSmoking cessation treatment0.5 mg once daily for Day 1-3, then 0.5 mg twice daily for Day 4-7, then 1 mg twice daily; duration of treatment is 12 weeks
Varenicline Tartrate 1 mg TabletN07BA03123T1002XXA/KKSmoking cessation treatment0.5 mg once daily for Day 1-3, then 0.5 mg twice daily for Day 4-7, then 1 mg twice daily; duration of treatment is 12 weeks
Varicella Virus Vaccine Live Attenuated InjectionJ07BK01000P4001XXA*i) Health staff working with children, pregnant women, transplant, cancer and immunocompromised patients who are at high risk of contacting varicella and transmitting it to at risk patients ii) Transplant patients or candidates who are: a) Immunocompetent and not receiving immunosuppressant drugs, do not have graft versus host disease 2 years or more after transplant b) Susceptible to Varicella-Zoster virus at least 3 weeks before grafting iii) Children: a) with impaired humoral immunity b) HIV-infected children more than 12 months of age, in CDC class N1 (asymptomatic) or A1 (mildly symptomatic) with age specific CD4 more than 25% c) with conditions that require systemic steroid therapy less than 2 mg/kg body weight or a total of 20 mg/day of prednisolone or its equivalent. [Those receiving high doses of systemic steroids at 2 mg/kg body weight or more of prednisolone for more than 2 weeks may be vaccinated after steroid therapy has been discontinued for at least three months] iv) Acute lymphoblastic leukemia (ALL) patients with negative history of varicella who:- a) are 12 months to 17 years of age b) have leukemia in remission for at least 12 months c) have a peripheral blood lymphocyte count 700 cells/ mm3 or more. [If platelet count of greater 100,000/mm3 within 24 hours of vaccination are not being submitted to radiotherapy. Chemotherapy should be withheld for seven days before and after immunisation] v) Susceptible subjects in clinical trials who will be submitted for chemotherapy vi) Children and susceptible patients on chronic dialysisADULT and CHILD 13 years or more: 2 doses of 0.5 ml SC injection separated by 4 - 8 weeks apart. CHILD 12 months - 12 years: 0.5ml SC as a single dose
Vasopressin 20 units/ml InjectionH01BA01000P3001XXAi) Pituitary diabetes insipidus ii) Oesophageal variceal bleedingi) 5 - 20 units SC or IM every 4 hours ii) 20 units in 100 - 200 ml 5% dextrose saline over 15 minutes as infusion which may be repeated after at intervals of 1 - 2 hours. Maximum: 4 doses
Vecuronium Bromide 10 mg/10 ml InjectionM03AC03320P3001XXA*As an adjunct in anaesthesia to produce skeletal muscle relaxationADULT & NEONATES > 5 MONTHS Initial: 80-100 mcg/kg as inj. Maintenance: 20-30 mcg/kg, adjust according to response. Alternatively, as continuous infusion at 0.8-1.4 mcg/kg/min after initial IV dose of 40-100 mcg/kg. NEONATE and INFANT up to 4 months: Initially 10 - 20 mcg/kg, then incremental dose to achieve response
Vecuronium Bromide 4 mg/ml InjectionM03AC03320P3002XXA*As an adjunct in anaesthesia to produce skeletal muscle relaxationADULT & NEONATES > 5 MONTHS Initial: 80-100 mcg/kg as inj. Maintenance: 20-30 mcg/kg, adjust according to response. Alternatively, as continuous infusion at 0.8-1.4 mcg/kg/min after initial IV dose of 40-100 mcg/kg. NEONATE and INFANT up to 4 months: Initially 10 - 20 mcg/kg, then incremental dose to achieve response.
Venlafaxine HCl 150 mg Extended Release CapsuleN06AX16110C2002XXA*i) Depression ii) Generalized anxiety disorder iii) Social anxiety disorder (social phobia) iv) Panic disorderi), ii) & iii) ADULT: 75 mg once daily. May increase dose by 75 mg/day every 4 days to a maximum dose of 225 mg/day, (severe depression: max: 375mg/day) iv) 37.5 mg/day for the first 4-7 days after which the dose should be increased to 75 mg once daily. CHILD and ADOLESCENT under 18 years not recommended.
Venlafaxine HCl 75 mg Extended Release CapsuleN06AX16110C2001XXA*i) Depression ii) Generalized anxiety disorder iii) Social anxiety disorder (social phobia) iv) Panic disorderi), ii) & iii) ADULT: 75 mg once daily. May increase dose by 75 mg/day every 4 days to a maximum dose of 225 mg/day, (severe depression: max: 375mg/day) iv) 37.5 mg/day for the first 4-7 days after which the dose should be increased to 75 mg once daily. CHILD and ADOLESCENT under 18 years not recommended
Verapamil HCl 2.5 mg/ml InjectionC08DA01110P3001XXA/KKSupraventricular tachycardiaInitially 5-10mg given by slow IV over at least 2 minutes. The dose can be repeated 10mg 30 minutes after the first dose if the initial response is not adequate.
Verapamil HCl 40 mg TabletC08DA01110T1001XXBi) Supraventricular tachyarrhythmias (SVT) prophylaxis ii) anginaADULT: 40 - 80 mg 3-4 times daily. In oral long term therapy, max: 480 mg daily
Vildagliptin 50 mg and Metformin HCl 1000 mg TabletA10BD08926T1002XXA*Treatment of type 2 diabetes mellitus patients who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone or who are already treated with the combination of vildagliptin and metformin as separate tablets.50 mg/850 mg or 50 mg/1000 mg twice daily. Maximum daily dose is 100 mg vildagliptin plus 2000 mg metformin hydrochloride.
Vildagliptin 50 mg and Metformin HCl 500 mg TabletA10BD08926T1003XXA*Treatment of type 2 diabetes mellitus patients who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone or who are already treated with the combination of vildagliptin and metformin as separate tablets.50/500mg or 50/850mg or 50/1000mg twice daily. Maximum daily dose is 100mg vildagliptin and 2000mg metformin.
Vildagliptin 50 mg and Metformin HCl 850 mg TabletA10BD08926T1001XXA*Treatment of type 2 diabetes mellitus patients who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone or who are already treated with the combination of vildagliptin and metformin as separate tablets.50 mg/850 mg or 50 mg/1000 mg twice daily. Maximum daily dose is 100 mg vildagliptin plus 2000 mg metformin hydrochloride.
Vildagliptin 50 mg TabletA10BH02000T1001XXA*i) As second line therapy in type 2 diabetes patients inadequately controlled on maximal tolerated dose of metformin monotherapy and high risk of hypoglycaemia. ii) As second line therapy in type 2 diabetes patients inadequately controlled on maximal tolerated dose of sulphonylurea and intolerant/contraindicated for metformin therapy. iii) As third line therapy in type 2 diabetes patients inadequately controlled with dual OAD combination therapy with sulphonylurea and metformin iv) As a monotherapy in type 2 diabetes mellitus patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. v)An adjunct to diet and exercise to improve glycaemic control in patients with type 2 diabetes mellitus: As a dual therapy in combination with insulin in patients with insufficient glycaemic control. Insulin dose and regimen should be optimized before addition of vildagliptin.ADULT over 18 years: 50mg bd when combine with metformin, 50 mg od when combine with sulphonylurea
Vinblastine Sulphate 10 mg InjectionL01CA01183P3002XXAHodgkin's disease, choriocarcinoma resistant to other chemotherapeutic agents, non-small cell lung cancer, Langerhans cell histiocytosisAdult: Initially, 3.7 mg/m2, increase dose weekly based on WBC counts in increments of about 1.8 mg/m2 until leukocyte count decreases to about 3000/mm3, or maximum weekly dose of 18.5 mg/m2 reached. Usual dose: 5.5-7.4 mg/m2 per week. Do not administer next dose, even though 7 days have lapsed unless the leukocyte count has returned to at least 4000/mm3. Child: Initial 2.5 mg/m2 of BSA, increased dose at weekly intervals in increments of about 1.25 mg/m2 until leukocyte count decreases to about 3000/ mm3, or maximum weekly dose of 12.5 mg/m2 reached. Do not increase dose once leukocyte count reaches approximately 3000 cells/mm3, instead, a dose of 1 increment smaller to be admin at wkly intervals for maintenance. Do not administer next dose, even though 7 days have lapsed unless the leukocyte count has returned to at least 4000/mm3.
Vincristine Sulphate 1 mg InjectionL01CA02183P3001XXAi) Solid tumours ii) Gestational trophoblastic disease iii) Non-Hodgkin's lymphoma iv) Multiple myeloma v) Acute lymphoblastic leukemiai) ADULT: 1.4 mg/m2 weekly (maximum 2 mg weekly) ii) Refer to protocol iii) 1.4 mg/m2 weekly (maximum 2 mg weekly) iv) 0.4 mg/m2 IV continuous infusion on days 1 - 4 v) Refer to protocol. CHILD: 1 mg/m2 to 2 mg/m2 weekly according to protocol (0.05 mg/kg for infants less than 10kg)
Vinorelbine 10 mg InjectionL01CA04000P4001XXA*i) First line treatment in non-small cell lung cancer in combination with cisplatin/ifosfomide ii) Metastatic breast canceri) Single agent: Adult 30mg/m2 IV administered over 6-10 minutes once weekly Combination with cisplatin : 30mg/m2 IV administered over 6-10mintes once weekly combination with cisplatin IV on days and 29 and then every 6 weeks or Vinolrebine administered at a dose of 25mg/m2 IV weekly in combination with cisplatin given every 4 weeks at a dose of 100mg/m2 ii) 25 - 30 mg/m2 diluted in saline solution, infused over 6 - 10 minutes, administered weekly or vinolrebine maybe given as an 8mg/m2 IV BOLUS followed by 8mg/m2 as a 96-hour intravenous infusion
Vinorelbine 50 mg InjectionL01CA04000P4002XXA*i) First line treatment in non-small cell lung cancer in combination with cisplatin/ifosfomide ii) Metastatic breast canceri) Single agent: Adult 30mg/m2 IV administered over 6-10 minutes once weekly Combination with cisplatin : 30mg/m2 IV administered over 6-10mintes once weekly combination with cisplatin IV on days and 29 and then every 6 weeks or Vinolrebine administered at a dose of 25mg/m2 IV weekly in combination with cisplatin given every 4 weeks at a dose of 100mg/m2 ii) 25 - 30 mg/m2 diluted in saline solution, infused over 6 - 10 minutes, administered weekly or vinolrebine maybe given as an 8mg/m2 IV BOLUS followed by 8mg/m2 as a 96-hour intravenous infusion.
Vitamin A & D (Cod Liver Oil)A11CB00901L5001XXCPrevention of rickettsNot more than 10 ml daily, allowance being made for Vitamin D obtained from other sources
Vitamin A & D Concentrate 25,000 units/0.6ml LiquidA11CB00901L5002XXBPrevention of ricketts0.06 - 0.6ml (2,500-25,000 IU of Vitamin A and 250-2,500 IU of D) daily, allowance being made for A and D obtained from other sources
Vitamin A 50,000 IU CapsuleA11CA01000C1001XXCChildren with measles malnutrition and serious infections. Category C can use this drug for Orang Asli and in Sabahi) 0-5 months, 50,000 IU ii) 6-11 months, 100,000 IU iii) 1-5 years, 200,000 IU. Frequency twice daily
Vitamin B Complex 10 ml InjectionA11EX00901P3001XXBProphylaxis and treatment of vitamin B deficiency1-2 ml daily by IM
Vitamin B Complex TabletA11EA00901T1001XXC+Prophylaxis and treatment of vitamin B deficiency1-2 tablets daily
Vitamin B1, B6, B12 InjectionA11DB00901P3001XXBFor deficiency or raised requirement of Vitamin B1, B6, B12Mild cases: 1 ampoule given by IM 2-3 times weekly. Severe cases: 1 ampoule daily
Vitamin B1, B6, B12 TabletA11DB00901T1001XXBFor deficiency or raised requirement of Vitamin B1, B6, B121 - 3 tablets 3 times daily swallowed unchewed.
Vitamin C 10% Eye DropsS01XA15000D2001XXBFor all types of severe chemical corneal burns especially acid and alkali burns1 to 4 times daily depending on severity of case
Vitamin E, B12, B6, Nicotinamide TabletA11E000901T1001XXATo improve appetite and growth. Neurasthenia, nausea and vomiting in pregnancy, radiation sickness and neuritis due to isoniazid therapy and alcoholism1 - 2 tablet daily
Vitamin K1 1 mg/ml InjectionB02BA01000P3001XXC+Vitamin K deficiency in neonatesProphylaxis of vitamin K deficiency bleeding in neonates Child: Neonate: 0.5-1 mg, given as a single dose via IM inj. Alternatively, 2 mg may be given orally, followed by a 2nd dose of 2 mg after 4-7 days. Intravenous Vitamin K deficiency bleeding in neonates Child: Infant: 1 mg by IV/IM/SC inj, further doses may be given if necessary
Vitamin K1 10 mg/ml InjectionB02BA01000P3002XXBHaemorrhage associated with hypoprothrombinaemia caused by overdose of anticoagulants0.5 - 20 mg by very slow IV at a rate not exceeding 1 mg per minute
Vitamin K1 Mixed Micelle 2 mg/0.2 ml InjectionB02BA01000P3004XXBPrevention of bleeding in neonatesHealthy neonate 2 mg orally at birth or soon after followed by 2 mg at 4 - 7 days. Exclusively breastfed baby, in addition, 2 mg orally at monthly intervals until end of breastfeeding period. Neonate at special risk, 1 mg IM/IV at birth or soon after if oral route is not suitable. Treatment: 1 mg IV initially. Further doses depend on clinical picture and coagulation status
Voriconazole 200 mg InjectionJ02AC03000P3001XXA*i) Treatment of immunocompromised patients with progressive, possibly life-threatening infections such as invasive aspergillosis, fluconazole-resistant serious invasive candidiasis, serious fungal infections caused by Scedosporium species and Fusarium species ii)Prevention of breakthrough fungal infections in febrile high-risk neutropenic patientsAdult and Children 12 years and greater: Loading dose: 6 mg/kg 12 hourly for first 24 hours. Maintenance: i) 4 mg/kg 12 hourly ii) 3 mg/kg 12 hourly. Dose may be increased to 4 mg/kg 12 hourly if response is inadequate. Children aged 2years to <12years with normal hepatic and renal function: No loading dose needed; 7mg/kg 12hourly
Voriconazole 200 mg TabletJ02AC03000T1002XXA*i) Treatment of immunocompromised patients with progressive, possibly life-threatening infections such as invasive aspergillosis, fluconazole-resistant serious invasive candidiasis, candidiasis of the oesophagus, serious fungal infections caused by Scedosporium species and Fusarium species ii) Prevention of breakthrough fungal infections in febrile high-risk neutropenic patientsAdult and Children 12 years and greater and over 40 kg: Loading dose: 400 mg 12 hourly for first 24 hours. Maintenance: 200 - 300 mg 12 hourly. Less than 40 kg: Loading dose: 200 mg 12 hourly for first 24 hours. Maintenance: 100 - 150 mg 12 hourly. Children aged 2years to <12years with normal hepatic and renal function: No loading dose needed; 200mg 12hourly
Voriconazole 50 mg TabletJ02AC03000T1001XXA*i) Treatment of immunocompromised patients with progressive, possibly life-threatening infections such as invasive aspergillosis, fluconazole-resistant serious invasive candidiasis, candidiasis of the oesophagus, serious fungal infections caused by Scedosporium species and Fusarium species ii) Prevention of breakthrough fungal infections in febrile high-risk neutropenic patientsADULT and CHILDREN 12 years and greater and over 40 kg: Loading dose: 400 mg 12 hourly for first 24 hours. Maintenance: 200 - 300 mg 12 hourly. Less than 40 kg: Loading dose: 200 mg 12 hourly for first 24 hours. Maintenance: 100 - 150 mg 12 hourly
Warfarin Sodium 1 mg TabletB01AA03520T1001XXBTreatment and prophylaxis of thromboembolic disordersInitially 10 mg daily for 2 days. Maintenance dose, 3-9 mg daily according to the INR (taken at the same time each day)
Warfarin Sodium 2 mg TabletB01AA03520T1002XXBTreatment and prophylaxis of thromboembolic disordersInitially 10 mg daily for 2 days. Maintenance dose, 3-9 mg daily according to the INR (taken at the same time each day)
Warfarin Sodium 3 mg TabletB01AA03520T1003XXBTreatment and prophylaxis of thromboembolic disordersInitially 10 mg daily for 2 days. Maintenance dose, 3-10 mg daily according to the INR (taken at the same time each day)
Warfarin Sodium 5 mg TabletB01AA03520T1004XXBTreatment and prophylaxis of thromboembolic disordersInitially 10 mg daily for 2 days. Maintenance dose, 3-10 mg daily according to the INR (taken at the same time each day)
Water for InjectionV07AB00000P3001XXC+As a diluent and vehicle for the administration of medicationsAccording to the needs of the patient
White Petroleum Anhydrous Liquid Landin, Mineral Oil Eye OintmentS01XA20900G5101XXAKeeping the eye lubricated and comfortable during the nightApply a small amount into the eye
Zidovudine 1% InjectionJ05AF01000P3001XXATo reduce the rate of maternal-foetal transmission of HIV in: i) HIV-positive pregnant women over 14 weeks of gestation ii) Their newborn infantsi) Prophylaxis of maternal-foetal HIV transmission during labour and delivery Adult: Loading dose: 2 mg/kg, followed by continuous infusion of 1 mg/kg/hr until umbilical cord is clamped. If caesarean section is planned, start the IV infusion 4 hr before the operation. Renal and Hepatic impairment: Dose reduction may be needed. HIV infection (to be discuss: not in indication) Adult: 1-2 mg/kg every 4 hr, given as 2-4 mg/ml infusion over 1 hr. Child: As continuous infusion: 20 mg/m2/hr. Alternatively, as intermittent infusion: 120 mg/m2 every 6 hr. Renal impairment: Haemodialysis or peritoneal dialysis: 1 mg/kg every 6-8 hr. ii) Prophylaxis of HIV infection in neonates Child: Neonates: 1.5 mg/kg every 6 hr. Start treatment within 12 hr after birth and continue for 1st 6 wk of life. Dose to be given via IV infusion over 30 minutes. Renal impairment: Dose adjustment may be needed.
Zidovudine 10 mg/ml SyrupJ05AF01000L9001XXA*i) Management of patients with asymptomatic and symptomatic (early or advanced) HIV infections with CD4 cell counts less than 500 cu. mm. ii) Neonatal prophylaxisi) HIV infection Adult: 600 mg daily in divided doses, in combination with other antiretroviral agents. Child: 6 wk - 12 yr: 160 mg/m2 every 8 hr. Max: 200 mg every 8 hr. May be used in combination with other anti-retrovirals. Renal and Hepatic impairment: Dose reduction may be needed. ii) Prophylaxis of HIV infection in neonates Child: Neonates: 2 mg/kg every 6 hr for 1st 6 wk of life, starting within 12 hr after birth. Renal and hepatic impairment: Dose adjustment may be needed.
Zidovudine 100 mg CapsuleJ05AF01000C1001XXA/KKi) Management of patients with asymptomatic and symptomatic (early or advanced) HIV infections with CD4 cell counts less than 500 cu. mm ii) Neonatal prophylaxisi) HIV infection Adult: 600 mg daily in divided doses, in combination with other antiretroviral agents. Child: 6 wk - 12 yr: 160 mg/m2 every 8 hr. Max: 200 mg every 8 hr. May be used in combination with other anti-retrovirals. Renal and Hepatic impairment: Dose reduction may be needed. ii) Prophylaxis of HIV infection in neonates Child: Neonates: 2 mg/kg every 6 hr for 1st 6 wk of life, starting within 12 hr after birth. Renal and hepatic impairment: Dose adjustment may be needed.
Zidovudine 300 mg & Lamivudine 150 mg TabletJ05AR01964T1001XXA/KKHIV infection in combination with at least one other antiretroviral drugADULT and CHILD over 12 years: 1 tablet twice daily
Zidovudine 300 mg TabletJ05AF01000T1001XXA*i) Management of patients with asymptomatic and symptomatic (early or advanced) HIV infections with CD4 cell counts < 500 cu. mm ii) HIV positive pregnant mothersHIV infection Adult: 600 mg daily in divided doses, in combination with other antiretroviral agents. Child: 6 wk - 12 yr: 160 mg/m2 every 8 hr. Max: 200 mg every 8 hr. May be used in combination with other anti-retrovirals. ii)Prophylaxis of maternal-foetal HIV transmission Adult: 100 mg 5 times daily or 200 mg tid or 300 mg bid. Start treatment after 14th wk of gestation until the start of labour. Haemodialysis or peritoneal dialysis (CrCl <10 ml/min: 100 mg every 6-8 hr.
Zinc Oxide CreamD02AB00000G1001XXC+Skin protective in various skin conditions such as nappy rash, eczema and problem skinApply 3 times daily or as required
Zinc Oxide OintmentD02AB00240G5001XXCSkin protective in various skin conditions such as nappy rash and eczemaApply 3 times daily or as required
Ziprasidone 20 mg/ml InjectionN05AE04110P3001XXA*Acute agitation in schizophreniaADULT: Initially 10 mg (every 2 hour) or 20 mg (every 4 hour). Maximum: 40 mg/day. IM administration more than 3 days has not been studied
Zoledronic Acid 4 mg InjectionM05BA08000P3001XXA*i) Treatment of hypercalcaemia of malignancy ii) Prevention of skeletal related events in patients with multiple myeloma involving multiple bone lesions4 mg reconstituted and should be given as a 15 minutes IV infusion every 3-4 weeks
Zolpidem Tartrate 10 mg TabletN05CF02123T1001XXAFor treatment of insomnia10-mg tablet daily. Stilnox should always be taken just before going to bed. In elderly patients or patients with hepatic insufficiency: Dosage should be halved ie, 5 mg. Dosage must never exceed 10 mg/day.
Zonisamide 100mg tabletN03AX15000T1001XXA*As adjunctive therapy in the treatment of partial seizures in adults with epilepsy. Restrictions: As adjunctive therapy in the treatment of partial seizures in adults with epilepsy when 1st line and 2nd line therapy failed.For adults, usually 100 to 200mg of zonisomide is to be administered orally 1 to 3 times a day initially. The dose is gradually increased at every one to two weeks up to 200-400mg daily, in 1 to 3 divided dose. The maximum daily dose should not exceed 600mg per day.
Zuclopenthixol 20 mg/ml DropsN05AF05000D5001XXA*Only for psychoses with insight or complianceAcute Schizophrenia and Other Acute Psychoses; Severe Acute States of Agitation; Mania: Oral treatment: Usually 10-50 mg/day. In moderate to severe cases initially 20 mg/day increased, if necessary, by 10-20 mg/day every 2-3 days to ≥75 mg daily.
Zuclopenthixol Acetate 100 mg/2 ml InjectionN05AF05122P3002XXA*Only for treatment of agitated and violent patients suffering from schizophrenia who are not responding to the available standard drugsClopixol-Acuphase: Clopixol-Acuphase is administered by IM injection. The dosage range should normally be 50-150 mg (1-3 mL) IM repeated if necessary, preferably with a time interval of 2-3 days. In a few patients, an additional injection may be needed 24-48 hrs following the 1st injection. In the maintenance therapy, treatment should be continued with oral Clopixol or Clopixol Depot IM after the following guidelines: Change to Oral Clopixol: 2-3 days after the last injection of Clopixol-Acuphase, a patient who has been treated with 100 mg Clopixol-Acuphase, oral treatment should be started at a dosage of about 40 mg daily, possibly in divided dosages. If necessary, the dose can be further increased by 10-20 mg every 2-3 days up to 75 mg or more.
Zuclopenthixol Acetate 50 mg/ml InjectionN05AF05122P3001XXA*Only for treatment of agitated and violent patients suffering from schizophrenia who are not responding to the available standard drugsClopixol-Acuphase: Clopixol-Acuphase is administered by IM injection. The dosage range should normally be 50-150 mg (1-3 mL) IM repeated if necessary, preferably with a time interval of 2-3 days. In a few patients, an additional injection may be needed 24-48 hrs following the 1st injection. In the maintenance therapy, treatment should be continued with oral Clopixol or Clopixol Depot IM after the following guidelines: Change to Oral Clopixol: 2-3 days after the last injection of Clopixol-Acuphase, a patient who has been treated with 100 mg Clopixol-Acuphase, oral treatment should be started at a dosage of about 40 mg daily, possibly in divided dosages. If necessary, the dose can be further increased by 10-20 mg every 2-3 days up to 75 mg or more.
Zuclopenthixol Decanoate 200 mg/ml InjectionN05AF05135P2001XXA*Only for treatment of agitated and violent patients suffering from schizophrenia who are not responding to the available standard drugsBy deep IM injection test dose 100 mg followed after 7 - 28 days by 100 - 200 mg or more followed by 200 - 400 mg at intervals of 2 - 4 weeks adjusted according to response. Maximum 600 mg weekly. Child not recommended
Entries Per Page
Page of